Structure: Image,SMILES,Substance Identification: Reaxys Registry Number,Links to Reaxys,Data Count,CAS Registry Number,Chemical Name,Linear Structure Formula,Molecular Formula,Molecular Weight,Type of Substance,Type and Modification,InChI Key,Composition: Comp. Name,Composition: Comp. Conc.,Composition: Comp. Attrib.,Field Availability,Number of Reactions,Number of References,LogP,H Bond Donors,H Bond Acceptors,Rotatable Bonds,TPSA,Lipinski Number,Veber Number,Target Name,Target Synonyms,Reaxys Target ID,Target Uniprot ID,Target PDB ID,Target GO ID,Target InterPro ID,"Target, Subunit, Species",Target Mutant/Chimera Details,Target Species (Bioactivity),Target Transfection,Substance Action on Target,Substance Effect,Bioassay Category,Bioassay Name,Bioassay Details,Biological Species/NCBI ID,Bioassay Pathology,(Clinical) findings / disease,Organs/Tissues,Cells/Cell Lines,Cell Fraction,Substance RN,Links to Reaxys,Smiles,Substance Name,Substance Dose,Substance Route of Adm.,Substance Dosing Regimen,Measurement Object,Medchem: Measurement Parameter,Unit,Qualitative value,Quantitative value,Deviation,Statistical sgnificance (Qualitative),Measured protein,Measured substance RN,Measured substance name,Statistical sgnificance (p-value),Measurement pX,Metabolite RN,Metabolite name,Concomitants: Compound RN,Concomitants: Compound name,Concomitants: Compound role,References,Links to Reaxys
,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1,1445814,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1445814&database=RX&origin=ReaxysOutput&ln=,(1 of 100),23214-92-8,"doxorubicin; adriamycin; DOX; doxil; doxorubicine; doxorubicin hydrochloride; Adriacin; DOXO; ADM; Adr; DXR; (8S,10S)-10-(4-amino-5-hydroxy-6-methyltetrahydro-2H pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl )-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; hydroxyldaunorubicin; hydroxydaunorubicin; doxorubucin; (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-tetracenyl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside; doxorobucin; NSC 123127; doxrubicin; caelyx; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside; hydroxydaunomycin; DOX·HCl; negwer; rubex; DXN; DXO",C27H29NO11,C27H29NO11,543.527,heterocyclic,,AOJJSUZBOXZQNB-TZSSRYMLSA-N,,,,Identification(43225); Physical Data(214); Spectra(316); Bioactivity(17663),467,54392,-0.044,6,9,5,206.07,2,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,1445814,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1445814&database=RX&origin=ReaxysOutput&ln=,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1,doxorubicin,0.001 - 10 μM,,,,IC50,μM,,293.2,,,,,,,3.53,,,,,,"Article; Chang, Xing;Wang, Junfang;Bian, Jiang;Liu, Zi;Guo, Ming;Li, Zengqiang;Wu, Yingliang;Zhai, Xin;Zuo, Daiying; Toxicology and Applied Pharmacology; vol. 450; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D118364301&database=RX&origin=ReaxysOutput&ln=
,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1,1445814,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1445814&database=RX&origin=ReaxysOutput&ln=,(1 of 100),23214-92-8,"doxorubicin; adriamycin; DOX; doxil; doxorubicine; doxorubicin hydrochloride; Adriacin; DOXO; ADM; Adr; DXR; (8S,10S)-10-(4-amino-5-hydroxy-6-methyltetrahydro-2H pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl )-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; hydroxyldaunorubicin; hydroxydaunorubicin; doxorubucin; (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-tetracenyl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside; doxorobucin; NSC 123127; doxrubicin; caelyx; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside; hydroxydaunomycin; DOX·HCl; negwer; rubex; DXN; DXO",C27H29NO11,C27H29NO11,543.527,heterocyclic,,AOJJSUZBOXZQNB-TZSSRYMLSA-N,,,,Identification(43225); Physical Data(214); Spectra(316); Bioactivity(17663),467,54392,-0.044,6,9,5,206.07,2,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Jurkat cell line,,1445814,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1445814&database=RX&origin=ReaxysOutput&ln=,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)C(=O)C2=CC=C1,doxorubicin,0.001 - 10 μM,,,,IC50,μM,,222.1,,,,,,,3.65,,,,,,"Article; Chang, Xing;Wang, Junfang;Bian, Jiang;Liu, Zi;Guo, Ming;Li, Zengqiang;Wu, Yingliang;Zhai, Xin;Zuo, Daiying; Toxicology and Applied Pharmacology; vol. 450; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D118364301&database=RX&origin=ReaxysOutput&ln=
,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC=C(O)C(O)=C2)=C1,317313,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D317313&database=RX&origin=ReaxysOutput&ln=,(2 of 100),117-39-5,"quercetol; Quercetin; 3,5,7,3',4'-pentahydroxyflavone; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; 3,3',4',5,7-pentahydroxyflavone; 3,3′,4′,5,7-pentahydroxyflavone; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 3,5,7,3′,4′-pentahydroxyflavone; quercetine; quercitin; 3,3’,4’,5,7-pentahydroxyflavone; 3,5,7,3’,4’-pentahydroxyflavone; quercitrin; sophoretin; flavin; 3,3',4',5,7-pentahydroxy-2-phenylchromen-4-one; pentahydroxy flavone; quarcetin; QRT; Que; 3,3',4',5,6-pentahydroxy flavone; Q4951; QCT",(HO)2C6H3C9H2O(O)(OH)3,C15H10O7,302.24,heterocyclic,,REFJWTPEDVJJIY-UHFFFAOYSA-N,,,,Identification(44665); Physical Data(1193); Spectra(1667); Bioactivity(10056),1465,53248,2.517,5,2,1,127.45,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,317313,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D317313&database=RX&origin=ReaxysOutput&ln=,OC1=CC(O)=C2C(OC(=C(O)C2=O)C2=CC=C(O)C(O)=C2)=C1,"table 4, compound quercetin",,,,,IC50,µM,,3.32,,,,,,,5.48,,,,,,"Article; El Amrani, Mustapha; Lai, Daowan; Debbab, Abdessamad; Aly, Amal H.; Siems, Karsten; Seidel, Carole; Schnekenburger, Michael; Gaigneaux, Anthoula; Diederich, Marc; Feger, Daniel; Lin, Wenhan; Proksch, Peter; Journal of Natural Products; vol. 77; 1; (2014); p. 49 - 56;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D62567567&database=RX&origin=ReaxysOutput&ln=
,OC(=O)C1=CC=CC=C1O,774890,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D774890&database=RX&origin=ReaxysOutput&ln=,(3 of 100),69-72-7,salicylic acid; 2-hydroxy-1-benzoic acid; o-hydroxybenzoic acid; 2-hydroxybenzoic acid; salicyclic acid,C6H4(OH)(CO2H),C7H6O3,138.123,isocyclic,,YGSDEFSMJLZEOE-UHFFFAOYSA-N,,,,Identification(42651); Physical Data(1841); Spectra(268); Bioactivity(3563),7366,48039,1.66,2,2,1,57.53,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),,Inhibitory activity of the compound against human ALK was determined by KinaseProfilerTM Assay,,,,,,,774890,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D774890&database=RX&origin=ReaxysOutput&ln=,OC(=O)C1=CC=CC=C1O,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; ALTICOR GLOBAL HOLDINGS INC.; US2007/154576; (2007); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091755&database=RX&origin=ReaxysOutput&ln=
,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,73010,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D73010&database=RX&origin=ReaxysOutput&ln=,(4 of 100),56-65-5,ATP; 5'-ATP; adenosine 5'-triphosphoric acid; adenosine triphosphate; adenosine 5'-triphosphate; adenosine-5′-triphosphate,(HO)2POOPO(OH)OPO(OH)OCH2C4H4O(OH)2(N4C5H4N),C10H16N5O13P3,507.184,heterocyclic,,ZKHQWZAMYRWXGA-KQYNXXCUSA-N,,,,Identification(47465); Physical Data(431); Spectra(266); Bioactivity(4282),869,46187,-5.533,7,18,8,308.56,1,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology substrate,,,,,,Sf21 cell line,,73010,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D73010&database=RX&origin=ReaxysOutput&ln=,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,ATP,,,,,Km (Michaelis constant),µM,,4.09,0.380000,,,,,,5.39,,,73010; 1719757,[33P]-ATP; Dithiothreitol,Marker; Other compound,"Article; Bossi, Roberto T.; Saccardo, M. Beatrice; Ardini, Elena; Menichincheri, Maria; Rusconi, Luisa; Magnaghi, Paola; Orsini, Paolo; Avanzi, Nilla; Borgia, Andrea Lombardi; Nesi, Marcella; Bandiera, Tiziano; Fogliatto, Gianpaolo; Bertrand, Jay A.; Biochemistry; vol. 49; 32; (2010); p. 6813 - 6825;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D8995706&database=RX&origin=ReaxysOutput&ln=
,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,73010,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D73010&database=RX&origin=ReaxysOutput&ln=,(4 of 100),56-65-5,ATP; 5'-ATP; adenosine 5'-triphosphoric acid; adenosine triphosphate; adenosine 5'-triphosphate; adenosine-5′-triphosphate,(HO)2POOPO(OH)OPO(OH)OCH2C4H4O(OH)2(N4C5H4N),C10H16N5O13P3,507.184,heterocyclic,,ZKHQWZAMYRWXGA-KQYNXXCUSA-N,,,,Identification(47465); Physical Data(431); Spectra(266); Bioactivity(4282),869,46187,-5.533,7,18,8,308.56,1,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology substrate,,,,,,,,73010,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D73010&database=RX&origin=ReaxysOutput&ln=,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,ATP,,,,,Km (Michaelis constant),µM,,30.7,,,,,,,4.51,,,73010; 73010,ATP; [33P]-ATP,CoEnzyme; Marker,"Article; Katayama, Ryohei; Khan, Tahsin M.; Benes, Cyril; Lifshits, Eugene; Ebi, Hiromichi; Rivera, Victor M.; Shakespeare, William C.; Iafrate, A. John; Engelman, Jeffrey A.; Shaw, Alice T.; Proceedings of the National Academy of Sciences of the United States of America; vol. 108; 18; (2011); p. 7535 - 7540;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D32168697&database=RX&origin=ReaxysOutput&ln=
,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,73010,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D73010&database=RX&origin=ReaxysOutput&ln=,(4 of 100),56-65-5,ATP; 5'-ATP; adenosine 5'-triphosphoric acid; adenosine triphosphate; adenosine 5'-triphosphate; adenosine-5′-triphosphate,(HO)2POOPO(OH)OPO(OH)OCH2C4H4O(OH)2(N4C5H4N),C10H16N5O13P3,507.184,heterocyclic,,ZKHQWZAMYRWXGA-KQYNXXCUSA-N,,,,Identification(47465); Physical Data(431); Spectra(266); Bioactivity(4282),869,46187,-5.533,7,18,8,308.56,1,1,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Radioligand (/ligand),binding activity,In Vitro (Efficacy),,Relative alpha michaelis menten constant of the compound towards ALK,,,,,,,73010,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D73010&database=RX&origin=ReaxysOutput&ln=,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,,,,,,Alpha Km,µM,=,4.3,,,,,,,,,,,,,"Article; Magnaghi, Paola; D'Alessio, Roberto; Valsasina, Barbara; Avanzi, Nilla; Rizzi, Simona; Asa, Daniela; Gasparri, Fabio; Cozzi, Liviana; Cucchi, Ulisse; Orrenius, Christian; Polucci, Paolo; Ballinari, Dario; Perrera, Claudia; Leone, Antonella; Cervi, Giovanni; Casale, Elena; Xiao, Yang; Wong, Chihunt; Anderson, Daniel J; Galvani, Arturo; Donati, Daniele; O'Brien, Tom; Jackson, Peter K; Isacchi, Antonella; Nature Chemical Biology; vol. 9; 9; (2013); p. 548 - 559;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D57705202&database=RX&origin=ReaxysOutput&ln=
,[H][C@@]12CC[C@@H](C)[C@@](O)(O1)C(=O)C(=O)N1CCCC[C@@]1([H])C(=O)O[C@@]([H])(CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C2)OC)[C@H](C)C[C@@H]1CC[C@@H](O)[C@@H](C1)OC,5848501,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D5848501&database=RX&origin=ReaxysOutput&ln=,(5 of 100),53123-88-9,"sirolimus; Rapamycin; Rapa; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; rapamune; RAP; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxy-3-methoxycyclohexyl]-1-methyl-ethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][ 1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; temsirolimus; HY-10219; CCI-779",C51H79O13N,C51H79NO13,914.187,heterocyclic,,QFJCIRLUMZQUOT-HPLJOQBZSA-N,,,,Identification(48503); Physical Data(48); Spectra(73); Bioactivity(5018),963,45606,4.321,3,14,6,195.43,2,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,5848501,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D5848501&database=RX&origin=ReaxysOutput&ln=,[H][C@@]12CC[C@@H](C)[C@@](O)(O1)C(=O)C(=O)N1CCCC[C@@]1([H])C(=O)O[C@@]([H])(CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C2)OC)[C@H](C)C[C@@H]1CC[C@@H](O)[C@@H](C1)OC,Rapamycin,0.500000 µM,,,,inhibition percentage,%,,-14.99,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,2062020,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2062020&database=RX&origin=ReaxysOutput&ln=,(6 of 100),10540-29-1,"tamoxifen; Tam; (Z)-tamoxifen; TMX; (Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine; tamoxifen citrate; (Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethan-1-amine; (2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine); (Z)-1-(p-dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; tamoxifene; nolvadex; (Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine; (Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine; (Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; ICI 46474",C26H29ON,C26H29NO,371.522,isocyclic,,NKANXQFJJICGDU-QPLCGJKRSA-N,,,,Identification(40090); Physical Data(69); Spectra(86); Bioactivity(4654),244,42500,7.138,0,1,8,12.47,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,2062020,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2062020&database=RX&origin=ReaxysOutput&ln=,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,CC(=O)OC1=CC=CC=C1C(O)=O,779271,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D779271&database=RX&origin=ReaxysOutput&ln=,(7 of 100),50-78-2,aspirin; acetylsalicylic acid; ASA; 2-acetoxybenzoic acid,C6H4OOCCH3COOH,C9H8O4,180.16,isocyclic,,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,,,,Identification(34645); Physical Data(616); Spectra(229); Bioactivity(5875),1437,39355,1.422,1,3,3,63.6,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),,Inhibitory activity of the compound against human ALK was determined by KinaseProfilerTM Assay,,,,,,,779271,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D779271&database=RX&origin=ReaxysOutput&ln=,CC(=O)OC1=CC=CC=C1C(O)=O,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; ALTICOR GLOBAL HOLDINGS INC.; US2007/154576; (2007); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091755&database=RX&origin=ReaxysOutput&ln=
,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,2049713,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2049713&database=RX&origin=ReaxysOutput&ln=,(8 of 100),15687-27-1,ibuprofen; 2-(p-isobutylphenyl)-propionic acid; 2-(4-isobutylphenyl)propanoic acid; 2-(4-(2-methylpropyl)phenyl)propanoic acid,HO2CCH(CH3)C6H4CH2CH(CH3)2,C13H18O2,206.285,isocyclic,,HEFNNWSXXWATRW-UHFFFAOYSA-N,,,,Identification(30343); Physical Data(773); Spectra(411); Bioactivity(3776),2358,32974,3.641,1,2,4,37.3,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),,Inhibitory activity of the compound against human ALK was determined by KinaseProfilerTM Assay,,,,,,,2049713,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2049713&database=RX&origin=ReaxysOutput&ln=,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; ALTICOR GLOBAL HOLDINGS INC.; US2007/154576; (2007); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091755&database=RX&origin=ReaxysOutput&ln=
,CN(C)C(=N)NC(N)=N,606492,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D606492&database=RX&origin=ReaxysOutput&ln=,(9 of 100),657-24-9,"dimethylbiguanide; metformin; [14C]-metformin; 1,1-dimethylbiguanide; Met",HNC(N(CH3)2)NHC(NH)NH2,C4H11N5,129.165,acyclic,,XZWYZXLIPXDOLR-UHFFFAOYSA-N,,,,Identification(29837); Physical Data(59); Spectra(67); Bioactivity(4040),324,31443,0.558,4,5,3,88.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,606492,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D606492&database=RX&origin=ReaxysOutput&ln=,CN(C)C(=N)NC(N)=N,metformin,1 mM,,,,inhibition rate,%,,5,,,,,,,,,,,,,"Article; Jaune, Emilie; Cavazza, Elisa; Ronco, Cyril; Grytsai, Oleksandr; Abbe, Patricia; Tekaya, Nedra; Zerhouni, Marwa; Beranger, Guillaume; Kaminski, Lisa; Bost, Frédéric; Gesson, Maeva; Tulic, Meri; Hofman, Paul; Ballotti, Robert; Passeron, Thierry; Botton, Thomas; Benhida, Rachid; Rocchi, Stéphane; Cell death and disease; vol. 12; 1; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82162958&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCCC(C)NC1=CC=NC2=C1C=CC(Cl)=C2,482809,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D482809&database=RX&origin=ReaxysOutput&ln=,(10 of 100),54-05-7,Chloroquine,C9NH5(Cl)NHCH(CH3)C3H6N(C2H5)2,C18H26ClN3,319.878,heterocyclic,,WHTVZRBIWZFKQO-UHFFFAOYSA-N,,,,Identification(23035); Physical Data(132); Spectra(100); Bioactivity(5619),101,27305,4.268,1,3,8,28.16,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,482809,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D482809&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCCC(C)NC1=CC=NC2=C1C=CC(Cl)=C2,chloroquine,20 μM,,,,apoptosis rate,%,,5.92,,,,,,,,,,,,,"Article; Shen, Jiwei; Wang, Junfang; Du, Jianan; Wang, Lijing; Zhou, Xuejiao; Chang, Xing; Li, Zengqiang; Zhai, Xin; Zuo, Daiying; Wu, Yingliang; Toxicology and Applied Pharmacology; vol. 383; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77978849&database=RX&origin=ReaxysOutput&ln=
,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,384532,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D384532&database=RX&origin=ReaxysOutput&ln=,(11 of 100),57-41-0,"phenythoin; phenytoin; 5,5-diphenylhydantoin; diphenylhydantoin; 5,5-diphenylimidazolidine-2,4-dione; PHT; 5,5-diphenyl-2,4-imidazolidinedione; dilantin; DPH; PHY",NH(CO)(CO)NHC(C6H5)2,C15H12N2O2,252.272,heterocyclic,,CXOFVDLJLONNDW-UHFFFAOYSA-N,,,,Identification(24976); Physical Data(246); Spectra(148); Bioactivity(2644),686,25734,2.653,2,4,2,58.2,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,384532,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D384532&database=RX&origin=ReaxysOutput&ln=,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,497341,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D497341&database=RX&origin=ReaxysOutput&ln=,(12 of 100),53-86-1,[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid; indomethacin; indometacin; indomethacine; 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid,ClC6H4COC8H3N(CH3)(CH3O)CH2COOH,C19H16ClNO4,357.793,heterocyclic,,CGIGDMFJXJATDK-UHFFFAOYSA-N,,,,Identification(13749); Physical Data(570); Spectra(224); Bioactivity(7207),1635,19978,3.418,1,4,5,68.53,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),,Inhibitory activity of the compound against human ALK was determined by KinaseProfilerTM Assay,,,,,,,497341,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D497341&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; ALTICOR GLOBAL HOLDINGS INC.; US2007/154576; (2007); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091755&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,(13 of 100),284461-73-0,sorafenib; bay 43-9006; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide; regorafenib; Nexavar; 4-(4-{[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino}phenoxy)-N-methyl-pyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl)aminoformyl)-4-pyridyloxy)phenyl)urea; cm4306; SRF; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpyridine-2-carboxamide; BAY 93-4006; SFN; SOR,C21H16ClF3N4O3,C21H16ClF3N4O3,464.831,heterocyclic,,MLDQJTXFUGDVEO-UHFFFAOYSA-N,,,,Identification(16766); Physical Data(98); Spectra(98); Bioactivity(2800),116,18641,3.752,3,6,9,92.35,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,Sorafenib,0.500000 µM,,,,inhibition percentage,%,,2.73,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,(13 of 100),284461-73-0,sorafenib; bay 43-9006; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide; regorafenib; Nexavar; 4-(4-{[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino}phenoxy)-N-methyl-pyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl)aminoformyl)-4-pyridyloxy)phenyl)urea; cm4306; SRF; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpyridine-2-carboxamide; BAY 93-4006; SFN; SOR,C21H16ClF3N4O3,C21H16ClF3N4O3,464.831,heterocyclic,,MLDQJTXFUGDVEO-UHFFFAOYSA-N,,,,Identification(16766); Physical Data(98); Spectra(98); Bioactivity(2800),116,18641,3.752,3,6,9,92.35,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,Sorafenib,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,(13 of 100),284461-73-0,sorafenib; bay 43-9006; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide; regorafenib; Nexavar; 4-(4-{[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino}phenoxy)-N-methyl-pyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl)aminoformyl)-4-pyridyloxy)phenyl)urea; cm4306; SRF; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpyridine-2-carboxamide; BAY 93-4006; SFN; SOR,C21H16ClF3N4O3,C21H16ClF3N4O3,464.831,heterocyclic,,MLDQJTXFUGDVEO-UHFFFAOYSA-N,,,,Identification(16766); Physical Data(98); Spectra(98); Bioactivity(2800),116,18641,3.752,3,6,9,92.35,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,BAY-43-9006,10 µM,,,,inhibition percentage,%,,3,,,,,,,1,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,(13 of 100),284461-73-0,sorafenib; bay 43-9006; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide; regorafenib; Nexavar; 4-(4-{[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino}phenoxy)-N-methyl-pyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl)aminoformyl)-4-pyridyloxy)phenyl)urea; cm4306; SRF; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpyridine-2-carboxamide; BAY 93-4006; SFN; SOR,C21H16ClF3N4O3,C21H16ClF3N4O3,464.831,heterocyclic,,MLDQJTXFUGDVEO-UHFFFAOYSA-N,,,,Identification(16766); Physical Data(98); Spectra(98); Bioactivity(2800),116,18641,3.752,3,6,9,92.35,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,BAY-43-9006,1 µM,,,,inhibition percentage,%,,8,,,,,,,1,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,(13 of 100),284461-73-0,sorafenib; bay 43-9006; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide; regorafenib; Nexavar; 4-(4-{[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino}phenoxy)-N-methyl-pyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl)aminoformyl)-4-pyridyloxy)phenyl)urea; cm4306; SRF; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpyridine-2-carboxamide; BAY 93-4006; SFN; SOR,C21H16ClF3N4O3,C21H16ClF3N4O3,464.831,heterocyclic,,MLDQJTXFUGDVEO-UHFFFAOYSA-N,,,,Identification(16766); Physical Data(98); Spectra(98); Bioactivity(2800),116,18641,3.752,3,6,9,92.35,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,103904444,3 nM,,,,pKi,,<,5.2,,,,,,,5.2,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,(13 of 100),284461-73-0,sorafenib; bay 43-9006; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide; regorafenib; Nexavar; 4-(4-{[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino}phenoxy)-N-methyl-pyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl)aminoformyl)-4-pyridyloxy)phenyl)urea; cm4306; SRF; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpyridine-2-carboxamide; BAY 93-4006; SFN; SOR,C21H16ClF3N4O3,C21H16ClF3N4O3,464.831,heterocyclic,,MLDQJTXFUGDVEO-UHFFFAOYSA-N,,,,Identification(16766); Physical Data(98); Spectra(98); Bioactivity(2800),116,18641,3.752,3,6,9,92.35,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,In vitro inhibitory activity of compound against ALK in presence of 82 uM ATP upon incubation for 1 h,,,,,,,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,,,,,,qualitative,,Not Published,,,,,,,,,,,,ATP,Other compound,Patent; CHINA NATIONAL PHARMACEUTICAL GROUP CORPORATION; WO2012/89137; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20156058&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,(13 of 100),284461-73-0,sorafenib; bay 43-9006; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide; regorafenib; Nexavar; 4-(4-{[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino}phenoxy)-N-methyl-pyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl)aminoformyl)-4-pyridyloxy)phenyl)urea; cm4306; SRF; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpyridine-2-carboxamide; BAY 93-4006; SFN; SOR,C21H16ClF3N4O3,C21H16ClF3N4O3,464.831,heterocyclic,,MLDQJTXFUGDVEO-UHFFFAOYSA-N,,,,Identification(16766); Physical Data(98); Spectra(98); Bioactivity(2800),116,18641,3.752,3,6,9,92.35,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,sorafenib,10 μmol/l,,,,inhibition percentage,%,,8,,,,,,,1,,,,,,"Article; Wecksler, Aaron T.; Hwang, Sung Hee; Wettersten, Hiromi I.; Gilda, Jennifer E.; Patton, Amy; Leon, Leonardo J.; Carraway, Kermit L.; Gomes, Aldrin V.; Baar, Keith; Weiss, Robert H.; Hammock, Bruce D.; Anti-Cancer Drugs; vol. 25; 4; (2014); p. 433 - 446;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63096631&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,(13 of 100),284461-73-0,sorafenib; bay 43-9006; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide; regorafenib; Nexavar; 4-(4-{[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino}phenoxy)-N-methyl-pyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl)aminoformyl)-4-pyridyloxy)phenyl)urea; cm4306; SRF; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpyridine-2-carboxamide; BAY 93-4006; SFN; SOR,C21H16ClF3N4O3,C21H16ClF3N4O3,464.831,heterocyclic,,MLDQJTXFUGDVEO-UHFFFAOYSA-N,,,,Identification(16766); Physical Data(98); Spectra(98); Bioactivity(2800),116,18641,3.752,3,6,9,92.35,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,sorafenib,1 μM,,,inhibition (%),tested,,Not Published,,,,,,,,,,,,,,Patent; UNIVERSITY OF CALIFORNIA; ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI; US2014/243357; (2014); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64119421&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,(13 of 100),284461-73-0,sorafenib; bay 43-9006; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide; regorafenib; Nexavar; 4-(4-{[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino}phenoxy)-N-methyl-pyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl)aminoformyl)-4-pyridyloxy)phenyl)urea; cm4306; SRF; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpyridine-2-carboxamide; BAY 93-4006; SFN; SOR,C21H16ClF3N4O3,C21H16ClF3N4O3,464.831,heterocyclic,,MLDQJTXFUGDVEO-UHFFFAOYSA-N,,,,Identification(16766); Physical Data(98); Spectra(98); Bioactivity(2800),116,18641,3.752,3,6,9,92.35,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,sorafenib,1 μM,,,,inhibition percentage,%,,20,,,,,,,1,,,,,,Patent; UNIVERSITY OF CALIFORNIA; (131 pag.)WO2016/22839; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68509258&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,(13 of 100),284461-73-0,sorafenib; bay 43-9006; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide; regorafenib; Nexavar; 4-(4-{[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino}phenoxy)-N-methyl-pyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl)aminoformyl)-4-pyridyloxy)phenyl)urea; cm4306; SRF; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpyridine-2-carboxamide; BAY 93-4006; SFN; SOR,C21H16ClF3N4O3,C21H16ClF3N4O3,464.831,heterocyclic,,MLDQJTXFUGDVEO-UHFFFAOYSA-N,,,,Identification(16766); Physical Data(98); Spectra(98); Bioactivity(2800),116,18641,3.752,3,6,9,92.35,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antiproliferative agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,,,,,,IC50,μM,,1.015,,,,,,,5.99,,,,,,"Article; Bold, Guido; Schnell, Christian; Furet, Pascal; McSheehy, Paul; Brüggen, Josef; Mestan, Jürgen; Manley, Paul W.; Drückes, Peter; Burglin, Marion; Dürler, Ursula; Loretan, Jacqueline; Reuter, Robert; Wartmann, Markus; Theuer, Andreas; Bauer-Probst, Beatrice; Martiny-Baron, Georg; Allegrini, Peter; Goepfert, Arnaud; Wood, Jeanette; Littlewood-Evans, Amanda; Journal of Medicinal Chemistry; vol. 59; 1; (2016); p. 132 - 146;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68050086&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,(13 of 100),284461-73-0,sorafenib; bay 43-9006; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide; regorafenib; Nexavar; 4-(4-{[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino}phenoxy)-N-methyl-pyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl)aminoformyl)-4-pyridyloxy)phenyl)urea; cm4306; SRF; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpyridine-2-carboxamide; BAY 93-4006; SFN; SOR,C21H16ClF3N4O3,C21H16ClF3N4O3,464.831,heterocyclic,,MLDQJTXFUGDVEO-UHFFFAOYSA-N,,,,Identification(16766); Physical Data(98); Spectra(98); Bioactivity(2800),116,18641,3.752,3,6,9,92.35,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,protein kinase inhibitor,In Vitro (Efficacy),,,,,,,,,9666200,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9666200&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,sorafenib,1 μM,,,of control,enzyme activity rate,%,,64,,,,,,,,,,,,,"Article; Blanco-Aparicio, Carmen; Albarrán, M. Isabel; Amezquita-Alves, Adrián; Cebriá, Antonio; García, Ana Belén; García-Campos, Francisco Javier; Martínez-Gago, Jaime; Martínez-González, Sonia; Martínez-Torrecuadrada, Jorge; Muñoz, Inés; Pastor, Joaquín; European Journal of Medicinal Chemistry; vol. 201; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80111848&database=RX&origin=ReaxysOutput&ln=
,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,1293536,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1293536&database=RX&origin=ReaxysOutput&ln=,(14 of 100),81-81-2,"warfarin; (R,S)-warfarin; rac-warfarin; 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; 4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one; 3-(α-acetonylbenzyl)-4-hydroxycoumarin; 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one; 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyran-2-one; Coumadin",CH3COCH2CH(C6H5)(C9H4O(O))OH,C19H16O4,308.334,heterocyclic,,PJVWKTKQMONHTI-UHFFFAOYSA-N,,,,Identification(18084); Physical Data(151); Spectra(126); Bioactivity(1616),81,18104,2.999,1,3,4,63.6,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,1293536,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1293536&database=RX&origin=ReaxysOutput&ln=,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,(15 of 100),152459-95-5,imatinib; gleevec; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; STI-571; N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; [4-((4-methyl-1-piperazinyl)methyl)]-N-[4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]phenyl]benzamide; NSC 759854; imitinib; Gleevac; glivec; IKT-001,C29H31N7O,C29H31N7O,493.611,heterocyclic,,KTUFNOKKBVMGRW-UHFFFAOYSA-N,,,,Identification(16166); Physical Data(124); Spectra(97); Bioactivity(2597),185,17716,3.037,2,8,8,86.28,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,Imatinib,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,(15 of 100),152459-95-5,imatinib; gleevec; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; STI-571; N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; [4-((4-methyl-1-piperazinyl)methyl)]-N-[4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]phenyl]benzamide; NSC 759854; imitinib; Gleevac; glivec; IKT-001,C29H31N7O,C29H31N7O,493.611,heterocyclic,,KTUFNOKKBVMGRW-UHFFFAOYSA-N,,,,Identification(16166); Physical Data(124); Spectra(97); Bioactivity(2597),185,17716,3.037,2,8,8,86.28,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,103905596,3 nM,,,,pKi,,<,5.3,,,,,,,5.3,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,(15 of 100),152459-95-5,imatinib; gleevec; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; STI-571; N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; [4-((4-methyl-1-piperazinyl)methyl)]-N-[4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]phenyl]benzamide; NSC 759854; imitinib; Gleevac; glivec; IKT-001,C29H31N7O,C29H31N7O,493.611,heterocyclic,,KTUFNOKKBVMGRW-UHFFFAOYSA-N,,,,Identification(16166); Physical Data(124); Spectra(97); Bioactivity(2597),185,17716,3.037,2,8,8,86.28,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,imatinib,1 μM,,,inhibition (%),tested,,Not Published,,,,,,,,,,,,,,Patent; UNIVERSITY OF CALIFORNIA; ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI; US2014/243357; (2014); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64119421&database=RX&origin=ReaxysOutput&ln=
,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,(15 of 100),152459-95-5,imatinib; gleevec; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; STI-571; N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; [4-((4-methyl-1-piperazinyl)methyl)]-N-[4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]phenyl]benzamide; NSC 759854; imitinib; Gleevac; glivec; IKT-001,C29H31N7O,C29H31N7O,493.611,heterocyclic,,KTUFNOKKBVMGRW-UHFFFAOYSA-N,,,,Identification(16166); Physical Data(124); Spectra(97); Bioactivity(2597),185,17716,3.037,2,8,8,86.28,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,,,,,,pIC50,,>,4.7,,,,,,,4.7,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,(15 of 100),152459-95-5,imatinib; gleevec; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; STI-571; N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; [4-((4-methyl-1-piperazinyl)methyl)]-N-[4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]phenyl]benzamide; NSC 759854; imitinib; Gleevac; glivec; IKT-001,C29H31N7O,C29H31N7O,493.611,heterocyclic,,KTUFNOKKBVMGRW-UHFFFAOYSA-N,,,,Identification(16166); Physical Data(124); Spectra(97); Bioactivity(2597),185,17716,3.037,2,8,8,86.28,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,,,,,,pIC50,,>,5.3,,,,,,,5.3,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,(15 of 100),152459-95-5,imatinib; gleevec; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; STI-571; N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; [4-((4-methyl-1-piperazinyl)methyl)]-N-[4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]phenyl]benzamide; NSC 759854; imitinib; Gleevac; glivec; IKT-001,C29H31N7O,C29H31N7O,493.611,heterocyclic,,KTUFNOKKBVMGRW-UHFFFAOYSA-N,,,,Identification(16166); Physical Data(124); Spectra(97); Bioactivity(2597),185,17716,3.037,2,8,8,86.28,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory activity of the compound against survival of human Karpas 299 cell line expressing NPM-ALK fusion protein upon incubation at 37 degree C for 72 h,,,,,Karpas-299 cell line,,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; SYNTA PHARMACEUTICALS CORP.; US2008/4266; (2008); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D452684&database=RX&origin=ReaxysOutput&ln=
,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,(15 of 100),152459-95-5,imatinib; gleevec; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; STI-571; N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; [4-((4-methyl-1-piperazinyl)methyl)]-N-[4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]phenyl]benzamide; NSC 759854; imitinib; Gleevac; glivec; IKT-001,C29H31N7O,C29H31N7O,493.611,heterocyclic,,KTUFNOKKBVMGRW-UHFFFAOYSA-N,,,,Identification(16166); Physical Data(124); Spectra(97); Bioactivity(2597),185,17716,3.037,2,8,8,86.28,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory activity of the compound against human NPM-ALK was determined,,,,,,,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; SYNTA PHARMACEUTICALS CORP.; US8034834; (2011); B2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091033&database=RX&origin=ReaxysOutput&ln=
,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,(15 of 100),152459-95-5,imatinib; gleevec; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; STI-571; N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; [4-((4-methyl-1-piperazinyl)methyl)]-N-[4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]phenyl]benzamide; NSC 759854; imitinib; Gleevac; glivec; IKT-001,C29H31N7O,C29H31N7O,493.611,heterocyclic,,KTUFNOKKBVMGRW-UHFFFAOYSA-N,,,,Identification(16166); Physical Data(124); Spectra(97); Bioactivity(2597),185,17716,3.037,2,8,8,86.28,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,imatinib,1 μM,,,,inhibition percentage,%,,0,,,,,,,1,,,,,,Patent; UNIVERSITY OF CALIFORNIA; (131 pag.)WO2016/22839; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68509258&database=RX&origin=ReaxysOutput&ln=
,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,(15 of 100),152459-95-5,imatinib; gleevec; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; STI-571; N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; [4-((4-methyl-1-piperazinyl)methyl)]-N-[4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]phenyl]benzamide; NSC 759854; imitinib; Gleevac; glivec; IKT-001,C29H31N7O,C29H31N7O,493.611,heterocyclic,,KTUFNOKKBVMGRW-UHFFFAOYSA-N,,,,Identification(16166); Physical Data(124); Spectra(97); Bioactivity(2597),185,17716,3.037,2,8,8,86.28,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK kinase,,,,,,,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,,,,,,IC50,µM,>,10,,,,,,,1,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/124413; (2006); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D416051&database=RX&origin=ReaxysOutput&ln=
,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,(15 of 100),152459-95-5,imatinib; gleevec; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; STI-571; N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; [4-((4-methyl-1-piperazinyl)methyl)]-N-[4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]phenyl]benzamide; NSC 759854; imitinib; Gleevac; glivec; IKT-001,C29H31N7O,C29H31N7O,493.611,heterocyclic,,KTUFNOKKBVMGRW-UHFFFAOYSA-N,,,,Identification(16166); Physical Data(124); Spectra(97); Bioactivity(2597),185,17716,3.037,2,8,8,86.28,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Synthetic,human,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,7671333,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7671333&database=RX&origin=ReaxysOutput&ln=,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,imatinib,1 μM,,,,inhibition percentage,%,,9.6764,,,,,,,1,,,,,,"Article; Kettle, Jason G.; Anjum, Rana; Barry, Evan; Bhavsar, Deepa; Brown, Crystal; Boyd, Scott; Campbell, Andrew; Goldberg, Kristin; Grondine, Michael; Guichard, Sylvie; Hardy, Christopher J.; Hunt, Tom; Jones, Rhys D. O.; Li, Xiuwei; Moleva, Olga; Ogg, Derek; Overman, Ross C.; Packer, Martin J.; Pearson, Stuart; Schimpl, Marianne; Shao, Wenlin; Smith, Aaron; Smith, James M.; Stead, Darren; Stokes, Steve; Tucker, Michael; Ye, Yang; Journal of Medicinal Chemistry; vol. 61; 19; (2018); p. 8797 - 8810;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75069628&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,(16 of 100),184475-35-2,gefitinib; iressa; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; ZD1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazoline-4-amine; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; gefinitib; geftinib; 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quianazoline; gefetinib; gef,C22H24N4ClFO3,C22H24ClFN4O3,446.909,heterocyclic,,XGALLCVXEZPNRQ-UHFFFAOYSA-N,,,,Identification(15678); Physical Data(128); Spectra(93); Bioactivity(3079),180,17566,3.18,1,5,8,68.74,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,Gefitinib,0.500000 µM,,,,inhibition percentage,%,,1.25,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,(16 of 100),184475-35-2,gefitinib; iressa; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; ZD1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazoline-4-amine; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; gefinitib; geftinib; 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quianazoline; gefetinib; gef,C22H24N4ClFO3,C22H24ClFN4O3,446.909,heterocyclic,,XGALLCVXEZPNRQ-UHFFFAOYSA-N,,,,Identification(15678); Physical Data(128); Spectra(93); Bioactivity(3079),180,17566,3.18,1,5,8,68.74,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,Gefitinib,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,(16 of 100),184475-35-2,gefitinib; iressa; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; ZD1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazoline-4-amine; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; gefinitib; geftinib; 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quianazoline; gefetinib; gef,C22H24N4ClFO3,C22H24ClFN4O3,446.909,heterocyclic,,XGALLCVXEZPNRQ-UHFFFAOYSA-N,,,,Identification(15678); Physical Data(128); Spectra(93); Bioactivity(3079),180,17566,3.18,1,5,8,68.74,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,Iressa (Gefitinib),3 µM,,,,inhibition percentage,%,,0 - 50,,,,,,,5.05,,,73010,ATP,CoEnzyme,"Article; Emanuel, Stuart L.; Hughes, Terry V.; Adams, Mary; Rugg, Catherine A.; Fuentes-Pesquera, Angel; Connolly, Peter J.; Pandey, Niranjan; Moreno-Mazza, Sandra; Butler, Jeannene; Borowski, Virna; Middleton, Steven A.; Gruninger, Robert H.; Story, Jennifer R.; Napier, Cheryl; Hollister, Beth; Greenberger, Lee M.; Molecular Pharmacology; vol. 73; 2; (2008); p. 338 - 348;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D7168640&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,(16 of 100),184475-35-2,gefitinib; iressa; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; ZD1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazoline-4-amine; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; gefinitib; geftinib; 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quianazoline; gefetinib; gef,C22H24N4ClFO3,C22H24ClFN4O3,446.909,heterocyclic,,XGALLCVXEZPNRQ-UHFFFAOYSA-N,,,,Identification(15678); Physical Data(128); Spectra(93); Bioactivity(3079),180,17566,3.18,1,5,8,68.74,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,Iressa,10 µM,,,,inhibition percentage,%,,27,,,,,,,4.57,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,(16 of 100),184475-35-2,gefitinib; iressa; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; ZD1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazoline-4-amine; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; gefinitib; geftinib; 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quianazoline; gefetinib; gef,C22H24N4ClFO3,C22H24ClFN4O3,446.909,heterocyclic,,XGALLCVXEZPNRQ-UHFFFAOYSA-N,,,,Identification(15678); Physical Data(128); Spectra(93); Bioactivity(3079),180,17566,3.18,1,5,8,68.74,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,Iressa,1 µM,,,,inhibition percentage,%,,7,,,,,,,1,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,(16 of 100),184475-35-2,gefitinib; iressa; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; ZD1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazoline-4-amine; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; gefinitib; geftinib; 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quianazoline; gefetinib; gef,C22H24N4ClFO3,C22H24ClFN4O3,446.909,heterocyclic,,XGALLCVXEZPNRQ-UHFFFAOYSA-N,,,,Identification(15678); Physical Data(128); Spectra(93); Bioactivity(3079),180,17566,3.18,1,5,8,68.74,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,103905343,3 nM,,,,pKi,,<,5.9,,,,,,,5.9,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,(16 of 100),184475-35-2,gefitinib; iressa; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; ZD1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazoline-4-amine; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; gefinitib; geftinib; 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quianazoline; gefetinib; gef,C22H24N4ClFO3,C22H24ClFN4O3,446.909,heterocyclic,,XGALLCVXEZPNRQ-UHFFFAOYSA-N,,,,Identification(15678); Physical Data(128); Spectra(93); Bioactivity(3079),180,17566,3.18,1,5,8,68.74,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,gefitinib,1 μM,,,inhibition (%),tested,,Not Published,,,,,,,,,,,,,,Patent; UNIVERSITY OF CALIFORNIA; ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI; US2014/243357; (2014); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64119421&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,(16 of 100),184475-35-2,gefitinib; iressa; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; ZD1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazoline-4-amine; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; gefinitib; geftinib; 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quianazoline; gefetinib; gef,C22H24N4ClFO3,C22H24ClFN4O3,446.909,heterocyclic,,XGALLCVXEZPNRQ-UHFFFAOYSA-N,,,,Identification(15678); Physical Data(128); Spectra(93); Bioactivity(3079),180,17566,3.18,1,5,8,68.74,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,gefetinib,1 μM,,,,inhibition percentage,%,,7,,,,,,,1,,,,,,Patent; UNIVERSITY OF CALIFORNIA; (131 pag.)WO2016/22839; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68509258&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,(16 of 100),184475-35-2,gefitinib; iressa; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; ZD1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazoline-4-amine; 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; gefinitib; geftinib; 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quianazoline; gefetinib; gef,C22H24N4ClFO3,C22H24ClFN4O3,446.909,heterocyclic,,XGALLCVXEZPNRQ-UHFFFAOYSA-N,,,,Identification(15678); Physical Data(128); Spectra(93); Bioactivity(3079),180,17566,3.18,1,5,8,68.74,4,2,epidermal growth factor-activated receptor [human]; ALK tyrosine kinase receptor [human],epidermal growth factor-activated receptor + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,epidermal growth factor-activated receptor [human]; ALK tyrosine kinase receptor [human],epidermal growth factor-activated receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,8949523,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8949523&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC=C(F)C(Cl)=C1)=NC=N2,gefitinib,,,,,survival rate decrease,,Not active,,,,,,,,1,,,,,,Patent; JEUK CO LTD; YONSEI UNIVERSITY; US2019/46514; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76026543&database=RX&origin=ReaxysOutput&ln=
,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,4768037,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D4768037&database=RX&origin=ReaxysOutput&ln=,(17 of 100),,"simvastatin; simvastatine; Zocor; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; simvastatin lactone; SIM; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Liponorm; Lipex; S6196; SVT",C25H38O5,C25H38O5,418.574,heterocyclic,,RYMZZMVNJRMUDD-HGQWONQESA-N,,,,Identification(15309); Physical Data(101); Spectra(129); Bioactivity(2521),187,16260,4.775,1,5,7,72.83,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,4768037,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D4768037&database=RX&origin=ReaxysOutput&ln=,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,2825000,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2825000&database=RX&origin=ReaxysOutput&ln=,(18 of 100),52-53-9,"Verapamil; 5-[(3,4-dimethoxyphenethyl)-methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; (±)-verapamil",C27H38O4N2,C27H38N2O4,454.61,isocyclic,,SGTNSNPWRIOYBX-UHFFFAOYSA-N,,,,Identification(11656); Physical Data(61); Spectra(73); Bioactivity(4158),68,15258,4.967,0,2,13,63.95,4,1,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,2825000,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2825000&database=RX&origin=ReaxysOutput&ln=,COC1=CC=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,CC(=O)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1,4241048,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D4241048&database=RX&origin=ReaxysOutput&ln=,(19 of 100),65277-42-1,"ketoconazole; ketokonazole; cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; 1‐(4‐(4‐(((2R,4S)‐2‐((1H‐imidazol‐1‐yl)methyl)-2‐(2,4‐dichlorophenyl)‐1,3‐dioxolan‐4‐yl)methoxy)phenyl)piperazin‐1‐yl)ethan‐1‐one",C26H28Cl2N4O4,C26H28Cl2N4O4,531.439,heterocyclic,,XMAYWYJOQHXEEK-OZXSUGGESA-N,,,,Identification(12760); Physical Data(161); Spectra(22); Bioactivity(2636),52,15052,4.082,0,7,8,69.06,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,4241048,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D4241048&database=RX&origin=ReaxysOutput&ln=,CC(=O)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12,987417,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D987417&database=RX&origin=ReaxysOutput&ln=,(20 of 100),525-66-6,propranolol; propanolol; (±)-propranolol,C16H21O2N,C16H21NO2,259.348,isocyclic,,AQHHHDLHHXJYJD-UHFFFAOYSA-N,,,,Identification(13112); Physical Data(243); Spectra(134); Bioactivity(2620),170,14481,3.028,2,2,6,41.49,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,987417,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D987417&database=RX&origin=ReaxysOutput&ln=,CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,Sunitinib,0.500000 µM,,,,inhibition percentage,%,,83.38,,,,,,,7,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,Sunitinib,,,,,Kd (dissociation constant),nM,,170,,,,,,,6.77,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,SU11248,,,,,IC50,µM,,2.3,,,,,,,5.64,,,506008,DMSO,Solvent,"Article; Mologni, Luca; Rostagno, Roberta; Brussolo, Stefania; Knowles, Phillip P.; Kjaer, Svend; Murray-Rust, Judith; Rosso, Enrico; Zambon, Alfonso; Scapozza, Leonardo; McDonald, Neil Q.; Lucchini, Vittorio; Gambacorti-Passerini, Carlo; Bioorganic and Medicinal Chemistry; vol. 18; 4; (2010); p. 1482 - 1496;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D8856094&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,Sutent,1 µM,,,,inhibition percentage,%,,61,,,,,,,6.19,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,Sutent,10 µM,,,,inhibition percentage,%,,85,,,,,,,5.75,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,Sunitinib,,,,,IC50,nM,,54.64,,,,,,,7.26,,,,,,"Article; Andreani, Aldo; Granaiola, Massimiliano; Leoni, Alberto; Locatelli, Alessandra; Morigi, Rita; Rambaldi, Mirella; Varoli, Lucilla; Lannigan, Deborah; Smith, Jeff; Scudiero, Dominic; Kondapaka, Sudhir; Shoemaker, Robert H.; European Journal of Medicinal Chemistry; vol. 46; 9; (2011); p. 4311 - 4323;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20030103&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,103905670,3 nM,,,,pKi,,<,5.8,,,,,,,5.8,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,sunitinib,1 μM,,,inhibition (%),tested,,Not Published,,,,,,,,,,,,,,Patent; UNIVERSITY OF CALIFORNIA; ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI; US2014/243357; (2014); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64119421&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,sunitinib,1 μM,,,,inhibition percentage,%,,93,,,,,,,7.12,,,,,,Patent; UNIVERSITY OF CALIFORNIA; (131 pag.)WO2016/22839; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68509258&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK kinase,,,,,,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,,,,,,IC50,µM,=,0.603,,,,,,,6.22,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/124413; (2006); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D416051&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Synthetic,human,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,sunitinib,1 μM,,,,inhibition percentage,%,,83.7725 - 87.1428,,,,,,,6.77,,,,,,"Article; Kettle, Jason G.; Anjum, Rana; Barry, Evan; Bhavsar, Deepa; Brown, Crystal; Boyd, Scott; Campbell, Andrew; Goldberg, Kristin; Grondine, Michael; Guichard, Sylvie; Hardy, Christopher J.; Hunt, Tom; Jones, Rhys D. O.; Li, Xiuwei; Moleva, Olga; Ogg, Derek; Overman, Ross C.; Packer, Martin J.; Pearson, Stuart; Schimpl, Marianne; Shao, Wenlin; Smith, Aaron; Smith, James M.; Stead, Darren; Stokes, Steve; Tucker, Michael; Ye, Yang; Journal of Medicinal Chemistry; vol. 61; 19; (2018); p. 8797 - 8810;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75069628&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,"(Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide",100 nM,,,,inhibition rate,%,,60,,,,,,,,,,,,,"Article; Backos, Donald S.; Casalvieri, Kimberly A.; Jordan, Craig T.; Matheson, Christopher J.; Minhajuddin, Mohammed; Reigan, Philip; European Journal of Medicinal Chemistry; vol. 197; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79572973&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,"(Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide",100 nM,,,,inhibition rate,%,,60,,,,,,,,,,,,,Patent; UNIVERSITY OF COLORADO (SYSTEM); WO2021/3339; (2021); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82228163&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,c,1156,y",,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,"(Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide",100 nM,,,,inhibition rate,%,,88,,,,,,,,,,,,,Patent; UNIVERSITY OF COLORADO (SYSTEM); WO2021/3339; (2021); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82228163&database=RX&origin=ReaxysOutput&ln=
,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,(21 of 100),557795-19-4,"sunitinib; Su11248; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; sutent; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",C22H27FN4O2,C22H27FN4O2,398.48,heterocyclic,,WINHZLLDWRZWRT-ATVHPVEESA-N,,,,Identification(13066); Physical Data(55); Spectra(56); Bioactivity(1564),150,13851,2.94,3,6,8,77.23,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,9364276,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9364276&database=RX&origin=ReaxysOutput&ln=,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,"(Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide",100 nM,,,,inhibition rate,%,,35,,,,,,,,,,,,,Patent; UNIVERSITY OF COLORADO (SYSTEM); WO2021/3339; (2021); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82228163&database=RX&origin=ReaxysOutput&ln=
,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,331267,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D331267&database=RX&origin=ReaxysOutput&ln=,(22 of 100),52-86-8,haloperidol; 4-[4-(p-chlorophenyl)-4-hydroxy-piperidino]-4'-fluorobutyrophenone; 4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one,C21H23ClFNO2,C21H23ClFNO2,375.871,heterocyclic,,LNEPOXFFQSENCJ-UHFFFAOYSA-N,,,,Identification(10602); Physical Data(134); Spectra(83); Bioactivity(3193),152,12907,4.02,1,3,6,40.54,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,331267,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D331267&database=RX&origin=ReaxysOutput&ln=,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,7662430,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7662430&database=RX&origin=ReaxysOutput&ln=,(23 of 100),169590-42-5,4-[5-(4-(methyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulphonamide; Celecoxib; Celebra; celebrex; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; 4-(5-p-tolyl-3-trifluoromethyl-pyrazol-1-yl)benzenesulfonamide; SC-58635; CLX; CXB; N-[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1yl]phenylsulfonyl]benzensulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl]benzenesulfonamide; PA08140+Celebrex; celecoxcib; celocoxib,C17H14N3SO2F3,C17H14F3N3O2S,381.378,heterocyclic,,RZEKVGVHFLEQIL-UHFFFAOYSA-N,,,,Identification(10284); Physical Data(341); Spectra(167); Bioactivity(3249),453,12578,3.892,1,5,4,86.36,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),,Inhibitory activity of the compound against human ALK was determined by KinaseProfilerTM Assay,,,,,,,7662430,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7662430&database=RX&origin=ReaxysOutput&ln=,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; ALTICOR GLOBAL HOLDINGS INC.; US2007/154576; (2007); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091755&database=RX&origin=ReaxysOutput&ln=
,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=C(C)C(OC)=C(C)C=N1,3628192,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D3628192&database=RX&origin=ReaxysOutput&ln=,(24 of 100),73590-58-6,omeprazole; (±)-omeprazole,C17H19SN3O3,C17H19N3O3S,345.422,heterocyclic,,SUBDBMMJDZJVOS-UHFFFAOYSA-N,,,,Identification(11102); Physical Data(71); Spectra(81); Bioactivity(1919),148,12404,0.604,1,4,5,96.31,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,protein kinase inhibitor,In Vitro (Efficacy),,,,,,,,,3628192,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D3628192&database=RX&origin=ReaxysOutput&ln=,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=C(C)C(OC)=C(C)C=N1,omeprazole,100 μM,,,,inhibition rate,%,,0,,,,,,,,,,,,,"Article; Nassar, Husam;Abu-Dahab, Rana;Taha, Mutasem; Medicinal Chemistry Research; vol. 30; 12; (2021); p. 2266 - 2276;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D104842867&database=RX&origin=ReaxysOutput&ln=
,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,3595485,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D3595485&database=RX&origin=ReaxysOutput&ln=,(25 of 100),105355-27-9,Pioglitazone,C19H20N2SO3,C19H20N2O3S,356.445,heterocyclic,,HYAFETHFCAUJAY-UHFFFAOYSA-N,,,,Identification(8599); Physical Data(33); Spectra(55); Bioactivity(1640),100,9696,2.341,1,4,7,93.59,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),,Inhibitory activity of the compound against human ALK was determined by KinaseProfilerTM Assay,,,,,,,3595485,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D3595485&database=RX&origin=ReaxysOutput&ln=,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; ALTICOR GLOBAL HOLDINGS INC.; US2007/154576; (2007); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091755&database=RX&origin=ReaxysOutput&ln=
,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2,256892,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D256892&database=RX&origin=ReaxysOutput&ln=,(26 of 100),50-49-7,impramine; IMIPRAMINE,C19H24N2,C19H24N2,280.413,heterocyclic,,BCGWQEUPMDMJNV-UHFFFAOYSA-N,,,,Identification(7622); Physical Data(100); Spectra(77); Bioactivity(1699),50,9232,4.03,0,2,4,6.48,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,256892,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D256892&database=RX&origin=ReaxysOutput&ln=,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,10502247,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10502247&database=RX&origin=ReaxysOutput&ln=,(27 of 100),231277-92-2,lapatanib; Lapatinib; tykerb; apatinib; GW-572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine; ([N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine]); N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine; tyverb; LAP; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-furan-2-yl]-4-quinazolinamine,C29H26ClFN4O4S,C29H26ClFN4O4S,581.067,heterocyclic,,BCFGMOOMADDAQU-UHFFFAOYSA-N,,,,Identification(7483); Physical Data(38); Spectra(37); Bioactivity(1514),159,8307,5.409,2,6,11,114.73,2,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,10502247,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10502247&database=RX&origin=ReaxysOutput&ln=,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,Lapatinib,0.500000 µM,,,,inhibition percentage,%,,-3.81,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,10502247,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10502247&database=RX&origin=ReaxysOutput&ln=,(27 of 100),231277-92-2,lapatanib; Lapatinib; tykerb; apatinib; GW-572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine; ([N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine]); N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine; tyverb; LAP; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-furan-2-yl]-4-quinazolinamine,C29H26ClFN4O4S,C29H26ClFN4O4S,581.067,heterocyclic,,BCFGMOOMADDAQU-UHFFFAOYSA-N,,,,Identification(7483); Physical Data(38); Spectra(37); Bioactivity(1514),159,8307,5.409,2,6,11,114.73,2,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,10502247,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10502247&database=RX&origin=ReaxysOutput&ln=,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,Lapatinib,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,10502247,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10502247&database=RX&origin=ReaxysOutput&ln=,(27 of 100),231277-92-2,lapatanib; Lapatinib; tykerb; apatinib; GW-572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine; ([N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine]); N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine; tyverb; LAP; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-furan-2-yl]-4-quinazolinamine,C29H26ClFN4O4S,C29H26ClFN4O4S,581.067,heterocyclic,,BCFGMOOMADDAQU-UHFFFAOYSA-N,,,,Identification(7483); Physical Data(38); Spectra(37); Bioactivity(1514),159,8307,5.409,2,6,11,114.73,2,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,10502247,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10502247&database=RX&origin=ReaxysOutput&ln=,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,Lapatinib,3 µM,,,,inhibition percentage,%,,0 - 50,,,,,,,5.05,,,73010,ATP,CoEnzyme,"Article; Emanuel, Stuart L.; Hughes, Terry V.; Adams, Mary; Rugg, Catherine A.; Fuentes-Pesquera, Angel; Connolly, Peter J.; Pandey, Niranjan; Moreno-Mazza, Sandra; Butler, Jeannene; Borowski, Virna; Middleton, Steven A.; Gruninger, Robert H.; Story, Jennifer R.; Napier, Cheryl; Hollister, Beth; Greenberger, Lee M.; Molecular Pharmacology; vol. 73; 2; (2008); p. 338 - 348;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D7168640&database=RX&origin=ReaxysOutput&ln=
,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,10502247,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10502247&database=RX&origin=ReaxysOutput&ln=,(27 of 100),231277-92-2,lapatanib; Lapatinib; tykerb; apatinib; GW-572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine; ([N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine]); N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine; tyverb; LAP; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-furan-2-yl]-4-quinazolinamine,C29H26ClFN4O4S,C29H26ClFN4O4S,581.067,heterocyclic,,BCFGMOOMADDAQU-UHFFFAOYSA-N,,,,Identification(7483); Physical Data(38); Spectra(37); Bioactivity(1514),159,8307,5.409,2,6,11,114.73,2,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,10502247,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10502247&database=RX&origin=ReaxysOutput&ln=,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,103905567,3 nM,,,,pKi,,<,5.9,,,,,,,5.9,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,CN1C=NC(N)=C2N=CN=C12,146087,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D146087&database=RX&origin=ReaxysOutput&ln=,(28 of 100),5142-23-4,M9281; 3-methyladenine; 3-MA; N(3)-methyladenine; 3-methyladenin; 3‐methyladenine; 3‐MA,N4C5H2(CH3)(NH2),C6H7N5,149.155,heterocyclic,,FSASIHFSFGAIJM-UHFFFAOYSA-N,,,,Identification(6646); Physical Data(18); Spectra(42); Bioactivity(1039),79,7532,0.242,1,5,0,69.62,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,146087,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D146087&database=RX&origin=ReaxysOutput&ln=,CN1C=NC(N)=C2N=CN=C12,3-methyladenine,,,,Annexin V+/PI+ cells,percentage,%,,6.85,,,,,,,,,,,,,"Article; Gou, Wenfeng; Guo, Ming; Li, Zengqiang; Shen, Jiwei; Wu, Yingliang; Xu, Xiaobo; Zhai, Xin; Zhang, Xiaoning; Zhou, Xuejiao; Zuo, Daiying; Biochimica et Biophysica Acta - Molecular Cell Research; vol. 1867; 7; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79457678&database=RX&origin=ReaxysOutput&ln=
,CN1C=NC(N)=C2N=CN=C12,146087,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D146087&database=RX&origin=ReaxysOutput&ln=,(28 of 100),5142-23-4,M9281; 3-methyladenine; 3-MA; N(3)-methyladenine; 3-methyladenin; 3‐methyladenine; 3‐MA,N4C5H2(CH3)(NH2),C6H7N5,149.155,heterocyclic,,FSASIHFSFGAIJM-UHFFFAOYSA-N,,,,Identification(6646); Physical Data(18); Spectra(42); Bioactivity(1039),79,7532,0.242,1,5,0,69.62,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,146087,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D146087&database=RX&origin=ReaxysOutput&ln=,CN1C=NC(N)=C2N=CN=C12,3-methyladenine,,,,Annexin V+/PI- cells,percentage,%,,3.45,,,,,,,,,,,,,"Article; Gou, Wenfeng; Guo, Ming; Li, Zengqiang; Shen, Jiwei; Wu, Yingliang; Xu, Xiaobo; Zhai, Xin; Zhang, Xiaoning; Zhou, Xuejiao; Zuo, Daiying; Biochimica et Biophysica Acta - Molecular Cell Research; vol. 1867; 7; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79457678&database=RX&origin=ReaxysOutput&ln=
,[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12,91866,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D91866&database=RX&origin=ReaxysOutput&ln=,(29 of 100),56-54-2,quinidine,CH2OC19H22N2O,C20H24N2O2,324.423,heterocyclic,,LOUPRKONTZGTKE-LHHVKLHASA-N,,,,Identification(6868); Physical Data(203); Spectra(42); Bioactivity(1021),414,6794,2.604,1,3,4,45.59,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,91866,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D91866&database=RX&origin=ReaxysOutput&ln=,[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1,11646488,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11646488&database=RX&origin=ReaxysOutput&ln=,(30 of 100),,"pazopanib; GW-786034; votrient; 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide",C21H23N7O2S,C21H23N7O2S,437.525,,,CUIHSIWYWATEQL-UHFFFAOYSA-N,,,,Identification(6363); Physical Data(16); Spectra(21); Bioactivity(581),48,6570,3.336,2,9,5,127.41,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,11646488,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11646488&database=RX&origin=ReaxysOutput&ln=,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1,Pazopanib,0.500000 µM,,,,inhibition percentage,%,,14.69,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1,11646488,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11646488&database=RX&origin=ReaxysOutput&ln=,(30 of 100),,"pazopanib; GW-786034; votrient; 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide",C21H23N7O2S,C21H23N7O2S,437.525,,,CUIHSIWYWATEQL-UHFFFAOYSA-N,,,,Identification(6363); Physical Data(16); Spectra(21); Bioactivity(581),48,6570,3.336,2,9,5,127.41,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,11646488,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11646488&database=RX&origin=ReaxysOutput&ln=,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1,GW-786034,,,,,Kd (dissociation constant),nM,,2200,,,,,,,5.66,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1,11646488,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11646488&database=RX&origin=ReaxysOutput&ln=,(30 of 100),,"pazopanib; GW-786034; votrient; 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide",C21H23N7O2S,C21H23N7O2S,437.525,,,CUIHSIWYWATEQL-UHFFFAOYSA-N,,,,Identification(6363); Physical Data(16); Spectra(21); Bioactivity(581),48,6570,3.336,2,9,5,127.41,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,11646488,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11646488&database=RX&origin=ReaxysOutput&ln=,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1,103905642,3 nM,,,,pKi,,,5.8,,,,,,,5.8,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1,11646488,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11646488&database=RX&origin=ReaxysOutput&ln=,(30 of 100),,"pazopanib; GW-786034; votrient; 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide",C21H23N7O2S,C21H23N7O2S,437.525,,,CUIHSIWYWATEQL-UHFFFAOYSA-N,,,,Identification(6363); Physical Data(16); Spectra(21); Bioactivity(581),48,6570,3.336,2,9,5,127.41,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,11646488,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11646488&database=RX&origin=ReaxysOutput&ln=,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1,,,,,,pIC50,,=,5.23,,,,,,,5.23,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1,11646488,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11646488&database=RX&origin=ReaxysOutput&ln=,(30 of 100),,"pazopanib; GW-786034; votrient; 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide",C21H23N7O2S,C21H23N7O2S,437.525,,,CUIHSIWYWATEQL-UHFFFAOYSA-N,,,,Identification(6363); Physical Data(16); Spectra(21); Bioactivity(581),48,6570,3.336,2,9,5,127.41,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,11646488,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11646488&database=RX&origin=ReaxysOutput&ln=,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1,,,,,,pIC50,,=,5.8,,,,,,,5.8,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)=CC(=C1)C(F)(F)F,10737140,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10737140&database=RX&origin=ReaxysOutput&ln=,(31 of 100),641571-10-0,nilotinib; AMN-107; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Tasigna; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; [Bodipy-FL]-Nilotinib,C28H22F3N7O,C28H22F3N7O,529.524,heterocyclic,,HHZIURLSWUIHRB-UHFFFAOYSA-N,,,,Identification(6110); Physical Data(56); Spectra(22); Bioactivity(866),129,6466,4.928,2,8,8,97.62,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,10737140,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10737140&database=RX&origin=ReaxysOutput&ln=,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)=CC(=C1)C(F)(F)F,Nilotinib,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008,DMSO,Other compound,"Article; Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 29; 11; (2011); p. 1046 - 1051;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009910&database=RX&origin=ReaxysOutput&ln=
,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)=CC(=C1)C(F)(F)F,10737140,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10737140&database=RX&origin=ReaxysOutput&ln=,(31 of 100),641571-10-0,nilotinib; AMN-107; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Tasigna; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; [Bodipy-FL]-Nilotinib,C28H22F3N7O,C28H22F3N7O,529.524,heterocyclic,,HHZIURLSWUIHRB-UHFFFAOYSA-N,,,,Identification(6110); Physical Data(56); Spectra(22); Bioactivity(866),129,6466,4.928,2,8,8,97.62,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,10737140,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10737140&database=RX&origin=ReaxysOutput&ln=,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)=CC(=C1)C(F)(F)F,Nilotinib,0.500000 µM,,,,inhibition percentage,%,,-2.53,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)=CC(=C1)C(F)(F)F,10737140,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10737140&database=RX&origin=ReaxysOutput&ln=,(31 of 100),641571-10-0,nilotinib; AMN-107; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Tasigna; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; [Bodipy-FL]-Nilotinib,C28H22F3N7O,C28H22F3N7O,529.524,heterocyclic,,HHZIURLSWUIHRB-UHFFFAOYSA-N,,,,Identification(6110); Physical Data(56); Spectra(22); Bioactivity(866),129,6466,4.928,2,8,8,97.62,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,10737140,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10737140&database=RX&origin=ReaxysOutput&ln=,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)=CC(=C1)C(F)(F)F,Nilotinib,<= 10 µM,,,,inhibition percentage,,Not active,,,,,,,,1,,,73010; 506008; 506008; 8187252; 1719757,ATP; DMSO; DMSO; Tween 20; Dithiothreitol,CoEnzyme; Solvent; Solvent; Other compound; Other compound,Article; Manley PW; Drueckes P; Fendrich G; Furet P; Liebetanz J; Martiny-Baron G; Mestan J; Trappe J; Wartmann M; Fabbro D; Biochimica et Biophysica Acta - General Subjects; vol. 1804; (2010); p. 445;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61984687&database=RX&origin=ReaxysOutput&ln=
,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)=CC(=C1)C(F)(F)F,10737140,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10737140&database=RX&origin=ReaxysOutput&ln=,(31 of 100),641571-10-0,nilotinib; AMN-107; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Tasigna; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; [Bodipy-FL]-Nilotinib,C28H22F3N7O,C28H22F3N7O,529.524,heterocyclic,,HHZIURLSWUIHRB-UHFFFAOYSA-N,,,,Identification(6110); Physical Data(56); Spectra(22); Bioactivity(866),129,6466,4.928,2,8,8,97.62,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,10737140,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10737140&database=RX&origin=ReaxysOutput&ln=,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)=CC(=C1)C(F)(F)F,Nilotinib,<= 10 µM,,,,inhibition percentage,,Not active,,,,,,,,1,,,73010; 506008; 506008; 8187252; 1719757,ATP; DMSO; DMSO; Tween 20; Dithiothreitol,CoEnzyme; Solvent; Solvent; Other compound; Other compound,Article; Manley PW; Drueckes P; Fendrich G; Furet P; Liebetanz J; Martiny-Baron G; Mestan J; Trappe J; Wartmann M; Fabbro D; Biochimica et Biophysica Acta - General Subjects; vol. 1804; (2010); p. 445;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61984687&database=RX&origin=ReaxysOutput&ln=
,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)=CC(=C1)C(F)(F)F,10737140,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10737140&database=RX&origin=ReaxysOutput&ln=,(31 of 100),641571-10-0,nilotinib; AMN-107; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Tasigna; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; [Bodipy-FL]-Nilotinib,C28H22F3N7O,C28H22F3N7O,529.524,heterocyclic,,HHZIURLSWUIHRB-UHFFFAOYSA-N,,,,Identification(6110); Physical Data(56); Spectra(22); Bioactivity(866),129,6466,4.928,2,8,8,97.62,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,Toxicity/Safety Pharmacology,Cell/tumor cell: proliferation/viability/growth,,,,,,Ba/F3 cell line,,10737140,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10737140&database=RX&origin=ReaxysOutput&ln=,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)=CC(=C1)C(F)(F)F,Nilotinib,< 3 µM,,,,inhibition percentage,,Not active,,,,,,,,1,,,,,,Article; Manley PW; Drueckes P; Fendrich G; Furet P; Liebetanz J; Martiny-Baron G; Mestan J; Trappe J; Wartmann M; Fabbro D; Biochimica et Biophysica Acta - General Subjects; vol. 1804; (2010); p. 445;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61984687&database=RX&origin=ReaxysOutput&ln=
,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)=CC(=C1)C(F)(F)F,10737140,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10737140&database=RX&origin=ReaxysOutput&ln=,(31 of 100),641571-10-0,nilotinib; AMN-107; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Tasigna; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; [Bodipy-FL]-Nilotinib,C28H22F3N7O,C28H22F3N7O,529.524,heterocyclic,,HHZIURLSWUIHRB-UHFFFAOYSA-N,,,,Identification(6110); Physical Data(56); Spectra(22); Bioactivity(866),129,6466,4.928,2,8,8,97.62,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,10737140,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10737140&database=RX&origin=ReaxysOutput&ln=,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)=CC(=C1)C(F)(F)F,AMN107,10 µM,,,,inhibition percentage,,Not active,,,,,,,,1,,,,,,"Article; Melnick, Jonathan S.; Janes, Jeff; Kim, Sungjoon; Chang, Jim Y.; Sipes, Daniel G.; Gunderson, Drew; Jarnes, Laura; Matzen, Jason T.; Garcia, Michael E.; Hood, Tami L.; Beigi, Ronak; Xia, Gang; Harig, Richard A.; Asatryan, Hayk; Yan, S. Frank; Zhou, Yingyao; Gu, Xiang-Ju; Saadat, Alham; Zhou, Vicki; King, Frederick J.; Shaw, Christopher M.; Su, Andrew I.; Downs, Robert; Gray, Nathanael S.; Schultz, Peter G.; Warmuth, Markus; Caldwell, Jeremy S.; Proceedings of the National Academy of Sciences of the United States of America; vol. 103; 9; (2006); p. 3153 - 3158;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20488268&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=CC=CC=C1SC1=CC=C2C(NN=C2\C=C\C2=NC=CC=C2)=C1,11333336,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11333336&database=RX&origin=ReaxysOutput&ln=,(32 of 100),319460-85-0,axitinib; AG-013736; N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide; (E)-N-methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole; (E)-axitinib; Inlyta,C22H18N4OS,C22H18N4OS,386.477,,,RITAVMQDGBJQJZ-FMIVXFBMSA-N,,,,Identification(6248); Physical Data(64); Spectra(38); Bioactivity(470),223,6454,4.715,2,5,6,95.97,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,11333336,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11333336&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=CC=CC=C1SC1=CC=C2C(NN=C2\C=C\C2=NC=CC=C2)=C1,AG-013736,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008,DMSO,Other compound,"Article; Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 29; 11; (2011); p. 1046 - 1051;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009910&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=CC=CC=C1SC1=CC=C2C(NN=C2\C=C\C2=NC=CC=C2)=C1,11333336,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11333336&database=RX&origin=ReaxysOutput&ln=,(32 of 100),319460-85-0,axitinib; AG-013736; N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide; (E)-N-methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole; (E)-axitinib; Inlyta,C22H18N4OS,C22H18N4OS,386.477,,,RITAVMQDGBJQJZ-FMIVXFBMSA-N,,,,Identification(6248); Physical Data(64); Spectra(38); Bioactivity(470),223,6454,4.715,2,5,6,95.97,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,11333336,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11333336&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=CC=CC=C1SC1=CC=C2C(NN=C2\C=C\C2=NC=CC=C2)=C1,103905539,3 nM,,,,pKi,,,5.7,,,,,,,5.7,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,CNC(=O)C1=CC=CC=C1SC1=CC=C2C(NN=C2\C=C\C2=NC=CC=C2)=C1,11333336,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11333336&database=RX&origin=ReaxysOutput&ln=,(32 of 100),319460-85-0,axitinib; AG-013736; N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide; (E)-N-methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole; (E)-axitinib; Inlyta,C22H18N4OS,C22H18N4OS,386.477,,,RITAVMQDGBJQJZ-FMIVXFBMSA-N,,,,Identification(6248); Physical Data(64); Spectra(38); Bioactivity(470),223,6454,4.715,2,5,6,95.97,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,11333336,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11333336&database=RX&origin=ReaxysOutput&ln=,CNC(=O)C1=CC=CC=C1SC1=CC=C2C(NN=C2\C=C\C2=NC=CC=C2)=C1,(E)-axitinib,1 μM,,,,inhibition percentage,%,,18,,,,,,,1,,,,,,"Article; Schmidt, Dorian; Rodat, Theo; Heintze, Linda; Weber, Jantje; Horbert, Rebecca; Girreser, Ulrich; Raeker, Tim; Bußmann, Lara; Kriegs, Malte; Hartke, Bernd; Peifer, Christian; ChemMedChem; vol. 13; 22; (2018); p. 2415 - 2426;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75377224&database=RX&origin=ReaxysOutput&ln=
,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,(33 of 100),183321-74-6,"erlotinib; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; Tarceva; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; OSI-774; [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine; 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazoline; erlotinib hydrochloride; CP-358774",C22H23N3O4,C22H23N3O4,393.442,heterocyclic,,AAKJLRGGTJKAMG-UHFFFAOYSA-N,,,,Identification(4700); Physical Data(76); Spectra(69); Bioactivity(2299),222,6340,2.704,1,5,10,74.73,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,Erlotinib,,,,,Kd (dissociation constant),nM,,1200,,,,,,,5.92,,,506008,DMSO,Other compound,"Article; Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 29; 11; (2011); p. 1046 - 1051;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009910&database=RX&origin=ReaxysOutput&ln=
,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,(33 of 100),183321-74-6,"erlotinib; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; Tarceva; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; OSI-774; [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine; 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazoline; erlotinib hydrochloride; CP-358774",C22H23N3O4,C22H23N3O4,393.442,heterocyclic,,AAKJLRGGTJKAMG-UHFFFAOYSA-N,,,,Identification(4700); Physical Data(76); Spectra(69); Bioactivity(2299),222,6340,2.704,1,5,10,74.73,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,Erlotinib,,,,,Kd (dissociation constant),nM,,1200,,,,,,,5.92,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,(33 of 100),183321-74-6,"erlotinib; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; Tarceva; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; OSI-774; [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine; 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazoline; erlotinib hydrochloride; CP-358774",C22H23N3O4,C22H23N3O4,393.442,heterocyclic,,AAKJLRGGTJKAMG-UHFFFAOYSA-N,,,,Identification(4700); Physical Data(76); Spectra(69); Bioactivity(2299),222,6340,2.704,1,5,10,74.73,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,103905339,3 nM,,,,pKi,,,5.6,,,,,,,5.6,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,(33 of 100),183321-74-6,"erlotinib; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; Tarceva; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; OSI-774; [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine; 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazoline; erlotinib hydrochloride; CP-358774",C22H23N3O4,C22H23N3O4,393.442,heterocyclic,,AAKJLRGGTJKAMG-UHFFFAOYSA-N,,,,Identification(4700); Physical Data(76); Spectra(69); Bioactivity(2299),222,6340,2.704,1,5,10,74.73,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,erlotinib,1 μM,,,inhibition (%),tested,,Not Published,,,,,,,,,,,,,,Patent; UNIVERSITY OF CALIFORNIA; ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI; US2014/243357; (2014); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64119421&database=RX&origin=ReaxysOutput&ln=
,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,(33 of 100),183321-74-6,"erlotinib; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; Tarceva; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; OSI-774; [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine; 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazoline; erlotinib hydrochloride; CP-358774",C22H23N3O4,C22H23N3O4,393.442,heterocyclic,,AAKJLRGGTJKAMG-UHFFFAOYSA-N,,,,Identification(4700); Physical Data(76); Spectra(69); Bioactivity(2299),222,6340,2.704,1,5,10,74.73,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,,,,,,pIC50,,=,6.03,,,,,,,6.03,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,(33 of 100),183321-74-6,"erlotinib; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; Tarceva; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; OSI-774; [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine; 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazoline; erlotinib hydrochloride; CP-358774",C22H23N3O4,C22H23N3O4,393.442,heterocyclic,,AAKJLRGGTJKAMG-UHFFFAOYSA-N,,,,Identification(4700); Physical Data(76); Spectra(69); Bioactivity(2299),222,6340,2.704,1,5,10,74.73,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,,,,,,pIC50,,=,5.6,,,,,,,5.6,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,(33 of 100),183321-74-6,"erlotinib; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; Tarceva; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; OSI-774; [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine; 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazoline; erlotinib hydrochloride; CP-358774",C22H23N3O4,C22H23N3O4,393.442,heterocyclic,,AAKJLRGGTJKAMG-UHFFFAOYSA-N,,,,Identification(4700); Physical Data(76); Spectra(69); Bioactivity(2299),222,6340,2.704,1,5,10,74.73,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,8798958,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8798958&database=RX&origin=ReaxysOutput&ln=,COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1,erlotinib,1 μM,,,,inhibition percentage,%,,5,,,,,,,1,,,,,,Patent; UNIVERSITY OF CALIFORNIA; (131 pag.)WO2016/22839; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68509258&database=RX&origin=ReaxysOutput&ln=
,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O,4279441,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D4279441&database=RX&origin=ReaxysOutput&ln=,(34 of 100),123948-87-8,topotecan; TPT; 9-(dimethylamino)methyl-10-hydroxycamptothecin; topotecan hydrochloride; Hycamtin; 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin,C23H23N3O5,C23H23N3O5,421.453,heterocyclic,,UCFGDBYHRUNTLO-QHCPKHFHSA-N,,,,Identification(5237); Physical Data(25); Spectra(34); Bioactivity(1236),55,5995,0.863,2,7,3,103.2,4,2,ALK tyrosine kinase receptor [human]; DNA topoisomerase 1 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + dna topoisomerase 1; dna topoisomerase i; top1,818511893 + 818289566,q9um73 + p11387,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1a31; 1a35; 1a36; 1ej9; 1k4s; 1k4t; 1lpq; 1nh3; 1r49; 1rr8; 1rrj; 1sc7; 1seu; 1t8i; 1tl8,,,ALK tyrosine kinase receptor [human]; DNA topoisomerase 1 [human],ALK tyrosine kinase receptor [human]:Wild; DNA topoisomerase 1 [human]:Wild,human; human,Non Transfected; Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,4279441,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D4279441&database=RX&origin=ReaxysOutput&ln=,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O,topotecan,0.5 mg/kg,intraperitoneal administration,Repeated,,TGI (tumor growth inhibition rate),,Active,,,,,,,,,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,7213017,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7213017&database=RX&origin=ReaxysOutput&ln=,(35 of 100),149647-78-9,vorinostat; saha; suberoylanilide hydroxamic acid; suberanilohydroxamic acid; N-hydroxy-N'-phenyloctanediamide; Zolinza; N-hydroxy-N’-phenyl-octanediamide; N-Hydroxy-N′-phenyloctanediamide; N1-hydroxy-N8-phenyloctanediamide; suberanoylhydroxamic acid; SML0061,C14H20N2O3,C14H20N2O3,264.324,isocyclic,,WAEXFXRVDQXREF-UHFFFAOYSA-N,,,,Identification(4181); Physical Data(64); Spectra(57); Bioactivity(3646),125,5968,1.852,3,3,10,78.43,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,phosphotransferase inhibitor,In Vitro (Efficacy),,,,,,,,,7213017,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7213017&database=RX&origin=ReaxysOutput&ln=,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,,10 nM,,,,inhibition rate,%,,12,,,,,,,,,,,,,"Article; Pan, Tao; Dan, Yanrong; Guo, Dafeng; Jiang, Junhao; Ran, Dongzhi; Zhang, Lin; Tian, Binghua; Yuan, Jianyong; Yu, Yu; Gan, Zongjie; European Journal of Medicinal Chemistry; vol. 224; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D93835987&database=RX&origin=ReaxysOutput&ln=
,CC1=C(CS(=O)C2=NC3=CC=CC=C3N2)N=CC=C1OCC(F)(F)F,4333393,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D4333393&database=RX&origin=ReaxysOutput&ln=,(36 of 100),103577-45-3,lansoprasole; Lansoprazole,C16H14F3O2N3S,C16H14F3N3O2S,369.367,heterocyclic,,MJIHNNLFOKEZEW-UHFFFAOYSA-N,,,,Identification(4693); Physical Data(44); Spectra(58); Bioactivity(793),132,5177,1.888,1,4,6,87.08,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,protein kinase inhibitor,In Vitro (Efficacy),,,,,,,,,4333393,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D4333393&database=RX&origin=ReaxysOutput&ln=,CC1=C(CS(=O)C2=NC3=CC=CC=C3N2)N=CC=C1OCC(F)(F)F,lansoprazole,100 μM,,,,inhibition rate,%,,0,,,,,,,,,,,,,"Article; Nassar, Husam;Abu-Dahab, Rana;Taha, Mutasem; Medicinal Chemistry Research; vol. 30; 12; (2021); p. 2266 - 2276;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D104842867&database=RX&origin=ReaxysOutput&ln=
,COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=CC(OC(F)F)=C3)=NC=C1,5361474,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D5361474&database=RX&origin=ReaxysOutput&ln=,(37 of 100),102625-70-7,"5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole; pantoprazole",C16H15F2N3O4S,C16H15F2N3O4S,383.376,heterocyclic,,IQPSEEYGBUAQFF-UHFFFAOYSA-N,,,,Identification(4762); Physical Data(27); Spectra(23); Bioactivity(486),57,5081,0.513,1,4,7,105.54,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,protein kinase inhibitor,In Vitro (Efficacy),,,,,,,,,5361474,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D5361474&database=RX&origin=ReaxysOutput&ln=,COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=CC(OC(F)F)=C3)=NC=C1,pantoprazole,100 μM,,,,inhibition rate,%,,0,,,,,,,,,,,,,"Article; Nassar, Husam;Abu-Dahab, Rana;Taha, Mutasem; Medicinal Chemistry Research; vol. 30; 12; (2021); p. 2266 - 2276;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D104842867&database=RX&origin=ReaxysOutput&ln=
,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,2056095,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2056095&database=RX&origin=ReaxysOutput&ln=,(38 of 100),56-53-1,diethylstilbestrol,C18H20O2,C18H20O2,268.356,isocyclic,,RGLYKWWBQGJZGM-ISLYRVAYSA-N,,,,Identification(4112); Physical Data(102); Spectra(48); Bioactivity(959),261,4732,5.556,2,0,4,40.46,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,2056095,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2056095&database=RX&origin=ReaxysOutput&ln=,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,CS(O)(=O)=O.CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,10229624,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10229624&database=RX&origin=ReaxysOutput&ln=,(39 of 100),,imatinib mesylate; gleevec; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate; STI571; imatinib; Glivec,C29H31N7O*CH4SO3,CH4O3S*C29H31N7O,589.718,heterocyclic,,YLMAHDNUQAMNNX-UHFFFAOYSA-N,,,,Identification(4074); Physical Data(95); Spectra(31); Bioactivity(785),28,4425,,3,11,8,149.03,1,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,10229624,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10229624&database=RX&origin=ReaxysOutput&ln=,CS(O)(=O)=O.CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,Imatinib,0.500000 µM,,,,inhibition percentage,%,,4.93,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,CS(O)(=O)=O.CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,10229624,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10229624&database=RX&origin=ReaxysOutput&ln=,(39 of 100),,imatinib mesylate; gleevec; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate; STI571; imatinib; Glivec,C29H31N7O*CH4SO3,CH4O3S*C29H31N7O,589.718,heterocyclic,,YLMAHDNUQAMNNX-UHFFFAOYSA-N,,,,Identification(4074); Physical Data(95); Spectra(31); Bioactivity(785),28,4425,,3,11,8,149.03,1,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,10229624,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10229624&database=RX&origin=ReaxysOutput&ln=,CS(O)(=O)=O.CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,Gleevac,10 µM,,,,inhibition percentage,%,,13,,,,,,,1,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,CS(O)(=O)=O.CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,10229624,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10229624&database=RX&origin=ReaxysOutput&ln=,(39 of 100),,imatinib mesylate; gleevec; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate; STI571; imatinib; Glivec,C29H31N7O*CH4SO3,CH4O3S*C29H31N7O,589.718,heterocyclic,,YLMAHDNUQAMNNX-UHFFFAOYSA-N,,,,Identification(4074); Physical Data(95); Spectra(31); Bioactivity(785),28,4425,,3,11,8,149.03,1,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,10229624,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10229624&database=RX&origin=ReaxysOutput&ln=,CS(O)(=O)=O.CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,Gleevac,1 µM,,,,inhibition percentage,%,,8,,,,,,,1,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,CS(O)(=O)=O.CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,10229624,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10229624&database=RX&origin=ReaxysOutput&ln=,(39 of 100),,imatinib mesylate; gleevec; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate; STI571; imatinib; Glivec,C29H31N7O*CH4SO3,CH4O3S*C29H31N7O,589.718,heterocyclic,,YLMAHDNUQAMNNX-UHFFFAOYSA-N,,,,Identification(4074); Physical Data(95); Spectra(31); Bioactivity(785),28,4425,,3,11,8,149.03,1,1,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,10229624,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10229624&database=RX&origin=ReaxysOutput&ln=,CS(O)(=O)=O.CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC(=CC=N3)C3=CC=CN=C3)=C2)CC1,Glivec (STI571),10 µM,,,,inhibition percentage,,Not active,,,,,,,,1,,,,,,"Article; Melnick, Jonathan S.; Janes, Jeff; Kim, Sungjoon; Chang, Jim Y.; Sipes, Daniel G.; Gunderson, Drew; Jarnes, Laura; Matzen, Jason T.; Garcia, Michael E.; Hood, Tami L.; Beigi, Ronak; Xia, Gang; Harig, Richard A.; Asatryan, Hayk; Yan, S. Frank; Zhou, Yingyao; Gu, Xiang-Ju; Saadat, Alham; Zhou, Vicki; King, Frederick J.; Shaw, Christopher M.; Su, Andrew I.; Downs, Robert; Gray, Nathanael S.; Schultz, Peter G.; Warmuth, Markus; Caldwell, Jeremy S.; Proceedings of the National Academy of Sciences of the United States of America; vol. 103; 9; (2006); p. 3153 - 3158;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20488268&database=RX&origin=ReaxysOutput&ln=
,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1,9161676,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9161676&database=RX&origin=ReaxysOutput&ln=,(40 of 100),443913-73-3,vandetanib; ZD-6474; Zactima; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; caprelsa; vandetinib,C22H24N4O2BrF,C22H24BrFN4O2,475.361,heterocyclic,,UHTHHESEBZOYNR-UHFFFAOYSA-N,,,,Identification(3843); Physical Data(38); Spectra(26); Bioactivity(442),27,4119,4.136,1,4,6,59.51,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,9161676,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9161676&database=RX&origin=ReaxysOutput&ln=,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1,Vandetanib,0.500000 µM,,,,inhibition percentage,%,,12.32,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1,9161676,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9161676&database=RX&origin=ReaxysOutput&ln=,(40 of 100),443913-73-3,vandetanib; ZD-6474; Zactima; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; caprelsa; vandetinib,C22H24N4O2BrF,C22H24BrFN4O2,475.361,heterocyclic,,UHTHHESEBZOYNR-UHFFFAOYSA-N,,,,Identification(3843); Physical Data(38); Spectra(26); Bioactivity(442),27,4119,4.136,1,4,6,59.51,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,9161676,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9161676&database=RX&origin=ReaxysOutput&ln=,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1,ZD-6474,,,,,Kd (dissociation constant),nM,,2100,,,,,,,5.68,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1,9161676,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9161676&database=RX&origin=ReaxysOutput&ln=,(40 of 100),443913-73-3,vandetanib; ZD-6474; Zactima; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; caprelsa; vandetinib,C22H24N4O2BrF,C22H24BrFN4O2,475.361,heterocyclic,,UHTHHESEBZOYNR-UHFFFAOYSA-N,,,,Identification(3843); Physical Data(38); Spectra(26); Bioactivity(442),27,4119,4.136,1,4,6,59.51,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,9161676,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9161676&database=RX&origin=ReaxysOutput&ln=,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1,103905338,3 nM,,,,pKi,,,5.8,,,,,,,5.8,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1,9161676,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9161676&database=RX&origin=ReaxysOutput&ln=,(40 of 100),443913-73-3,vandetanib; ZD-6474; Zactima; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; caprelsa; vandetinib,C22H24N4O2BrF,C22H24BrFN4O2,475.361,heterocyclic,,UHTHHESEBZOYNR-UHFFFAOYSA-N,,,,Identification(3843); Physical Data(38); Spectra(26); Bioactivity(442),27,4119,4.136,1,4,6,59.51,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,9161676,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9161676&database=RX&origin=ReaxysOutput&ln=,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1,vandetanib,,,,,IC50,nM,,2363.3,,,,,,,5.63,,,,,,Patent; CSPC PHARMACEUTICAL GROUP LIMITED; EP3181554; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71499679&database=RX&origin=ReaxysOutput&ln=
,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C,4338399,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D4338399&database=RX&origin=ReaxysOutput&ln=,(41 of 100),97322-87-7,Troglitazone,C24H27NO5S,C24H27NO5S,441.548,heterocyclic,,GXPHKUHSUJUWKP-UHFFFAOYSA-N,,,,Identification(3458); Physical Data(19); Spectra(14); Bioactivity(1230),45,4120,3.603,2,3,5,110.16,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),,Inhibitory activity of the compound against human ALK was determined by KinaseProfilerTM Assay,,,,,,,4338399,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D4338399&database=RX&origin=ReaxysOutput&ln=,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; ALTICOR GLOBAL HOLDINGS INC.; US2007/154576; (2007); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091755&database=RX&origin=ReaxysOutput&ln=
,[NH3][Pt]([NH3])(Cl)Cl,11324567,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11324567&database=RX&origin=ReaxysOutput&ln=,(42 of 100),15663-27-1,cisplatine; cisplatin; cDDP; DDP; cis-diamminedichloroplatinum II; cis-diamminedichloro platinum; (SP-4-2)-diammine(dichlorido)platinum(II); cis-diammineplatinum(II) dichloride; cis-diamine-dichloroplatinum (II); cis-dichloro-diammine platinum; cisplatinum; cis-diamminedichloridoplatinum(II); cis-DDP,Cl2H6N2Pt,Cl2H6N2Pt,300.047,Coordination compound,,LXZZYRPGZAFOLE-UHFFFAOYSA-L,,,,Identification(301); Physical Data(26); Spectra(31); Bioactivity(2511),99,3771,0.093,2,2,0,52.04,4,2,ALK tyrosine kinase receptor [human];+apoptosis regulator bcl-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + apoptosis regulator bcl-2; bcl2,818511893 + 818458014,q9um73 + p10415,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1g5m; 1gjh; 1ysw; 2o21; 2o22; 2o2f; 2w3l; 2xa0; 4aq3; 4ieh; 4lvt; 4lxd; 4man; 5agw; 5agx; 5fcg; 5jsn; 5vau; 5vax; 5vay; 6gl8; 6iwb; 6o0k; 6o0l; 6o0m; 6o0o; 6o0p; 7lhb,,,ALK tyrosine kinase receptor [human]; apoptosis regulator bcl-2 [human],ALK tyrosine kinase receptor [human]:Wild + apoptosis regulator bcl-2 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,A-549 cell line,,11324567,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11324567&database=RX&origin=ReaxysOutput&ln=,[NH3][Pt]([NH3])(Cl)Cl,cisplatin,,,,,IC50,μM,,62,,,,,,,4.21,,,,,,"Article; Mayakrishnan, Sivakalai;Kathirvelan, Devarajan;Arun, Yuvaraj;Saranraj, Krishnan;Balachandran, Chandrasekaran;Aoki, Shin;Yuvaraj, Pannerselvam;Maheswarai, Narayanan Uma; New Journal of Chemistry; vol. 46; 21; (2022); p. 10089 - 10106;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D117982892&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1,11404252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11404252&database=RX&origin=ReaxysOutput&ln=,(43 of 100),,cediranib; AZD2171; 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline; 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline; Recentin,C25H27FN4O3,C25H27FN4O3,450.513,,,XXJWYDDUDKYVKI-UHFFFAOYSA-N,,,,Identification(3521); Physical Data(8); Spectra(12); Bioactivity(276),21,3608,4.122,1,4,8,72.5,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,11404252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11404252&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1,AZD-2171,,,,,Kd (dissociation constant),nM,,2300,,,,,,,5.64,,,506008,DMSO,Other compound,"Article; Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 29; 11; (2011); p. 1046 - 1051;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009910&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1,11404252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11404252&database=RX&origin=ReaxysOutput&ln=,(43 of 100),,cediranib; AZD2171; 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline; 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline; Recentin,C25H27FN4O3,C25H27FN4O3,450.513,,,XXJWYDDUDKYVKI-UHFFFAOYSA-N,,,,Identification(3521); Physical Data(8); Spectra(12); Bioactivity(276),21,3608,4.122,1,4,8,72.5,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,11404252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11404252&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1,103905340,3 nM,,,,pKi,,,5.5,,,,,,,5.5,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,(44 of 100),302962-49-8,"dasatinib; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; BMS 354825; Sprycel; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; DAS",C22H26ClN7O2S,C22H26ClN7O2S,488.013,heterocyclic,,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,,,,Identification(2711); Physical Data(92); Spectra(65); Bioactivity(1259),298,3551,1.991,3,9,8,134.75,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,dasatinib,1 μM,,,inhibition (%),tested,,Not Published,,,,,,,,,,,,,,Patent; UNIVERSITY OF CALIFORNIA; ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI; US2014/243357; (2014); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64119421&database=RX&origin=ReaxysOutput&ln=
,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,(44 of 100),302962-49-8,"dasatinib; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; BMS 354825; Sprycel; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; DAS",C22H26ClN7O2S,C22H26ClN7O2S,488.013,heterocyclic,,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,,,,Identification(2711); Physical Data(92); Spectra(65); Bioactivity(1259),298,3551,1.991,3,9,8,134.75,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,,,,,,pIC50,,>,4.7,,,,,,,4.7,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,(44 of 100),302962-49-8,"dasatinib; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; BMS 354825; Sprycel; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; DAS",C22H26ClN7O2S,C22H26ClN7O2S,488.013,heterocyclic,,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,,,,Identification(2711); Physical Data(92); Spectra(65); Bioactivity(1259),298,3551,1.991,3,9,8,134.75,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,,,,,,pIC50,,>,5.3,,,,,,,5.3,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,(44 of 100),302962-49-8,"dasatinib; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; BMS 354825; Sprycel; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; DAS",C22H26ClN7O2S,C22H26ClN7O2S,488.013,heterocyclic,,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,,,,Identification(2711); Physical Data(92); Spectra(65); Bioactivity(1259),298,3551,1.991,3,9,8,134.75,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,dasatinib,1 μM,,,,inhibition percentage,%,,2,,,,,,,1,,,,,,Patent; UNIVERSITY OF CALIFORNIA; (131 pag.)WO2016/22839; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68509258&database=RX&origin=ReaxysOutput&ln=
,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,(44 of 100),302962-49-8,"dasatinib; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; BMS 354825; Sprycel; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; DAS",C22H26ClN7O2S,C22H26ClN7O2S,488.013,heterocyclic,,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,,,,Identification(2711); Physical Data(92); Spectra(65); Bioactivity(1259),298,3551,1.991,3,9,8,134.75,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,dasatinib,,,,,Ki (inhibition constant),μM,,5.79,,,,,,,5.24,,,,,,"Article; Herner, András; Marjanovic, Jasmina; Lewandowski, Tracey M.; Marin, Violeta; Patterson, Melanie; Miesbauer, Laura; Ready, Damien; Williams, Jon; Vasudevan, Anil; Lin, Qing; Journal of the American Chemical Society; vol. 138; 44; (2016); p. 14609 - 14615;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70006425&database=RX&origin=ReaxysOutput&ln=
,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,(44 of 100),302962-49-8,"dasatinib; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; BMS 354825; Sprycel; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; DAS",C22H26ClN7O2S,C22H26ClN7O2S,488.013,heterocyclic,,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,,,,Identification(2711); Physical Data(92); Spectra(65); Bioactivity(1259),298,3551,1.991,3,9,8,134.75,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,alveolar rhabdomyosarcoma cell line,,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,dasatinib,,,,,IC50,μM,,0.64,,,,,,,6.19,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,(44 of 100),302962-49-8,"dasatinib; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; BMS 354825; Sprycel; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; DAS",C22H26ClN7O2S,C22H26ClN7O2S,488.013,heterocyclic,,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,,,,Identification(2711); Physical Data(92); Spectra(65); Bioactivity(1259),298,3551,1.991,3,9,8,134.75,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,embryonal rhabdomyosarcoma cell line,,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,dasatinib,,,,,IC50,μM,,6.88,,,,,,,5.16,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,(44 of 100),302962-49-8,"dasatinib; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; BMS 354825; Sprycel; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; DAS",C22H26ClN7O2S,C22H26ClN7O2S,488.013,heterocyclic,,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,,,,Identification(2711); Physical Data(92); Spectra(65); Bioactivity(1259),298,3551,1.991,3,9,8,134.75,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,alveolar rhabdomyosarcoma cell line,,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,dasatinib,,,,,IC50,μM,,6.44,,,,,,,5.19,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,(44 of 100),302962-49-8,"dasatinib; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; BMS 354825; Sprycel; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; DAS",C22H26ClN7O2S,C22H26ClN7O2S,488.013,heterocyclic,,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,,,,Identification(2711); Physical Data(92); Spectra(65); Bioactivity(1259),298,3551,1.991,3,9,8,134.75,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,embryonal rhabdomyosarcoma cell line,,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,dasatinib,,,,,IC50,μM,,0.31,,,,,,,6.51,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,(44 of 100),302962-49-8,"dasatinib; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; BMS 354825; Sprycel; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; DAS",C22H26ClN7O2S,C22H26ClN7O2S,488.013,heterocyclic,,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,,,,Identification(2711); Physical Data(92); Spectra(65); Bioactivity(1259),298,3551,1.991,3,9,8,134.75,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,9966762,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9966762&database=RX&origin=ReaxysOutput&ln=,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1,N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide,1 μM,,,,percentage of remaining kinase activity,%,>,75,,,,,,,,,,,,,Patent; IOMX THERAPEUTICS AG; EP3901151; (2021); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D104926516&database=RX&origin=ReaxysOutput&ln=
,OC(=O)CCCC1=CC=CC=C1,638180,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D638180&database=RX&origin=ReaxysOutput&ln=,(45 of 100),1821-12-1,4-Phenylbutyric acid; 4-PBA; 4-phenylbutanoic acid; phenylbutyric acid; PBA,HOOCCH2CH2CH2C6H5,C10H12O2,164.204,isocyclic,,OBKXEAXTFZPCHS-UHFFFAOYSA-N,,,,Identification(2316); Physical Data(133); Spectra(93); Bioactivity(513),2225,3501,2.187,1,2,4,37.3,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,638180,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D638180&database=RX&origin=ReaxysOutput&ln=,OC(=O)CCCC1=CC=CC=C1,4-phenylbutyric acid,,,,Annexin V+/PI+ cells,percentage,%,,5.77,,,,,,,,,,,,,"Article; Gou, Wenfeng; Guo, Ming; Li, Zengqiang; Shen, Jiwei; Wu, Yingliang; Xu, Xiaobo; Zhai, Xin; Zhang, Xiaoning; Zhou, Xuejiao; Zuo, Daiying; Biochimica et Biophysica Acta - Molecular Cell Research; vol. 1867; 7; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79457678&database=RX&origin=ReaxysOutput&ln=
,OC(=O)CCCC1=CC=CC=C1,638180,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D638180&database=RX&origin=ReaxysOutput&ln=,(45 of 100),1821-12-1,4-Phenylbutyric acid; 4-PBA; 4-phenylbutanoic acid; phenylbutyric acid; PBA,HOOCCH2CH2CH2C6H5,C10H12O2,164.204,isocyclic,,OBKXEAXTFZPCHS-UHFFFAOYSA-N,,,,Identification(2316); Physical Data(133); Spectra(93); Bioactivity(513),2225,3501,2.187,1,2,4,37.3,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,638180,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D638180&database=RX&origin=ReaxysOutput&ln=,OC(=O)CCCC1=CC=CC=C1,4-phenylbutyric acid,,,,Annexin V+/PI- cells,percentage,%,,0.58,,,,,,,,,,,,,"Article; Gou, Wenfeng; Guo, Ming; Li, Zengqiang; Shen, Jiwei; Wu, Yingliang; Xu, Xiaobo; Zhai, Xin; Zhang, Xiaoning; Zhou, Xuejiao; Zuo, Daiying; Biochimica et Biophysica Acta - Molecular Cell Research; vol. 1867; 7; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79457678&database=RX&origin=ReaxysOutput&ln=
,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,9100307,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9100307&database=RX&origin=ReaxysOutput&ln=,(46 of 100),380843-75-4,"bosutinib; ski 606; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; bosulif; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; KIN001-160; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl) propoxy]quinoline-3-carbonitrile",C26H29Cl2N5O3,C26H29Cl2N5O3,530.454,heterocyclic,,UBPYILGKFZZVDX-UHFFFAOYSA-N,,,,Identification(2964); Physical Data(64); Spectra(20); Bioactivity(441),67,3222,3.635,1,5,9,82.88,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,9100307,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9100307&database=RX&origin=ReaxysOutput&ln=,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,Bosutinib,1 µM,,,,inhibition percentage,%,,68,,,,,,,6.33,,,73010; 73010,ATP; [33P]-ATP,CoEnzyme; Marker,Article; Remsing Rix; Rix; Colinge; Hantschel; Bennett; Stranzl; Mueller; Baumgartner; Valent; Augustin; Till; Superti-Furga; Leukemia; vol. 23; 3; (2009); p. 477 - 485;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D27119030&database=RX&origin=ReaxysOutput&ln=
,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,9100307,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9100307&database=RX&origin=ReaxysOutput&ln=,(46 of 100),380843-75-4,"bosutinib; ski 606; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; bosulif; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; KIN001-160; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl) propoxy]quinoline-3-carbonitrile",C26H29Cl2N5O3,C26H29Cl2N5O3,530.454,heterocyclic,,UBPYILGKFZZVDX-UHFFFAOYSA-N,,,,Identification(2964); Physical Data(64); Spectra(20); Bioactivity(441),67,3222,3.635,1,5,9,82.88,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,9100307,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9100307&database=RX&origin=ReaxysOutput&ln=,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,Bosutinib,10 µM,,,,inhibition percentage,%,,91,,,,,,,6,,,73010; 73010,ATP; [33P]-ATP,CoEnzyme; Marker,Article; Remsing Rix; Rix; Colinge; Hantschel; Bennett; Stranzl; Mueller; Baumgartner; Valent; Augustin; Till; Superti-Furga; Leukemia; vol. 23; 3; (2009); p. 477 - 485;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D27119030&database=RX&origin=ReaxysOutput&ln=
,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,9100307,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9100307&database=RX&origin=ReaxysOutput&ln=,(46 of 100),380843-75-4,"bosutinib; ski 606; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; bosulif; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; KIN001-160; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl) propoxy]quinoline-3-carbonitrile",C26H29Cl2N5O3,C26H29Cl2N5O3,530.454,heterocyclic,,UBPYILGKFZZVDX-UHFFFAOYSA-N,,,,Identification(2964); Physical Data(64); Spectra(20); Bioactivity(441),67,3222,3.635,1,5,9,82.88,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,9100307,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9100307&database=RX&origin=ReaxysOutput&ln=,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,SKI-606,,,,,Kd (dissociation constant),nM,,690,,,,,,,6.16,,,506008,DMSO,Other compound,"Article; Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 29; 11; (2011); p. 1046 - 1051;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009910&database=RX&origin=ReaxysOutput&ln=
,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,9100307,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9100307&database=RX&origin=ReaxysOutput&ln=,(46 of 100),380843-75-4,"bosutinib; ski 606; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; bosulif; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; KIN001-160; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl) propoxy]quinoline-3-carbonitrile",C26H29Cl2N5O3,C26H29Cl2N5O3,530.454,heterocyclic,,UBPYILGKFZZVDX-UHFFFAOYSA-N,,,,Identification(2964); Physical Data(64); Spectra(20); Bioactivity(441),67,3222,3.635,1,5,9,82.88,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,9100307,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9100307&database=RX&origin=ReaxysOutput&ln=,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,Bosutinib,0.500000 µM,,,,inhibition percentage,%,,34.01,,,,,,,6.01,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,9100307,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9100307&database=RX&origin=ReaxysOutput&ln=,(46 of 100),380843-75-4,"bosutinib; ski 606; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; bosulif; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; KIN001-160; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl) propoxy]quinoline-3-carbonitrile",C26H29Cl2N5O3,C26H29Cl2N5O3,530.454,heterocyclic,,UBPYILGKFZZVDX-UHFFFAOYSA-N,,,,Identification(2964); Physical Data(64); Spectra(20); Bioactivity(441),67,3222,3.635,1,5,9,82.88,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Sf9 cell line,,9100307,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9100307&database=RX&origin=ReaxysOutput&ln=,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,SKI-606,,,,,IC50,nM,,5720,1115,,,,,,5.24,,,73010; 73010; 506008,ATP; [33P]-ATP; DMSO,CoEnzyme; Marker; Solvent,"Article; Puttini, Miriam; Coluccia, Addolorata Maria Luce; Boschelli, Frank; Cleris, Loredana; Marchesi, Edoardo; Donella-Deana, Arianna; Ahmed, Shaheen; Redaelli, Sara; Piazza, Rocco; Magistroni, Vera; Andreoni, Federica; Scapozza, Leonardo; Formelli, Franca; Gambacorti-Passerini, Carlo; Cancer Research; vol. 66; 23; (2006); p. 11314 - 11322;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D23361330&database=RX&origin=ReaxysOutput&ln=
,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,9100307,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9100307&database=RX&origin=ReaxysOutput&ln=,(46 of 100),380843-75-4,"bosutinib; ski 606; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; bosulif; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; KIN001-160; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl) propoxy]quinoline-3-carbonitrile",C26H29Cl2N5O3,C26H29Cl2N5O3,530.454,heterocyclic,,UBPYILGKFZZVDX-UHFFFAOYSA-N,,,,Identification(2964); Physical Data(64); Spectra(20); Bioactivity(441),67,3222,3.635,1,5,9,82.88,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,Inhibitory concentration of the compound against the oncogenic nucleophosmin-anaplastic lymphoma kinase (NPM-ALK),,,,,,,9100307,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9100307&database=RX&origin=ReaxysOutput&ln=,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,,,,,,IC50,nM,~,150,,,,,,,6.82,,,,,,"Review; Li, Rongshi; Morris, Stephan W.; Medicinal Research Reviews; vol. 28; 3; (2008); p. 372 - 412;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25771579&database=RX&origin=ReaxysOutput&ln=
,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,(47 of 100),209783-80-2,Entinostat; MS-275; N-(2-aminophenyl)-4-[N-(pyridin-3-yl)methoxycarbonylaminomethyl]benzamide; SNDX-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]benzamide; 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]carbamate; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate,C21H20N4O3,C21H20N4O3,376.415,heterocyclic,,INVTYAOGFAGBOE-UHFFFAOYSA-N,,,,Identification(2700); Physical Data(26); Spectra(14); Bioactivity(640),32,3135,2.203,3,7,9,106.34,4,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,entinostat,,,,,IC50,μM,,2.54,,,,,,,5.6,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,(47 of 100),209783-80-2,Entinostat; MS-275; N-(2-aminophenyl)-4-[N-(pyridin-3-yl)methoxycarbonylaminomethyl]benzamide; SNDX-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]benzamide; 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]carbamate; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate,C21H20N4O3,C21H20N4O3,376.415,heterocyclic,,INVTYAOGFAGBOE-UHFFFAOYSA-N,,,,Identification(2700); Physical Data(26); Spectra(14); Bioactivity(640),32,3135,2.203,3,7,9,106.34,4,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,SK-N-BE(2) cell line,,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,entinostat,,,,,IC50,μM,,0.43,,,,,,,6.37,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,(47 of 100),209783-80-2,Entinostat; MS-275; N-(2-aminophenyl)-4-[N-(pyridin-3-yl)methoxycarbonylaminomethyl]benzamide; SNDX-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]benzamide; 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]carbamate; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate,C21H20N4O3,C21H20N4O3,376.415,heterocyclic,,INVTYAOGFAGBOE-UHFFFAOYSA-N,,,,Identification(2700); Physical Data(26); Spectra(14); Bioactivity(640),32,3135,2.203,3,7,9,106.34,4,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,A-549 cell line,,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,entinostat,,,,,IC50,μM,,3.2,,,,,,,5.49,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,(47 of 100),209783-80-2,Entinostat; MS-275; N-(2-aminophenyl)-4-[N-(pyridin-3-yl)methoxycarbonylaminomethyl]benzamide; SNDX-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]benzamide; 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]carbamate; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate,C21H20N4O3,C21H20N4O3,376.415,heterocyclic,,INVTYAOGFAGBOE-UHFFFAOYSA-N,,,,Identification(2700); Physical Data(26); Spectra(14); Bioactivity(640),32,3135,2.203,3,7,9,106.34,4,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,MDA-MB-231 cell line,,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,entinostat,,,,,IC50,μM,,2.51,,,,,,,5.6,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,(47 of 100),209783-80-2,Entinostat; MS-275; N-(2-aminophenyl)-4-[N-(pyridin-3-yl)methoxycarbonylaminomethyl]benzamide; SNDX-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]benzamide; 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]carbamate; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate,C21H20N4O3,C21H20N4O3,376.415,heterocyclic,,INVTYAOGFAGBOE-UHFFFAOYSA-N,,,,Identification(2700); Physical Data(26); Spectra(14); Bioactivity(640),32,3135,2.203,3,7,9,106.34,4,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,entinostat,,,,,IC50,μM,,8.83,,,,,,,5.05,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,(47 of 100),209783-80-2,Entinostat; MS-275; N-(2-aminophenyl)-4-[N-(pyridin-3-yl)methoxycarbonylaminomethyl]benzamide; SNDX-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]benzamide; 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]carbamate; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate,C21H20N4O3,C21H20N4O3,376.415,heterocyclic,,INVTYAOGFAGBOE-UHFFFAOYSA-N,,,,Identification(2700); Physical Data(26); Spectra(14); Bioactivity(640),32,3135,2.203,3,7,9,106.34,4,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,A-549 cell line,,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,entinostat,1 μM,,,,percentage of cells in G1 phase,%,,66.54,,,,,,,,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,(47 of 100),209783-80-2,Entinostat; MS-275; N-(2-aminophenyl)-4-[N-(pyridin-3-yl)methoxycarbonylaminomethyl]benzamide; SNDX-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]benzamide; 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]carbamate; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate,C21H20N4O3,C21H20N4O3,376.415,heterocyclic,,INVTYAOGFAGBOE-UHFFFAOYSA-N,,,,Identification(2700); Physical Data(26); Spectra(14); Bioactivity(640),32,3135,2.203,3,7,9,106.34,4,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,A-549 cell line,,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,entinostat,1 μM,,,,percentage of cells in G2 phase,%,,22.14,,,,,,,,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,(47 of 100),209783-80-2,Entinostat; MS-275; N-(2-aminophenyl)-4-[N-(pyridin-3-yl)methoxycarbonylaminomethyl]benzamide; SNDX-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]benzamide; 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]carbamate; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate,C21H20N4O3,C21H20N4O3,376.415,heterocyclic,,INVTYAOGFAGBOE-UHFFFAOYSA-N,,,,Identification(2700); Physical Data(26); Spectra(14); Bioactivity(640),32,3135,2.203,3,7,9,106.34,4,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,A-549 cell line,,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,entinostat,1 μM,,,,percentage of cells in S phase,%,,11.32,,,,,,,1,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,(47 of 100),209783-80-2,Entinostat; MS-275; N-(2-aminophenyl)-4-[N-(pyridin-3-yl)methoxycarbonylaminomethyl]benzamide; SNDX-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]benzamide; 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]carbamate; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate,C21H20N4O3,C21H20N4O3,376.415,heterocyclic,,INVTYAOGFAGBOE-UHFFFAOYSA-N,,,,Identification(2700); Physical Data(26); Spectra(14); Bioactivity(640),32,3135,2.203,3,7,9,106.34,4,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,entinostat,1 μM,,,,percentage of cells in G1 phase,%,,67.16,,,,,,,,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,(47 of 100),209783-80-2,Entinostat; MS-275; N-(2-aminophenyl)-4-[N-(pyridin-3-yl)methoxycarbonylaminomethyl]benzamide; SNDX-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]benzamide; 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]carbamate; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate,C21H20N4O3,C21H20N4O3,376.415,heterocyclic,,INVTYAOGFAGBOE-UHFFFAOYSA-N,,,,Identification(2700); Physical Data(26); Spectra(14); Bioactivity(640),32,3135,2.203,3,7,9,106.34,4,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,entinostat,1 μM,,,,percentage of cells in G2 phase,%,,8.82,,,,,,,,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,(47 of 100),209783-80-2,Entinostat; MS-275; N-(2-aminophenyl)-4-[N-(pyridin-3-yl)methoxycarbonylaminomethyl]benzamide; SNDX-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]benzamide; 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]carbamate; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate,C21H20N4O3,C21H20N4O3,376.415,heterocyclic,,INVTYAOGFAGBOE-UHFFFAOYSA-N,,,,Identification(2700); Physical Data(26); Spectra(14); Bioactivity(640),32,3135,2.203,3,7,9,106.34,4,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,8442710,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8442710&database=RX&origin=ReaxysOutput&ln=,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,entinostat,1 μM,,,,percentage of cells in S phase,%,,24.02,,,,,,,1,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,O=C1C=C(OC2=C1C=CC=C2C1=CC=CC=C1)N1CCOCC1,8156139,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8156139&database=RX&origin=ReaxysOutput&ln=,(48 of 100),154447-36-6,LY 294002; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 2-morpholin-4-yl-8-phenylchromen-4-one; 2-(4-morpholinyl)-8-phenylchromone; 2-(4-morpholino)-8-phenyl-4H-1-benzopyran-4-one; 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one; 2-morpholino-8-phenyl-4H-chromen-4-one; LY-29004; LY29400,C19H17O3N,C19H17NO3,307.349,heterocyclic,,CZQHHVNHHHRRDU-UHFFFAOYSA-N,,,,Identification(1229); Physical Data(7); Spectra(10); Bioactivity(1932),43,3043,4.04,0,3,2,38.77,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,8156139,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8156139&database=RX&origin=ReaxysOutput&ln=,O=C1C=C(OC2=C1C=CC=C2C1=CC=CC=C1)N1CCOCC1,LY 294002,0.500000 µM,,,,inhibition percentage,%,,7.65,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,O=C1C=C(OC2=C1C=CC=C2C1=CC=CC=C1)N1CCOCC1,8156139,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8156139&database=RX&origin=ReaxysOutput&ln=,(48 of 100),154447-36-6,LY 294002; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 2-morpholin-4-yl-8-phenylchromen-4-one; 2-(4-morpholinyl)-8-phenylchromone; 2-(4-morpholino)-8-phenyl-4H-1-benzopyran-4-one; 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one; 2-morpholino-8-phenyl-4H-chromen-4-one; LY-29004; LY29400,C19H17O3N,C19H17NO3,307.349,heterocyclic,,CZQHHVNHHHRRDU-UHFFFAOYSA-N,,,,Identification(1229); Physical Data(7); Spectra(10); Bioactivity(1932),43,3043,4.04,0,3,2,38.77,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,8156139,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8156139&database=RX&origin=ReaxysOutput&ln=,O=C1C=C(OC2=C1C=CC=C2C1=CC=CC=C1)N1CCOCC1,"Supporting Information, Table 3, LY294002",,,,,IC50,nM,,6.36,,,,,,,8.2,,,73010; 73010,ATP; [33P]-ATP,CoEnzyme; Marker,"Article; Reddy, M. V. Ramana; Akula, Balireddy; Cosenza, Stephen C.; Athuluridivakar, Saikrishna; Mallireddigari, Muralidhar R.; Pallela, Venkat R.; Billa, Vinay K.; Subbaiah, D. R. C. Venkata; Bharathi, E. Vijaya; Vasquez-Del Carpio, Rodrigo; Padgaonkar, Amol; Baker, Stacey J.; Reddy, E. Premkumar; Journal of Medicinal Chemistry; vol. 57; 3; (2014); p. 578 - 599;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D62891556&database=RX&origin=ReaxysOutput&ln=
,CCOC1=CC2=C(C=C1NC(=O)\C=C\CN(C)C)C(NC1=CC(Cl)=C(OCC3=NC=CC=C3)C=C1)=C(C=N2)C#N,9971763,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9971763&database=RX&origin=ReaxysOutput&ln=,(49 of 100),698387-09-6,neratinib; HKI-272; (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide; nerlynx; (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide,C30H29ClN6O3,C30H29ClN6O3,557.052,heterocyclic,,JWNPDZNEKVCWMY-VQHVLOKHSA-N,,,,Identification(2844); Physical Data(22); Spectra(13); Bioactivity(285),35,2993,3.866,2,7,12,112.4,3,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,9971763,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9971763&database=RX&origin=ReaxysOutput&ln=,CCOC1=CC2=C(C=C1NC(=O)\C=C\CN(C)C)C(NC1=CC(Cl)=C(OCC3=NC=CC=C3)C=C1)=C(C=N2)C#N,HKI-272,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008,DMSO,Other compound,"Article; Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 29; 11; (2011); p. 1046 - 1051;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009910&database=RX&origin=ReaxysOutput&ln=
,OC1=CC(\C=C\C2=CC=C(O)C(O)=C2)=CC(O)=C1,1879860,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1879860&database=RX&origin=ReaxysOutput&ln=,(50 of 100),10083-24-6,trans-piceatannol; piceatannol,C14H12O4,C14H12O4,244.247,isocyclic,,CDRPUGZCRXZLFL-OWOJBTEDSA-N,,,,Identification(2568); Physical Data(47); Spectra(142); Bioactivity(576),78,2909,3.193,4,0,2,80.92,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,1879860,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1879860&database=RX&origin=ReaxysOutput&ln=,OC1=CC(\C=C\C2=CC=C(O)C(O)=C2)=CC(O)=C1,103905107,3 nM,,,,pKi,,,6.6,,,,,,,6.6,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=C(O)C2=C(OC3=C(C=C(O)C(O)=C3)C2=O)C=C1O,65853,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D65853&database=RX&origin=ReaxysOutput&ln=,(51 of 100),4773-96-0,"mangiferin; 1,3,6,7-tetrahydroxyxanthone-C-2-β-D-glucoside; 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one; magniferin; 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxyxanthone; C2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxyxanthone; 1,3,6,7-tetrahydroxyxanthone-2-C-glucoside; mangiferine",C19H18O11,C19H18O11,422.345,heterocyclic,,AEDDIBAIWPIIBD-ZJKJAXBQSA-N,,,,Identification(2660); Physical Data(87); Spectra(212); Bioactivity(486),92,2878,-0.228,8,6,2,197.37,3,1,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against phosphorylation of peptide substrate by recombinant Anaplastic lymphoma kinase in presence of ATP upon incubation in 250 mM HEPES, pH 7.0 by homogeneous time resolved fluorescence (HTRF) assay",,,,,,,65853,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D65853&database=RX&origin=ReaxysOutput&ln=,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=C(O)C2=C(OC3=C(C=C(O)C(O)=C3)C2=O)C=C1O,,,,,,IC50,µM,=,0.81,,,,,,,6.09,,,,ATP,Other compound,"Article; Han, Sun-Young; Chin, Young-Won; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 26; 3; (2011); p. 445 - 448;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D32080675&database=RX&origin=ReaxysOutput&ln=
,[H][C@]12C[C@H]([C@@H](OC)[C@](C)(O1)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1,7345336,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7345336&database=RX&origin=ReaxysOutput&ln=,(52 of 100),,"N-benzoylstaurosporine; midostaurin; PKC-412; CGP41251; 4'-N-benzoylstaurosporine; staurosporine N-benzoyl; N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-benzamide; Rydapt",C35H30N4O4,C35H30N4O4,570.648,heterocyclic,,BMGQWWVMWDBQGC-IIFHNQTCSA-N,,,,Identification(2300); Physical Data(12); Spectra(9); Bioactivity(390),10,2474,7.797,1,8,4,77.73,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,7345336,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7345336&database=RX&origin=ReaxysOutput&ln=,[H][C@]12C[C@H]([C@@H](OC)[C@](C)(O1)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1,"N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methylbenzamide",0.3 nM - 10 μM,,,,IC50,μM,,0.645,,,,,,,6.19,,,,,,"Article; Manley, Paul W.; Caravatti, Giorgio; Furet, Pascal; Roesel, Johannes; Tran, Phi; Wagner, Trixie; Wartmann, Markus; Biochemistry; vol. 57; 38; (2018); p. 5576 - 5590;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74911412&database=RX&origin=ReaxysOutput&ln=
,[H][C@]12C[C@H]([C@@H](OC)[C@](C)(O1)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1,7345336,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7345336&database=RX&origin=ReaxysOutput&ln=,(52 of 100),,"N-benzoylstaurosporine; midostaurin; PKC-412; CGP41251; 4'-N-benzoylstaurosporine; staurosporine N-benzoyl; N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-benzamide; Rydapt",C35H30N4O4,C35H30N4O4,570.648,heterocyclic,,BMGQWWVMWDBQGC-IIFHNQTCSA-N,,,,Identification(2300); Physical Data(12); Spectra(9); Bioactivity(390),10,2474,7.797,1,8,4,77.73,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3-NPM-ALK cell line,,7345336,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7345336&database=RX&origin=ReaxysOutput&ln=,[H][C@]12C[C@H]([C@@H](OC)[C@](C)(O1)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1,"N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methylbenzamide",,,,,GI50,nM,,364,,,,,,,6.44,,,,,,"Article; Manley, Paul W.; Caravatti, Giorgio; Furet, Pascal; Roesel, Johannes; Tran, Phi; Wagner, Trixie; Wartmann, Markus; Biochemistry; vol. 57; 38; (2018); p. 5576 - 5590;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74911412&database=RX&origin=ReaxysOutput&ln=
,CC[C@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=CC=C2)=N1,7694281,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7694281&database=RX&origin=ReaxysOutput&ln=,(53 of 100),186692-46-6,roscovitine; seliciclib; (R)-roscovitine; CYC202; roscovitin; 6-benzylamino-2-[(R)-1-ethyl-2-hydroxyethylamino]-9-isopropylpurine; 2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; (R)-2-((6-(benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol,C19H26N6O,C19H26N6O,354.455,heterocyclic,,BTIHMVBBUGXLCJ-OAHLLOKOSA-N,,,,Identification(2186); Physical Data(19); Spectra(16); Bioactivity(1256),8,2458,3.506,3,7,8,87.89,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,7694281,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7694281&database=RX&origin=ReaxysOutput&ln=,CC[C@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=CC=C2)=N1,Roscovitine,0.500000 µM,,,,inhibition percentage,%,,4.39,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,CC[C@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=CC=C2)=N1,7694281,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7694281&database=RX&origin=ReaxysOutput&ln=,(53 of 100),186692-46-6,roscovitine; seliciclib; (R)-roscovitine; CYC202; roscovitin; 6-benzylamino-2-[(R)-1-ethyl-2-hydroxyethylamino]-9-isopropylpurine; 2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; (R)-2-((6-(benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol,C19H26N6O,C19H26N6O,354.455,heterocyclic,,BTIHMVBBUGXLCJ-OAHLLOKOSA-N,,,,Identification(2186); Physical Data(19); Spectra(16); Bioactivity(1256),8,2458,3.506,3,7,8,87.89,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,7694281,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7694281&database=RX&origin=ReaxysOutput&ln=,CC[C@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=CC=C2)=N1,Roscovitine/CYC-202,,,,,Kd (dissociation constant),nM,,2300,,,,,,,5.64,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,CC[C@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=CC=C2)=N1,7694281,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7694281&database=RX&origin=ReaxysOutput&ln=,(53 of 100),186692-46-6,roscovitine; seliciclib; (R)-roscovitine; CYC202; roscovitin; 6-benzylamino-2-[(R)-1-ethyl-2-hydroxyethylamino]-9-isopropylpurine; 2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; (R)-2-((6-(benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol,C19H26N6O,C19H26N6O,354.455,heterocyclic,,BTIHMVBBUGXLCJ-OAHLLOKOSA-N,,,,Identification(2186); Physical Data(19); Spectra(16); Bioactivity(1256),8,2458,3.506,3,7,8,87.89,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Sf9 cell line,,7694281,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7694281&database=RX&origin=ReaxysOutput&ln=,CC[C@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=CC=C2)=N1,Roscovitine,,,,,IC50,µM,,65,,,,,,,4.19,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; PEG-20000,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Sroka, Irene M.; Heiss, Elke H.; Havlicek, Libor; Totzke, Frank; Aristei, Yasmin; Pechan, Paul; Kubbutat, Michael H. G.; Strnad, Miroslav; Dirsch, Verena M.; Molecular Pharmacology; vol. 77; 2; (2010); p. 255 - 261;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20013330&database=RX&origin=ReaxysOutput&ln=
,CC[C@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=CC=C2)=N1,7694281,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7694281&database=RX&origin=ReaxysOutput&ln=,(53 of 100),186692-46-6,roscovitine; seliciclib; (R)-roscovitine; CYC202; roscovitin; 6-benzylamino-2-[(R)-1-ethyl-2-hydroxyethylamino]-9-isopropylpurine; 2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; (R)-2-((6-(benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol,C19H26N6O,C19H26N6O,354.455,heterocyclic,,BTIHMVBBUGXLCJ-OAHLLOKOSA-N,,,,Identification(2186); Physical Data(19); Spectra(16); Bioactivity(1256),8,2458,3.506,3,7,8,87.89,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,7694281,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7694281&database=RX&origin=ReaxysOutput&ln=,CC[C@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=CC=C2)=N1,Roscovitine,1 µM,,,,inhibition percentage,%,,16,,,,,,,1,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,CC[C@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=CC=C2)=N1,7694281,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7694281&database=RX&origin=ReaxysOutput&ln=,(53 of 100),186692-46-6,roscovitine; seliciclib; (R)-roscovitine; CYC202; roscovitin; 6-benzylamino-2-[(R)-1-ethyl-2-hydroxyethylamino]-9-isopropylpurine; 2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; (R)-2-((6-(benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol,C19H26N6O,C19H26N6O,354.455,heterocyclic,,BTIHMVBBUGXLCJ-OAHLLOKOSA-N,,,,Identification(2186); Physical Data(19); Spectra(16); Bioactivity(1256),8,2458,3.506,3,7,8,87.89,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,7694281,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7694281&database=RX&origin=ReaxysOutput&ln=,CC[C@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=CC=C2)=N1,Roscovitine,10 µM,,,,inhibition percentage,%,,57,,,,,,,5.12,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,,,,,IC50,nM,,2.3,,,,,,,8.64,,,73010,ATP,CoEnzyme,Patent; GUANGDONG NEWOPP BIOPHARMACEUTICALS; WO2013/13308; (2013); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D35460980&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,"Staurosporine, Streptomyces sp.",0.500000 µM,,,,inhibition percentage,%,,99.14,,,,,,,7.58,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,10 µM,,,,inhibition percentage,%,,97.89,,,,,,,6.28,,,73010; 8187252; 1719757,ATP; Tween 20; Dithiothreitol,CoEnzyme; Other compound; Other compound,Article; Xu F; Jia Y; Wen Q; Wang X; Zhang L; Zhang Y; Yang K; Xu W; European Journal of Medicinal Chemistry; vol. 64; (2013); p. 377 - 388;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61986930&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,,,,,Kd (dissociation constant),nM,,32,,,,,,,7.49,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,30 nM,,,,inhibition percentage,%,,93.8,,,,,,,8.7,,,73010; 506008; 8187252; 1719757,ATP; DMSO; Tween 20; Dithiothreitol,CoEnzyme; Solvent; Other compound; Other compound,Patent; SIENNA BIOPHARMACEUTICALS INC; BIO 3 RESEARCH; WO2006/10628; (2006); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D392302&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,3.00000E-05 µM,,,,IC50,nM,,1 - 100,,,,,,,9,,,2114647; 73010; 1719757,Triton X100; ATP; Dithiothreitol,Other compound; CoEnzyme; Other compound,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D35487146&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,30 nM,,,,inhibition percentage,%,,93.85,,,,,,,8.71,,,73010; 506008,ATP; DMSO,CoEnzyme; Solvent,Patent; AVRO LIFE SCIENCES; WO2007/22999; (2007); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D428230&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Sf9 cell line,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,0 µM,,,,IC50,nM,~,300,,,,,,,6.52,,,506008,DMSO,Solvent,Patent; FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI; EP1454992; (2004); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D345929&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Sf9 cell line,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,1 µM,,,,inhibition percentage,%,,100,,,,,,,7.28,,,506008,DMSO,Solvent,Patent; FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI; EP1454992; (2004); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D345929&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,,,,,IC50,nM,,2.71,,,,,,,8.57,,,,,,"Article; Kim, Mi-Hyun; Kim, Minjung; Yu, Hana; Kim, Hwan; Yoo, Kyung Ho; Sim, Taebo; Hah, Jung-Mi; Bioorganic and Medicinal Chemistry; vol. 19; 6; (2011); p. 1915 - 1923;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D9021135&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,10 µM,,,,inhibition percentage,%,,94,,,,,,,6.19,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,1 µM,,,,inhibition percentage,%,,97,,,,,,,7.28,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,,,,,IC50,nM,,2.36,,,,,,,8.63,,,,,,"Article; Andreani, Aldo; Granaiola, Massimiliano; Leoni, Alberto; Locatelli, Alessandra; Morigi, Rita; Rambaldi, Mirella; Varoli, Lucilla; Lannigan, Deborah; Smith, Jeff; Scudiero, Dominic; Kondapaka, Sudhir; Shoemaker, Robert H.; European Journal of Medicinal Chemistry; vol. 46; 9; (2011); p. 4311 - 4323;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20030103&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Sf21 cell line,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,Ki (inhibition constant),nM,,5.56,0.750000,,,,,,8.25,,,73010; 73010; 1719757,ATP; [33P]-ATP; Dithiothreitol,CoEnzyme; Marker; Other compound,"Article; Bossi, Roberto T.; Saccardo, M. Beatrice; Ardini, Elena; Menichincheri, Maria; Rusconi, Luisa; Magnaghi, Paola; Orsini, Paolo; Avanzi, Nilla; Borgia, Andrea Lombardi; Nesi, Marcella; Bandiera, Tiziano; Fogliatto, Gianpaolo; Bertrand, Jay A.; Biochemistry; vol. 49; 32; (2010); p. 6813 - 6825;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D8995706&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Sf9 cell line,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,,,,,IC50,nM,,150,41,,,,,,6.82,,,73010; 73010,ATP; [32P]-ATP,CoEnzyme; Marker,"Article; Gunby, Rosalind Helen; Tartari, Carmen Julia; Porchia, Francesca; Donella-Deana, Arianna; Scapozza, Leonardo; Gambacorti-Passerini, Carlo; Haematologica; vol. 90; 7; (2005); p. 988 - 990;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D22672230&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Sf9 cell line,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,,,,,IC50,nM,,678,21,,,,,,6.17,,,73010,ATP,CoEnzyme,"Article; Gunby, Rosalind Helen; Tartari, Carmen Julia; Porchia, Francesca; Donella-Deana, Arianna; Scapozza, Leonardo; Gambacorti-Passerini, Carlo; Haematologica; vol. 90; 7; (2005); p. 988 - 990;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D22672230&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Sf9 cell line,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,0 µM,,,,IC50,nM,,123,,,,,,,6.91,,,73010; 73010,ATP; [32P]-ATP,CoEnzyme; Marker,"Article; Gunby, Rosalind Helen; Tartari, Carmen Julia; Porchia, Francesca; Donella-Deana, Arianna; Scapozza, Leonardo; Gambacorti-Passerini, Carlo; Haematologica; vol. 90; 7; (2005); p. 988 - 990;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D22672230&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,"In vitro inhibitory concentration of the compound against ALK (5-10 mU) using 0.66 mg/ml myelin basic protein as substrate and 500 cpm/pmol [GAMMA-33P]ATP as radio ligand upon incubation in 25 mM Tris buffer, pH 7.5 for 40 minutes at RT was determined",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,11,,,,,,,7.96,,,,MYELIN BASIC PROTEIN; [GAMMA-33P]ATP,Substrate; Radioligand,"Article; El-Gamal, Mohammed I.; Oh, Chang-Hyun; Bulletin of the Korean Chemical Society; vol. 33; 5; (2012); p. 1571 - 1576;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20163773&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,Inhibitory concentration of compound against ALK,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,3,,,,,,,8.52,,,,,,"Conference Paper; Kim, Hyangmi; Kim, Minjung; Lee, Junghun; Yu, Hana; Hah, Jung-Mi; Bioorganic and Medicinal Chemistry; vol. 19; 22; (2011); p. 6760 - 6767;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20060258&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,"table 4, compound staurosporine",,,,,IC50,µM,,0.03,,,,,,,7.52,,,,,,"Article; El Amrani, Mustapha; Lai, Daowan; Debbab, Abdessamad; Aly, Amal H.; Siems, Karsten; Seidel, Carole; Schnekenburger, Michael; Gaigneaux, Anthoula; Diederich, Marc; Feger, Daniel; Lin, Wenhan; Proksch, Peter; Journal of Natural Products; vol. 77; 1; (2014); p. 49 - 56;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D62567567&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,"Percent inhibition of ALK upon incubation with 10 uM compound in Hepes/Tris buffer, pH 7.4 for 30 min at RT",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,= 10 µM,,,,inhibition percentage,%,=,97.89,,,,,,,6.28,,,,,,"Article; Xu, Fuming; Jia, Yuping; Wen, Qingli; Wang, Xuejian; Zhang, Lei; Zhang, Yingjie; Yang, Kanghui; Xu, Wenfang; European Journal of Medicinal Chemistry; vol. 64; (2013); p. 377 - 388;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D35743216&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,1 μM,,,inhibition (%),tested,,Not Published,,,,,,,,,,,,,,Patent; UNIVERSITY OF CALIFORNIA; ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI; US2014/243357; (2014); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64119421&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of compound against Anaplastic lymphoma kinase ( R1275Q ),,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,27.4,,,,,,,7.56,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of compound against Anaplastic lymphoma kinase ( L1196M ),,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,4.5,,,,,,,8.35,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of compound against Anaplastic lymphoma kinase ( F1174L ),,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,8.1,,,,,,,8.09,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,1.361,,,,,,,8.87,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,1.817,,,,,,,8.74,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,2.249,,,,,,,8.65,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,2.393,,,,,,,8.62,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,0.254,,,,,,,9.6,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,0.002,,,,,,,11.7,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,3.435,,,,,,,8.46,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,3.533,,,,,,,8.45,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,3.674,,,,,,,8.44,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,4.179,,,,,,,8.38,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,4.6,,,,,,,8.34,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,5.192,,,,,,,8.28,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,6.072,,,,,,,8.22,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,6.176,,,,,,,8.21,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against Anaplastic lymphoma kinase upon incubation for 30 min at RT in 50 mM HEPES, pH 7.5 in presence of 5 uM ATP using poly-GT as substrate",,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,0.714,,,,,,,9.15,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of compound against Anaplastic lymphoma kinase ( GTx-ALK ),,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,µM,=,0.002,,,,,,,8.7,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of compound against wild type Anaplastic lymphoma kinase,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,=,7.1,,,,,,,8.15,,,,,,Patent; CHEMBRIDGE CORPORATION; ONCTERNAL THERAPEUTICS INC; US2012/65233; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091179&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK kinase,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,nM,<,1,,,,,,,9,,,,,,"Article; Im, Daseul; Jung, Kyungjin; Yang, Songyi; Aman, Waqar; Hah, Jung-Mi; European Journal of Medicinal Chemistry; vol. 102; (2015); p. 600 - 610;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D66992999&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,1 μM,,,,inhibition percentage,%,,97,,,,,,,7.28,,,,,,Patent; UNIVERSITY OF CALIFORNIA; (131 pag.)WO2016/22839; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68509258&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,nM,,6.7,,,,,,,8.17,,,,,,"Article; Zhao, Junjun; Fang, Lei; Zhang, Xiaobing; Liang, Yan; Gou, Shaohua; Bioorganic and Medicinal Chemistry; vol. 24; 16; (2016); p. 3483 - 3493;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69262010&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,20 - 200 μM,,,,IC50,M,,2.23E-09,,,,,,,8.65,,,73010,ATP,Other compound,"Article; Beesu, Mallesh; Caruso, Giuseppe; Salyer, Alex C. D.; Shukla, Nijunj M.; Khetani, Karishma K.; Smith, Luke J.; Fox, Lauren M.; Tanji, Hiromi; Ohto, Umeharu; Shimizu, Toshiyuki; David, Sunil A.; Journal of Medicinal Chemistry; vol. 59; 7; (2016); p. 3311 - 3330;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68846612&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,c,1156,y",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,μM,,0.0017,,,,,,,8.77,,,,,,"Article; Mah, Shinmee; Park, Jung Hee; Jung, Hoi-Yun; Ahn, Kukcheol; Choi, Soyeon; Tae, Hyun Seop; Jung, Kyung Hee; Rho, Jin Kyung; Lee, Jae Cheol; Hong, Soon-Sun; Hong, Sungwoo; Journal of Medicinal Chemistry; vol. 60; 22; (2017); p. 9205 - 9221;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72672148&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,nM,,1.7 - 0.0019,,,,,,,8.77,,,73010,ATP,Other compound,"Article; Mah, Shinmee; Park, Jung Hee; Jung, Hoi-Yun; Ahn, Kukcheol; Choi, Soyeon; Tae, Hyun Seop; Jung, Kyung Hee; Rho, Jin Kyung; Lee, Jae Cheol; Hong, Soon-Sun; Hong, Sungwoo; Journal of Medicinal Chemistry; vol. 60; 22; (2017); p. 9205 - 9221;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72672148&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,nM,,0.67 - 0.00078,,,,,,,9.17,,,73010,ATP,Other compound,"Article; Mah, Shinmee; Park, Jung Hee; Jung, Hoi-Yun; Ahn, Kukcheol; Choi, Soyeon; Tae, Hyun Seop; Jung, Kyung Hee; Rho, Jin Kyung; Lee, Jae Cheol; Hong, Soon-Sun; Hong, Sungwoo; Journal of Medicinal Chemistry; vol. 60; 22; (2017); p. 9205 - 9221;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72672148&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,f,1174,l",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,μM,,0.0016,,,,,,,8.8,,,,,,"Article; Mah, Shinmee; Park, Jung Hee; Jung, Hoi-Yun; Ahn, Kukcheol; Choi, Soyeon; Tae, Hyun Seop; Jung, Kyung Hee; Rho, Jin Kyung; Lee, Jae Cheol; Hong, Soon-Sun; Hong, Sungwoo; Journal of Medicinal Chemistry; vol. 60; 22; (2017); p. 9205 - 9221;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72672148&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1269,a",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,μM,,0.00074,,,,,,,9.13,,,,,,"Article; Mah, Shinmee; Park, Jung Hee; Jung, Hoi-Yun; Ahn, Kukcheol; Choi, Soyeon; Tae, Hyun Seop; Jung, Kyung Hee; Rho, Jin Kyung; Lee, Jae Cheol; Hong, Soon-Sun; Hong, Sungwoo; Journal of Medicinal Chemistry; vol. 60; 22; (2017); p. 9205 - 9221;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72672148&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1152,r",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,μM,,0.0029,,,,,,,8.54,,,,,,"Article; Mah, Shinmee; Park, Jung Hee; Jung, Hoi-Yun; Ahn, Kukcheol; Choi, Soyeon; Tae, Hyun Seop; Jung, Kyung Hee; Rho, Jin Kyung; Lee, Jae Cheol; Hong, Soon-Sun; Hong, Sungwoo; Journal of Medicinal Chemistry; vol. 60; 22; (2017); p. 9205 - 9221;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72672148&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,μM,,0.0038,,,,,,,8.42,,,,,,"Article; Mah, Shinmee; Park, Jung Hee; Jung, Hoi-Yun; Ahn, Kukcheol; Choi, Soyeon; Tae, Hyun Seop; Jung, Kyung Hee; Rho, Jin Kyung; Lee, Jae Cheol; Hong, Soon-Sun; Hong, Sungwoo; Journal of Medicinal Chemistry; vol. 60; 22; (2017); p. 9205 - 9221;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72672148&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,nM,,1.7,,,,,,,8.77,,,,,,"Article; Hawkinson, Jon E.; Sinville, Rondedrick; Mudaliar, Deepti; Shetty, Jagathpala; Ward, Timothy; Herr, John C.; Georg, Gunda I.; ChemMedChem; vol. 12; 22; (2017); p. 1857 - 1865;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72656874&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,M,,1.81E-09,,,,,,,8.74,,,,,,"Article; Jeffries, Daniel E.; Lindsley, Craig W.; Journal of Organic Chemistry; vol. 82; 1; (2017); p. 431 - 437;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71061227&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,nM,,7.1,,,,,,,8.15,,,,,,"Article; Gao, Jun-Bo; Yang, Shuang-Jing; Yan, Zi-Ru; Zhang, Xing-Jie; Pu, De-Bing; Wang, Li-Xia; Li, Xiao-Li; Zhang, Rui-Han; Xiao, Wei-Lie; Journal of Natural Products; vol. 81; 4; (2018); p. 998 - 1006;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73687991&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,M,,1.44E-09,,,,,,,8.84,,,,,,"Article; Bernard-Gauthier, Vadim; Bailey, Justin J.; Mossine, Andrew V.; Lindner, Simon; Vomacka, Lena; Aliaga, Arturo; Shao, Xia; Quesada, Carole A.; Sherman, Phillip; Mahringer, Anne; Kostikov, Alexey; Grand'Maison, Marilyn; Rosa-Neto, Pedro; Soucy, Jean-Paul; Thiel, Alexander; Kaplan, David R.; Fricker, Gert; Wängler, Björn; Bartenstein, Peter; Schirrmacher, Ralf; Scott, Peter J. H.; Journal of Medicinal Chemistry; vol. 60; 16; (2017); p. 6897 - 6910;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71972906&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,30 nM,,,,inhibition percentage,%,,93.8,,,,,,,8.7,,,73010,ATP,Other compound,Patent; AVRO LIFE SCIENCES; EP1919979; (2017); B2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975494&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,<= 100 μM,,,,IC50,M,,1.09E-09,,,,,,,8.96,,,73010,ATP,Substrate,"Article; Hou, Weijie; Ren, Yan; Zhang, Zhenhua; Sun, Huan; Ma, Yongfen; Yan, Bo; Bioorganic and Medicinal Chemistry; vol. 26; 8; (2018); p. 1740 - 1750;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73309700&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,1.00000E-11 M,,,,IC50,nM,,1.61,,,,,,,8.79,,,1719757; 506008; 73010; 8187252,Dithiothreitol; DMSO; ATP; Tween 20,Other compound; Solvent; CoEnzyme; Other compound,Patent; CHEMBRIDGE CORPORATION; WO2009/117097; (2009); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D8780206&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,Inhibitory activity of compound against ALK was determined,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; GUANGDONG NEWOPP BIOPHARMACEUTICALS; WO2013/113097; (2013); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D38051440&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,<= 20 μM,,,,IC50,M,,2.86E-09,,,,,,,8.54,,,73010,ATP,Other compound,"Article; Abbott, Jason R.; Patel, Pratiq A.; Howes, Jennifer E.; Akan, Denis T.; Kennedy, J. Phillip; Burns, Michael C.; Browning, Carrie F.; Sun, Qi; Rossanese, Olivia W.; Phan, Jason; Waterson, Alex G.; Fesik, Stephen W.; ACS Medicinal Chemistry Letters; vol. 9; 9; (2018); p. 941 - 946;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74738457&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,stuarosporine,,,,,IC50,M,,1.97E-09,,,,,,,8.71,,,,,,"Article; Harris, Philip A.; Faucher, Nicolas; George, Nicolas; Eidam, Patrick M.; King, Bryan W.; White, Gemma V.; Anderson, Niall A.; Bandyopadhyay, Deepak; Beal, Allison M.; Beneton, Veronique; Berger, Scott B.; Campobasso, Nino; Campos, Sebastien; Capriotti, Carol A.; Cox, Julie A.; Daugan, Alain; Donche, Frederic; Fouchet, Marie-Hélène; Finger, Joshua N.; Geddes, Brad; Gough, Peter J.; Grondin, Pascal; Hoffman, Bonnie L.; Hoffman, Sandra J.; Hutchinson, Susan E.; Jeong, Jae U.; Jigorel, Emilie; Lamoureux, Pauline; Leister, Lara K.; Lich, John D.; Mahajan, Mukesh K.; Meslamani, Jamel; Mosley, Julie E.; Nagilla, Rakesh; Nassau, Pamela M.; Ng, Sze-Ling; Ouellette, Michael T.; Pasikanti, Kishore K.; Potvain, Florent; Reilly, Michael A.; Rivera, Elizabeth J.; Sautet, Stéphane; Schaeffer, Michelle C.; Sehon, Clark A.; Sun, Helen; Thorpe, James H.; Totoritis, Rachel D.; Ward, Paris; Wellaway, Natalie; Wisnoski, David D.; Woolven, James M.; Bertin, John; Marquis, Robert W.; Journal of Medicinal Chemistry; vol. 62; 10; (2019); p. 5096 - 5110;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76648539&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,M,,2.45E-09,,,,,,,8.61,,,,,,"Article; Nguyen, William; Jacobson, Jonathan; Jarman, Kate E.; Jousset Sabroux, Helene; Harty, Leigh; McMahon, James; Lewin, Sharon R.; Purcell, Damian F.; Sleebs, Brad E.; Journal of Medicinal Chemistry; vol. 62; 10; (2019); p. 5148 - 5175;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76713084&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,M,,1.91E-09,,,,,,,8.72,,,,,,"Article; Harris, Philip A.; Marinis, Jill M.; Lich, John D.; Berger, Scott B.; Chirala, Anirudh; Cox, Julie A.; Eidam, Patrick M.; Finger, Joshua N.; Gough, Peter J.; Jeong, Jae U.; Kang, James; Kasparcova, Viera; Leister, Lara K.; Mahajan, Mukesh K.; Miller, George; Nagilla, Rakesh; Ouellette, Michael T.; Reilly, Michael A.; Rendina, Alan R.; Rivera, Elizabeth J.; Sun, Helen H.; Thorpe, James H.; Totoritis, Rachel D.; Wang, Wei; Wu, Dongling; Zhang, Daohua; Bertin, John; Marquis, Robert W.; ACS Medicinal Chemistry Letters; vol. 10; 6; (2019); p. 857 - 862;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77039396&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,M,,2.98E-09,,,,,,,8.53,,,73010,ATP,Other compound,"Article; Amin, Shantu; Jaiswal, Aruna S.; Law, Brian K.; Narayan, Satya; Ramisetti, Srinivasa; Sharma, Arun K.; Singh, Parvesh; Singh-Pillay, Ashona; European Journal of Medicinal Chemistry; vol. 161; (2019); p. 456 - 467;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75265030&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,M,,1.52E-09,,,,,,,8.82,,,73010,ATP,Substrate,"Article; Blobaum, Anna L.; Borza, Corina M.; Jeffries, Daniel E.; Lindsley, Craig W.; Pozzi, Ambra; ACS Medicinal Chemistry Letters; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D78618745&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,protein kinase inhibitor,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,M,,2.45E-09,,,,,,,8.61,,,,,,"Article; Blackmore, Timothy R.; Jacobson, Jonathan; Jarman, Kate E.; Lewin, Sharon R.; Nguyen, William; Purcell, Damian F.; Sabroux, Helene Jousset; Sleebs, Brad E.; European Journal of Medicinal Chemistry; vol. 195; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79450658&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,20 - 100 μM,,,,IC50,μM,,1.98E-09,,,,,,,,,,,,,"Article; Li, Bo; Li, Wei; Li, Xue; Quan, Xu; Tan, Bin; Zhang, Xiaomeng; Zhao, Liwen; Zheng, Guochuang; Bioorganic and medicinal chemistry letters; vol. 30; 16; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80038982&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,,,,,,IC50,M,,2.06E-09,,,,,,,8.69,,,,,,"Article; Thakur, Ashish; Tawa, Gregory J.; Henderson, Mark J.; Danchik, Carina; Liu, Suiyang; Shah, Pranav; Wang, Amy Q.; Dunn, Garrett; Kabir, Md; Padilha, Elias C.; Xu, Xin; Simeonov, Anton; Kharbanda, Surender; Stone, Richard; Grewal, Gurmit; Journal of Medicinal Chemistry; vol. 63; 8; (2020); p. 4256 - 4292;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79839792&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,enzyme inhibitor,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,20 - 100 μM,,,,IC50,M,,1.35E-09,,,,,,,8.87,,,,,,"Article; Wang, Junwei;He, Guangchao;Li, Hui;Ge, Yiran;Wang, Shuping;Xu, Yungen;Zhu, Qihua; European Journal of Medicinal Chemistry; vol. 213; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81811251&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,M,,2.763E-09,,,,,,,8.56,,,,,,"Article; Yu, Mingfeng;Long, Yi;Yang, Yuchao;Li, Manjun;Teo, Theodosia;Noll, Benjamin;Philip, Stephen;Wang, Shudong; European Journal of Medicinal Chemistry; vol. 218; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D83636309&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,M,,2.56E-09,,,,,,,8.59,,,,,,"Article; Huang, Jianhang; Wang, Xinren; Dong, Ruinan; Liu, Xiaoyue; Li, Hongmei; Zhang, Tianyi; Xu, Junyu; Liu, Chenhe; Zhang, Yanmin; Hou, Shaohua; Tang, Weifang; Lu, Tao; Chen, Yadong; Journal of Medicinal Chemistry; vol. 64; 17; (2021); p. 12548 - 12571;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D99665570&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,7.63E-11 - 2.00E-05 M,,,,activity percentage,%,,-2.85 - 81.36,,,,,,,,,,,,,"Article; Becker, Cora; Fleischmann, Bernd K.; Forster, Michael; Freitag, Patricia; Hesse, Michael; Laufer, Stefan; Lohmann, Stefan; Schade, Dennis; Sievers, Sonja; Carrillo García, Carmen; Journal of Medicinal Chemistry; vol. 65; 2; (2022); p. 1505 - 1524;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D108172753&database=RX&origin=ReaxysOutput&ln=
,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,(54 of 100),62996-74-1,"staurosporine; staurosporin; Sts; stausporine; STSP; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3’,2’, 1’-lm]pyrrolo[3,4-j][1 ,7]benzodiazonin-1-one; [9S-(9α,10β,11β,13α)]-2,3,10,11,12,13-hexa-hydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-g,h:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; straurosporine",C28H26N4O3,C28H26N4O3,466.539,heterocyclic,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,,,,Identification(147); Physical Data(18); Spectra(30); Bioactivity(3053),154,2410,6.052,2,7,2,69.45,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,6674025,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D6674025&database=RX&origin=ReaxysOutput&ln=,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,staurosporine,,,,,IC50,nM,,5.5,,,,,,,8.26,,,,,,"Article; Cheng, Yanfang; Wang, Qian; Zhang, Zhikang; Zhao, Chao; Zhou, Huihao; Xu, Jun; Gu, Qiong; Phytomedicine; vol. 101; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D117165381&database=RX&origin=ReaxysOutput&ln=
,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2,5482739,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D5482739&database=RX&origin=ReaxysOutput&ln=,(55 of 100),103745-39-7,fasudil; 1-(5-isoquinolinesulfonyl)homopiperazine; HA-1077,C14H17N3O2S,C14H17N3O2S,291.374,heterocyclic,,NGOGFTYYXHNFQH-UHFFFAOYSA-N,,,,Identification(2183); Physical Data(5); Spectra(13); Bioactivity(435),95,2385,0.886,1,5,2,70.68,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,5482739,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D5482739&database=RX&origin=ReaxysOutput&ln=,O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2,103905390,3 nM,,,,pKi,,<,5.2,,,,,,,5.2,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,8638800,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8638800&database=RX&origin=ReaxysOutput&ln=,(56 of 100),212141-54-3,vatalanib; PTK 787; 1-(4-chloro-anilino)-4-(pyridin-4-yl-methyl)-phthalazine,C20H15ClN4,C20H15ClN4,346.819,heterocyclic,,YCOYDOIWSSHVCK-UHFFFAOYSA-N,,,,Identification(2234); Physical Data(3); Spectra(5); Bioactivity(332),13,2332,4.36,1,4,4,50.7,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,8638800,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8638800&database=RX&origin=ReaxysOutput&ln=,ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,Vatalanib,0.500000 µM,,,,inhibition percentage,%,,-1.78,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,8638800,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8638800&database=RX&origin=ReaxysOutput&ln=,(56 of 100),212141-54-3,vatalanib; PTK 787; 1-(4-chloro-anilino)-4-(pyridin-4-yl-methyl)-phthalazine,C20H15ClN4,C20H15ClN4,346.819,heterocyclic,,YCOYDOIWSSHVCK-UHFFFAOYSA-N,,,,Identification(2234); Physical Data(3); Spectra(5); Bioactivity(332),13,2332,4.36,1,4,4,50.7,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,8638800,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8638800&database=RX&origin=ReaxysOutput&ln=,ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,PTK-787,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,8638800,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8638800&database=RX&origin=ReaxysOutput&ln=,(56 of 100),212141-54-3,vatalanib; PTK 787; 1-(4-chloro-anilino)-4-(pyridin-4-yl-methyl)-phthalazine,C20H15ClN4,C20H15ClN4,346.819,heterocyclic,,YCOYDOIWSSHVCK-UHFFFAOYSA-N,,,,Identification(2234); Physical Data(3); Spectra(5); Bioactivity(332),13,2332,4.36,1,4,4,50.7,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,8638800,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8638800&database=RX&origin=ReaxysOutput&ln=,ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,PTK-787,10 µM,,,,inhibition percentage,%,,1,,,,,,,1,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,8638800,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8638800&database=RX&origin=ReaxysOutput&ln=,(56 of 100),212141-54-3,vatalanib; PTK 787; 1-(4-chloro-anilino)-4-(pyridin-4-yl-methyl)-phthalazine,C20H15ClN4,C20H15ClN4,346.819,heterocyclic,,YCOYDOIWSSHVCK-UHFFFAOYSA-N,,,,Identification(2234); Physical Data(3); Spectra(5); Bioactivity(332),13,2332,4.36,1,4,4,50.7,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,8638800,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8638800&database=RX&origin=ReaxysOutput&ln=,ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,PTK-787,1 µM,,,,inhibition percentage,%,,8,,,,,,,1,,,73010; 73010,ATP; ATP; Brij-35 detergent,CoEnzyme; CoEnzyme; Other compound,"Article; Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.; Nature Chemical Biology; vol. 4; 11; (2008); p. 691 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25250782&database=RX&origin=ReaxysOutput&ln=
,ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,8638800,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8638800&database=RX&origin=ReaxysOutput&ln=,(56 of 100),212141-54-3,vatalanib; PTK 787; 1-(4-chloro-anilino)-4-(pyridin-4-yl-methyl)-phthalazine,C20H15ClN4,C20H15ClN4,346.819,heterocyclic,,YCOYDOIWSSHVCK-UHFFFAOYSA-N,,,,Identification(2234); Physical Data(3); Spectra(5); Bioactivity(332),13,2332,4.36,1,4,4,50.7,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,8638800,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8638800&database=RX&origin=ReaxysOutput&ln=,ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,103905548,3 nM,,,,pKi,,<,5.4,,,,,,,5.4,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,8638800,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8638800&database=RX&origin=ReaxysOutput&ln=,(56 of 100),212141-54-3,vatalanib; PTK 787; 1-(4-chloro-anilino)-4-(pyridin-4-yl-methyl)-phthalazine,C20H15ClN4,C20H15ClN4,346.819,heterocyclic,,YCOYDOIWSSHVCK-UHFFFAOYSA-N,,,,Identification(2234); Physical Data(3); Spectra(5); Bioactivity(332),13,2332,4.36,1,4,4,50.7,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Inhibitor,,In Vitro (Efficacy),,Inhibitory activity against human Anaplastic lymphoma kinase at a compound concentration 10uM,human,,,,,,8638800,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8638800&database=RX&origin=ReaxysOutput&ln=,ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,,,,,,inhibition percentage,%,=,68,,,,,,,,,,,,,"Article; Hess-Stunnpp, Holger; Haberey, Martin; Thierauch, Karl-Heinz; ChemBioChem; vol. 6; 3; (2005); p. 550 - 557;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D22551325&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,ibrutinib,0.3 μM,,,,inhibition percentage,%,,-1.8,,,,,,,1,,,,,,"Article; Kawahata, Wataru; Asami, Tokiko; Kiyoi, Takao; Irie, Takayuki; Taniguchi, Haruka; Asamitsu, Yuko; Inoue, Tomoko; Miyake, Takahiro; Sawa, Masaaki; Journal of Medicinal Chemistry; vol. 61; 19; (2018); p. 8917 - 8933;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75078448&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,ibrutinib,0.3 μM,,,,inhibition percentage,%,,-1.1,,,,,,,1,,,,,,"Article; Kawahata, Wataru; Asami, Tokiko; Kiyoi, Takao; Irie, Takayuki; Taniguchi, Haruka; Asamitsu, Yuko; Inoue, Tomoko; Miyake, Takahiro; Sawa, Masaaki; Journal of Medicinal Chemistry; vol. 61; 19; (2018); p. 8917 - 8933;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75078448&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,ALK tyrosine kinase receptor:Wild; Echinoderm microtubule-associated protein-like 4:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,ibrutinib,0.3 μM,,,,inhibition percentage,%,,-5,,,,,,,1,,,,,,"Article; Kawahata, Wataru; Asami, Tokiko; Kiyoi, Takao; Irie, Takayuki; Taniguchi, Haruka; Asamitsu, Yuko; Inoue, Tomoko; Miyake, Takahiro; Sawa, Masaaki; Journal of Medicinal Chemistry; vol. 61; 19; (2018); p. 8917 - 8933;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75078448&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor; Nucleophosmin,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + npm; npm1; nucleolar phosphoprotein b23; nucleolar protein no38; nucleophosmin; numatrin,820152764 + 820016608,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Nucleophosmin,ALK tyrosine kinase receptor:Wild; Nucleophosmin:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,ibrutinib,0.3 μM,,,,inhibition percentage,%,,-1.6,,,,,,,1,,,,,,"Article; Kawahata, Wataru; Asami, Tokiko; Kiyoi, Takao; Irie, Takayuki; Taniguchi, Haruka; Asamitsu, Yuko; Inoue, Tomoko; Miyake, Takahiro; Sawa, Masaaki; Journal of Medicinal Chemistry; vol. 61; 19; (2018); p. 8917 - 8933;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75078448&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NBL-S cell line,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,ibrutinib,10 μM,,,,percentage of viable cells decrease,,High,,,,,,,,,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,SH-SY5Y cell line,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,ibrutinib,2.5 μM,,,,percentage of viable cells decrease,,Low,,,,,,,,,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,ibrutinib,20 mg/kg,intraperitoneal administration,Repeated,,tumor volume decrease,,High,,,,,,,,,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NBL-S cell line,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,ibrutinib,,,,cleaved,protein expression level increase,,Active,,,,Caspase-3,,,,,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,apoptosis inducing factor,In Vivo (Animal models),,,,,,,,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,ibrutinib,20 mg/kg,intraperitoneal administration,Repeated,cleaved,protein expression level increase,,High,,,,Caspase-3,,,,,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,ibrutinib,2.5 μM,,,,percentage of cells in G0/G1 phase,%,,73.75,,,,,,,6.05,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,ibrutinib,2.5 μM,,,,apoptotic cell percentage,%,,18.8,,,,,,,,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,ibrutinib,,,,,IC50,μM,>,10,,,,,,,1,,,,,,"Article; Pulz, Robert; Angst, Daniela; Dawson, Janet; Gessier, Francois; Gutmann, Sascha; Hersperger, Rene; Hinniger, Alexandra; Janser, Philipp; Koch, Guido; Revesz, Laszlo; Vulpetti, Anna; Waelchli, Rudolf; Zimmerlin, Alfred; Cenni, Bruno; ACS Medicinal Chemistry Letters; vol. 10; 10; (2019); p. 1467 - 1472;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77846181&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,,10 μM,,,,percentage of control,%,,56,,,,,,,,,,,,,"Article; Ma, Bin; Bohnert, Tonika; Otipoby, Kevin L.; Tien, Eric; Arefayene, Million; Bai, Judy; Bajrami, Bekim; Bame, Eris; Chan, Timothy R.; Humora, Michael; Macphee, J. Michael; Marcotte, Douglas; Mehta, Devangi; Metrick, Claire M.; Moniz, George; Polack, Evelyne; Poreci, Urjana; Prefontaine, Annick; Sheikh, Sarah; Schroeder, Patricia; Smirnakis, Karen; Zhang, Lei; Zheng, Fengmei; Hopkins, Brian T.; Journal of Medicinal Chemistry; vol. 63; 21; (2020); p. 12526 - 12541;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81880466&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,c,1156,y",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,,10 μM,,,,percentage of control,%,,100,,,,,,,,,,,,,"Article; Ma, Bin; Bohnert, Tonika; Otipoby, Kevin L.; Tien, Eric; Arefayene, Million; Bai, Judy; Bajrami, Bekim; Bame, Eris; Chan, Timothy R.; Humora, Michael; Macphee, J. Michael; Marcotte, Douglas; Mehta, Devangi; Metrick, Claire M.; Moniz, George; Polack, Evelyne; Poreci, Urjana; Prefontaine, Annick; Sheikh, Sarah; Schroeder, Patricia; Smirnakis, Karen; Zhang, Lei; Zheng, Fengmei; Hopkins, Brian T.; Journal of Medicinal Chemistry; vol. 63; 21; (2020); p. 12526 - 12541;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81880466&database=RX&origin=ReaxysOutput&ln=
,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,(57 of 100),,"ibrutinib; PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine -1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; IBR",C25H24N6O2,C25H24N6O2,440.505,,,XYFPWWZEPKGCCK-GOSISDBHSA-N,,,,Identification(1830); Physical Data(152); Spectra(73); Bioactivity(606),185,2311,4.115,1,7,6,99.16,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,13102252,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D13102252&database=RX&origin=ReaxysOutput&ln=,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,,10 μM,,,,percentage of control,%,,100,,,,,,,,,,,,,"Article; Ma, Bin; Bohnert, Tonika; Otipoby, Kevin L.; Tien, Eric; Arefayene, Million; Bai, Judy; Bajrami, Bekim; Bame, Eris; Chan, Timothy R.; Humora, Michael; Macphee, J. Michael; Marcotte, Douglas; Mehta, Devangi; Metrick, Claire M.; Moniz, George; Polack, Evelyne; Poreci, Urjana; Prefontaine, Annick; Sheikh, Sarah; Schroeder, Patricia; Smirnakis, Karen; Zhang, Lei; Zheng, Fengmei; Hopkins, Brian T.; Journal of Medicinal Chemistry; vol. 63; 21; (2020); p. 12526 - 12541;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81880466&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,(58 of 100),442-51-3,"harmine; 7-methoxy-1-methyl-9H-pyrido[3,4-b]indole; 7-methoxy-1-methyl-β-carboline; 1-methyl-7-methoxy-β-carboline",CH3OC11H6N2CH3,C13H12N2O,212.251,heterocyclic,,BXNJHAXVSOCGBA-UHFFFAOYSA-N,,,,Identification(1801); Physical Data(97); Spectra(180); Bioactivity(587),728,2259,2.509,1,2,1,37.91,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,Binding affinity towards ALK expressed in T7 bacteriophage derived from Escherichia coli BL21 upon incubation with 10 uM compound (dissolved in DMSO) for 1 hour at RT measured as Affinity score,,,,,,,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,,,,,Selectivity Score,number,,,100,,,,,,,,,,,,,"Article; Tahtouh, Tania; Elkins, Jonathan M.; Filippakopoulos, Panagis; Soundararajan, Meera; Burgy, Guillaume; Durieu, Emilie; Cochet, Claude; Schmid, Ralf S.; Lo, Donald C.; Delhommel, Florent; Oberholzer, Anselm E.; Pearl, Laurence H.; Carreaux, François; Bazureau, Jean-Pierre; Knapp, Stefan; Meijer, Laurent; Journal of Medicinal Chemistry; vol. 55; 21; (2012); p. 9312 - 9330;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D35314663&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,(58 of 100),442-51-3,"harmine; 7-methoxy-1-methyl-9H-pyrido[3,4-b]indole; 7-methoxy-1-methyl-β-carboline; 1-methyl-7-methoxy-β-carboline",CH3OC11H6N2CH3,C13H12N2O,212.251,heterocyclic,,BXNJHAXVSOCGBA-UHFFFAOYSA-N,,,,Identification(1801); Physical Data(97); Spectra(180); Bioactivity(587),728,2259,2.509,1,2,1,37.91,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,harmine,10 μM,,,,inhibition percentage,%,,8,,,,,,,1,,,,,,"Article; Kumar, Kunal; Wang, Peng; Sanchez, Roberto; Swartz, Ethan A; Stewart, Andrew F.; Devita, Robert J.; Journal of Medicinal Chemistry; vol. 61; 17; (2018); p. 7687 - 7699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74883482&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,(58 of 100),442-51-3,"harmine; 7-methoxy-1-methyl-9H-pyrido[3,4-b]indole; 7-methoxy-1-methyl-β-carboline; 1-methyl-7-methoxy-β-carboline",CH3OC11H6N2CH3,C13H12N2O,212.251,heterocyclic,,BXNJHAXVSOCGBA-UHFFFAOYSA-N,,,,Identification(1801); Physical Data(97); Spectra(180); Bioactivity(587),728,2259,2.509,1,2,1,37.91,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,c,1156,y",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,harmine,10 μM,,,,inhibition percentage,%,,13,,,,,,,1,,,,,,"Article; Kumar, Kunal; Wang, Peng; Sanchez, Roberto; Swartz, Ethan A; Stewart, Andrew F.; Devita, Robert J.; Journal of Medicinal Chemistry; vol. 61; 17; (2018); p. 7687 - 7699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74883482&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,(58 of 100),442-51-3,"harmine; 7-methoxy-1-methyl-9H-pyrido[3,4-b]indole; 7-methoxy-1-methyl-β-carboline; 1-methyl-7-methoxy-β-carboline",CH3OC11H6N2CH3,C13H12N2O,212.251,heterocyclic,,BXNJHAXVSOCGBA-UHFFFAOYSA-N,,,,Identification(1801); Physical Data(97); Spectra(180); Bioactivity(587),728,2259,2.509,1,2,1,37.91,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,harmine,10 μM,,,,inhibition percentage,%,,0,,,,,,,1,,,,,,"Article; Kumar, Kunal; Wang, Peng; Sanchez, Roberto; Swartz, Ethan A; Stewart, Andrew F.; Devita, Robert J.; Journal of Medicinal Chemistry; vol. 61; 17; (2018); p. 7687 - 7699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74883482&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,(58 of 100),442-51-3,"harmine; 7-methoxy-1-methyl-9H-pyrido[3,4-b]indole; 7-methoxy-1-methyl-β-carboline; 1-methyl-7-methoxy-β-carboline",CH3OC11H6N2CH3,C13H12N2O,212.251,heterocyclic,,BXNJHAXVSOCGBA-UHFFFAOYSA-N,,,,Identification(1801); Physical Data(97); Spectra(180); Bioactivity(587),728,2259,2.509,1,2,1,37.91,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,harmine,10 μM,,,,inhibition rate,%,,8,,,,,,,,,,,,,"Article; Kumar, Kunal; Wang, Peng; Wilson, Jessica; Zlatanic, Viktor; Berrouet, Cecilia; Khamrui, Susmita; Secor, Cody; Swartz, Ethan A.; Lazarus, Michael; Sanchez, Roberto; Stewart, Andrew F.; Garcia-Ocana, Adolfo; Devita, Robert J.; Journal of Medicinal Chemistry; vol. 63; 6; (2020); p. 2986 - 3003;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79525382&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,(58 of 100),442-51-3,"harmine; 7-methoxy-1-methyl-9H-pyrido[3,4-b]indole; 7-methoxy-1-methyl-β-carboline; 1-methyl-7-methoxy-β-carboline",CH3OC11H6N2CH3,C13H12N2O,212.251,heterocyclic,,BXNJHAXVSOCGBA-UHFFFAOYSA-N,,,,Identification(1801); Physical Data(97); Spectra(180); Bioactivity(587),728,2259,2.509,1,2,1,37.91,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,c,1156,y",,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,harmine,10 μM,,,,inhibition rate,%,,13,,,,,,,,,,,,,"Article; Kumar, Kunal; Wang, Peng; Wilson, Jessica; Zlatanic, Viktor; Berrouet, Cecilia; Khamrui, Susmita; Secor, Cody; Swartz, Ethan A.; Lazarus, Michael; Sanchez, Roberto; Stewart, Andrew F.; Garcia-Ocana, Adolfo; Devita, Robert J.; Journal of Medicinal Chemistry; vol. 63; 6; (2020); p. 2986 - 3003;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79525382&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,(58 of 100),442-51-3,"harmine; 7-methoxy-1-methyl-9H-pyrido[3,4-b]indole; 7-methoxy-1-methyl-β-carboline; 1-methyl-7-methoxy-β-carboline",CH3OC11H6N2CH3,C13H12N2O,212.251,heterocyclic,,BXNJHAXVSOCGBA-UHFFFAOYSA-N,,,,Identification(1801); Physical Data(97); Spectra(180); Bioactivity(587),728,2259,2.509,1,2,1,37.91,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,178813,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D178813&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,harmine,10 μM,,,,inhibition rate,%,,0,,,,,,,,,,,,,"Article; Kumar, Kunal; Wang, Peng; Wilson, Jessica; Zlatanic, Viktor; Berrouet, Cecilia; Khamrui, Susmita; Secor, Cody; Swartz, Ethan A.; Lazarus, Michael; Sanchez, Roberto; Stewart, Andrew F.; Garcia-Ocana, Adolfo; Devita, Robert J.; Journal of Medicinal Chemistry; vol. 63; 6; (2020); p. 2986 - 3003;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79525382&database=RX&origin=ReaxysOutput&ln=
,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,5857899,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D5857899&database=RX&origin=ReaxysOutput&ln=,(59 of 100),50679-08-8,terfenadine; terfenedine,C32H41NO2,C32H41NO2,471.683,heterocyclic,,GUGOEEXESWIERI-UHFFFAOYSA-N,,,,Identification(1631); Physical Data(59); Spectra(30); Bioactivity(609),20,2234,7.105,2,3,9,43.7,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,5857899,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D5857899&database=RX&origin=ReaxysOutput&ln=,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,CN1C(=O)N(C2=C1C=NC1=CC=C(C=C21)C1=CC2=CC=CC=C2N=C1)C1=CC=C(C=C1)C(C)(C)C#N,12748665,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12748665&database=RX&origin=ReaxysOutput&ln=,(60 of 100),,"2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile; BEZ235; dactolisib; NVP-BEZ235; 2-methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile; 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile",C30H23N5O,C30H23N5O,469.546,,,JOGKUKXHTYWRGZ-UHFFFAOYSA-N,,,,Identification(1871); Physical Data(19); Spectra(17); Bioactivity(257),20,2060,4.918,0,6,3,73.12,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,12748665,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12748665&database=RX&origin=ReaxysOutput&ln=,CN1C(=O)N(C2=C1C=NC1=CC=C(C=C21)C1=CC2=CC=CC=C2N=C1)C1=CC=C(C=C1)C(C)(C)C#N,103905146,3 nM,,,,pKi,,,6.1,,,,,,,6.1,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,CN1C(=O)N(C2=C1C=NC1=CC=C(C=C21)C1=CC2=CC=CC=C2N=C1)C1=CC=C(C=C1)C(C)(C)C#N,12748665,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12748665&database=RX&origin=ReaxysOutput&ln=,(60 of 100),,"2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile; BEZ235; dactolisib; NVP-BEZ235; 2-methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile; 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile",C30H23N5O,C30H23N5O,469.546,,,JOGKUKXHTYWRGZ-UHFFFAOYSA-N,,,,Identification(1871); Physical Data(19); Spectra(17); Bioactivity(257),20,2060,4.918,0,6,3,73.12,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,12748665,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12748665&database=RX&origin=ReaxysOutput&ln=,CN1C(=O)N(C2=C1C=NC1=CC=C(C=C21)C1=CC2=CC=CC=C2N=C1)C1=CC=C(C=C1)C(C)(C)C#N,,,,,,pIC50,,>,4.7,,,,,,,4.7,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,CN1C(=O)N(C2=C1C=NC1=CC=C(C=C21)C1=CC2=CC=CC=C2N=C1)C1=CC=C(C=C1)C(C)(C)C#N,12748665,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12748665&database=RX&origin=ReaxysOutput&ln=,(60 of 100),,"2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile; BEZ235; dactolisib; NVP-BEZ235; 2-methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile; 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile",C30H23N5O,C30H23N5O,469.546,,,JOGKUKXHTYWRGZ-UHFFFAOYSA-N,,,,Identification(1871); Physical Data(19); Spectra(17); Bioactivity(257),20,2060,4.918,0,6,3,73.12,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,12748665,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12748665&database=RX&origin=ReaxysOutput&ln=,CN1C(=O)N(C2=C1C=NC1=CC=C(C=C21)C1=CC2=CC=CC=C2N=C1)C1=CC=C(C=C1)C(C)(C)C#N,,,,,,pIC50,,=,5.67,,,,,,,5.67,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,CN1C(=O)N(C2=C1C=NC1=CC=C(C=C21)C1=CC2=CC=CC=C2N=C1)C1=CC=C(C=C1)C(C)(C)C#N,12748665,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12748665&database=RX&origin=ReaxysOutput&ln=,(60 of 100),,"2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile; BEZ235; dactolisib; NVP-BEZ235; 2-methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile; 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile",C30H23N5O,C30H23N5O,469.546,,,JOGKUKXHTYWRGZ-UHFFFAOYSA-N,,,,Identification(1871); Physical Data(19); Spectra(17); Bioactivity(257),20,2060,4.918,0,6,3,73.12,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,12748665,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12748665&database=RX&origin=ReaxysOutput&ln=,CN1C(=O)N(C2=C1C=NC1=CC=C(C=C21)C1=CC2=CC=CC=C2N=C1)C1=CC=C(C=C1)C(C)(C)C#N,,,,,,pIC50,,>,5.9,,,,,,,5.9,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,CN1C(=O)N(C2=C1C=NC1=CC=C(C=C21)C1=CC2=CC=CC=C2N=C1)C1=CC=C(C=C1)C(C)(C)C#N,12748665,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12748665&database=RX&origin=ReaxysOutput&ln=,(60 of 100),,"2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile; BEZ235; dactolisib; NVP-BEZ235; 2-methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile; 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile",C30H23N5O,C30H23N5O,469.546,,,JOGKUKXHTYWRGZ-UHFFFAOYSA-N,,,,Identification(1871); Physical Data(19); Spectra(17); Bioactivity(257),20,2060,4.918,0,6,3,73.12,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,12748665,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12748665&database=RX&origin=ReaxysOutput&ln=,CN1C(=O)N(C2=C1C=NC1=CC=C(C=C21)C1=CC2=CC=CC=C2N=C1)C1=CC=C(C=C1)C(C)(C)C#N,,,,,,pIC50,,=,6.1,,,,,,,6.1,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1,2226282,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2226282&database=RX&origin=ReaxysOutput&ln=,(61 of 100),,"xanthohumol; 3'-(3,3-dimethylallyl)-2',4',4-trihydroxy-6'-methoxychalcone; ((E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one); (E)-1-(2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 2',4',4-trihydroxy-6'-methoxy-3'-prenylchalcone; methoxy isobavachalcone; 3’-[3,3-dimethyl allyl]-2’,4’,4-trihydroxy-6’-methoxychalcone",C21H22O5,C21H22O5,354.403,isocyclic,,ORXQGKIUCDPEAJ-YRNVUSSQSA-N,,,,Identification(1656); Physical Data(45); Spectra(102); Bioactivity(487),87,1872,4.642,3,1,6,86.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),,Inhibitory activity of the compound against human ALK was determined by KinaseProfilerTM Assay,,,,,,,2226282,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2226282&database=RX&origin=ReaxysOutput&ln=,COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; ALTICOR GLOBAL HOLDINGS INC.; US2007/154576; (2007); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68091755&database=RX&origin=ReaxysOutput&ln=
,[H][C@@]12CCC3=CC(=CC=C3[C@@]1(C)CCC[C@@]2(C)C(O)=O)C(C)C,2059290,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2059290&database=RX&origin=ReaxysOutput&ln=,(62 of 100),1740-19-8,"dehydroabietic acid; DHAA; DHA; (1R,4aS,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid; abieta-8,11,13-trien-18-oic acid; 8,11,13-abietatrien-18-oic acid; DAA",(CH3)(COOH)CCH2CH2CH2C(CH3)CHCH2CH2CCCHCHC(CH(CH3)2)CH,C20H28O2,300.441,isocyclic,,NFWKVWVWBFBAOV-MISYRCLQSA-N,,,,Identification(1352); Physical Data(129); Spectra(119); Bioactivity(255),1371,1735,5.731,1,2,2,37.3,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,2059290,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2059290&database=RX&origin=ReaxysOutput&ln=,[H][C@@]12CCC3=CC(=CC=C3[C@@]1(C)CCC[C@@]2(C)C(O)=O)C(C)C,dehydroabietic acid,~ 166 μM,,,,inhibition percentage,%,,17.6,,,,,,,1,,,,,,"Article; Gao, Jun-Bo; Yang, Shuang-Jing; Yan, Zi-Ru; Zhang, Xing-Jie; Pu, De-Bing; Wang, Li-Xia; Li, Xiao-Li; Zhang, Rui-Han; Xiao, Wei-Lie; Journal of Natural Products; vol. 81; 4; (2018); p. 998 - 1006;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73687991&database=RX&origin=ReaxysOutput&ln=
,CC1=CC(O)=C2C(=O)C3=C(C=C(O)C=C3O)C(=O)C2=C1,1888141,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1888141&database=RX&origin=ReaxysOutput&ln=,(63 of 100),518-82-1,"1,6,8-trihydroxy-3-methyl-9,10-anthraquinone; emodin; 1,3,8-trihydroxy-6-methylanthraquinone",C6H2OHCH3COCOC6H2OHOH,C15H10O5,270.241,isocyclic,,RHMXXJGYXNZAPX-UHFFFAOYSA-N,,,,Identification(578); Physical Data(200); Spectra(399); Bioactivity(1117),498,1710,2.327,3,2,0,94.83,4,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,,Activator,,In Vitro (Efficacy),,,,,,,HT22 cell line,,1888141,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1888141&database=RX&origin=ReaxysOutput&ln=,CC1=CC(O)=C2C(=O)C3=C(C=C(O)C=C3O)C(=O)C2=C1,emodin,1 - 5 μM,,,,percentage increase,,Active,,,,Tau-1,,,,6,,,,,,Patent; SEOUL NATIONAL UNIVERSITY; EP2873424; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D66210295&database=RX&origin=ReaxysOutput&ln=
,CC1=CC(O)=C2C(=O)C3=C(C=C(O)C=C3O)C(=O)C2=C1,1888141,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1888141&database=RX&origin=ReaxysOutput&ln=,(63 of 100),518-82-1,"1,6,8-trihydroxy-3-methyl-9,10-anthraquinone; emodin; 1,3,8-trihydroxy-6-methylanthraquinone",C6H2OHCH3COCOC6H2OHOH,C15H10O5,270.241,isocyclic,,RHMXXJGYXNZAPX-UHFFFAOYSA-N,,,,Identification(578); Physical Data(200); Spectra(399); Bioactivity(1117),498,1710,2.327,3,2,0,94.83,4,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,,Activator,,In Vitro (Efficacy),,,,,,,HT22 cell line,,1888141,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1888141&database=RX&origin=ReaxysOutput&ln=,CC1=CC(O)=C2C(=O)C3=C(C=C(O)C=C3O)C(=O)C2=C1,emodin,1 - 5 μM,,,Ser 396/404 phosphorylation,percentage decrease,,Active,,,,PHD Finger Protein 1 (PHF1),,,,6,,,,,,Patent; SEOUL NATIONAL UNIVERSITY; EP2873424; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D66210295&database=RX&origin=ReaxysOutput&ln=
,CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO,11099648,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11099648&database=RX&origin=ReaxysOutput&ln=,(64 of 100),606143-52-6,selumetinib; AZD6244; ARRY-142886; 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide; 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; 6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; refametinib,C17H15N4O3FBrCl,C17H15BrClFN4O3,457.687,,,CYOHGALHFOKKQC-UHFFFAOYSA-N,,,,Identification(1529); Physical Data(4); Spectra(7); Bioactivity(250),18,1709,3.696,3,5,7,88.41,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,11099648,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11099648&database=RX&origin=ReaxysOutput&ln=,CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO,AZD-6244/ARRY-886,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008,DMSO,Other compound,"Article; Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 29; 11; (2011); p. 1046 - 1051;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009910&database=RX&origin=ReaxysOutput&ln=
,O[C@@H](CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=CC=C(F)C=C23)=C1C,15426924,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D15426924&database=RX&origin=ReaxysOutput&ln=,(65 of 100),341031-54-7,sunitinib malate; sunitinib L-malate; sutent; SU11248,C4H6O5*C22H27FN4O2,C4H6O5*C22H27FN4O2,532.569,,,LBWFXVZLPYTWQI-IPOVEDGCSA-N,,,,Identification(1694); Physical Data(37); Spectra(32); Bioactivity(158),40,1659,,6,11,11,172.06,0,0,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,phosphotransferase inhibitor,In Vitro (Efficacy),,,,,,,,,15426924,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D15426924&database=RX&origin=ReaxysOutput&ln=,O[C@@H](CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=CC=C(F)C=C23)=C1C,,100 nM,,,,enzyme activity inhibition rate,%,,60,,,,,,,,,,,,,Patent; UNIVERSITY OF COLORADO (SYSTEM); WO2022/6412; (2022); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D112149829&database=RX&origin=ReaxysOutput&ln=
,COC1=CC=CC(=C1N)C1=CC(=O)C2=C(O1)C=CC=C2,8148190,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8148190&database=RX&origin=ReaxysOutput&ln=,(66 of 100),,2-(2-amino-3-methoxyphenyl)chromen-4-one; PD 98059; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; PD098059; 2'-amino-3'-methoxyflavone; 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one; 2-(2-amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran; 2′-amino-3′-methoxyflavone; PD 98095,C16H13NO3,C16H13NO3,267.284,heterocyclic,,QFWCYNPOPKQOKV-UHFFFAOYSA-N,,,,Identification(524); Physical Data(5); Spectra(5); Bioactivity(1129),9,1641,2.73,1,2,2,61.55,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,8148190,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8148190&database=RX&origin=ReaxysOutput&ln=,COC1=CC=CC(=C1N)C1=CC(=O)C2=C(O1)C=CC=C2,PD 98059,0.500000 µM,,,,inhibition percentage,%,,15.85,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,CN1CC[C@H]([C@@H](O)C1)C1=C2OC(=CC(=O)C2=C(O)C=C1O)C1=C(Cl)C=CC=C1,8362824,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8362824&database=RX&origin=ReaxysOutput&ln=,(67 of 100),,flavopiridol,C21H20ClNO5,C21H20ClNO5,401.847,heterocyclic,,BIIVYFLTOXDAOV-PXAZEXFGSA-N,,,,Identification(1545); Bioactivity(109),,1548,2.697,3,3,2,90.23,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,8362824,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8362824&database=RX&origin=ReaxysOutput&ln=,CN1CC[C@H]([C@@H](O)C1)C1=C2OC(=CC(=O)C2=C(O)C=C1O)C1=C(Cl)C=CC=C1,103905277,3 nM,,,,pKi,,,6.2,,,,,,,6.2,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,CCOC1=CC2=C(C=C1NC(=O)\C=C\CN(C)C)C(NC1=CC(Cl)=C(F)C=C1)=C(C=N2)C#N,9301287,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9301287&database=RX&origin=ReaxysOutput&ln=,(68 of 100),257933-82-7,"pelitinib; EKB-569; 3-cyano-4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-ethoxy-quinoline",C24H23ClFN5O2,C24H23ClFN5O2,467.93,heterocyclic,,WVUNYSQLFKLYNI-AATRIKPKSA-N,,,,Identification(1414); Physical Data(4); Spectra(3); Bioactivity(166),19,1523,3.565,2,6,9,90.28,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,9301287,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D9301287&database=RX&origin=ReaxysOutput&ln=,CCOC1=CC2=C(C=C1NC(=O)\C=C\CN(C)C)C(NC1=CC(Cl)=C(F)C=C1)=C(C=N2)C#N,EKB-569,,,,,Kd (dissociation constant),nM,,7100,,,,,,,5.15,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,CS(=O)(=O)N1CCN(CC2=CC3=NC(=NC(N4CCOCC4)=C3S2)C2=CC=CC3=C2C=NN3)CC1,15630067,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D15630067&database=RX&origin=ReaxysOutput&ln=,(69 of 100),957054-30-7,"pictilisib; GDC0941; 4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine; pictrelisib; RG-7321; 2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine",C23H27N7O3S2,C23H27N7O3S2,513.644,,,LHNIIDJUOCFXAP-UHFFFAOYSA-N,,,,Identification(1332); Physical Data(14); Spectra(17); Bioactivity(344),28,1507,2.018,1,10,5,144.17,3,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,15630067,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D15630067&database=RX&origin=ReaxysOutput&ln=,CS(=O)(=O)N1CCN(CC2=CC3=NC(=NC(N4CCOCC4)=C3S2)C2=CC=CC3=C2C=NN3)CC1,GDC-0941,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008,DMSO,Other compound,"Article; Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 29; 11; (2011); p. 1046 - 1051;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009910&database=RX&origin=ReaxysOutput&ln=
,CS(=O)(=O)N1CCN(CC2=CC3=NC(=NC(N4CCOCC4)=C3S2)C2=CC=CC3=C2C=NN3)CC1,15630067,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D15630067&database=RX&origin=ReaxysOutput&ln=,(69 of 100),957054-30-7,"pictilisib; GDC0941; 4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine; pictrelisib; RG-7321; 2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine",C23H27N7O3S2,C23H27N7O3S2,513.644,,,LHNIIDJUOCFXAP-UHFFFAOYSA-N,,,,Identification(1332); Physical Data(14); Spectra(17); Bioactivity(344),28,1507,2.018,1,10,5,144.17,3,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,15630067,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D15630067&database=RX&origin=ReaxysOutput&ln=,CS(=O)(=O)N1CCN(CC2=CC3=NC(=NC(N4CCOCC4)=C3S2)C2=CC=CC3=C2C=NN3)CC1,,10 μM,,,,residual binding percentage,%,,100,,,,,,,,,,,,,"Article; Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jürgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.; Journal of Medicinal Chemistry; vol. 60; 17; (2017); p. 7524 - 7538;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72081213&database=RX&origin=ReaxysOutput&ln=
,COCC1=C(N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1)C(C)C,8366578,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8366578&database=RX&origin=ReaxysOutput&ln=,(70 of 100),145599-86-6,"cerivastatin; (3R,5S,6E)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid",C26H34FNO5,C26H34FNO5,459.558,heterocyclic,,SEERZIQQUAZTOL-ANMDKAQQSA-N,,,,Identification(1184); Physical Data(14); Spectra(5); Bioactivity(311),1,1472,3.421,3,6,11,99.88,4,1,ALK tyrosine kinase receptor [human]; 3-hydroxy-3-methylglutaryl-coenzyme A reductase [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + 3-hydroxy-3-methylglutaryl-coenzyme a reductase; hmg-coa reductase; hmgcr,818511893 + 818261531,q9um73 + p04035,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1dq8; 1dq9; 1dqa; 1hw8; 1hw9; 1hwi; 1hwj; 1hwk; 1hwl; 2q1l; 2q6b; 2q6c; 2r4f; 3bgl; 3cct; 3ccw; 3ccz; 3cd0; 3cd5; 3cd7; 3cda; 3cdb,,,ALK tyrosine kinase receptor [human]; 3-hydroxy-3-methylglutaryl-coenzyme A reductase [human],ALK tyrosine kinase receptor [human]:Wild; 3-hydroxy-3-methylglutaryl-coenzyme A reductase [human]:Wild,human; human,Non Transfected; Non Transfected,,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H358 cell line,,8366578,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8366578&database=RX&origin=ReaxysOutput&ln=,COCC1=C(N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1)C(C)C,cerivastatin,,,,,tested,,Not Published,,,,,,,,,,,,,,Patent; JEUK CO LTD; YONSEI UNIVERSITY; US2019/46514; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76026543&database=RX&origin=ReaxysOutput&ln=
,COCC1=C(N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1)C(C)C,8366578,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8366578&database=RX&origin=ReaxysOutput&ln=,(70 of 100),145599-86-6,"cerivastatin; (3R,5S,6E)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid",C26H34FNO5,C26H34FNO5,459.558,heterocyclic,,SEERZIQQUAZTOL-ANMDKAQQSA-N,,,,Identification(1184); Physical Data(14); Spectra(5); Bioactivity(311),1,1472,3.421,3,6,11,99.88,4,1,ALK tyrosine kinase receptor [human]; 3-hydroxy-3-methylglutaryl-coenzyme A reductase [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + 3-hydroxy-3-methylglutaryl-coenzyme a reductase; hmg-coa reductase; hmgcr,818511893 + 818261531,q9um73 + p04035,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1dq8; 1dq9; 1dqa; 1hw8; 1hw9; 1hwi; 1hwj; 1hwk; 1hwl; 2q1l; 2q6b; 2q6c; 2r4f; 3bgl; 3cct; 3ccw; 3ccz; 3cd0; 3cd5; 3cd7; 3cda; 3cdb,,,ALK tyrosine kinase receptor [human]; 3-hydroxy-3-methylglutaryl-coenzyme A reductase [human],ALK tyrosine kinase receptor [human]:Wild; 3-hydroxy-3-methylglutaryl-coenzyme A reductase [human]:Wild,human; human,Non Transfected; Non Transfected,,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC-9 cell line,,8366578,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8366578&database=RX&origin=ReaxysOutput&ln=,COCC1=C(N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1)C(C)C,cerivastatin,,,,,tested,,Not Published,,,,,,,,,,,,,,Patent; JEUK CO LTD; YONSEI UNIVERSITY; US2019/46514; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76026543&database=RX&origin=ReaxysOutput&ln=
,CC1(C)CNC2=C1C=CC(NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1)=C2,11751576,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11751576&database=RX&origin=ReaxysOutput&ln=,(71 of 100),453562-69-1,motesanib; AMG-706,C22H23N5O,C22H23N5O,373.458,,,RAHBGWKEPAQNFF-UHFFFAOYSA-N,,,,Identification(1407); Physical Data(1); Spectra(1); Bioactivity(98),6,1450,2.988,3,6,6,78.94,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,11751576,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11751576&database=RX&origin=ReaxysOutput&ln=,CC1(C)CNC2=C1C=CC(NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1)=C2,AMG-706,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,CC1(C)CNC2=C1C=CC(NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1)=C2,11751576,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11751576&database=RX&origin=ReaxysOutput&ln=,(71 of 100),453562-69-1,motesanib; AMG-706,C22H23N5O,C22H23N5O,373.458,,,RAHBGWKEPAQNFF-UHFFFAOYSA-N,,,,Identification(1407); Physical Data(1); Spectra(1); Bioactivity(98),6,1450,2.988,3,6,6,78.94,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"In vitro percent remaining activity of recombinant human ALK in presence of 10 uM ATP upon incubation in 20 mM Hepes, pH 7.5 for 120 mins at 25 degree C using HotSpot assay at a concentration of 0.5 uM",,,,,,,11751576,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11751576&database=RX&origin=ReaxysOutput&ln=,CC1(C)CNC2=C1C=CC(NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1)=C2,,,,,Remaining activity,percentage,%,=,96.45,,,,,,,,,,,,,"Article; Vijayan; He, Peng; Modi, Vivek; Duong-Ly, Krisna C.; Ma, Haiching; Peterson, Jeffrey R.; Dunbrack, Roland L.; Levy, Ronald M.; Journal of Medicinal Chemistry; vol. 58; 1; (2015); p. 466 - 479;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D66620300&database=RX&origin=ReaxysOutput&ln=
,CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C1F,12833468,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12833468&database=RX&origin=ReaxysOutput&ln=,(72 of 100),,"vemurafenib; PLX4032; propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide; N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide; zelboraf; RG7204; N-(3-[[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl)-1-propanesulfonamide; N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide; vemurafinib; R05185426",C23H18ClF2N3O3S,C23H18ClF2N3O3S,489.93,,,GPXBXXGIAQBQNI-UHFFFAOYSA-N,,,,Identification(1061); Physical Data(31); Spectra(21); Bioactivity(391),105,1430,6.392,2,6,7,100.3,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,12833468,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12833468&database=RX&origin=ReaxysOutput&ln=,CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C1F,PLX-4032,1 µM,,,,inhibition percentage,%,<,10,,,,,,,1,,,73010,ATP,CoEnzyme,"Article; Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; Dandrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith; Nature; vol. 467; 7315; (2010); p. 596 - 599;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D30616139&database=RX&origin=ReaxysOutput&ln=
,CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1,2162244,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2162244&database=RX&origin=ReaxysOutput&ln=,(73 of 100),37517-30-9,Acebutolol,C18H28N2O4,C18H28N2O4,336.431,isocyclic,,GOEMGAFJFRBGGG-UHFFFAOYSA-N,,,,Identification(1234); Physical Data(47); Spectra(18); Bioactivity(160),9,1414,1.715,3,5,11,87.66,4,1,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,2162244,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D2162244&database=RX&origin=ReaxysOutput&ln=,CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,COC1=CC=C(C=C(C#N)C#N)C=C1,1869845,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1869845&database=RX&origin=ReaxysOutput&ln=,(74 of 100),2826-26-8,2-(4-methoxyphenylmethylene)malononitrile; p-methoxybenzylidenemalononitrile; 2-(4-methoxybenzylidene)malononitrile; (4-methoxybenzylidene)malononitrile; 2‐(4‐methoxybenzylidene)malononitrile,C4N2HC6H4CH3O,C11H8N2O,184.197,isocyclic,,UOHFCPXBKJPCAD-UHFFFAOYSA-N,,,,Identification(292); Physical Data(142); Spectra(197); Bioactivity(143),1372,1386,1.573,0,2,2,56.81,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,1869845,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D1869845&database=RX&origin=ReaxysOutput&ln=,COC1=CC=C(C=C(C#N)C#N)C=C1,AG 9,0.500000 µM,,,,inhibition percentage,%,,-10.29,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,OC1=CC=C(O)C(CNC2=CC=C(C=C2)C(=O)OC23CC4CC(CC(C4)C2)C3)=C1,10602008,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10602008&database=RX&origin=ReaxysOutput&ln=,(75 of 100),241127-58-2,Adaphostin,C24H27NO4,C24H27NO4,393.483,isocyclic,,YJZSUCFGHXQWDM-UHFFFAOYSA-N,,,,Identification(1356); Physical Data(4); Spectra(2); Bioactivity(82),8,1368,5.38,3,3,6,78.79,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Sf9 cell line,,10602008,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10602008&database=RX&origin=ReaxysOutput&ln=,OC1=CC=C(O)C(CNC2=CC=C(C=C2)C(=O)OC23CC4CC(CC(C4)C2)C3)=C1,adaphostin,,,,,IC50,µM,,23,,,,,,,4.64,,,73010,ATP,CoEnzyme,"Article; Gunby, Rosalind Helen; Tartari, Carmen Julia; Porchia, Francesca; Donella-Deana, Arianna; Scapozza, Leonardo; Gambacorti-Passerini, Carlo; Haematologica; vol. 90; 7; (2005); p. 988 - 990;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D22672230&database=RX&origin=ReaxysOutput&ln=
,CN1CC[C@@H]([C@H](O)C1)C1=C(O)C=C(O)C2=C1OC(=CC2=O)C1=CC=CC=C1Cl,10038073,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10038073&database=RX&origin=ReaxysOutput&ln=,(76 of 100),146426-40-6,"flavopiridol; alvocidib; NSC 649890; 2-(2-chlorophenyl)-5,7-dihydroxy-8-((3S,4R)-3-hydroxy-1-methylpiperidin-4-yl)-4H-chromen-4-one",C21H20ClNO5,C21H20ClNO5,401.847,heterocyclic,,BIIVYFLTOXDAOV-YVEFUNNKSA-N,,,,Identification(1253); Physical Data(2); Spectra(3); Bioactivity(507),58,1297,2.697,3,3,2,90.23,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,10038073,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10038073&database=RX&origin=ReaxysOutput&ln=,CN1CC[C@@H]([C@H](O)C1)C1=C(O)C=C(O)C2=C1OC(=CC2=O)C1=CC=CC=C1Cl,Flavopiridol,,,,,Kd (dissociation constant),nM,,670,,,,,,,6.17,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O,10219048,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10219048&database=RX&origin=ReaxysOutput&ln=,(77 of 100),571190-30-2,"PD 0332991; palbociclib; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; ibrance; 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidine-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylammino)-8H-pyrido-[2,3-d]-pyrimidin-7-one; (6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one); PD-332991",C24H29N7O2,C24H29N7O2,447.54,heterocyclic,,AHJRHEGDXFFMBM-UHFFFAOYSA-N,,,,Identification(890); Physical Data(82); Spectra(51); Bioactivity(438),403,1259,2.415,2,9,5,103.35,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,10219048,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10219048&database=RX&origin=ReaxysOutput&ln=,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O,103905660,3 nM,,,,pKi,,,5.8,,,,,,,5.8,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O,10219048,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10219048&database=RX&origin=ReaxysOutput&ln=,(77 of 100),571190-30-2,"PD 0332991; palbociclib; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; ibrance; 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidine-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylammino)-8H-pyrido-[2,3-d]-pyrimidin-7-one; (6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one); PD-332991",C24H29N7O2,C24H29N7O2,447.54,heterocyclic,,AHJRHEGDXFFMBM-UHFFFAOYSA-N,,,,Identification(890); Physical Data(82); Spectra(51); Bioactivity(438),403,1259,2.415,2,9,5,103.35,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,10219048,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10219048&database=RX&origin=ReaxysOutput&ln=,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O,,,,,,pIC50,,=,5.19,,,,,,,5.19,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O,10219048,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10219048&database=RX&origin=ReaxysOutput&ln=,(77 of 100),571190-30-2,"PD 0332991; palbociclib; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; ibrance; 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidine-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylammino)-8H-pyrido-[2,3-d]-pyrimidin-7-one; (6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one); PD-332991",C24H29N7O2,C24H29N7O2,447.54,heterocyclic,,AHJRHEGDXFFMBM-UHFFFAOYSA-N,,,,Identification(890); Physical Data(82); Spectra(51); Bioactivity(438),403,1259,2.415,2,9,5,103.35,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,10219048,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10219048&database=RX&origin=ReaxysOutput&ln=,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O,,,,,,pIC50,,=,5.5,,,,,,,5.5,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O,10219048,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10219048&database=RX&origin=ReaxysOutput&ln=,(77 of 100),571190-30-2,"PD 0332991; palbociclib; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; ibrance; 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidine-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylammino)-8H-pyrido-[2,3-d]-pyrimidin-7-one; (6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one); PD-332991",C24H29N7O2,C24H29N7O2,447.54,heterocyclic,,AHJRHEGDXFFMBM-UHFFFAOYSA-N,,,,Identification(890); Physical Data(82); Spectra(51); Bioactivity(438),403,1259,2.415,2,9,5,103.35,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,10219048,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10219048&database=RX&origin=ReaxysOutput&ln=,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O,,,,,,pIC50,,>,5.5,,,,,,,5.5,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O,10219048,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10219048&database=RX&origin=ReaxysOutput&ln=,(77 of 100),571190-30-2,"PD 0332991; palbociclib; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; ibrance; 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidine-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylammino)-8H-pyrido-[2,3-d]-pyrimidin-7-one; (6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one); PD-332991",C24H29N7O2,C24H29N7O2,447.54,heterocyclic,,AHJRHEGDXFFMBM-UHFFFAOYSA-N,,,,Identification(890); Physical Data(82); Spectra(51); Bioactivity(438),403,1259,2.415,2,9,5,103.35,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,10219048,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10219048&database=RX&origin=ReaxysOutput&ln=,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O,,,,,,pIC50,,=,5.8,,,,,,,5.8,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,BIBW-2992,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008,DMSO,Other compound,"Article; Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 29; 11; (2011); p. 1046 - 1051;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009910&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1299 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,< 0.5 μM,,,of fragmented nuclei,fold increase,,Not active,,,,,,,,1,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCC78 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,0.5 - 10 μM,,,,viable cell count decrease,,Active,,,,,,,,6.3,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCC78 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,< 0.5 μM,,,,viable cell count decrease,,Low,,,,,,,,,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCC78 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,< 0.5 μM,,,of fragmented nuclei,fold increase,,Not active,,,,,,,,1,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1299 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,0.5 - 10 μM,,,,viable cell count decrease,,Active,,,,,,,,6.3,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1299 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,< 0.5 μM,,,,viable cell count decrease,,Low,,,,,,,,,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCC78 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,< 0.5 μM,,,of fragmented nuclei,fold increase,,Not active,,,,,,,,1,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1299 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,< 0.5 μM,,,of fragmented nuclei,fold increase,,Not active,,,,,,,,1,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCC78 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,0.5 - 10 μM,,,,viable cell count decrease,,Active,,,,,,,,6.3,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCC78 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,< 0.5 μM,,,,viable cell count decrease,,Low,,,,,,,,,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1299 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,0.5 - 10 μM,,,,viable cell count decrease,,Active,,,,,,,,6.3,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1299 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,< 0.5 μM,,,,viable cell count decrease,,Low,,,,,,,,,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,NCI-H1299 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,200 nM,,,,inhibition percentage,,Active,,,,,,,,6.7,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,NCI-H1299 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,200 nM,,,phosphorylation,protein expression level decrease,,Active,,,,Epidermal growth factor receptor,,,,6.7,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,HCC78 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,200 nM,,,,inhibition percentage,,Active,,,,,,,,6.7,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,HCC78 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,200 nM,,,phosphorylation,protein expression level decrease,,Active,,,,Epidermal growth factor receptor,,,,6.7,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,NCI-H1299 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,200 nM,,,,inhibition percentage,,Active,,,,,,,,6.7,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,HCC78 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,200 nM,,,,inhibition percentage,,Active,,,,,,,,6.7,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,NCI-H1299 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,200 nM,,,phosphorylation,protein expression level decrease,,Active,,,,Epidermal growth factor receptor,,,,6.7,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,ALK tyrosine kinase receptor [human];+Epidermal growth factor receptor [human];+Receptor tyrosine-protein kinase erbB-2 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + egfr; epidermal growth factor receptor; erbb; erbb1; her1; proto-oncogene c-erbb-1; receptor tyrosine-protein kinase erbb-1 + cd340; erbb2; her2; metastatic lymph node gene 19 protein; mln 19; mln19; neu; ngl; p185erbb2; proto-oncogene c-erbb-2; proto-oncogene neu; receptor tyrosine-protein kinase erbb-2; tyrosine kinase-type cell surface receptor her2,818511893 + 818478681 + 818186600,q9um73 + p00533 + p04626,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1ivo; 1mox; 1nql; 1yy9; 1z9i; 2gs6; 2gs7; 2itn; 2itq; 2itv; 2jit; 2jiu; 2jiv; 2ks1; 2m0b; 2m20; 2n5s; 2rf9; 2rfd; 2rfe; 2rgp; 3b2u; 3b2v; 3bel; 3buo; 3c09; 3g5v; 3g5y; 3gop; 3gt8; 3ika; 3lzb; 3njp; 3ob2; 3op0; 3p0y; 3pfv; 3poz; 3qwq; 3vrp; 3vrr; 3w2o; 3w2p; 3w2q; 3w2r; 3w2s; 3w32; 3w33; 4g5p; 4i21; 4i24; 4jq7; 4jq8; 4jr3; 4jrv; 4krl; 4krm; 4kro; 4krp; 4li5; 4ll0; 4lqm; 4lrm; 4r3p; 4r3r; 4riw; 4rix; 4riy; 4uip; 4uv7; 4wd5; 4wkq; 4wrg; 4zjv; 4zse; 5cnn; 5cno; 5czh; 5czi; 5d41; 5fed; 5fee; 5gnk; 5gty; 5hcx; 5hcy; 5hcz; 5j9y; 5j9z; 5lv6; 5sx4; 5sx5; 5wb7; 5wb8; 5x2a; 5x2c; 5x2f; 5xdk; 5xdl; 5xgn; 5xwd; 5y25; 5yu9; 5zto; 5zwj; 6aru; 6b3s; 6d8e; 6duk; 6jrx; 6jwl; 6jx0; 6jx4; 6jxt; 6jz0; 6p1d; 6p1l; 6p8q; 6s9b; 6s9d; 6tfu; 6tfv; 6tfw; 6tfy; 6tfz; 6tg0; 6tg1; 6v5n; 6v5p; 6v66; 6v6k; 6v6o; 6vhn; 6wa2; 6wak; 6wxn; 6xl4; 6z4b; 6z4d; 7a2a; 7jxi; 7jxk; 7jxl; 7jxm; 7jxp; 7jxq; 7jxw; 7k1h; 7lgs; 7oxb + 1mfg; 1mfl; 1mw4; 1n8z; 1qr1; 1s78; 2a91; 2jwa; 2ks1; 2l4k; 2n2a; 3be1; 3h3b; 3mzw; 3n85; 3pp0; 3rcd; 3wlw; 3wsq; 4gfu; 4hrl; 4hrm; 4hrn; 5k33; 5kwg; 5my6; 5o4g; 5ob4; 5tqs; 6att; 6bgt; 6j71; 6lbx; 6oge; 7jxh; 7mn5; 7mn6,,,ALK tyrosine kinase receptor [human]; Epidermal growth factor receptor [human]; Receptor tyrosine-protein kinase erbB-2 [human],ALK tyrosine kinase receptor [human]:Wild + Epidermal growth factor receptor [human]:Wild + Receptor tyrosine-protein kinase erbB-2 [human]:Wild,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,HCC78 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,200 nM,,,phosphorylation,protein expression level decrease,,Active,,,,Epidermal growth factor receptor,,,,6.7,,,,,,"Article; Chen, Hui; Zhang, Qiang; Zhang, Yu; Jia, Bin; Zhang, Bin; Wang, Changli; OncoTargets and Therapy; vol. 11; (2018); p. 8201 - 8209;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75539790&database=RX&origin=ReaxysOutput&ln=
,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,(78 of 100),850140-72-6,"afatinib; BIBW2992; 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; Gilotrif; (E)-4-dimethylamino-but-2-enoic acid {4-(3-chloro-4-fluorophenylamino)-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}amide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-([(3S)-tetrahydro-3-furanyl]oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; giotrif",C24H25ClFN5O3,C24H25ClFN5O3,485.946,,,ULXXDDBFHOBEHA-CWDCEQMOSA-N,,,,Identification(871); Physical Data(25); Spectra(10); Bioactivity(257),60,1212,3.101,2,7,9,88.61,4,2,epidermal growth factor-activated receptor [human]; ALK tyrosine kinase receptor [human],epidermal growth factor-activated receptor + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,epidermal growth factor-activated receptor [human]; ALK tyrosine kinase receptor [human],epidermal growth factor-activated receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,11746023,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11746023&database=RX&origin=ReaxysOutput&ln=,CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1,afatinib,,,,,survival rate decrease,,Not active,,,,,,,,1,,,,,,Patent; JEUK CO LTD; YONSEI UNIVERSITY; US2019/46514; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76026543&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Chimera,human,Transfected,Inhibitor,,Toxicity/Safety Pharmacology,Cell/tumor cell: proliferation/viability/growth,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,2 PF-2341066,,,,,IC50,µM,,0.19,10,,,,,,6.72,,,1723797,Glutamine,Other compound,"Article; Deng, Xianming; Wang, Jinhua; Zhang, Jianming; Sim, Taebo; Kim, Nam Doo; Sasaki, Takaaki; Luther, William; George, Rani E.; Jaenne, Pasi A.; Gray, Nathanael S.; ACS Medicinal Chemistry Letters; vol. 2; 5; (2011); p. 379 - 384;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D9051269&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,PF-2341066,,,,,IC50,nM,>,2,,,,,,,8.7,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,Patent; BETTA PHARMACEUTICALS CO LTD; WO2012/48259; (2012); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20107914&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,Crizotinib,,,,,IC50,nM,,2.1,,,,,,,8.68,,,73010,ATP,CoEnzyme,Patent; GUANGDONG NEWOPP BIOPHARMACEUTICALS; WO2013/13308; (2013); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D35460980&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],"ALK tyrosine kinase receptor [human]:Mutated:Substitution,1,Cysteine,1156,Tyrosine",human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,Crizotinib,,,,,IC50,nM,<,1.2,,,,,,,8.92,,,73010,ATP,CoEnzyme,Patent; GUANGDONG NEWOPP BIOPHARMACEUTICALS; WO2013/13308; (2013); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D35460980&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,Crizotinib,,,,,Kd (dissociation constant),nM,,3.3,,,,,,,8.48,,,506008,DMSO,Other compound,"Article; Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 29; 11; (2011); p. 1046 - 1051;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009910&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,Crizotinib,3.00000E-05 µM,,,,IC50,nM,,1 - 100,,,,,,,9,,,2114647; 73010; 1719757,Triton X100; ATP; Dithiothreitol,Other compound; CoEnzyme; Other compound,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D35487146&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,103905245,3 nM,,,,pKi,,,8.5,,,,,,,8.5,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,"63 (PF-02341066, Crizotinib)",,,,,IC50,nM,,20,20,,,,,,7.7,,,,,,"Article; Cui, J. Jean; Tran-Dubé, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.; Journal of Medicinal Chemistry; vol. 54; 18; (2011); p. 6342 - 6363;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20025975&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,Crizotinib,,,,,IC50,nM,,3.6,,,,,,,8.44,,,73010; 73010,ATP; [33P]-ATP,CoEnzyme; Marker,"Article; Katayama, Ryohei; Khan, Tahsin M.; Benes, Cyril; Lifshits, Eugene; Ebi, Hiromichi; Rivera, Victor M.; Shakespeare, William C.; Iafrate, A. John; Engelman, Jeffrey A.; Shaw, Alice T.; Proceedings of the National Academy of Sciences of the United States of America; vol. 108; 18; (2011); p. 7535 - 7540;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D32168697&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,Crizotinib,,,,,Ki (inhibition constant),nM,,0.69,,,,,,,9.16,,,73010; 73010,ATP; [33P]-ATP,CoEnzyme; Marker,"Article; Katayama, Ryohei; Khan, Tahsin M.; Benes, Cyril; Lifshits, Eugene; Ebi, Hiromichi; Rivera, Victor M.; Shakespeare, William C.; Iafrate, A. John; Engelman, Jeffrey A.; Shaw, Alice T.; Proceedings of the National Academy of Sciences of the United States of America; vol. 108; 18; (2011); p. 7535 - 7540;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D32168697&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,Inhibitory concentration of the compound against proliferation of ALCL cell line expressing NPM-ALK (Anaplastic lymphoma kinase),,,,,anaplastic large cell lymphoma cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,~,30,,,,,,,7.52,,,,,,"Review; Li, Rongshi; Morris, Stephan W.; Medicinal Research Reviews; vol. 28; 3; (2008); p. 372 - 412;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25771579&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,Inhibitory concentration of the compound against NPM-ALK oncogenic fusion variant of Anaplastic lymphoma kinase (ALK) expressed by human anaplastic large cell lymphoma (ALCL) KARPAS299 cell line,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,24,,,,,,,7.62,,,,,,"Article; Okamoto, Masako; Kojima, Hirotatsu; Saito, Nae; Okabe, Takayoshi; Masuda, Yoshiaki; Furuya, Toshio; Nagano, Tetsuo; Bioorganic and Medicinal Chemistry; vol. 19; 10; (2011); p. 3086 - 3095;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D9045720&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,Inhibitory concentration of the compound against NSCLC cell line expressing ALK,,,,,lung non-small cell carcinoma cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Enzyme Activity,IC50,nM,=,20,,,,,,,7.7,,,,,,"Chapter; Bronson, Joanne; Dhar, Murali; Ewing, William; Lonberg, Nils; Annual Reports in Medicinal Chemistry; vol. 47; (2012); p. 499 - 569;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D34736595&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against I1171T mutant ALK phosphorylation in Ba/F3 cell line upon incubation for overnight,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,IC50,qualitative,,,,,,,,,,,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against G1269S mutant ALK phosphorylation in Ba/F3 cell line upon incubation for overnight,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,1366,52,,,,,,5.86,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against ALK phosphorylation in Ba/F3 cell linein presence of 10 ng/ml IL-3 upon incubation for overnight,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,IC50,qualitative,,,,,,,,,,,,,,IL-3,Other compound,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against F1245C mutant ALK phosphorylation in Ba/F3 cell line upon incubation for overnight,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,IC50,qualitative,,,,,,,,,,,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against F1174C mutant ALK phosphorylation in Ba/F3 cell line upon incubation for overnight,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,165,112,,,,,,6.78,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against T1151K mutant ALK phosphorylation in Ba/F3 cell line upon incubation for overnight,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,IC50,qualitative,,,,,,,,,,,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against E1210K mutant ALK phosphorylation in Ba/F3 cell line upon incubation for overnight,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,IC50,qualitative,,,,,,,,,,,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against L1196M mutant ALK phosphorylation in Ba/F3 cell line upon incubation for overnight,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,1162,209,,,,,,5.94,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against R1275Q mutant ALK phosphorylation in Ba/F3 cell line upon incubation for overnight,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,47,8,,,,,,7.33,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against L1152V mutant ALK phosphorylation in Ba/F3 cell line upon incubation for overnight,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,IC50,qualitative,,,,,,,,,,,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against ALK phosphorylation in non-small-cell lung cancer NCI-H2342 cells,,,,,NCI-H2342 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,IC50,qualitative,,,,,,,,,,,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against S1206R mutant ALK phosphorylation in Ba/F3 cell line upon incubation for overnight,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,356,173,,,,,,6.45,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,In vitro growth inhibitory concentration of compound against non-small-cell lung cancer NCI-H838 cell line expressing ALK upon incubation for 72 h,,,,,NCI-H838 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Growth inhibition,GI50,nM,=,1307,270,,,,,,5.88,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against C1156Y mutant ALK phosphorylation in Ba/F3 cell line upon incubation for overnight,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,408,67,,,,,,6.39,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against ALK phosphorylation in non-small-cell lung cancer NCI-H838 cells,,,,,NCI-H838 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,IC50,qualitative,,,,,,,,,,,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against ALK phosphorylation in non-small-cell lung cancer H3122 cells,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,43,37,,,,,,7.37,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against ALK phosphorylation in non-small-cell lung cancer H2228 cells,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,55,4,,,,,,7.26,,,,,,"Article; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Zhu, Xiaotian; Ning, Yaoyu; Wardwell, Scott D.; Moran, Lauren; Mohemmad, Qurish K.; Anjum, Rana; Wang, Yihan; Narasimhan, Narayana I.; Dalgarno, David; Shakespeare, William C.; Miret, Juan J.; Clackson, Tim; Rivera, Victor M.; Chemical Biology and Drug Design; vol. 78; 6; (2011); p. 999 - 1005;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31545939&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,Inhibitory concentration of the compound (dissolved in 2% DMSO) against Anaplastic lymphoma kinase,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,<,1,,,,,,,9,,,,,,"Article; Wang, Yuanxiang; Ai, Jing; Yue, Jinfeng; Peng, Xia; Ji, Yinchun; Zhao, Ailing; Gao, Xin; Wang, Ying; Chen, Yi; Liu, Gang; Gao, Zhaobing; Geng, Meiyu; Zhang, Ao; MedChemComm; vol. 3; 11; (2012); p. 1423 - 1427;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D35240887&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,Inhibitory concentration of compound against ALK phosphorylation in cells upon incubation for 1 h by ELISA method,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Enzyme Phosphorylation,IC50,nM,=,24,,,,,,,7.62,,,,,,"Article; Tartari, Carmen J.; Scapozza, Leonardo; Gambacorti-Passerini, Carlo; Current Topics in Medicinal Chemistry; vol. 11; 11; (2011); p. 1406 - 1419;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D32250622&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,Inhibitory concentration of compound against proliferation of NPM/ALK positive Karpas-299 cells upon incubation for 24-72 h,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,cell proliferation,IC50,nM,=,32,,,,,,,7.49,,,,,,"Article; Tartari, Carmen J.; Scapozza, Leonardo; Gambacorti-Passerini, Carlo; Current Topics in Medicinal Chemistry; vol. 11; 11; (2011); p. 1406 - 1419;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D32250622&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,Inhibitory concentration of compound against proliferation of NPM/ALK positive SU-DHL-1 cells upon incubation for 24-72 h,,,,,SU-DHL-1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,cell proliferation,IC50,nM,=,43,,,,,,,7.37,,,,,,"Article; Tartari, Carmen J.; Scapozza, Leonardo; Gambacorti-Passerini, Carlo; Current Topics in Medicinal Chemistry; vol. 11; 11; (2011); p. 1406 - 1419;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D32250622&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,Inhibitory concentration of the compound against NPM-ALK tyrosine phosphorylation in Karpas-299 cells,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Npm-Alk Tyrosine Phosphorylation,IC50,nM,=,24,,,,,,,7.62,,,,,,"Review; Cheng, Mangeng; Ott, Gregory R.; Anti-Cancer Agents in Medicinal Chemistry; vol. 10; 3; (2010); p. 236 - 249;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D29756539&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,Inhibitory concentration of the compound against NPM-ALK tyrosine phosphorylation in SU-DHL-1 cells,,,,,SU-DHL-1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Npm-Alk Tyrosine Phosphorylation,IC50,nM,=,24,,,,,,,7.62,,,,,,"Review; Cheng, Mangeng; Ott, Gregory R.; Anti-Cancer Agents in Medicinal Chemistry; vol. 10; 3; (2010); p. 236 - 249;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D29756539&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,Inhibitory concentration of the compound against NPM-ALK phosphorylation in Karpas-299 cells determined by immunoblotting,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Phosphorylation of NPM-Anaplastic Lymphoma Kinase,IC50,nM,=,24,,,,,,,7.62,,,,,,"Article; Milkiewicz, Karen L.; Weinberg, Linda R.; Albom, Mark S.; Angeles, Thelma S.; Cheng, Mangeng; Ghose, Arup K.; Roemmele, Renee C.; Theroff, Jay P.; Underiner, Ted L.; Zificsak, Craig A.; Dorsey, Bruce D.; Bioorganic and Medicinal Chemistry; vol. 18; 12; (2010); p. 4351 - 4362;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D8911700&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,"Inhibitory concentration of compound against anaplastic lymphoma kinase in presence of MgATP upon incubation using 250 uM KKKSPGEYVNIEFG as substrate and 500 cpm/pmol [GAMMA-33P]ATP as radio ligand in 8 mM MOPS, pH 7.0 for 40 min at RT was determined",,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,µM,=,0.02,,,,,,,7.7,,,,KKKSPGEYVNIEFG; MgATP; [GAMMA-33P]ATP,Substrate; Other compound; Radioligand,Article; Huan-Zhang Xie; Hai Lan; You-Li Pan; Jun Zou; Ze-Rong Wang; Lin-Li Li; Qi Huang; Hui Zhang; Sheng-Yong Yang; Chemical biology and drug design; vol. 81; 2; (2013); p. 175 - 184;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D62542121&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,"table 1, compond crizotinib; table 2, compond crizotinib; table 3, compound crizotinib",,,,,IC50,nM,,36,,,,,,,7.44,,,,,,"Article; Park, Chi Hoon; Choe, Hyeonjeong; Jang, In-Young; Kwon, So Yeong; Latif, Muhammad; Lee, Heung Kyoung; Lee, Hyeon Ji; Yang, Eun Hye; Yun, Jeong In; Chae, Chong Hak; Cho, Sung Yun; Choi, Sang Un; Ha, Jae Du; Jung, Heejung; Kim, Hyoung Rae; Kim, Pilho; Lee, Chong Ock; Yun, Chang-Soo; Lee, Kwangho; Bioorganic and Medicinal Chemistry Letters; vol. 23; 22; (2013); p. 6192 - 6196;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61690959&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,"Table 1, Compd crizotinib; Table 3, compd crizotinib",,,,,IC50,nM,,28,7,,,,,,7.55,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Liu, Zhiqing; Ai, Jing; Peng, Xia; Song, Zilan; Wu, Kui; Zhang, Jing; Yao, Qizheng; Chen, Yi; Ji, Yinchun; Yang, Yanhong; Geng, Meiyu; Zhang, Ao; ACS Medicinal Chemistry Letters; vol. 5; 4; (2014); p. 304 - 308;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63306645&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,Cell/tumor cell: proliferation/viability/growth,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,"Table 1, Compd crizotinib; Table 3, compd crizotinib",,,,,IC50,nM,,200,,,,,,,6.7,,,,,,"Article; Liu, Zhiqing; Ai, Jing; Peng, Xia; Song, Zilan; Wu, Kui; Zhang, Jing; Yao, Qizheng; Chen, Yi; Ji, Yinchun; Yang, Yanhong; Geng, Meiyu; Zhang, Ao; ACS Medicinal Chemistry Letters; vol. 5; 4; (2014); p. 304 - 308;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63306645&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,Inhibitory concentration of compound against ALK in presence of 50 uM ATP was determined,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,110,,,,,,,6.96,,,,,,"Article; Li, Jingrong; Wu, Nan; Tian, Yuanxin; Zhang, Jiajie; Wu, Shuguang; ACS Medicinal Chemistry Letters; vol. 4; 8; (2013); p. 806 - 810;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D39563179&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against phosphorylation of human mutant Anaplastic Lymphoma Kinase (ALK) G1202R in NIH-3T3 cells upon incubation for 1 hr by ELISA-SANDWICH METHOD,,,,,NIH 3T3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Alk Phosphorylation,IC (inhibitory concentration),nM,=,1148,,,,,,,5.94,,,,,,"Article; Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4720 - 4744;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718026&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Insertion,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against phosphorylation of human mutant Anaplastic Lymphoma Kinase (ALK) 1151Tins in NIH-3T3 cells upon incubation for 1 hr by ELISA-SANDWICH METHOD,,,,,NIH 3T3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Alk Phosphorylation,IC (inhibitory concentration),nM,=,3039,,,,,,,5.52,,,,,,"Article; Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4720 - 4744;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718026&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against phosphorylation of human mutant Anaplastic Lymphoma Kinase (ALK) L1196M in NIH-3T3 cells upon incubation for 1 hr by ELISA-SANDWICH METHOD,,,,,NIH 3T3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Alk Phosphorylation,IC (inhibitory concentration),nM,=,843,,,,,,,6.07,,,,,,"Article; Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4720 - 4744;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718026&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Radioligand (/ligand),binding activity,In Vitro (Efficacy),,"Binding affinity of the compound towards human mutant Anaplastic Lymphoma Kinase (ALK) L1196M upon incubation in 25 mM Hepes, pH 7.1 for 1 hr using 3 uM 5-FAM-KKSRGDYMTMQIG-CONH2 as substrate",,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,Ki (inhibition constant),nM,=,8.2,,,,,,,8.09,,,,,,"Article; Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4720 - 4744;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718026&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Radioligand (/ligand),binding activity,In Vitro (Efficacy),,"Binding affinity of the compound towards human wild-type Anaplastic Lymphoma Kinase (ALK) upon incubation in 25 mM Hepes, pH 7.1 for 1 hr using 3 uM 5-FAM-KKSRGDYMTMQIG-CONH2 as substrate",,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,Ki (inhibition constant),nM,=,0.74,,,,,,,9.13,,,,,,"Article; Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4720 - 4744;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718026&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against phosphorylation of human wild-type ANAPLASTIC LYMPHOMA KINASE (ALK) in NIH-3T3 cells upon incubation for 1 hr by ELISA-SANDWICH METHOD,,,,,NIH 3T3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Alk Phosphorylation,IC (inhibitory concentration),nM,=,80,,,,,,,7.1,,,,,,"Article; Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4720 - 4744;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718026&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Lipophilic efficiency of the compound towards phosphorylation of human mutant Anaplastic Lymphoma Kinase (ALK) L1196M in NIH-3T3 cells upon incubation for 1 hr by ELISA-SANDWICH METHOD,,,,,NIH 3T3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Alk Phosphorylation,LIPE,nM,=,4.1,,,,,,,,,,,,,"Article; Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4720 - 4744;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718026&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against phosphorylation of human mutant Anaplastic Lymphoma Kinase (ALK) F1174L in NIH-3T3 cells upon incubation for 1 hr by ELISA-SANDWICH METHOD,,,,,NIH 3T3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Alk Phosphorylation,IC (inhibitory concentration),nM,=,165,,,,,,,6.78,,,,,,"Article; Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4720 - 4744;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718026&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against phosphorylation of human mutant Anaplastic Lymphoma Kinase (ALK) C1156Y in NIH-3T3 cells upon incubation for 1 hr by ELISA-SANDWICH METHOD,,,,,NIH 3T3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Alk Phosphorylation,IC (inhibitory concentration),nM,=,478,,,,,,,6.32,,,,,,"Article; Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4720 - 4744;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718026&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against phosphorylation of human mutant Anaplastic Lymphoma Kinase (ALK) G1269A in NIH-3T3 cells upon incubation for 1 hr by ELISA-SANDWICH METHOD,,,,,NIH 3T3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Alk Phosphorylation,IC (inhibitory concentration),nM,=,605,,,,,,,6.22,,,,,,"Article; Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4720 - 4744;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718026&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against phosphorylation of human mutant Anaplastic Lymphoma Kinase (ALK) S1206Y in NIH-3T3 cells upon incubation for 1 hr by ELISA-SANDWICH METHOD,,,,,NIH 3T3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Alk Phosphorylation,IC (inhibitory concentration),nM,=,626,,,,,,,6.2,,,,,,"Article; Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4720 - 4744;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718026&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against phosphorylation of human mutant Anaplastic Lymphoma Kinase (ALK) L1152R in NIH-3T3 cells upon incubation for 1 hr by ELISA-SANDWICH METHOD,,,,,NIH 3T3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Alk Phosphorylation,IC (inhibitory concentration),nM,=,1026,,,,,,,5.99,,,,,,"Article; Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4720 - 4744;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718026&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.03 - 10000 nM,,,,IC50,μM,,0.01,,,,,,,8,,,,,,"Article; Yun, Jeong In; Yang, Eun Hye; Latif, Muhammad; Lee, Hyeon Ji; Lee, Kwangho; Yun, Chang-Soo; Park, Chi Hoon; Lee, Chong Ock; Chae, Chong Hak; Cho, Sung Yun; Jung, Hee Jung; Kim, Pilho; Choi, Sang Un; Kim, Hyoung Rae; Archives of Pharmacal Research; vol. 37; 7; (2014); p. 873 - 881;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63941508&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,L,1196,M",,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.03 - 10000 nM,,,,IC50,μM,,0.22,,,,,,,6.66,,,,,,"Article; Yun, Jeong In; Yang, Eun Hye; Latif, Muhammad; Lee, Hyeon Ji; Lee, Kwangho; Yun, Chang-Soo; Park, Chi Hoon; Lee, Chong Ock; Chae, Chong Hak; Cho, Sung Yun; Jung, Hee Jung; Kim, Pilho; Choi, Sang Un; Kim, Hyoung Rae; Archives of Pharmacal Research; vol. 37; 7; (2014); p. 873 - 881;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63941508&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor; Hepatocyte growth factor receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hepatocyte growth factor receptor activity; hepatocyte growth factor-activated receptor; hgf receptor; hgf-activated receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,820152764 + 817016264,,,go:0005008,ipr:ipr026830,ALK tyrosine kinase receptor; Hepatocyte growth factor receptor,ALK tyrosine kinase receptor:Wild; Hepatocyte growth factor receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,HCC4006 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,μM,>,5,,,,,,,5.3,,,,,,Patent; ROCHE HOLDING AG; WO2014/138364; (2014); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64121410&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor; Hepatocyte growth factor receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hepatocyte growth factor receptor activity; hepatocyte growth factor-activated receptor; hgf receptor; hgf-activated receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,820152764 + 817016264,,,go:0005008,ipr:ipr026830,ALK tyrosine kinase receptor; Hepatocyte growth factor receptor,ALK tyrosine kinase receptor:Wild; Hepatocyte growth factor receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,HCC4006 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,μM,>,5,,,,,,,5.3,,,,,,Patent; ROCHE HOLDING AG; WO2014/138364; (2014); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64121410&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor; Hepatocyte growth factor receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hepatocyte growth factor receptor activity; hepatocyte growth factor-activated receptor; hgf receptor; hgf-activated receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,820152764 + 817016264,,,go:0005008,ipr:ipr026830,ALK tyrosine kinase receptor; Hepatocyte growth factor receptor,ALK tyrosine kinase receptor:Wild; Hepatocyte growth factor receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,HCC4006 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,μM,,3.6,,,,,,,5.44,,,8798958,erlotinib,Other compound,Patent; ROCHE HOLDING AG; WO2014/138364; (2014); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64121410&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory concentration of compound (Dissolved in DMSO) against ALK using 20 ug/ml POLY (GLU,TYR)4:1(SIGMA) as substrate in presence of 10 uM of ATP with 50 mM HEPES buffer, pH 7.4 upon incubation for 60 mins at 37 degree C by ELISA",,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,13.7,,,,,,,7.86,,,,,,"Article; Song, Zilan; Yang, Yanhong; Liu, Zhiqing; Peng, Xia; Guo, Junfeng; Yang, Xinying; Wu, Kui; Ai, Jing; Ding, Jian; Geng, Meiyu; Zhang, Ao; Journal of Medicinal Chemistry; vol. 58; 1; (2015); p. 197 - 211;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64671986&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory concentration of compound (Dissolved in DMSO) against ALK L1196M using 20 ug/ml POLY (GLU,TYR)4:1(SIGMA) as substrate in presence of 10 uM of ATP with 50 mM HEPES buffer, pH 7.4 upon incubation for 60 mins at 37 degree C by ELISA",,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,122,,,,,,,6.91,,,,,,"Article; Song, Zilan; Yang, Yanhong; Liu, Zhiqing; Peng, Xia; Guo, Junfeng; Yang, Xinying; Wu, Kui; Ai, Jing; Ding, Jian; Geng, Meiyu; Zhang, Ao; Journal of Medicinal Chemistry; vol. 58; 1; (2015); p. 197 - 211;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64671986&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,pIC50,,=,8.37,,,,,,,8.37,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,pIC50,,=,8.3,,,,,,,8.3,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,pIC50,,=,8.5,,,,,,,8.5,,,,,,"Article; Gao, Cen; Cahya, Suntara; Nicolaou, Christos A.; Wang, Jibo; Watson, Ian A.; Cummins, David J.; Iversen, Philip W.; Vieth, Michal; Journal of Medicinal Chemistry; vol. 56; 17; (2013); p. 6991 - 7002;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61335421&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vitro (Efficacy),,Inhibitory concentration of compound against tumor cell growth in human KARPAS-299 cell line harboring NPM-ALK fusion variant,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Growth inhibition,IC50,nM,,74 - 566,,,,,,,7.13,,,,,,"Review; Cui, J. Jean; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4427 - 4453;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718010&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vitro (Efficacy),,Inhibitory concentration of compound against tumor cell growth in human Kelly neuroblastoma cell line harboring ALK activating mutation,,,,,Kelly cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Growth inhibition,IC50,nM,,74 - 566,,,,,,,7.13,,,,,,"Review; Cui, J. Jean; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4427 - 4453;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718010&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vitro (Efficacy),,Inhibitory concentration of compound against tumor cell growth in human SU-DHL-1 cell line harboring NPM-ALK fusion variant,,,,,SU-DHL-1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,Growth inhibition,IC50,nM,,74 - 566,,,,,,,7.13,,,,,,"Review; Cui, J. Jean; Journal of Medicinal Chemistry; vol. 57; 11; (2014); p. 4427 - 4453;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D63718010&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0 - 500 nM,,,,IC50,nM,,76.3,,,,,,,7.12,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,7.8 nM,,,,inhibition percentage,%,,15,,,,,,,1,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15.6 nM,,,,inhibition percentage,%,,18,,,,,,,1,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,30 nM,,,,inhibition percentage,%,,20,,,,,,,1,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,31.25 nM,,,,inhibition percentage,%,,34,,,,,,,7.22,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,65 nM,,,,inhibition percentage,%,,43,,,,,,,7.06,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,62.5 nM,,,,inhibition percentage,%,,49,,,,,,,7.19,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,125 nM,,,,inhibition percentage,%,,64,,,,,,,7.15,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,,inhibition percentage,%,,70,,,,,,,6.97,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,500 nM,,,,inhibition percentage,%,,75,,,,,,,6.78,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1000 nM,,,,inhibition percentage,%,,76,,,,,,,6.5,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1500 nM,,,,inhibition percentage,%,,77,,,,,,,6.35,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0 - 1500 nM,,,,IC50,nM,,27.2,,,,,,,7.57,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15.6 nM,,,,inhibition percentage,%,,17,,,,,,,1,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 nM,,,,inhibition percentage,%,,29,,,,,,,7.44,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,30 nM,,,,inhibition percentage,%,,43,,,,,,,7.4,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,31.25 nM,,,,inhibition percentage,%,,65,,,,,,,7.77,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,7.8 nM,,,,inhibition percentage,%,,6,,,,,,,1,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,62.5 nM,,,,inhibition percentage,%,,73,,,,,,,7.64,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,125 nM,,,,inhibition percentage,%,,84,,,,,,,7.62,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,,inhibition percentage,%,,89,,,,,,,7.51,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,500 nM,,,,inhibition percentage,%,,91,,,,,,,7.31,,,73010,ATP,Substrate,Patent; JSR CORPORATION; WO2015/23553; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65376353&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.0006,,,,,,,9.22,,,,,,"Article; Abdelazem, Ahmed Z.; Al-Sanea, Mohammad M.; Park, Byung Sun; Park, Hye Mi; Yoo, Kyung Ho; Sim, Taebo; Park, Jong Bae; Lee, Seung-Hoon; Lee, So Ha; European Journal of Medicinal Chemistry; vol. 90; (2015); p. 195 - 208;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64666391&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,Crizotinib,,,,,IC50,μM,,0.036,,,,,,,7.44,,,,,,Patent; PINOTBIO INC; EP2883875; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D66512364&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK kinase,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,24,,,,,,,7.62,,,,,,Patent; ROCHE HOLDING AG; WO2015/66452; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D66155960&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.036,,,,,,,7.44,,,,,,Patent; PINOTBIO INC; US2015/152069; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D66336851&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,Leucine,1196,Methionine",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.22,,,,,,,6.66,,,,,,Patent; PINOTBIO INC; US2015/152069; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D66336851&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,,5,,,,,,,8.3,,,,,,"Article; He, Xueqian; Zhang, Zhenzhen; Chen, Yinghan; Che, Qian; Zhu, Tianjiao; Gu, Qianqun; Li, Dehai; Journal of Natural Products; vol. 78; 11; (2015); p. 2841 - 2845;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67658408&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of compound against wild type ALK using 5 ul ADENOSINE TRIPHOSPHATE (ATP) as substrate upon incubation at RT for 30 mins,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,µM,=,0.01,,,,,,,8,,,,,,Patent; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY; BAYER AG; WO2015/130014; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67118864&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of compound against L1196M mutant ALK using 5 ul ADENOSINE TRIPHOSPHATE (ATP) as substrate upon incubation at RT for 30 mins,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,µM,=,0.22,,,,,,,6.66,,,,,,Patent; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY; BAYER AG; WO2015/130014; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67118864&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory concentration of the compound against 128 nM mutant S1206Y human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",,,,,Sf9 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,200,,,,,,,6.7,,,,,,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67125752&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory concentration of the compound against 1 nM mutant L1196M human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",,,,,Sf9 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,529,,,,,,,6.28,,,,,,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67125752&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory concentration of the compound against 1 nM mutant L1196M human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",,,,,Sf9 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,427,,,,,,,6.37,,,,,,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67125752&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory concentration of the compound against 1 nM mutant F1174L human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",,,,,Sf9 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,66,,,,,,,7.18,,,,,,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67125752&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory concentration of the compound against 2 nM mutant G1269A human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",,,,,Sf9 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,821,,,,,,,6.09,,,,,,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67125752&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory concentration of the compound against 2 nM mutant G1269A human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",,,,,Sf9 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,580,,,,,,,6.24,,,,,,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67125752&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",,,,,Sf9 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,=,34.5,,,,,,,7.46,,,,,,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67125752&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against mutant ANAPLASTIC LYMPHOMA KINASE L1196M upon incubation for 30 mins at RT in presence of 5 ul ATP using Biotinylated peptide as susbstrate by HOMOGENEOUS TIME RESOLVED FLUORESCENCE (HTRF) ASSAY,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,µM,=,0.22,,,,,,,6.66,,,,,,Patent; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY; WO2015/194764; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68727379&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against wild type ANAPLASTIC LYMPHOMA KINASE upon incubation for 30 mins at RT in presence of 5 ul ATP using Biotinylated peptide as substrate by HOMOGENEOUS TIME RESOLVED FLUORESCENCE (HTRF) ASSAY,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,µM,=,0.036,,,,,,,7.44,,,,,,Patent; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY; WO2015/194764; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68727379&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,HEK293 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,Kd (dissociation constant),nM,,4.8,,,,,,,8.32,,,,,,"Article; Kumar, Anish; Shanthi; Ramanathan; Molecular Informatics; vol. 34; 2-3; (2015); p. 105 - 114;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65388502&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,Cysteine,1156,Tyrosine",,Transfected,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,HEK293 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,Kd (dissociation constant),nM,,2.2,,,,,,,8.66,,,,,,"Article; Kumar, Anish; Shanthi; Ramanathan; Molecular Informatics; vol. 34; 2-3; (2015); p. 105 - 114;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65388502&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,7.8 - 1500 nM,,,,IC50,nM,,76.3,,,,67722,adenosine 5'-diphosphate,,7.12,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15.6 nM,,,,inhibition percentage,%,,17,,,,67722,adenosine 5'-diphosphate,,1,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 nM,,,,inhibition percentage,%,,29,,,,67722,adenosine 5'-diphosphate,,7.44,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,30 nM,,,,inhibition percentage,%,,43,,,,67722,adenosine 5'-diphosphate,,7.4,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,31.25 nM,,,,inhibition percentage,%,,65,,,,67722,adenosine 5'-diphosphate,,7.77,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,7.8 nM,,,,inhibition percentage,%,,6,,,,67722,adenosine 5'-diphosphate,,1,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,62.5 nM,,,,inhibition percentage,%,,73,,,,67722,adenosine 5'-diphosphate,,7.64,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,125 nM,,,,inhibition percentage,%,,84,,,,67722,adenosine 5'-diphosphate,,7.62,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,,inhibition percentage,%,,89,,,,67722,adenosine 5'-diphosphate,,7.51,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,500 nM,,,,inhibition percentage,%,,91,,,,67722,adenosine 5'-diphosphate,,7.31,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,7.8 nM,,,,inhibition percentage,%,,15,,,,67722,adenosine 5'-diphosphate,,1,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15.6 nM,,,,inhibition percentage,%,,18,,,,67722,adenosine 5'-diphosphate,,1,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,30 nM,,,,inhibition percentage,%,,20,,,,67722,adenosine 5'-diphosphate,,1,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,31.25 nM,,,,inhibition percentage,%,,34,,,,67722,adenosine 5'-diphosphate,,7.22,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,65 nM,,,,inhibition percentage,%,,43,,,,67722,adenosine 5'-diphosphate,,7.06,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,62.5 nM,,,,inhibition percentage,%,,49,,,,67722,adenosine 5'-diphosphate,,7.19,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,125 nM,,,,inhibition percentage,%,,64,,,,67722,adenosine 5'-diphosphate,,7.15,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,,inhibition percentage,%,,70,,,,67722,adenosine 5'-diphosphate,,6.97,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,500 nM,,,,inhibition percentage,%,,75,,,,67722,adenosine 5'-diphosphate,,6.78,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1000 nM,,,,inhibition percentage,%,,76,,,,67722,adenosine 5'-diphosphate,,6.5,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1500 nM,,,,inhibition percentage,%,,77,,,,67722,adenosine 5'-diphosphate,,6.35,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,7.8 - 500 nM,,,,IC50,nM,,27.2,,,,67722,adenosine 5'-diphosphate,,7.57,,,73010,ATP,Other compound,Patent; M MED GLOBAL; US2016/106439; (2016); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68845594&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nmol/l,,25,,,,,,,7.6,,,73010,ATP,Other compound,"Article; Wang, Yu; Zhang, Guogang; Hu, Gang; Bu, Yanxin; Lei, Hongrui; Zuo, Daiying; Han, Mengting; Zhai, Xin; Gong, Ping; European Journal of Medicinal Chemistry; vol. 123; (2016); p. 80 - 89;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69330748&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,Leucine,1196,Methionine",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nmol/l,,980,,,,,,,6.01,,,73010,ATP,Other compound,"Article; Wang, Yu; Zhang, Guogang; Hu, Gang; Bu, Yanxin; Lei, Hongrui; Zuo, Daiying; Han, Mengting; Zhai, Xin; Gong, Ping; European Journal of Medicinal Chemistry; vol. 123; (2016); p. 80 - 89;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69330748&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],"ALK tyrosine kinase receptor [human]:Mutated:Substitution,1,Cysteine,1097,Serine",human,Transfected,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,1 mM,,,,kon,ms-1,,11700000,,,,,,,,,,,,,"Article; Tu, Chih-Hsiang; Lin, Wen-Hsing; Peng, Yi-Hui; Hsu, Tsu; Wu, Jian-Sung; Chang, Chun-Yu; Lu, Cheng-Tai; Lyu, Ping-Chiang; Shih, Chuan; Jiaang, Weir-Torn; Wu, Su-Ying; Journal of Medicinal Chemistry; vol. 59; 8; (2016); p. 3906 - 3919;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68887217&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],"ALK tyrosine kinase receptor [human]:Mutated:Substitution,1,Cysteine,1097,Serine",human,Transfected,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,Sf21 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,1 mM,,,,koff,s-1,,0.0355,,,,,,,,,,,,,"Article; Tu, Chih-Hsiang; Lin, Wen-Hsing; Peng, Yi-Hui; Hsu, Tsu; Wu, Jian-Sung; Chang, Chun-Yu; Lu, Cheng-Tai; Lyu, Ping-Chiang; Shih, Chuan; Jiaang, Weir-Torn; Wu, Su-Ying; Journal of Medicinal Chemistry; vol. 59; 8; (2016); p. 3906 - 3919;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68887217&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,0.64,,,,,,,9.19,,,73010,ATP,Other compound,"Article; Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.; Journal of Medicinal Chemistry; vol. 59; 10; (2016); p. 4948 - 4964;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68998272&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,SU-DHL-1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,92.3,,,,,,,7.03,,,,,,"Article; Han, Mei; Wang, Chengyan; Ji, Yinchun; Song, Zilan; Xing, Li; Su, Yi; Wang, Xisheng; Zhang, Ao; Ai, Jing; Geng, Meiyu; Bioorganic and Medicinal Chemistry Letters; vol. 26; 22; (2016); p. 5399 - 5402;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69924852&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,104.9,,,,,,,6.98,,,,,,"Article; Han, Mei; Wang, Chengyan; Ji, Yinchun; Song, Zilan; Xing, Li; Su, Yi; Wang, Xisheng; Zhang, Ao; Ai, Jing; Geng, Meiyu; Bioorganic and Medicinal Chemistry Letters; vol. 26; 22; (2016); p. 5399 - 5402;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69924852&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,100.9,,,,,,,7,,,,,,"Article; Han, Mei; Wang, Chengyan; Ji, Yinchun; Song, Zilan; Xing, Li; Su, Yi; Wang, Xisheng; Zhang, Ao; Ai, Jing; Geng, Meiyu; Bioorganic and Medicinal Chemistry Letters; vol. 26; 22; (2016); p. 5399 - 5402;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69924852&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SK-N-BE(2) cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 nM - 10 μM,,,,IC50,nM,,710,,,,,,,6.15,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1152,r; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,DFCI076 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 nM - 10 μM,,,,IC50,nM,,233 - 0.248,,,,,,,6.63,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1269,a; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,DFCI114 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 nM - 10 μM,,,,IC50,nM,,1615 - 1.697,,,,,,,5.79,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,f,1174,l; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 nM - 10 μM,,,,IC50,nM,,211,,,,,,,6.68,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,f,1174,l; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,LA-N-1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 nM - 10 μM,,,,IC50,nM,,1346,,,,,,,5.87,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,f,1174,l; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 nM - 10 μM,,,,IC50,nM,,523,,,,,,,6.28,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,f,1174,l; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SK-N-SH cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 nM - 10 μM,,,,IC50,nM,,370,,,,,,,6.43,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SK-N-FI cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 nM - 10 μM,,,,IC50,nM,,1469,,,,,,,5.83,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SK-N-AS cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 nM - 10 μM,,,,IC50,nM,,1473,,,,,,,5.83,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Wild,,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,56,,,,,,,7.25,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Wild,,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.05,,,,,,,7.3,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.315,,,,,,,6.5,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,c,1156,y",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.184,,,,,,,6.74,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,r",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.482,,,,,,,6.32,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1152,r; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.697,,,,,,,6.16,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1269,a; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.553,,,,,,,6.26,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,s,1206,y",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.133,,,,,,,6.88,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,c,1156,y",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,144,,,,,,,6.84,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,r",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,549,,,,,,,6.26,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1152,r; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,645,,,,,,,6.19,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,328,,,,,,,6.48,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1269,a; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,512,,,,,,,6.29,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,s,1206,y",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,65,,,,,,,7.19,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,,10.5,,,,,,,7.98,,,25176367,,Other compound,"Article; Gao, Yang; Ye, De-Yong; Zhou, Wei-Cheng; Chu, Yong; European Journal of Medicinal Chemistry; vol. 135; (2017); p. 370 - 381;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71108067&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,f,1174,l",,Transfected,Inhibitor,antiproliferative agent,In Vitro (Efficacy),,,,,,,Ba/F3-EML4-ALK cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,GI50,μM,,0.32,,,,,,,6.49,,,,,,"Article; Chen, Yongfei; Wu, Jiaxin; Wang, Aoli; Qi, Ziping; Jiang, Taoshan; Chen, Cheng; Zou, Fengming; Hu, Chen; Wang, Wei; Wu, Hong; Hu, Zhenquan; Wang, Wenchao; Wang, Beilei; Wang, Li; Ren, Tao; Zhang, Shanchun; Liu, Qingsong; Liu, Jing; European Journal of Medicinal Chemistry; vol. 139; (2017); p. 674 - 697;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71895642&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,c,1156,y",,Transfected,Inhibitor,antiproliferative agent,In Vitro (Efficacy),,,,,,,BA/F3-TEL cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,GI50,μM,,0.15,,,,,,,6.82,,,,,,"Article; Chen, Yongfei; Wu, Jiaxin; Wang, Aoli; Qi, Ziping; Jiang, Taoshan; Chen, Cheng; Zou, Fengming; Hu, Chen; Wang, Wei; Wu, Hong; Hu, Zhenquan; Wang, Wenchao; Wang, Beilei; Wang, Li; Ren, Tao; Zhang, Shanchun; Liu, Qingsong; Liu, Jing; European Journal of Medicinal Chemistry; vol. 139; (2017); p. 674 - 697;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71895642&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,Transfected,Inhibitor,antiproliferative agent,In Vitro (Efficacy),,,,,,,BA/F3-TEL cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,GI50,μM,,0.59,,,,,,,6.23,,,,,,"Article; Chen, Yongfei; Wu, Jiaxin; Wang, Aoli; Qi, Ziping; Jiang, Taoshan; Chen, Cheng; Zou, Fengming; Hu, Chen; Wang, Wei; Wu, Hong; Hu, Zhenquan; Wang, Wenchao; Wang, Beilei; Wang, Li; Ren, Tao; Zhang, Shanchun; Liu, Qingsong; Liu, Jing; European Journal of Medicinal Chemistry; vol. 139; (2017); p. 674 - 697;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71895642&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,Transfected,Inhibitor,antiproliferative agent,In Vitro (Efficacy),,,,,,,BA/F3-TEL cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,GI50,μM,,0.43,,,,,,,6.37,,,,,,"Article; Chen, Yongfei; Wu, Jiaxin; Wang, Aoli; Qi, Ziping; Jiang, Taoshan; Chen, Cheng; Zou, Fengming; Hu, Chen; Wang, Wei; Wu, Hong; Hu, Zhenquan; Wang, Wenchao; Wang, Beilei; Wang, Li; Ren, Tao; Zhang, Shanchun; Liu, Qingsong; Liu, Jing; European Journal of Medicinal Chemistry; vol. 139; (2017); p. 674 - 697;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71895642&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,EC50,nmol,,0.47,,,,,,,,,,,,,"Article; Luo, Lian-Xiang; Li, Ying; Niu, Yu-Zhen; Wang, Yu-Wei; Wang, Qian-Qian; Fan, Xing-Xing; Xu, Jia-Hui; Liu, Liang; Leung, Elaine Lai-Han; Yao, Xiao-Jun; MedChemComm; vol. 8; 10; (2017); p. 1914 - 1918;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72420019&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2.5 μM,,,phosphorylation,percentage decrease,,Active,,,,ALK tyrosine kinase receptor,,,,5.6,,,,,,"Article; Luo, Lian-Xiang; Li, Ying; Niu, Yu-Zhen; Wang, Yu-Wei; Wang, Qian-Qian; Fan, Xing-Xing; Xu, Jia-Hui; Liu, Liang; Leung, Elaine Lai-Han; Yao, Xiao-Jun; MedChemComm; vol. 8; 10; (2017); p. 1914 - 1918;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72420019&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2.5 μM,,,phosphorylation,percentage decrease,,Active,,,,Dual specificity mitogen-activated protein kinase kinase 2,,,,5.6,,,,,,"Article; Luo, Lian-Xiang; Li, Ying; Niu, Yu-Zhen; Wang, Yu-Wei; Wang, Qian-Qian; Fan, Xing-Xing; Xu, Jia-Hui; Liu, Liang; Leung, Elaine Lai-Han; Yao, Xiao-Jun; MedChemComm; vol. 8; 10; (2017); p. 1914 - 1918;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72420019&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2.5 μM,,,phosphorylation,percentage decrease,,Active,,,,Signal transducer and activator of transcription 3,,,,5.6,,,,,,"Article; Luo, Lian-Xiang; Li, Ying; Niu, Yu-Zhen; Wang, Yu-Wei; Wang, Qian-Qian; Fan, Xing-Xing; Xu, Jia-Hui; Liu, Liang; Leung, Elaine Lai-Han; Yao, Xiao-Jun; MedChemComm; vol. 8; 10; (2017); p. 1914 - 1918;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72420019&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2.5 μM,,,phosphorylation,percentage decrease,,Active,,,,RAC-alpha serine/threonine-protein kinase,,,,5.6,,,,,,"Article; Luo, Lian-Xiang; Li, Ying; Niu, Yu-Zhen; Wang, Yu-Wei; Wang, Qian-Qian; Fan, Xing-Xing; Xu, Jia-Hui; Liu, Liang; Leung, Elaine Lai-Han; Yao, Xiao-Jun; MedChemComm; vol. 8; 10; (2017); p. 1914 - 1918;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72420019&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2.5 μM,,,Apoptotic cells,apoptotic cell percentage,%,,26.1,,,,,,,,,,,,,"Article; Luo, Lian-Xiang; Li, Ying; Niu, Yu-Zhen; Wang, Yu-Wei; Wang, Qian-Qian; Fan, Xing-Xing; Xu, Jia-Hui; Liu, Liang; Leung, Elaine Lai-Han; Yao, Xiao-Jun; MedChemComm; vol. 8; 10; (2017); p. 1914 - 1918;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72420019&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,32.2,,,,,,,7.49,,,,,,"Article; Wang, Yu; Chen, Shaowei; Hu, Gang; Wang, Jiao; Gou, Wenfeng; Zuo, Daiying; Gu, Yucheng; Gong, Ping; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 143; (2018); p. 123 - 136;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72656773&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS;+ALK tyrosine kinase receptor;+Hepatocyte growth factor receptor,c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros-1; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hepatocyte growth factor receptor activity; hepatocyte growth factor-activated receptor; hgf receptor; hgf-activated receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,820045325 + 820152764 + 817016264,,,go:0005008,ipr:ipr026830,ALK tyrosine kinase receptor; Hepatocyte growth factor receptor; Proto-oncogene tyrosine-protein kinase ROS,Proto-oncogene tyrosine-protein kinase ROS:Wild + ALK tyrosine kinase receptor:Wild + Hepatocyte growth factor receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,IMS-M2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,60.9,,,,,,,7.22,,,,,,"Article; Smith, Kristen M.; Fagan, Patrick C.; Pomari, Elena; Germano, Giuseppe; Frasson, Chiara; Walsh, Colin; Silverman, Ian; Bonvini, Paolo; Li, Gang; Molecular Cancer Therapeutics; vol. 17; 2; (2018); p. 455 - 463;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73087442&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS;+ALK tyrosine kinase receptor;+Hepatocyte growth factor receptor,c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros-1; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hepatocyte growth factor receptor activity; hepatocyte growth factor-activated receptor; hgf receptor; hgf-activated receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,820045325 + 820152764 + 817016264,,,go:0005008,ipr:ipr026830,ALK tyrosine kinase receptor; Hepatocyte growth factor receptor; Proto-oncogene tyrosine-protein kinase ROS,Proto-oncogene tyrosine-protein kinase ROS:Wild + ALK tyrosine kinase receptor:Wild + Hepatocyte growth factor receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,M0-91 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,121.9,,,,,,,6.91,,,,,,"Article; Smith, Kristen M.; Fagan, Patrick C.; Pomari, Elena; Germano, Giuseppe; Frasson, Chiara; Walsh, Colin; Silverman, Ian; Bonvini, Paolo; Li, Gang; Molecular Cancer Therapeutics; vol. 17; 2; (2018); p. 455 - 463;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73087442&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS;+ALK tyrosine kinase receptor;+Hepatocyte growth factor receptor,c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros-1; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hepatocyte growth factor receptor activity; hepatocyte growth factor-activated receptor; hgf receptor; hgf-activated receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,820045325 + 820152764 + 817016264,,,go:0005008,ipr:ipr026830,ALK tyrosine kinase receptor; Hepatocyte growth factor receptor; Proto-oncogene tyrosine-protein kinase ROS,Proto-oncogene tyrosine-protein kinase ROS:Wild + ALK tyrosine kinase receptor:Wild + Hepatocyte growth factor receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Kasumi-1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>,1000,,,,,,,6,,,,,,"Article; Smith, Kristen M.; Fagan, Patrick C.; Pomari, Elena; Germano, Giuseppe; Frasson, Chiara; Walsh, Colin; Silverman, Ian; Bonvini, Paolo; Li, Gang; Molecular Cancer Therapeutics; vol. 17; 2; (2018); p. 455 - 463;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73087442&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,355,,,,,,,6.45,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>,9000,,,,,,,5.05,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,s,1206,y",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,353,,,,,,,6.45,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1152,r",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,148,,,,,,,6.83,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SU-DHL-1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,155,,,,,,,6.81,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,176,,,,,,,6.75,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3-EML4-ALK cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,57.5,,,,,,,7.24,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3-EML4-ALK cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,340,,,,,,,6.47,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3-EML4-ALK cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,564,,,,,,,6.25,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC78 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,889,,,,,,,6.05,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,644,,,,,,,6.19,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,1.8,,,,,,,8.74,,,,,,"Article; Iikubo, Kazuhiko; Kondoh, Yutaka; Shimada, Itsuro; Matsuya, Takahiro; Mori, Kenichi; Ueno, Yoko; Okada, Minoru; Chemical and Pharmaceutical Bulletin; vol. 66; 3; (2018); p. 251 - 262;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73319905&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor;+Nucleophosmin,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + npm; npm1; nucleolar phosphoprotein b23; nucleolar protein no38; nucleophosmin; numatrin,820152764 + 820016608,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Nucleophosmin,ALK tyrosine kinase receptor:Wild + Nucleophosmin:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,2,,,,,,,8.7,,,,,,"Article; Iikubo, Kazuhiko; Kondoh, Yutaka; Shimada, Itsuro; Matsuya, Takahiro; Mori, Kenichi; Ueno, Yoko; Okada, Minoru; Chemical and Pharmaceutical Bulletin; vol. 66; 3; (2018); p. 251 - 262;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73319905&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,2,,,,,,,8.7,,,,,,"Article; Iikubo, Kazuhiko; Kondoh, Yutaka; Shimada, Itsuro; Matsuya, Takahiro; Mori, Kenichi; Ueno, Yoko; Okada, Minoru; Chemical and Pharmaceutical Bulletin; vol. 66; 3; (2018); p. 251 - 262;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73319905&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,1.5,,,,,,,8.82,,,,,,"Article; Iikubo, Kazuhiko; Kondoh, Yutaka; Shimada, Itsuro; Matsuya, Takahiro; Mori, Kenichi; Ueno, Yoko; Okada, Minoru; Chemical and Pharmaceutical Bulletin; vol. 66; 3; (2018); p. 251 - 262;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73319905&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor;+Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,ALK tyrosine kinase receptor:Chimera + Echinoderm microtubule-associated protein-like 4:Chimera,,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Ba/F3-EML4-ALK cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,54.92,,,,,,,7.26,,,,,,Patent; XIAMEN UNIVERSITY; EP3290420; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73460087&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor;+Nucleophosmin,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + npm; npm1; nucleolar phosphoprotein b23; nucleolar protein no38; nucleophosmin; numatrin,820152764 + 820016608,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Nucleophosmin,ALK tyrosine kinase receptor:Chimera + Nucleophosmin:Chimera,,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Ba/F3-NPM-ALK cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,inhibition percentage,,ND,,,,,,,,,,,,,,Patent; XIAMEN UNIVERSITY; EP3290420; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73460087&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4;+ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"Echinoderm microtubule-associated protein-like 4:Chimera + ALK tyrosine kinase receptor:Chimera:Substitution,1,l,1196,m",,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Ba/F3-EML4-ALK (L1196M) cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,741.73,,,,,,,6.13,,,,,,Patent; XIAMEN UNIVERSITY; EP3290420; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73460087&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,1077.33,,,,,,,5.97,,,,,,Patent; XIAMEN UNIVERSITY; EP3290420; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73460087&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.001 - 10 μM,,,,inhibition percentage,,Active,,,,,,,,9,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.001 - 10 μM,,,,inhibition percentage,,Active,,,,,,,,9,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,KP-N-RT-BM-1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.001 - 10 μM,,,,inhibition percentage,,Active,,,,,,,,9,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.001 - 10 μM,,,,inhibition percentage,,Active,,,,,,,,9,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.5 μM,,,,inhibition percentage,%,>,80,,,,,,,6.9,,,73010,ATP,Other compound,"Article; May-Dracka, Tricia L.; Arduini, Robert; Bertolotti-Ciarlet, Andrea; Bhisetti, Govinda; Brickelmaier, Margot; Cahir-McFarland, Ellen; Enyedy, Istvan; Fontenot, Jason D.; Hesson, Thomas; Little, Kevin; Lyssikatos, Joe; Marcotte, Douglas; McKee, Timothy; Murugan, Paramasivam; Patterson, Thomas; Peng, Hairuo; Rushe, Mia; Silvian, Laura; Spilker, Kerri; Wu, Ping; Xin, Zhili; Burkly, Linda C.; Bioorganic and Medicinal Chemistry Letters; vol. 28; 10; (2018); p. 1964 - 1971;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73793125&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,MHCC97-H cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.01 - 10000 nM,,,,IC50,nM,,78.57,,,,,,,7.1,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Huh-7 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.01 - 10000 nM,,,,IC50,nM,,70.35,,,,,,,7.15,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Hep 3B2.1-7 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.01 - 10000 nM,,,,IC50,nM,,77.05,,,,,,,7.11,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.01 - 10000 nM,,,,IC50,nM,,10.91,,,,,,,7.96,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCCLM3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.01 - 10000 nM,,,,IC50,nM,,15.18,,,,,,,7.82,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK expressed in Escherichia coli BL21 upon incubation at RT for 1 hour,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,,,,,,IC50,nM,<,100,,,,,,,7,,,,,,Patent; BETTA PHARMACEUTICALS CO LTD; WO2009/154769; (2009); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D8809891&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,LNCaP cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,5 μM,,,,cell viability decrease,,Active,,,,,,,,5.3,,,,,,"Article; Carneiro, Benedito A.; Pamarthy, Sahithi; Shah, Ami N.; Sagar, Vinay; Unno, Kenji; Han, HuiYing; Yang, Ximing J.; Costa, Rubens B.; Nagy, Rebecca J.; Lanman, Richard B.; Kuzel, Timothy M.; Ross, Jeffrey S.; Gay, Laurie; Elvin, Julia A.; Ali, Siraj M.; Cristofanilli, Massimo; Chae, Young K.; Giles, Francis J.; Abdulkadir, Sarki A.; Clinical Cancer Research; vol. 24; 12; (2018); p. 2732 - 2739;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74731219&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,LNCaP cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,5 μM,,,,cell viability decrease,,Active,,,,,,,,5.3,,,,,,"Article; Carneiro, Benedito A.; Pamarthy, Sahithi; Shah, Ami N.; Sagar, Vinay; Unno, Kenji; Han, HuiYing; Yang, Ximing J.; Costa, Rubens B.; Nagy, Rebecca J.; Lanman, Richard B.; Kuzel, Timothy M.; Ross, Jeffrey S.; Gay, Laurie; Elvin, Julia A.; Ali, Siraj M.; Cristofanilli, Massimo; Chae, Young K.; Giles, Francis J.; Abdulkadir, Sarki A.; Clinical Cancer Research; vol. 24; 12; (2018); p. 2732 - 2739;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74731219&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,LNCaP cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,5 μM,,,,cell viability decrease,,Active,,,,,,,,5.3,,,,,,"Article; Carneiro, Benedito A.; Pamarthy, Sahithi; Shah, Ami N.; Sagar, Vinay; Unno, Kenji; Han, HuiYing; Yang, Ximing J.; Costa, Rubens B.; Nagy, Rebecca J.; Lanman, Richard B.; Kuzel, Timothy M.; Ross, Jeffrey S.; Gay, Laurie; Elvin, Julia A.; Ali, Siraj M.; Cristofanilli, Massimo; Chae, Young K.; Giles, Francis J.; Abdulkadir, Sarki A.; Clinical Cancer Research; vol. 24; 12; (2018); p. 2732 - 2739;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74731219&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,LNCaP cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,10 μM,,,,cell viability decrease,,Active,,,,,,,,5,,,,,,"Article; Carneiro, Benedito A.; Pamarthy, Sahithi; Shah, Ami N.; Sagar, Vinay; Unno, Kenji; Han, HuiYing; Yang, Ximing J.; Costa, Rubens B.; Nagy, Rebecca J.; Lanman, Richard B.; Kuzel, Timothy M.; Ross, Jeffrey S.; Gay, Laurie; Elvin, Julia A.; Ali, Siraj M.; Cristofanilli, Massimo; Chae, Young K.; Giles, Francis J.; Abdulkadir, Sarki A.; Clinical Cancer Research; vol. 24; 12; (2018); p. 2732 - 2739;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74731219&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,LNCaP cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,10 μM,,,,cell viability decrease,,Active,,,,,,,,5,,,,,,"Article; Carneiro, Benedito A.; Pamarthy, Sahithi; Shah, Ami N.; Sagar, Vinay; Unno, Kenji; Han, HuiYing; Yang, Ximing J.; Costa, Rubens B.; Nagy, Rebecca J.; Lanman, Richard B.; Kuzel, Timothy M.; Ross, Jeffrey S.; Gay, Laurie; Elvin, Julia A.; Ali, Siraj M.; Cristofanilli, Massimo; Chae, Young K.; Giles, Francis J.; Abdulkadir, Sarki A.; Clinical Cancer Research; vol. 24; 12; (2018); p. 2732 - 2739;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74731219&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,LNCaP cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,10 μM,,,,cell viability decrease,,Active,,,,,,,,5,,,,,,"Article; Carneiro, Benedito A.; Pamarthy, Sahithi; Shah, Ami N.; Sagar, Vinay; Unno, Kenji; Han, HuiYing; Yang, Ximing J.; Costa, Rubens B.; Nagy, Rebecca J.; Lanman, Richard B.; Kuzel, Timothy M.; Ross, Jeffrey S.; Gay, Laurie; Elvin, Julia A.; Ali, Siraj M.; Cristofanilli, Massimo; Chae, Young K.; Giles, Francis J.; Abdulkadir, Sarki A.; Clinical Cancer Research; vol. 24; 12; (2018); p. 2732 - 2739;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74731219&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC-3 [Human prostate carcinoma] cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,10 μM,,,,cell viability decrease,,Active,,,,,,,,5,,,,,,"Article; Carneiro, Benedito A.; Pamarthy, Sahithi; Shah, Ami N.; Sagar, Vinay; Unno, Kenji; Han, HuiYing; Yang, Ximing J.; Costa, Rubens B.; Nagy, Rebecca J.; Lanman, Richard B.; Kuzel, Timothy M.; Ross, Jeffrey S.; Gay, Laurie; Elvin, Julia A.; Ali, Siraj M.; Cristofanilli, Massimo; Chae, Young K.; Giles, Francis J.; Abdulkadir, Sarki A.; Clinical Cancer Research; vol. 24; 12; (2018); p. 2732 - 2739;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74731219&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,22Rv1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,10 μM,,,,cell viability decrease,,Not active,,,,,,,,1,,,,,,"Article; Carneiro, Benedito A.; Pamarthy, Sahithi; Shah, Ami N.; Sagar, Vinay; Unno, Kenji; Han, HuiYing; Yang, Ximing J.; Costa, Rubens B.; Nagy, Rebecca J.; Lanman, Richard B.; Kuzel, Timothy M.; Ross, Jeffrey S.; Gay, Laurie; Elvin, Julia A.; Ali, Siraj M.; Cristofanilli, Massimo; Chae, Young K.; Giles, Francis J.; Abdulkadir, Sarki A.; Clinical Cancer Research; vol. 24; 12; (2018); p. 2732 - 2739;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74731219&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human];+Echinoderm microtubule-associated protein-like 4 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,818511893 + 818533525,q9um73 + q9hc35,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 4cgc,,,ALK tyrosine kinase receptor [human]; Echinoderm microtubule-associated protein-like 4 [human],ALK tyrosine kinase receptor [human]:Wild + Echinoderm microtubule-associated protein-like 4 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.087,,,,,,,7.06,,,,,,"Article; Guo, Ming; Zuo, Daiying; Zhang, Junlong; Xing, Lingyun; Gou, Wenfeng; Jiang, Feng; Jiang, Nan; Zhang, Dajun; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 158; (2018); p. 322 - 333;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74852954&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human];+Nucleophosmin [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + npm; npm1; nucleolar phosphoprotein b23; nucleolar protein no38; nucleophosmin; numatrin,818511893 + 818246336,q9um73 + p06748,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 2llh; 2p1b; 2vxd; 5ehd,,,ALK tyrosine kinase receptor [human]; Nucleophosmin [human],ALK tyrosine kinase receptor [human]:Wild + Nucleophosmin [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.24,,,,,,,6.62,,,,,,"Article; Guo, Ming; Zuo, Daiying; Zhang, Junlong; Xing, Lingyun; Gou, Wenfeng; Jiang, Feng; Jiang, Nan; Zhang, Dajun; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 158; (2018); p. 322 - 333;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74852954&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,32.2,,,,,,,4.49,,,,,,"Article; Guo, Ming; Zuo, Daiying; Zhang, Junlong; Xing, Lingyun; Gou, Wenfeng; Jiang, Feng; Jiang, Nan; Zhang, Dajun; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 158; (2018); p. 322 - 333;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74852954&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor;+Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,ALK tyrosine kinase receptor:Chimera + Echinoderm microtubule-associated protein-like 4:Chimera,,Transfected,Inhibitor,antiproliferative agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,11.05,,,,,,,7.95,,,,,,Patent; SINO BIOPHARMACEUTICAL LIMITED; EP3381925; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75122127&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,anti-migratory agent,In Vitro (Efficacy),,,,,,,Calu-3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μmol/l,,,,inhibition percentage,,Active,,,,,,,,6,,,8464529,cilengitide,Other compound,"Article; Noh, Ka-Won; Sohn, Insuk; Song, Ji-Young; Shin, Hyun-Tae; Kim, Yu-Jin; Jung, Kyungsoo; Sung, Minjung; Kim, Mingi; An, Sungbin; Han, Joungho; Lee, Se-Hoon; Lee, Mi-Sook; Choi, Yoon-La; Clinical Cancer Research; vol. 24; 17; (2018); p. 4162 - 4174;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74782871&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,BEAS-2B cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μmol/l,,,,cell growth inhibition (%),,Active,,,S,,,,,6,,,8464529,cilengitide,Other compound,"Article; Noh, Ka-Won; Sohn, Insuk; Song, Ji-Young; Shin, Hyun-Tae; Kim, Yu-Jin; Jung, Kyungsoo; Sung, Minjung; Kim, Mingi; An, Sungbin; Han, Joungho; Lee, Se-Hoon; Lee, Mi-Sook; Choi, Yoon-La; Clinical Cancer Research; vol. 24; 17; (2018); p. 4162 - 4174;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74782871&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,anti-migratory agent,In Vitro (Efficacy),,,,,,,BEAS-2B cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.5 μmol/l,,,,inhibition percentage,,Active,,,,,,,,6.3,,,,,,"Article; Noh, Ka-Won; Sohn, Insuk; Song, Ji-Young; Shin, Hyun-Tae; Kim, Yu-Jin; Jung, Kyungsoo; Sung, Minjung; Kim, Mingi; An, Sungbin; Han, Joungho; Lee, Se-Hoon; Lee, Mi-Sook; Choi, Yoon-La; Clinical Cancer Research; vol. 24; 17; (2018); p. 4162 - 4174;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74782871&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,100 mg/kg,oral administration,Repeated,,TGI (tumor growth inhibition rate),,Active,,,,,,,,,,,8464529,cilengitide,Other compound,"Article; Noh, Ka-Won; Sohn, Insuk; Song, Ji-Young; Shin, Hyun-Tae; Kim, Yu-Jin; Jung, Kyungsoo; Sung, Minjung; Kim, Mingi; An, Sungbin; Han, Joungho; Lee, Se-Hoon; Lee, Mi-Sook; Choi, Yoon-La; Clinical Cancer Research; vol. 24; 17; (2018); p. 4162 - 4174;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74782871&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818511893 + 818354751,q9um73 + p08581,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human],ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,A-549 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,EC50,μmol/l,,0.11,,,,,,,6.96,,,,,,"Article; Hoang, Trish T.; Caglar Tanrikulu; Vatland, Quinn A.; Hoang, Trieu M.; Raines, Ronald T.; Molecular Cancer Therapeutics; vol. 17; 12; (2018); p. 2622 - 2632;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75549494&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.000508 - 10 μM,,,,GI50,μM,,0.073,,,,,,,7.14,,,,,,Patent; PRECEDO PHARMACEUTICALS; (75 pag.)EP3392245; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75341707&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3-NPM-ALK cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.000508 - 10 μM,,,,GI50,μM,,0.042,,,,,,,7.38,,,,,,Patent; PRECEDO PHARMACEUTICALS; (75 pag.)EP3392245; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75341707&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NBL-S cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,,percentage of viable cells decrease,,High,,,,,,,,,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,SH-SY5Y cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,,percentage of viable cells decrease,,Not active,,,,,,,,1,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,20 mg/kg,intraperitoneal administration,Repeated,,tumor volume decrease,,Moderate,,,,,,,,,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NBL-S cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,cleaved,protein expression level increase,,Active,,,,Caspase-3,,,,,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,apoptosis inducing factor,In Vivo (Animal models),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,20 mg/kg,intraperitoneal administration,Repeated,cleaved,protein expression level increase,,High,,,,Caspase-3,,,,,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,,percentage of cells in G0/G1 phase,%,,68.1,,,,,,,6.93,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor;+Inhibitor of Bruton tyrosine kinase,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + btki; ibtk; inhibitor of bruton tyrosine kinase; kiaa1417,820152764 + 820113485,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Inhibitor of Bruton tyrosine kinase,ALK tyrosine kinase receptor:Wild + Inhibitor of Bruton tyrosine kinase:Wild,,Non Transfected,,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,,apoptotic cell percentage,%,,18.3,,,,,,,,,,,,,"Article; Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Rönnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui; Oncogene; (2018); p. 1 - 15;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74387858&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,1 - 10,,,,,,,9,,,32376584,phospholipase C-gamma,Substrate,Patent; SHENZHEN TARGETRX INC; EP3415518; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75691224&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>=,100,,,,,,,7,,,32376584,phospholipase C-gamma,Substrate,Patent; SHENZHEN TARGETRX INC; EP3415518; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75691224&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,1 - 10,,,,,,,9,,,,,,Patent; SHENZHEN TARGETRX INC; EP3415518; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75691224&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>=,100,,,,,,,7,,,,,,Patent; SHENZHEN TARGETRX INC; EP3415518; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75691224&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SK-N-BE(2) cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.01 - 10 μM,,,,IC50,μM,,0.86,,,,,,,6.07,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SK-N-BE(2) cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.8 μM,,,,inhibition percentage,,Active,,,,,,,,6.1,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,8 μM,,,in presence of HDAC8i,TGI (tumor growth inhibition rate),,Active,,,,,,,,5.1,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SK-N-BE(2) cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,Tyr 705 phosphorylation,fold,no unit,,0.5,,,Signal transducer and activator of transcription 3,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SK-N-BE(2) cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,acetylation,protein expression level,no unit,,1,,,Structural maintenance of chromosomes protein 3,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SK-N-BE(2) cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,Y473,fold,no unit,,1.1,,,,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SK-N-BE(2) cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,,fold,no unit,,0.5,,,,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,Tyr 705 phosphorylation,fold,no unit,,0.7,,,Signal transducer and activator of transcription 3,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,Tyr 705 phosphorylation,fold,no unit,,0.5,,,Signal transducer and activator of transcription 3,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,LA-N-5 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,Tyr 705 phosphorylation,fold,no unit,,0.7,,,Signal transducer and activator of transcription 3,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,acetylation,protein expression level,no unit,,1.1,,,Structural maintenance of chromosomes protein 3,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,acetylation,protein expression level,no unit,,1.2,,,Structural maintenance of chromosomes protein 3,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,LA-N-5 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,acetylation,protein expression level,no unit,,1.3,,,Structural maintenance of chromosomes protein 3,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,Y473,fold,no unit,,0.7,,,,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,Y473,fold,no unit,,0.2,,,,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,LA-N-5 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,Y473,fold,no unit,,0.2,,,,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,,fold,no unit,,0.2,,,,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,,fold,no unit,,0,,,,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,LA-N-5 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.6 μM,,,,fold,no unit,,0.4,,,,,,,,,,,,,"Article; Shen, Jing; Najafi, Sara; Stäble, Sina; Fabian, Johannes; Koeneke, Emily; Kolbinger, Fiona R.; Wrobel, Jagoda K.; Meder, Benjamin; Distel, Martin; Heimburg, Tino; Sippl, Wolfgang; Jung, Manfred; Peterziel, Heike; Kranz, Dominique; Boutros, Michael; Westermann, Frank; Witt, Olaf; Oehme, Ina; Cell Death and Differentiation; vol. 25; 12; (2018); p. 2053 - 2070;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76584107&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.27,,,,,,,6.57,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3-EML4-ALK (G1202R) cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,>,5,,,,,,,5.3,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,>,5,,,,,,,5.3,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCC78 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.23,,,,,,,6.64,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,A549 (G1202R) cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,1.17,,,,,,,5.93,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,A-549 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,2.31,,,,,,,5.64,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.097,,,,,,,7.01,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,10.3,,,,,,,7.99,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,toxic substance,Toxicity/Safety Pharmacology,,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,50 mg/kg,oral administration,Repeated,,tested,,Not published,,,,,,,,,,,,,,Patent; HONGYUN BIOTECH; EP3498716; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77088103&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor;+Nucleophosmin,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + npm; npm1; nucleolar phosphoprotein b23; nucleolar protein no38; nucleophosmin; numatrin,820152764 + 820016608,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Nucleophosmin,ALK tyrosine kinase receptor:Chimera + Nucleophosmin:Chimera,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,3.3 μM,,,,inhibition percentage,%,,96.54,,,,,,,6.76,,,,,,Patent; HONGYUN BIOTECH; EP3498716; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77088103&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor;+Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,ALK tyrosine kinase receptor:Chimera + Echinoderm microtubule-associated protein-like 4:Chimera,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,3.3 μM,,,,inhibition percentage,%,,98.47,,,,,,,6.76,,,,,,Patent; HONGYUN BIOTECH; EP3498716; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77088103&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,185,,,,,,,6.73,,,,,,Patent; HONGYUN BIOTECH; EP3498716; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77088103&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,61,,,,,,,7.21,,,,,,Patent; HONGYUN BIOTECH; EP3498716; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77088103&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,50 mg/kg,oral administration,Repeated,,tested,,Not published,,,,,,,,,,,,,,Patent; HONGYUN BIOTECH; EP3498716; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77088103&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC-9/GR1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,2.4,,,,,,,5.62,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC-9/GR1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,2.3,,,,,,,5.64,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC-9/GR3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,1,,,,,,,6,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC-9/GR4 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,2.1,,,,,,,5.68,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC-9/GR5 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,2.1,,,,,,,5.68,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC-9/ER cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,1.4,,,,,,,5.85,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC9-GR1-AZD1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.7,,,,,,,6.15,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC9-GR1-AZD2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,1.3,,,,,,,5.89,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC9-GR1-AZD3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.6,,,,,,,6.22,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC9-GR1-AZD4 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.7,,,,,,,6.15,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC-9 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,2,,,,,,,5.7,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC9-GR4-AZD1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,1.9,,,,,,,5.72,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,PC9-GR4-AZD2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,5.8,,,,,,,5.24,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818354751 + 818511893,p08581 + q9um73,1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,Hepatocyte growth factor receptor [human]; ALK tyrosine kinase receptor [human],Hepatocyte growth factor receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,1.5,,,,,,,5.82,,,,,,"Article; Bertran-Alamillo, Jordi; Cattan, Valérie; Schoumacher, Marie; Codony-Servat, Jordi; Giménez-Capitán, Ana; Cantero, Frédérique; Burbridge, Mike; Rodríguez, Sonia; Teixidó, Cristina; Roman, Ruth; Castellví, Josep; García-Román, Silvia; Codony-Servat, Carles; Viteri, Santiago; Cardona, Andrés-Felipe; Karachaliou, Niki; Rosell, Rafael; Molina-Vila, Miguel-Angel; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76452343&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,1.8,,,,,,,8.74,,,,,,"Article; Fushimi, Makoto; Fujimori, Ikuo; Wakabayashi, Takeshi; Hasui, Tomoaki; Kawakita, Youichi; Imamura, Keisuke; Kato, Tomoko; Murakami, Morio; Ishii, Tsuyoshi; Kikko, Yorifumi; Kasahara, Maki; Nakatani, Atsushi; Hiura, Yuto; Miyamoto, Maki; Saikatendu, Kumar; Zou, Hua; Lane, Scott Weston; Lawson, J. David; Imoto, Hiroshi; Journal of Medicinal Chemistry; vol. 62; 10; (2019); p. 4915 - 4935;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76648754&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,HEK293 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,Phospho-ALK (Tyr1604),IC50,nM,,37,,,,,,,7.43,,,,,,"Article; Fushimi, Makoto; Fujimori, Ikuo; Wakabayashi, Takeshi; Hasui, Tomoaki; Kawakita, Youichi; Imamura, Keisuke; Kato, Tomoko; Murakami, Morio; Ishii, Tsuyoshi; Kikko, Yorifumi; Kasahara, Maki; Nakatani, Atsushi; Hiura, Yuto; Miyamoto, Maki; Saikatendu, Kumar; Zou, Hua; Lane, Scott Weston; Lawson, J. David; Imoto, Hiroshi; Journal of Medicinal Chemistry; vol. 62; 10; (2019); p. 4915 - 4935;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76648754&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,"3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine",,,,,IC50,μM,,2.8,,,,,,,5.55,,,,,,"Article; Radaram, Bhasker; Pisaneschi, Federica; Rao, Yi; Yang, Ping; Piwnica-Worms, David; Alauddin, Mian M.; European Journal of Medicinal Chemistry; vol. 182; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77505619&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3-TEL-ALK cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,GI50,μM,,0.141,,,,,,,6.85,,,,,,"Article; Nam, Yunju; Hwang, Dongkeun; Kim, Namdoo; Seo, Hong-Seog; Selim, Khalid B.; Sim, Taebo; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 34; 1; (2019); p. 1426 - 1438;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77554041&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,30,,,,,,,7.52,,,,,,"Article; Chen, Wenteng; Guo, Xiao; Zhang, Can; Ke, Di; Zhang, Guolin; Yu, Yongping; European Journal of Medicinal Chemistry; vol. 183; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77805363&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,human,,glioblastoma,,glioblastoma multiforme cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,reduction of viability,EC50,nM,,5600,,,,,,,5.25,,,,,,"Article; Choi, Peter J.; Cooper, Elizabeth; Schweder, Patrick; Mee, Edward; Faull, Richard; Denny, William A.; Dragunow, Mike; Park, Thomas I.-H.; Jose, Jiney; Bioorganic and Medicinal Chemistry Letters; vol. 29; 18; (2019); p. 2617 - 2621;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77393965&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,human,,glioblastoma,,glioblastoma multiforme cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,540,,,,,,,6.27,,,,,,"Article; Choi, Peter J.; Cooper, Elizabeth; Schweder, Patrick; Mee, Edward; Faull, Richard; Denny, William A.; Dragunow, Mike; Park, Thomas I.-H.; Jose, Jiney; Bioorganic and Medicinal Chemistry Letters; vol. 29; 18; (2019); p. 2617 - 2621;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77393965&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,human,,glioblastoma,,glioblastoma multiforme cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,EC50,μM,,4.3,,,,,,,5.37,,,,,,"Article; Choi, Peter J.; Cooper, Elizabeth; Schweder, Patrick; Mee, Edward; Faull, Richard; Denny, William A.; Dragunow, Mike; Park, Thomas I.-H.; Jose, Jiney; Bioorganic and Medicinal Chemistry Letters; vol. 29; 18; (2019); p. 2617 - 2621;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77393965&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4;+ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"Echinoderm microtubule-associated protein-like 4:Chimera + ALK tyrosine kinase receptor:Chimera:Substitution,1,g,1202,r",,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HEK293T cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizoitinib,,,,,IC50,nM,,2109,,,,,,,5.68,,,,,,"Article; Chen, Jinju; Jiang, Biao; Kong, Ying; Li, Yan; Lin, Haifan; Qiu, Xing; Ren, Chaowei; Song, Xiaoling; Sun, Ning; Yang, Xiaobao; Zhang, Jianshui; Zhong, Hui; Zhou, Yuedong; European Journal of Medicinal Chemistry; vol. 193; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79291484&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,protein tyrosine kinase inhibitor,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,21,,,,,,,7.68,,,,,,"Article; Berger, Walter; Bielec, Bjoern; Heffeter, Petra; Keppler, Bernhard K.; Kowol, Christian R.; Schueffl, Hemma; Terenzi, Alessio; Bioorganic Chemistry; vol. 99; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79422920&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,at 21% O2 (normoxic conditions),IC50,μM,,20.9,,,,,,,4.68,,,,,,"Article; Berger, Walter; Bielec, Bjoern; Heffeter, Petra; Keppler, Bernhard K.; Kowol, Christian R.; Schueffl, Hemma; Terenzi, Alessio; Bioorganic Chemistry; vol. 99; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79422920&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,at 21% O2 (normoxic conditions),IC50,μM,,15.5,,,,,,,4.81,,,,,,"Article; Berger, Walter; Bielec, Bjoern; Heffeter, Petra; Keppler, Bernhard K.; Kowol, Christian R.; Schueffl, Hemma; Terenzi, Alessio; Bioorganic Chemistry; vol. 99; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79422920&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,at 1% O2 (hypoxic conditions),IC50,μM,,17.8,,,,,,,4.75,,,,,,"Article; Berger, Walter; Bielec, Bjoern; Heffeter, Petra; Keppler, Bernhard K.; Kowol, Christian R.; Schueffl, Hemma; Terenzi, Alessio; Bioorganic Chemistry; vol. 99; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79422920&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,at 1% O2 (hypoxic conditions),IC50,μM,,12.8,,,,,,,4.89,,,,,,"Article; Berger, Walter; Bielec, Bjoern; Heffeter, Petra; Keppler, Bernhard K.; Kowol, Christian R.; Schueffl, Hemma; Terenzi, Alessio; Bioorganic Chemistry; vol. 99; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79422920&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.0001 - 100 μM,,,,IC50,μM,,1.7,,,,,,,5.77,,,,,,"Article; Munira, Sirajam; Nakayama, Yuji; Saito, Youhei; Yuki, Ryuzaburo; Cancers; vol. 12; 4; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79649020&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,spindle misorientation and chromosome misalignment,increase rate,,Active,,,,,,,,6,,,,,,"Article; Munira, Sirajam; Nakayama, Yuji; Saito, Youhei; Yuki, Ryuzaburo; Cancers; vol. 12; 4; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79649020&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,,mitosis index change,,Not active,,,,,,,,1,,,,,,"Article; Munira, Sirajam; Nakayama, Yuji; Saito, Youhei; Yuki, Ryuzaburo; Cancers; vol. 12; 4; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79649020&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,number of cells with misaligned chromosome,increase rate,,Active,,,,,,,,6,,,,,,"Article; Munira, Sirajam; Nakayama, Yuji; Saito, Youhei; Yuki, Ryuzaburo; Cancers; vol. 12; 4; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79649020&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,,prophase/prometaphase duration,min,,74,,,,,,,,,,,,,"Article; Munira, Sirajam; Nakayama, Yuji; Saito, Youhei; Yuki, Ryuzaburo; Cancers; vol. 12; 4; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79649020&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,,metaphase duration,min,,83,,,,,,,,,,,,,"Article; Munira, Sirajam; Nakayama, Yuji; Saito, Youhei; Yuki, Ryuzaburo; Cancers; vol. 12; 4; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79649020&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,5 - 5000 nM,,,,inhibition rate,,Active,,,,,,,,8.3,,,,,,Patent; IN3BIO LTD; D HONDT; WO2020/30977; (2020); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79178420&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.1 - 5 μM,,,,decrease rate,,Active,,,,,,,,7,,,,,,Patent; IN3BIO LTD; D HONDT; WO2020/30977; (2020); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79178420&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.1 - 5 μM,,,Tyr 705 phosphorylation,decrease rate,,Active,,,,Signal transducer and activator of transcription 3,,,,7,,,,,,Patent; IN3BIO LTD; D HONDT; WO2020/30977; (2020); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79178420&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.025 - 2.5 μM,,,Tyr 705 phosphorylation,decrease rate,,Active,,,,Signal transducer and activator of transcription 3,,,,7.6,,,,,,Patent; IN3BIO LTD; D HONDT; WO2020/30977; (2020); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79178420&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.1 - 5 μM,,,,decrease rate,,Active,,,,,,,,7,,,,,,Patent; IN3BIO LTD; D HONDT; WO2020/30977; (2020); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79178420&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>,100 - 1,,,,,,,7,,,,,,Patent; KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY; WO2020/85742; (2020); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79966391&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>,100 - 1,,,,,,,7,,,,,,Patent; KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY; WO2020/85742; (2020); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79966391&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,,Inhibitor,,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>,100 - 1,,,,,,,7,,,,,,Patent; KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY; WO2020/85742; (2020); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79966391&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1269,a",,,Inhibitor,,In Vitro (Efficacy),,,,,,,SNU-2535 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,>,1,,,,,,,6,,,,,,Patent; KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY; WO2020/85742; (2020); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79966391&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antiproliferative agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.087,,,,,,,7.06,,,,,,"Article; Chen, Yuxiang; Guo, Ming; Li, Tong; Li, Wei; Wei, Shangfei; Zhai, Xin; Zhao, Tianming; Zhu, Minglin; Bioorganic and Medicinal Chemistry; vol. 28; 20; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80618080&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,32,,,,,,,7.49,,,,,,"Article; Chen, Yuxiang; Guo, Ming; Li, Tong; Li, Wei; Wei, Shangfei; Zhai, Xin; Zhao, Tianming; Zhu, Minglin; Bioorganic and Medicinal Chemistry; vol. 28; 20; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80618080&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,891,,,,,,,6.05,,,,,,"Article; Chen, Yuxiang; Guo, Ming; Li, Tong; Li, Wei; Wei, Shangfei; Zhai, Xin; Zhao, Tianming; Zhu, Minglin; Bioorganic and Medicinal Chemistry; vol. 28; 20; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80618080&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,apoptosis rate increase,no unit,,1.97,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,Ser 757 phosphorylation,protein phosphorylation level decrease,%,,32,,S,Serine/threonine-protein kinase ULK1,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-146a-5p,miRNA expression level decrease,no unit,,2.0383,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-363-5p,miRNA expression level decrease,no unit,,2.8992,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-143-3p,miRNA expression level decrease,no unit,,2.0704,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-10b-3p,miRNA expression level decrease,no unit,,5.0548,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-15a-5p,miRNA expression level increase,no unit,,2.0232,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-425-5p,miRNA expression level increase,no unit,,2.4347,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-9-5p,miRNA expression level increase,no unit,,2.1883,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-219a-5p,miRNA expression level increase,no unit,,3.0043,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-31-5p,miRNA expression level increase,no unit,,3.2204,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-26a-5p,miRNA expression level increase,no unit,,2.2241,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-7-5p,miRNA expression level decrease,no unit,,2.6411,,S,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-425-3p,miRNA expression level increase,no unit,,2.1882,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-191-5p,miRNA expression level increase,no unit,,2.0509,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-497-5p,miRNA expression level increase,no unit,,6.1522,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-190a-5p,miRNA expression level increase,no unit,,2.1526,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SU-DHL-1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,500 nM,,,of hsa-miR-7-5p,miRNA expression level decrease,,Active,,,S,,,,,6.3,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,FE-PD cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,500 nM,,,of hsa-miR-7-5p,miRNA expression level change,,Not active,,,,,,,,1,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-222-5p,miRNA expression level decrease,no unit,,6.7695,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-221-5p,miRNA expression level decrease,no unit,,2.6084,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-19a-5p,miRNA expression level decrease,no unit,,4.402,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-92a-1-5p,miRNA expression level decrease,no unit,,2.7998,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,of hsa-miR-885-5p,miRNA expression level decrease,no unit,,2.2267,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,500 nM,,,,percentage of viable cells decrease,%,,46 - 50,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,500 nM,,,,percentage of viable cells decrease,%,,69,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,125 nM,,,,autophagosome formation increase,no unit,,2.3,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,125 nM,,,,autophagosome formation increase,no unit,,4.9,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,protein expression level increase,no unit,,1.43,,S,RAF proto-oncogene serine/threonine-protein kinase,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,125 nM,,,,percentage of autophagic cells,%,,57,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,125 nM,,,,percentage of autophagic cells,%,,79,,,,,,,,,,,,,"Article; Sorrentino, Domenico; Frentzel, Julie; Mitou, Géraldine; Blasco, Rafael B.; Torossian, Avédis; Hoareau-Aveilla, Coralie; Pighi, Chiara; Farcé, Manon; Meggetto, Fabienne; Manenti, Stéphane; Espinos, Estelle; Chiarle, Roberto; Giuriato, Sylvie; Cancers; vol. 12; 10; (2020); p. 1 - 22;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81174816&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.15 - 0.3 μM,,,,percentage of viable cells increase,%,,16,,,,,,,,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.15 - 0.3 μM,,,EC50,increase rate,no unit,,1.4,,,,,,,,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,,In Vivo (Animal models),,,Bagg albino mouse,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,enzyme activity increase,,Not active,,,,"Cytochrome P450, E-class, CYP3A",,,,1,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,toxic substance,Toxicity/Safety Pharmacology,,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,body weight change,,Not active,,,,,,,,1,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,toxic substance,Toxicity/Safety Pharmacology,,,Bagg albino mouse,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,creatinine blood level,mg/dl,<,2,,,,,,,,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,toxic substance,Toxicity/Safety Pharmacology,,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,liver weight change,,Not active,,,,,,,,1,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,toxic substance,Toxicity/Safety Pharmacology,,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,Spleen weight change,,Not active,,,,,,,,1,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,toxic substance,Toxicity/Safety Pharmacology,,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,lung weight change,,Not active,,,,,,,,1,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,toxic substance,Toxicity/Safety Pharmacology,,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,heart weight change,,Not active,,,,,,,,1,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,toxic substance,Toxicity/Safety Pharmacology,,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,kidney weight change,,Not active,,,,,,,,1,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,toxic substance,Toxicity/Safety Pharmacology,,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,brain weight change,,Not active,,,,,,,,1,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,toxic substance,Toxicity/Safety Pharmacology,,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,testicular weight change,,Not active,,,,,,,,1,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,tumor volume decrease,,Active,,,S,,,,,,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,concentration change,,Not active,,,,Insulin-like growth factor,,,,1,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,concentration change,,Not active,,,,Thrombospondin-1,,,,1,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,EC50,μM,,0.15,,,,,,,6.82,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,EC50,μM,,2.4,,,,,,,5.62,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.15 - 0.3 μM,,,,percentage of cells in G1 phase increase,,Active,,,,,,,,6.82,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.15 - 0.3 μM,,,,percentage of late apoptotic cells increase,,Active,,,S,,,,,6.82,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,,toxic substance,Toxicity/Safety Pharmacology,,,Bagg albino mouse,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,specific enzyme activity,U/l,<,80,,,Alanine aminotransferase 1,,,,,,,,,,Article; Bland; Shrestha; Bower; Rosengren; Ashton; Biochemical Pharmacology; vol. 183; (2021);,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81701071&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,tumor volume decrease rate,%,,52,,,,,,,,,,,,,Article; Shrestha; Bland; Bower; Rosengren; Ashton; Journal of Pharmacology and Experimental Therapeutics; vol. 374; 1; (2020); p. 134 - 140;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82219637&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,25 mg/kg,oral administration,Repeated,,proliferating cells rate,%,>=,60 - 70,,,,,,,,,,,,,Article; Shrestha; Bland; Bower; Rosengren; Ashton; Journal of Pharmacology and Experimental Therapeutics; vol. 374; 1; (2020); p. 134 - 140;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82219637&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,<,1,,,,,,,9,,,73010,ATP,Other compound,Patent; EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY; EP3782993; (2021); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82890176&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,protein tyrosine kinase inhibitor,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,106,,,,,,,6.97,,,,,,Patent; PRIMEGENE BEIJING; EP3786167; (2021); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D83057361&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,phosphotransferase inhibitor,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,2.6,,,,,,,8.59,,,,,,"Article; Pan, Tao; Dan, Yanrong; Guo, Dafeng; Jiang, Junhao; Ran, Dongzhi; Zhang, Lin; Tian, Binghua; Yuan, Jianyong; Yu, Yu; Gan, Zongjie; European Journal of Medicinal Chemistry; vol. 224; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D93835987&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,DNA glycosylase/AP lyase ROS1 [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],dna glycosylase/ap lyase ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818511893 + 818354751,q9um73 + p08581,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; DNA glycosylase/AP lyase ROS1 [human]; Hepatocyte growth factor receptor [human],DNA glycosylase/AP lyase ROS1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,UM-Chor1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,cell viability decrease,,Low,,,,,,,,,,,,,,"Article; Scheipl, Susanne; Barnard, Michelle; Lohberger, Birgit; Zettl, Richard; Brcic, Iva; Liegl-Atzwanger, Bernadette; Rinner, Beate; Meindl, Claudia; Fröhlich, Eleonore; Cellular Oncology; vol. 44; 6; (2021); p. 1231 - 1242;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D100873553&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,DNA glycosylase/AP lyase ROS1 [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],dna glycosylase/ap lyase ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818511893 + 818354751,q9um73 + p08581,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; DNA glycosylase/AP lyase ROS1 [human]; Hepatocyte growth factor receptor [human],DNA glycosylase/AP lyase ROS1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,MUG-Chor1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,4 μM,,,,protein expression level increase,,Active,,,,Vascular endothelial growth factor A,,,,5.4,,,,,,"Article; Scheipl, Susanne; Barnard, Michelle; Lohberger, Birgit; Zettl, Richard; Brcic, Iva; Liegl-Atzwanger, Bernadette; Rinner, Beate; Meindl, Claudia; Fröhlich, Eleonore; Cellular Oncology; vol. 44; 6; (2021); p. 1231 - 1242;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D100873553&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,DNA glycosylase/AP lyase ROS1 [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],dna glycosylase/ap lyase ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818511893 + 818354751,q9um73 + p08581,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; DNA glycosylase/AP lyase ROS1 [human]; Hepatocyte growth factor receptor [human],DNA glycosylase/AP lyase ROS1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,UM-Chor1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,4 μM,,,,protein expression level increase,,Active,,,,Transforming growth factor alpha,,,,5.4,,,,,,"Article; Scheipl, Susanne; Barnard, Michelle; Lohberger, Birgit; Zettl, Richard; Brcic, Iva; Liegl-Atzwanger, Bernadette; Rinner, Beate; Meindl, Claudia; Fröhlich, Eleonore; Cellular Oncology; vol. 44; 6; (2021); p. 1231 - 1242;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D100873553&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,DNA glycosylase/AP lyase ROS1 [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],dna glycosylase/ap lyase ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818511893 + 818354751,q9um73 + p08581,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; DNA glycosylase/AP lyase ROS1 [human]; Hepatocyte growth factor receptor [human],DNA glycosylase/AP lyase ROS1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,UM-Chor1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,4 μM,,,,protein expression level increase,,Low,,,,Vascular endothelial growth factor A,,,,,,,,,,"Article; Scheipl, Susanne; Barnard, Michelle; Lohberger, Birgit; Zettl, Richard; Brcic, Iva; Liegl-Atzwanger, Bernadette; Rinner, Beate; Meindl, Claudia; Fröhlich, Eleonore; Cellular Oncology; vol. 44; 6; (2021); p. 1231 - 1242;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D100873553&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,DNA glycosylase/AP lyase ROS1 [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],dna glycosylase/ap lyase ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818511893 + 818354751,q9um73 + p08581,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; DNA glycosylase/AP lyase ROS1 [human]; Hepatocyte growth factor receptor [human],DNA glycosylase/AP lyase ROS1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,U-CH1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,cell viability decrease,,Low,,,,,,,,,,,,,,"Article; Scheipl, Susanne; Barnard, Michelle; Lohberger, Birgit; Zettl, Richard; Brcic, Iva; Liegl-Atzwanger, Bernadette; Rinner, Beate; Meindl, Claudia; Fröhlich, Eleonore; Cellular Oncology; vol. 44; 6; (2021); p. 1231 - 1242;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D100873553&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,DNA glycosylase/AP lyase ROS1 [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],dna glycosylase/ap lyase ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818511893 + 818354751,q9um73 + p08581,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; DNA glycosylase/AP lyase ROS1 [human]; Hepatocyte growth factor receptor [human],DNA glycosylase/AP lyase ROS1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,MUG-Chor1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,cell viability decrease,,Low,,,,,,,,,,,,,,"Article; Scheipl, Susanne; Barnard, Michelle; Lohberger, Birgit; Zettl, Richard; Brcic, Iva; Liegl-Atzwanger, Bernadette; Rinner, Beate; Meindl, Claudia; Fröhlich, Eleonore; Cellular Oncology; vol. 44; 6; (2021); p. 1231 - 1242;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D100873553&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,DNA glycosylase/AP lyase ROS1 [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],dna glycosylase/ap lyase ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818511893 + 818354751,q9um73 + p08581,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; DNA glycosylase/AP lyase ROS1 [human]; Hepatocyte growth factor receptor [human],DNA glycosylase/AP lyase ROS1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,MUG-CC1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,cell viability decrease,,Low,,,,,,,,,,,,,,"Article; Scheipl, Susanne; Barnard, Michelle; Lohberger, Birgit; Zettl, Richard; Brcic, Iva; Liegl-Atzwanger, Bernadette; Rinner, Beate; Meindl, Claudia; Fröhlich, Eleonore; Cellular Oncology; vol. 44; 6; (2021); p. 1231 - 1242;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D100873553&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,213,,,,,,,6.67,,,8469413,vincristine,Other compound,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>,200,,,,,,,6.7,,,8469413,vincristine,Other compound,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,41,,,,,,,7.39,,,8469413,vincristine,Other compound,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,298,,,,,,,6.53,,,8469413,vincristine,Other compound,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>,200,,,,,,,6.7,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H596 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>,200,,,,,,,6.7,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Calu-6 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>,200,,,,,,,6.7,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC78 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>,200,,,,,,,6.7,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,78 - 210,,,,,,,7.11,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>,200,,,,,,,6.7,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,5 - 40 μM,,,,cell viability decrease,,Active,,,,,,,,5.3,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [mouse];+ALK tyrosine kinase receptor [mouse];+Hepatocyte growth factor receptor [mouse],c-ros receptor tyrosine kinase; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros-1; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,821130693 + 821117021 + 821109792,q78dx7 + p97793 + p16056,,,,ALK tyrosine kinase receptor [mouse]; Hepatocyte growth factor receptor [mouse]; Proto-oncogene tyrosine-protein kinase ROS [mouse],Proto-oncogene tyrosine-protein kinase ROS [mouse]:Wild + ALK tyrosine kinase receptor [mouse]:Wild + Hepatocyte growth factor receptor [mouse]:Wild,mouse,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,Institute for Cancer Research mouse,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,35 mg/kg,intragastric administration,Repeated,,alanine aminotransferase level increase,,Active,,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [mouse];+ALK tyrosine kinase receptor [mouse];+Hepatocyte growth factor receptor [mouse],c-ros receptor tyrosine kinase; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros-1; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,821130693 + 821117021 + 821109792,q78dx7 + p97793 + p16056,,,,ALK tyrosine kinase receptor [mouse]; Hepatocyte growth factor receptor [mouse]; Proto-oncogene tyrosine-protein kinase ROS [mouse],Proto-oncogene tyrosine-protein kinase ROS [mouse]:Wild + ALK tyrosine kinase receptor [mouse]:Wild + Hepatocyte growth factor receptor [mouse]:Wild,mouse,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,Institute for Cancer Research mouse,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,35 mg/kg,intragastric administration,Repeated,,alkaline phosphatase level increase,,Active,,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,cell viability percentage,%,,91,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,percentage of early apoptotic cells,%,,2.2,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,percentage of late apoptotic cells,%,,1.8,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,percentage of necrotic cells,%,,5,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 - 20 μM,,,,protein expression level decrease,,Active,,,S,Kelch-like ECH-associated protein 1,,,,4.82,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,20 μM,,,,protein expression level increase,,Active,,,,Nuclear factor erythroid 2-related factor 2,,,,4.7,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [mouse];+ALK tyrosine kinase receptor [mouse];+Hepatocyte growth factor receptor [mouse],c-ros receptor tyrosine kinase; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros-1; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,821130693 + 821117021 + 821109792,q78dx7 + p97793 + p16056,,,,ALK tyrosine kinase receptor [mouse]; Hepatocyte growth factor receptor [mouse]; Proto-oncogene tyrosine-protein kinase ROS [mouse],Proto-oncogene tyrosine-protein kinase ROS [mouse]:Wild + ALK tyrosine kinase receptor [mouse]:Wild + Hepatocyte growth factor receptor [mouse]:Wild,mouse,Non Transfected,,,In Vivo (Animal models),,,Institute for Cancer Research mouse,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,35 mg/kg,intragastric administration,Repeated,,protein expression level decrease,,Active,,,,Kelch-like ECH-associated protein 1,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [mouse];+ALK tyrosine kinase receptor [mouse];+Hepatocyte growth factor receptor [mouse],c-ros receptor tyrosine kinase; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros-1; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,821130693 + 821117021 + 821109792,q78dx7 + p97793 + p16056,,,,ALK tyrosine kinase receptor [mouse]; Hepatocyte growth factor receptor [mouse]; Proto-oncogene tyrosine-protein kinase ROS [mouse],Proto-oncogene tyrosine-protein kinase ROS [mouse]:Wild + ALK tyrosine kinase receptor [mouse]:Wild + Hepatocyte growth factor receptor [mouse]:Wild,mouse,Non Transfected,,,In Vivo (Animal models),,,Institute for Cancer Research mouse,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,35 mg/kg,intragastric administration,Repeated,,protein expression level increase,,Active,,,,Nuclear factor erythroid 2-related factor 2,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,percentage of early apoptotic cells,%,,1.4,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,percentage of late apoptotic cells,%,,2.9,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,percentage of necrotic cells,%,,10.6,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,cell viability percentage,%,,78.7,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,percentage of early apoptotic cells,%,,5,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,percentage of late apoptotic cells,%,,3.9,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,percentage of necrotic cells,%,,12.4,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,5 μM,,,,cell viability percentage,%,,73.7,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,cell viability percentage,%,,78.7 - 82.8,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,20 μM,,,,cell viability percentage,%,,81.6,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,8 μM,,,,cell viability percentage,%,,88.4,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,8 μM,,,,percentage of early apoptotic cells,%,,1.9,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,percentage of early apoptotic cells,%,,3.5 - 4.7,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,20 μM,,,,percentage of early apoptotic cells,%,,4.7,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,5 μM,,,,percentage of early apoptotic cells,%,,5.2,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,percentage of late apoptotic cells,%,,2.4 - 3.8,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,8 μM,,,,percentage of late apoptotic cells,%,,3.4,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,20 μM,,,,percentage of late apoptotic cells,%,,4.7,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,5 μM,,,,percentage of late apoptotic cells,%,,6.9,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,percentage of necrotic cells,%,,10 - 13.9,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,5 μM,,,,percentage of necrotic cells,%,,14.2,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,8 μM,,,,percentage of necrotic cells,%,,6.2,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,20 μM,,,,percentage of necrotic cells,%,,8.9,,,,,,,1,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,,hepatotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,15 μM,,,,cell viability percentage,%,,85,,,,,,,,,,,,,"Article; Fang, Dongmei; Gong, Hui; Guo, Lin; Tang, Tingli; Yan, Miao; Zhang, Bikui; Zhang, Leiyi; Zhou, Yueyin; Frontiers in Oncology; vol. 12; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115625427&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,CLB-Ga cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,,cell viability decrease,,Active,,,,,,,,6.6,,,,,,"Article; Arefin, Badrul; Claeys, Arne; Gabre, Jonatan L.; Hallberg, Bengt; Kurhe, Yeshwant; Lind, Dan E.; Palmer, Ruth H.; Siaw, Joachim Tetteh; Szydzik, Joanna; Umapathy, Ganesh; Van den Eynden, Jimmy; Nature Communications; vol. 12; 1; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D107554009&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,SK-N-AS cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,,cell viability decrease,,Not active,,,,,,,,1,,,,,,"Article; Arefin, Badrul; Claeys, Arne; Gabre, Jonatan L.; Hallberg, Bengt; Kurhe, Yeshwant; Lind, Dan E.; Palmer, Ruth H.; Siaw, Joachim Tetteh; Szydzik, Joanna; Umapathy, Ganesh; Van den Eynden, Jimmy; Nature Communications; vol. 12; 1; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D107554009&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,IMR-32 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,,cell viability decrease,,Not active,,,,,,,,1,,,,,,"Article; Arefin, Badrul; Claeys, Arne; Gabre, Jonatan L.; Hallberg, Bengt; Kurhe, Yeshwant; Lind, Dan E.; Palmer, Ruth H.; Siaw, Joachim Tetteh; Szydzik, Joanna; Umapathy, Ganesh; Van den Eynden, Jimmy; Nature Communications; vol. 12; 1; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D107554009&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,CLB-Ge1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,,cell viability decrease,,Active,,,,,,,,6.6,,,,,,"Article; Arefin, Badrul; Claeys, Arne; Gabre, Jonatan L.; Hallberg, Bengt; Kurhe, Yeshwant; Lind, Dan E.; Palmer, Ruth H.; Siaw, Joachim Tetteh; Szydzik, Joanna; Umapathy, Ganesh; Van den Eynden, Jimmy; Nature Communications; vol. 12; 1; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D107554009&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,CLB-Bar cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,250 nM,,,,cell viability decrease,,Active,,,,,,,,6.6,,,,,,"Article; Arefin, Badrul; Claeys, Arne; Gabre, Jonatan L.; Hallberg, Bengt; Kurhe, Yeshwant; Lind, Dan E.; Palmer, Ruth H.; Siaw, Joachim Tetteh; Szydzik, Joanna; Umapathy, Ganesh; Van den Eynden, Jimmy; Nature Communications; vol. 12; 1; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D107554009&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Wild,,Transfected; Transfected,Inhibitor,cytotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,>,100 - 500,,,,,,,7,,,,,,Patent; NUVALENT; PHARMA RESOURCES GMBH; WO2021/226269; (2021); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105723270&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H929 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,number of mitotic cells fold increas,no unit,~,8,,,,,,,,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,U2OS cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,microtubule network decrease,,Active,,,,,,,,,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,KMS-11 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,1.4,,,,,,,5.85,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,OPM-2 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,1.46,,,,,,,5.84,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,L-363 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,1.71,,,,,,,5.77,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,RPMI-8226 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,1.91,,,,,,,5.72,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,JJN-3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,3.07,,,,,,,5.51,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,CCRF-CEM cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,0.43,,,,,,,6.37,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,NB4 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,0.63,,,,,,,6.2,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,HL-60 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,0.74,,,,,,,6.13,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,MOLT-4 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,1.18,,,,,,,5.93,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,CCRF/ADR5000 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,29.15,,,,,,,4.53,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,NCI-H929 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,0.53,,,,,,,6.28,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,human,,acute myeloid leukemia,,AML blast cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,3.031 - 97.57,,,,,,,5.52,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,MOLP-8 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,0.77,,,,,,,6.11,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,KMS-12-BM cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,0.8,,,,,,,6.1,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,AMO1 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.003 - 100 μM,,,,IC50,μM,,1.21,,,,,,,5.92,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H929 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,mitosis rate,%,~,37 - 80,,,,,,,,,,,,,"Article; Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik; Bülbül, Yagmur; Crudo, Francesco; Marko, Doris; Munder, Markus; Klauck, Sabine M.; Efferth, Thomas; Pharmaceuticals; vol. 14; 11; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105715611&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,111,,,,,,,6.95,,,,,,"Article; Liu, Xile;Zhang, Lu;Wan, Haiwen;Zhu, Zhenzhen;Jin, Jing;Qin, Yuxin;Mao, Weifeng;Yan, Kang;Fang, Douglas;Jiang, Wen;Hu, Lihong;Chen, Jinhua;Chen, Kevin;Chen, Shuhui;Li, Jian;Zhao, Shuyong;Zheng, Shansong;Zhang, Long;Ding, Charles Z.; Bioorganic and Medicinal Chemistry Letters; vol. 66; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D116954124&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,138,,,,,,,6.86,,,,,,"Article; Liu, Xile;Zhang, Lu;Wan, Haiwen;Zhu, Zhenzhen;Jin, Jing;Qin, Yuxin;Mao, Weifeng;Yan, Kang;Fang, Douglas;Jiang, Wen;Hu, Lihong;Chen, Jinhua;Chen, Kevin;Chen, Shuhui;Li, Jian;Zhao, Shuyong;Zheng, Shansong;Zhang, Long;Ding, Charles Z.; Bioorganic and Medicinal Chemistry Letters; vol. 66; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D116954124&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,7,,,,,,,8.15,,,,,,"Article; Liu, Xile;Zhang, Lu;Wan, Haiwen;Zhu, Zhenzhen;Jin, Jing;Qin, Yuxin;Mao, Weifeng;Yan, Kang;Fang, Douglas;Jiang, Wen;Hu, Lihong;Chen, Jinhua;Chen, Kevin;Chen, Shuhui;Li, Jian;Zhao, Shuyong;Zheng, Shansong;Zhang, Long;Ding, Charles Z.; Bioorganic and Medicinal Chemistry Letters; vol. 66; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D116954124&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,μM,,0.8,,,,,,,6.1,,,,,,"Article; Bertho, Jerome;Bisson, William H.;Ceccon, Monica;D'Attoma, Joseph;Gambacorti-Passerini, Carlo;Goekjian, Peter;Gueyrard, David;Mologni, Luca;Orsato, Alexandre;Pannilunghi, Sara;Scapozza, Leonardo;Schneider, Cedric;Tardy, Sébastien;Vece, Vito;Viltadi, Michela;Zambon, Alfonso; European Journal of Medicinal Chemistry; vol. 238; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D117833688&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Echinoderm microtubule-associated protein-like 4;+ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"Echinoderm microtubule-associated protein-like 4:Wild + ALK tyrosine kinase receptor:Mutated:Substitution,1,g,120,r",,Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,50 mg/kg,oral administration,Repeated,Tumor growth inhibition,T/C (treated/control),%,,84.3,,,,,,,,,,,,,"Article; Fang, Douglas D.;Tao, Ran;Wang, Guangfeng;Li, Yuanbao;Zhang, Kaixiang;Xu, Chunhua;Zhai, Guoqin;Wang, Qixin;Wang, Jingwen;Tang, Chunyang;Min, Ping;Xiong, Dengkun;Chen, Jianyong;Wang, Shaomeng;Yang, Dajun;Zhai, Yifan; BMC Cancer; vol. 22; 1; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D118448146&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,,,,,IC50,nM,,1 - 100,,,,,,,9,,,,,,Patent; SINO BIOPHARMACEUTICAL LIMITED; EP4019021; (2022); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D118084159&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,apoptotic antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,10 μM,,,,apoptosis rate,%,,47.55,,,,,,,,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,apoptotic antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.4 μM,,,,apoptosis rate,%,<,40,,,,,,,,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.05 - 24 μM,,,,IC50,μM,,9.26,,,,,,,5.03,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.05 - 0.24 μM,,,,IC50,μM,,5.81,,,,,,,5.24,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.05 - 24 μM,,,,IC50,μM,,7.55,,,,,,,5.12,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.05 - 24 μM,,,,IC50,μM,,5,,,,,,,5.3,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.05 - 24 μM,,,,IC50,μM,,7.44,,,,,,,5.13,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.05 - 24 μM,,,,IC50,μM,,7.02,,,,,,,5.15,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.002 - 20 μM,,,,IC50,μM,,10.13,,,,,,,5,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.001 - 10 μM,,,,IC50,μM,,4.25,,,,,,,5.37,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.001 - 10 μM,,,,IC50,μM,,5.28,,,,,,,5.28,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1299 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,10 μM,,,,colony formation rate,%,,66,,,,,,,,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.4 μM,,,,colony formation rate,%,,84,,,,,,,,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,3 μM,,,,colony formation rate,%,,57.5,,,,,,,,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,ALK tyrosine kinase receptor [human]; DNA topoisomerase 1 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + dna topoisomerase 1; dna topoisomerase i; top1,818511893 + 818289566,q9um73 + p11387,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1a31; 1a35; 1a36; 1ej9; 1k4s; 1k4t; 1lpq; 1nh3; 1r49; 1rr8; 1rrj; 1sc7; 1seu; 1t8i; 1tl8,,,ALK tyrosine kinase receptor [human]; DNA topoisomerase 1 [human],ALK tyrosine kinase receptor [human]:Wild; DNA topoisomerase 1 [human]:Wild,human; human,Non Transfected; Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,50 mg/kg,intragastric administration,Repeated,,TGI (tumor growth inhibition rate),,Active,,,,,,,,,,,,,,"Article; Liu, Zhen;Li, Xinran;Gao, Junling;Yin, Panpan;Teng, Yuou;Yu, Peng; Biochemical Pharmacology; vol. 205; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121009255&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,,apoptosis rate,%,<,24,,,,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.001 - 10 μM,,,,IC50,μM,,4.11,,,,,,,5.39,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.001 - 10 μM,,,,IC50,μM,,2.62,,,,,,,5.58,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,0.001 - 10 μM,,,,IC50,μM,,5.28,,,,,,,5.28,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,of phosphorylated,protein expression level,no unit,,0.44,,,RAC serine/threonine-protein kinase,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,of phosphorylated,protein expression level,no unit,,0.83,,,RAC serine/threonine-protein kinase,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,of phosphorylated,protein expression level,no unit,,0.79,,,JUN kinase,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,of phosphorylated,protein expression level,no unit,,0.6,,,JUN kinase,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,of phosphorylated,protein expression level,no unit,,1.12,,,JUN kinase,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,of phosphorylated,protein expression level,no unit,,0.08,,,Ephrin type-B receptor 2,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,of phosphorylated,protein expression level,no unit,,0.12,,,Ephrin type-B receptor 2,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,of phosphorylated,protein expression level,no unit,,1.27,,,Ephrin type-B receptor 2,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,of phosphorylated,protein expression level,no unit,,1.1,,,Mitogen-activated protein kinase 14A,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,of phosphorylated,protein expression level,no unit,,0.63,,,Mitogen-activated protein kinase 14A,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,of phosphorylated,protein expression level,no unit,,0.23,,,Mitogen-activated protein kinase 14A,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,,protein expression level,no unit,,0.66,,,epidermal growth factor-activated receptor,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,,protein expression level,no unit,,2.23,,,epidermal growth factor-activated receptor,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,of phosphorylated,protein expression level,no unit,,0.56,,,epidermal growth factor-activated receptor,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,of phosphorylated,protein expression level,no unit,,1.04,,,epidermal growth factor-activated receptor,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,,protein expression level,no unit,,0.56,,,Cytochrome c,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,,protein expression level,no unit,,0.42,,,Cytochrome c,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,,protein expression level,no unit,,0.56,,,Cytochrome c,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,,protein expression level,no unit,,0.6,,,"Apoptosis regulator, Bcl-2",,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,,protein expression level,no unit,,0.64,,,"Apoptosis regulator, Bcl-2",,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,,protein expression level,no unit,,0.91,,,"Apoptosis regulator, Bcl-2",,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,,protein expression level,no unit,,0.77,,,Apoptosis regulator BAX,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,,protein expression level,no unit,,0.36,,,Apoptosis regulator BAX,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,,protein expression level,no unit,,1,,,Apoptosis regulator BAX,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,,protein expression level,no unit,,0.77,,,Bcl-2-like protein 1 (isoform Bcl-X(L)),,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,,protein expression level,no unit,,0.59,,,Bcl-2-like protein 1 (isoform Bcl-X(L)),,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,,protein expression level,no unit,,1.16,,,Bcl-2-like protein 1 (isoform Bcl-X(L)),,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,,protein expression level,no unit,,1.14,,,RAC serine/threonine-protein kinase,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,,protein expression level,no unit,,0.92,,,RAC serine/threonine-protein kinase,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,,protein expression level,no unit,,1.88,,,RAC serine/threonine-protein kinase,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,,protein expression level,no unit,,1.32,,,JUN kinase,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,,protein expression level,no unit,,0.05,,,JUN kinase,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,,protein expression level,no unit,,0.85,,,JUN kinase,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,,protein expression level,no unit,,0.77,,,Ephrin type-B receptor 2,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,,protein expression level,no unit,,0.37,,,Ephrin type-B receptor 2,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,,protein expression level,no unit,,1.26,,,Ephrin type-B receptor 2,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,,protein expression level,no unit,,0.96,,,Mitogen-activated protein kinase 14A,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1.25 μM,,,,protein expression level,no unit,,0.81,,,Mitogen-activated protein kinase 14A,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC827 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,2 μM,,,,protein expression level,no unit,,0.45,,,Mitogen-activated protein kinase 14A,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,(79 of 100),,"crizotinib; PF-02341066; PF-2341066; Xalkori; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; (R)-crizotinib; critozinib; CZT",C21H22Cl2FN5O,C21H22Cl2FN5O,450.343,,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,,,,Identification(733); Physical Data(36); Spectra(38); Bioactivity(563),170,1199,4.827,2,5,5,77.99,4,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human];+Hepatocyte growth factor receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + hepatocyte growth factor receptor; hgf receptor; hgf/sf receptor; met; proto-oncogene c-met; scatter factor receptor; sf receptor; tyrosine-protein kinase met,818268477 + 818511893 + 818354751,p08922 + q9um73 + p08581,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 1fyr; 1r0p; 1r1w; 1shy; 1ssl; 2g15; 2rfn; 2rfs; 2uzx; 2uzy; 2wd1; 2wgj; 2wkm; 3a4p; 3bux; 3c1x; 3ccn; 3cd8; 3ce3; 3cth; 3ctj; 3dkc; 3dkf; 3dkg; 3efj; 3efk; 3f66; 3f82; 3i5n; 3l8v; 3lq8; 3q6u; 3q6w; 3qti; 3r7o; 3rhk; 3u6h; 3u6i; 3vw8; 3zbx; 3zc5; 3zcl; 3zxz; 3zze; 4aoi; 4ap7; 4deg; 4deh; 4dei; 4eev; 4gg5; 4gg7; 4iwd; 4k3j; 4knb; 4mxc; 4o3t; 4o3u; 4r1v; 4r1y; 4xmo; 4xyf; 5dg5; 5eob; 5eyc; 5eyd; 5hlw; 5hni; 5ho6; 5hoa; 5hor; 5hti; 5lsp; 5t3q; 5uab; 5uad; 5ya5; 6gcu; 6i04; 6sd9; 6sdc; 6sdd; 6sde; 6ubw; 6wvz; 7b3q; 7b3t; 7b3v; 7b3w; 7b3z; 7b40; 7b41; 7b42; 7b43; 7b44; 7mo7; 7mo8; 7mo9; 7moa; 7mob,,,ALK tyrosine kinase receptor [human]; Hepatocyte growth factor receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild + Hepatocyte growth factor receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,12133926,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12133926&database=RX&origin=ReaxysOutput&ln=,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,crizotinib,1 μM,,,of phosphorylated,protein expression level,no unit,,1,,,RAC serine/threonine-protein kinase,,,,,,,,,,"Article; Liu, Zhen;Xu, Ye;Guo, Lvqian;Li, Xinran;Gao, Junling;Xie, Weiran;Zhao, Lianbo;Teng, Yuou;Li, Xuejiao;Yu, Peng; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 38; 1; (2023); p. 1 - 11;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D121327190&database=RX&origin=ReaxysOutput&ln=
,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,18703668,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18703668&database=RX&origin=ReaxysOutput&ln=,(80 of 100),941678-49-5,"ruxolitinib; (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile; INCB018424; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; jakafi; (R)-ruxolitinib; Rux",C17H18N6,C17H18N6,306.37,,,HFNKQEVNSGCOJV-OAHLLOKOSA-N,,,,Identification(995); Physical Data(16); Spectra(29); Bioactivity(277),148,1179,2.696,1,6,4,83.18,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,18703668,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18703668&database=RX&origin=ReaxysOutput&ln=,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,INCB18424,,,,,Kd (dissociation constant),nM,,1500,,,,,,,5.82,,,506008,DMSO,Other compound,"Article; Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 29; 11; (2011); p. 1046 - 1051;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009910&database=RX&origin=ReaxysOutput&ln=
,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,18703668,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18703668&database=RX&origin=ReaxysOutput&ln=,(80 of 100),941678-49-5,"ruxolitinib; (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile; INCB018424; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; jakafi; (R)-ruxolitinib; Rux",C17H18N6,C17H18N6,306.37,,,HFNKQEVNSGCOJV-OAHLLOKOSA-N,,,,Identification(995); Physical Data(16); Spectra(29); Bioactivity(277),148,1179,2.696,1,6,4,83.18,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,18703668,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18703668&database=RX&origin=ReaxysOutput&ln=,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,103905276,3 nM,,,,pKi,,,5.9,,,,,,,5.9,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,NC1=CC(=C(C=N1)C1=CC(=NC(=N1)N1CCOCC1)N1CCOCC1)C(F)(F)F,12938097,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12938097&database=RX&origin=ReaxysOutput&ln=,(81 of 100),,"4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine; BKM120; Buparlisib; NVP-BKM120; 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine; 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)-pyridin-2-amine; 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-2-pyrimidinamine; 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-(2,6-di(4-morpholinyl)-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine",C18H21F3N6O2,C18H21F3N6O2,410.399,,,CWHUFRVAEUJCEF-UHFFFAOYSA-N,,,,Identification(1075); Physical Data(11); Spectra(18); Bioactivity(140),32,1139,2.656,1,8,4,89.63,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,12938097,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12938097&database=RX&origin=ReaxysOutput&ln=,NC1=CC(=C(C=N1)C1=CC(=NC(=N1)N1CCOCC1)N1CCOCC1)C(F)(F)F,,10 μM,,,,residual binding percentage,%,,72,,,,,,,,,,,,,"Article; Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jürgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.; Journal of Medicinal Chemistry; vol. 60; 17; (2017); p. 7524 - 7538;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72081213&database=RX&origin=ReaxysOutput&ln=
,NC1=CC(=C(C=N1)C1=CC(=NC(=N1)N1CCOCC1)N1CCOCC1)C(F)(F)F,12938097,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12938097&database=RX&origin=ReaxysOutput&ln=,(81 of 100),,"4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine; BKM120; Buparlisib; NVP-BKM120; 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine; 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)-pyridin-2-amine; 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-2-pyrimidinamine; 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-(2,6-di(4-morpholinyl)-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine",C18H21F3N6O2,C18H21F3N6O2,410.399,,,CWHUFRVAEUJCEF-UHFFFAOYSA-N,,,,Identification(1075); Physical Data(11); Spectra(18); Bioactivity(140),32,1139,2.656,1,8,4,89.63,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],"ALK tyrosine kinase receptor [human]:Mutated:Substitution,1,c,1156,y",human,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,12938097,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12938097&database=RX&origin=ReaxysOutput&ln=,NC1=CC(=C(C=N1)C1=CC(=NC(=N1)N1CCOCC1)N1CCOCC1)C(F)(F)F,,10 μM,,,,residual binding percentage,%,,76,,,,,,,,,,,,,"Article; Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jürgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.; Journal of Medicinal Chemistry; vol. 60; 17; (2017); p. 7524 - 7538;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72081213&database=RX&origin=ReaxysOutput&ln=
,NC1=CC(=C(C=N1)C1=CC(=NC(=N1)N1CCOCC1)N1CCOCC1)C(F)(F)F,12938097,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12938097&database=RX&origin=ReaxysOutput&ln=,(81 of 100),,"4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine; BKM120; Buparlisib; NVP-BKM120; 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine; 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)-pyridin-2-amine; 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-2-pyrimidinamine; 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-(2,6-di(4-morpholinyl)-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine",C18H21F3N6O2,C18H21F3N6O2,410.399,,,CWHUFRVAEUJCEF-UHFFFAOYSA-N,,,,Identification(1075); Physical Data(11); Spectra(18); Bioactivity(140),32,1139,2.656,1,8,4,89.63,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],"ALK tyrosine kinase receptor [human]:Mutated:Substitution,1,l,1196,m",human,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,12938097,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12938097&database=RX&origin=ReaxysOutput&ln=,NC1=CC(=C(C=N1)C1=CC(=NC(=N1)N1CCOCC1)N1CCOCC1)C(F)(F)F,,10 μM,,,,residual binding percentage,%,,74,,,,,,,,,,,,,"Article; Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jürgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.; Journal of Medicinal Chemistry; vol. 60; 17; (2017); p. 7524 - 7538;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72081213&database=RX&origin=ReaxysOutput&ln=
,CS(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=C(F)C=C1)C1=CC=NC=C1,8078222,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8078222&database=RX&origin=ReaxysOutput&ln=,(82 of 100),,4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine; SB 203580; 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; 4-[5-(4-fluorophenyl)-2-[4-(methyl-sulfinyl)phenyl]-1H-imidazol-4-yl]pyridine,C21H16FN3OS,C21H16FN3OS,377.442,heterocyclic,,CDMGBJANTYXAIV-UHFFFAOYSA-N,,,,Identification(284); Physical Data(3); Spectra(1); Bioactivity(691),,1129,3.754,1,4,4,77.85,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,8078222,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8078222&database=RX&origin=ReaxysOutput&ln=,CS(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=C(F)C=C1)C1=CC=NC=C1,SB 203580,0.500000 µM,,,,inhibition percentage,%,,-4.76,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,CS(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=C(F)C=C1)C1=CC=NC=C1,8078222,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8078222&database=RX&origin=ReaxysOutput&ln=,(82 of 100),,4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine; SB 203580; 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; 4-[5-(4-fluorophenyl)-2-[4-(methyl-sulfinyl)phenyl]-1H-imidazol-4-yl]pyridine,C21H16FN3OS,C21H16FN3OS,377.442,heterocyclic,,CDMGBJANTYXAIV-UHFFFAOYSA-N,,,,Identification(284); Physical Data(3); Spectra(1); Bioactivity(691),,1129,3.754,1,4,4,77.85,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,8078222,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8078222&database=RX&origin=ReaxysOutput&ln=,CS(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=C(F)C=C1)C1=CC=NC=C1,SB-203580,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,CS(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=C(F)C=C1)C1=CC=NC=C1,8078222,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8078222&database=RX&origin=ReaxysOutput&ln=,(82 of 100),,4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine; SB 203580; 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; 4-[5-(4-fluorophenyl)-2-[4-(methyl-sulfinyl)phenyl]-1H-imidazol-4-yl]pyridine,C21H16FN3OS,C21H16FN3OS,377.442,heterocyclic,,CDMGBJANTYXAIV-UHFFFAOYSA-N,,,,Identification(284); Physical Data(3); Spectra(1); Bioactivity(691),,1129,3.754,1,4,4,77.85,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,8078222,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8078222&database=RX&origin=ReaxysOutput&ln=,CS(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=C(F)C=C1)C1=CC=NC=C1,103904989,3 nM,,,,pKi,,<,5.2,,,,,,,5.2,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,O=C1C2=C3C(NN=C3C3=C1C=CC=C3)=CC=C2,746890,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D746890&database=RX&origin=ReaxysOutput&ln=,(83 of 100),129-56-6,"2H-dibenzo[cd,g]indazol-6-one; SP600125",C14H8N2O,C14H8N2O,220.23,heterocyclic,,ACPOUJIDANTYHO-UHFFFAOYSA-N,,,,Identification(174); Physical Data(15); Spectra(15); Bioactivity(775),18,1056,3.821,1,3,0,45.75,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,746890,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D746890&database=RX&origin=ReaxysOutput&ln=,O=C1C2=C3C(NN=C3C3=C1C=CC=C3)=CC=C2,SP600125,,,,,IC50,µM,>,10,,,,,,,1,,,73010; 73010,ATP; [33P]-ATP,CoEnzyme; Marker,"Article; Colombo, Riccardo; Caldarelli, Marina; Mennecozzi, Milena; Giorgini, Maria Laura; Sola, Francesco; Cappella, Paolo; Perrera, Claudia; Re Depaolini, Stefania; Rusconi, Luisa; Cucchi, Ulisse; Avanzi, Nilla; Bertrand, Jay Aaron; Bossi, Roberto Tiberio; Pesenti, Enrico; Galvani, Arturo; Isacchi, Antonella; Colotta, Francesco; Donati, Daniele; Moll, Juergen; Cancer Research; vol. 70; 24; (2010); p. 10255 - 10264;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31004324&database=RX&origin=ReaxysOutput&ln=
,O=C1C2=C3C(NN=C3C3=C1C=CC=C3)=CC=C2,746890,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D746890&database=RX&origin=ReaxysOutput&ln=,(83 of 100),129-56-6,"2H-dibenzo[cd,g]indazol-6-one; SP600125",C14H8N2O,C14H8N2O,220.23,heterocyclic,,ACPOUJIDANTYHO-UHFFFAOYSA-N,,,,Identification(174); Physical Data(15); Spectra(15); Bioactivity(775),18,1056,3.821,1,3,0,45.75,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,746890,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D746890&database=RX&origin=ReaxysOutput&ln=,O=C1C2=C3C(NN=C3C3=C1C=CC=C3)=CC=C2,JNK Inhibitor II,0.500000 µM,,,,inhibition percentage,%,,8.33,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,O=C1C2=C3C(NN=C3C3=C1C=CC=C3)=CC=C2,746890,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D746890&database=RX&origin=ReaxysOutput&ln=,(83 of 100),129-56-6,"2H-dibenzo[cd,g]indazol-6-one; SP600125",C14H8N2O,C14H8N2O,220.23,heterocyclic,,ACPOUJIDANTYHO-UHFFFAOYSA-N,,,,Identification(174); Physical Data(15); Spectra(15); Bioactivity(775),18,1056,3.821,1,3,0,45.75,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,746890,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D746890&database=RX&origin=ReaxysOutput&ln=,O=C1C2=C3C(NN=C3C3=C1C=CC=C3)=CC=C2,T3/4,10 µM,,,,inhibition percentage,%,>,50,,,,,,,5,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol; Brij-35 detergent; Phosphatase inhibitor cocktail; Protease inhibitor cocktail,CoEnzyme; Solvent; Other compound; Other compound; Other compound; Other compound,"Article; Okamoto, Masako; Kojima, Hirotatsu; Saito, Nae; Okabe, Takayoshi; Masuda, Yoshiaki; Furuya, Toshio; Nagano, Tetsuo; Bioorganic and Medicinal Chemistry; vol. 19; 10; (2011); p. 3086 - 3095;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D9045720&database=RX&origin=ReaxysOutput&ln=
,O=C1C2=C3C(NN=C3C3=C1C=CC=C3)=CC=C2,746890,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D746890&database=RX&origin=ReaxysOutput&ln=,(83 of 100),129-56-6,"2H-dibenzo[cd,g]indazol-6-one; SP600125",C14H8N2O,C14H8N2O,220.23,heterocyclic,,ACPOUJIDANTYHO-UHFFFAOYSA-N,,,,Identification(174); Physical Data(15); Spectra(15); Bioactivity(775),18,1056,3.821,1,3,0,45.75,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,746890,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D746890&database=RX&origin=ReaxysOutput&ln=,O=C1C2=C3C(NN=C3C3=C1C=CC=C3)=CC=C2,"anthra[1,9-cd]pyrazole-6(2H)-one",10 μM,,,,inhibition percentage,%,,51,,,,,,,5.02,,,,,,Article; Jemaa; Galluzzi; Kepp; Senovilla; Brands; Boemer; Koppitz; Lienau; Prechtl; Schulze; Siemeister; Wengner; Mumberg; Ziegelbauer; Abrieu; Castedo; Vitale; Kroemer; Cell Death and Differentiation; vol. 20; 11; (2013); p. 1532 - 1545;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61563213&database=RX&origin=ReaxysOutput&ln=
,O=C1C2=C3C(NN=C3C3=C1C=CC=C3)=CC=C2,746890,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D746890&database=RX&origin=ReaxysOutput&ln=,(83 of 100),129-56-6,"2H-dibenzo[cd,g]indazol-6-one; SP600125",C14H8N2O,C14H8N2O,220.23,heterocyclic,,ACPOUJIDANTYHO-UHFFFAOYSA-N,,,,Identification(174); Physical Data(15); Spectra(15); Bioactivity(775),18,1056,3.821,1,3,0,45.75,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,746890,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D746890&database=RX&origin=ReaxysOutput&ln=,O=C1C2=C3C(NN=C3C3=C1C=CC=C3)=CC=C2,"anthra[1,9-cd]pyrazole-6(2H)-one",10 μM,,,,inhibition percentage,%,,-6,,,,,,,1,,,,,,Article; Jemaa; Galluzzi; Kepp; Senovilla; Brands; Boemer; Koppitz; Lienau; Prechtl; Schulze; Siemeister; Wengner; Mumberg; Ziegelbauer; Abrieu; Castedo; Vitale; Kroemer; Cell Death and Differentiation; vol. 20; 11; (2013); p. 1532 - 1545;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D61563213&database=RX&origin=ReaxysOutput&ln=
,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,(84 of 100),1211441-98-3,"ribociclib; LEE011; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; kisqali; 7-cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide; rebociclib",C23H30N8O,C23H30N8O,434.544,,,RHXHGRAEPCAFML-UHFFFAOYSA-N,,,,Identification(975); Physical Data(14); Spectra(21); Bioactivity(146),151,1035,2.882,2,9,6,91.21,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro median-effective dose of the compound against proliferation of neuroblastoma NB-1691 cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,NB-1691 cell line,,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,,,,,cell proliferation,ED50,nM,=,2647.3,,,,,,,5.58,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,(84 of 100),1211441-98-3,"ribociclib; LEE011; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; kisqali; 7-cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide; rebociclib",C23H30N8O,C23H30N8O,434.544,,,RHXHGRAEPCAFML-UHFFFAOYSA-N,,,,Identification(975); Physical Data(14); Spectra(21); Bioactivity(146),151,1035,2.882,2,9,6,91.21,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma NB-1691 cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,NB-1691 cell line,,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,,,,,cell proliferation,IC50,nM,=,314.8,,,,,,,6.5,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,(84 of 100),1211441-98-3,"ribociclib; LEE011; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; kisqali; 7-cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide; rebociclib",C23H30N8O,C23H30N8O,434.544,,,RHXHGRAEPCAFML-UHFFFAOYSA-N,,,,Identification(975); Physical Data(14); Spectra(21); Bioactivity(146),151,1035,2.882,2,9,6,91.21,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma SK-N-F1 cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,SK-N-FI cell line,,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,,,,,cell proliferation,IC50,µM,>,6,,,,,,,5.22,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,(84 of 100),1211441-98-3,"ribociclib; LEE011; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; kisqali; 7-cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide; rebociclib",C23H30N8O,C23H30N8O,434.544,,,RHXHGRAEPCAFML-UHFFFAOYSA-N,,,,Identification(975); Physical Data(14); Spectra(21); Bioactivity(146),151,1035,2.882,2,9,6,91.21,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma NB-1643 het cell line expressing mutant R1275Q ALK upon incubation for 72 hrs,,,,,NB-1643 cell line,,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,,,,,cell proliferation,IC50,nM,=,749.5,,,,,,,6.12,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,(84 of 100),1211441-98-3,"ribociclib; LEE011; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; kisqali; 7-cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide; rebociclib",C23H30N8O,C23H30N8O,434.544,,,RHXHGRAEPCAFML-UHFFFAOYSA-N,,,,Identification(975); Physical Data(14); Spectra(21); Bioactivity(146),151,1035,2.882,2,9,6,91.21,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma SK-N-AS cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,SK-N-AS cell line,,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,,,,,cell proliferation,IC50,nM,=,4724.5,,,,,,,5.33,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,(84 of 100),1211441-98-3,"ribociclib; LEE011; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; kisqali; 7-cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide; rebociclib",C23H30N8O,C23H30N8O,434.544,,,RHXHGRAEPCAFML-UHFFFAOYSA-N,,,,Identification(975); Physical Data(14); Spectra(21); Bioactivity(146),151,1035,2.882,2,9,6,91.21,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro median-effective dose of the compound against proliferation of neuroblastoma SK-N-BE(2)-C cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,SK-N-BE(2)-C cell line,,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,,,,,cell proliferation,ED50,nM,=,446,,,,,,,6.35,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,(84 of 100),1211441-98-3,"ribociclib; LEE011; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; kisqali; 7-cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide; rebociclib",C23H30N8O,C23H30N8O,434.544,,,RHXHGRAEPCAFML-UHFFFAOYSA-N,,,,Identification(975); Physical Data(14); Spectra(21); Bioactivity(146),151,1035,2.882,2,9,6,91.21,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma SK-N-BE(2)-C cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,SK-N-BE(2)-C cell line,,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,,,,,cell proliferation,IC50,nM,=,145.8,,,,,,,6.84,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,(84 of 100),1211441-98-3,"ribociclib; LEE011; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; kisqali; 7-cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide; rebociclib",C23H30N8O,C23H30N8O,434.544,,,RHXHGRAEPCAFML-UHFFFAOYSA-N,,,,Identification(975); Physical Data(14); Spectra(21); Bioactivity(146),151,1035,2.882,2,9,6,91.21,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro median-effective dose of the compound against against proliferation of neuroblastoma SH-SY5Y cell line expressing mutant F1174L ALK upon incubation for 72 hrs,,,,,SH-SY5Y cell line,,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,,,,,cell proliferation,ED50,nM,=,1500,,,,,,,5.82,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,(84 of 100),1211441-98-3,"ribociclib; LEE011; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; kisqali; 7-cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide; rebociclib",C23H30N8O,C23H30N8O,434.544,,,RHXHGRAEPCAFML-UHFFFAOYSA-N,,,,Identification(975); Physical Data(14); Spectra(21); Bioactivity(146),151,1035,2.882,2,9,6,91.21,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma SH-SY5Y cell line expressing mutant F1174L ALK upon incubation for 72 hrs,,,,,SH-SY5Y cell line,,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,,,,,cell proliferation,IC50,nM,=,111,,,,,,,6.95,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,(84 of 100),1211441-98-3,"ribociclib; LEE011; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; kisqali; 7-cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide; rebociclib",C23H30N8O,C23H30N8O,434.544,,,RHXHGRAEPCAFML-UHFFFAOYSA-N,,,,Identification(975); Physical Data(14); Spectra(21); Bioactivity(146),151,1035,2.882,2,9,6,91.21,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro median-effective dose of the compound against proliferation of neuroblastoma NB-1643 het cell line expressing mutant R1275Q ALK upon incubation for 72 hrs,,,,,NB-1643 cell line,,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,,,,,cell proliferation,ED50,nM,=,788.4,,,,,,,6.1,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,(84 of 100),1211441-98-3,"ribociclib; LEE011; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; kisqali; 7-cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide; rebociclib",C23H30N8O,C23H30N8O,434.544,,,RHXHGRAEPCAFML-UHFFFAOYSA-N,,,,Identification(975); Physical Data(14); Spectra(21); Bioactivity(146),151,1035,2.882,2,9,6,91.21,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro median-effective dose of the compound against proliferation of neuroblastoma NBEBC1 cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,NB-EbC1 cell line,,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,,,,,cell proliferation,ED50,nM,=,1258.7,,,,,,,5.9,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,(84 of 100),1211441-98-3,"ribociclib; LEE011; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; kisqali; 7-cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide; rebociclib",C23H30N8O,C23H30N8O,434.544,,,RHXHGRAEPCAFML-UHFFFAOYSA-N,,,,Identification(975); Physical Data(14); Spectra(21); Bioactivity(146),151,1035,2.882,2,9,6,91.21,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma NBEBC1 cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,NB-EbC1 cell line,,20117577,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D20117577&database=RX&origin=ReaxysOutput&ln=,CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N1C1CCCC1,,,,,cell proliferation,IC50,nM,=,328,,,,,,,6.48,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,[H][C@@]12CCC(=O)[C@@]1(C)C[C@@H](OC(C)=O)C1=C2C(=O)C2=C3C(=CO2)C(=O)O[C@H](COC)[C@]13C,67676,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D67676&database=RX&origin=ReaxysOutput&ln=,(85 of 100),19545-26-7,wortmannin; wortmanin,C23H24O8,C23H24O8,428.439,heterocyclic,,QDLHCMPXEPAAMD-QAIWCSMKSA-N,,,,Identification(122); Physical Data(12); Spectra(13); Bioactivity(931),212,1015,0.714,0,7,4,109.11,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,67676,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D67676&database=RX&origin=ReaxysOutput&ln=,[H][C@@]12CCC(=O)[C@@]1(C)C[C@@H](OC(C)=O)C1=C2C(=O)C2=C3C(=CO2)C(=O)O[C@H](COC)[C@]13C,Wortmannin,0.500000 µM,,,,inhibition percentage,%,,-2.75,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,O[C@H]([C@@H](O)C(O)=O)C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1,8460643,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8460643&database=RX&origin=ReaxysOutput&ln=,(86 of 100),56392-17-7,metoprolol tartrate; (±)-1-(isopropylamino)-3-[(p-2-methoxyethyl) phenoxy]-2-propanol (2:1) dextro-tartrate salt,C15H25NO3*C15H25NO3*C4H6O6,C4H6O6*2C15H25NO3,684.825,isocyclic,,WPTKISQJQVFSQI-LREBCSMRSA-N,,,,Identification(1001); Physical Data(11); Spectra(1); Bioactivity(87),6,1000,-0.61,6,9,12,165.78,3,0,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory activity of the compound (dissolved in DMSO) against recombinant GST-tagged ALK using 7.0 ng BIOTINYL-POLY(GT) as substrate in presence of 10 uM ATP upon incubation in 50 mM Tris-HCl, pH 7.5 at RT for 30 min by KinaseGlo Luminescent Kinase Assay",,,,,,,8460643,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8460643&database=RX&origin=ReaxysOutput&ln=,O[C@H]([C@@H](O)C(O)=O)C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; CHEMBRIDGE CORPORATION; US2015/11539; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68441299&database=RX&origin=ReaxysOutput&ln=
,OC(=O)CCC(O)=O.ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,8664962,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8664962&database=RX&origin=ReaxysOutput&ln=,(87 of 100),,vatalanib succinate; N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine succinate; (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl]ammonium hydrogen succinate; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate; vatalanib,C20H15ClN4*C4H6O4,C4H6O4*C20H15ClN4,464.908,heterocyclic,,LLDWLPRYLVPDTG-UHFFFAOYSA-N,,,,Identification(954); Physical Data(2); Spectra(2); Bioactivity(53),,984,,3,8,7,125.3,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,8664962,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8664962&database=RX&origin=ReaxysOutput&ln=,OC(=O)CCC(O)=O.ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,PTK/ZK,10 µM,,,,inhibition percentage,%,,68,,,,,,,5.33,,,,,,"Article; Hess-Stumpp, Holger; Haberey, Martin; Thierauch, Karl-Heinz; ChemBioChem; vol. 6; 3; (2005); p. 550 - 557;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D22505141&database=RX&origin=ReaxysOutput&ln=
,OC(=O)CCC(O)=O.ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,8664962,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8664962&database=RX&origin=ReaxysOutput&ln=,(87 of 100),,vatalanib succinate; N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine succinate; (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl]ammonium hydrogen succinate; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate; vatalanib,C20H15ClN4*C4H6O4,C4H6O4*C20H15ClN4,464.908,heterocyclic,,LLDWLPRYLVPDTG-UHFFFAOYSA-N,,,,Identification(954); Physical Data(2); Spectra(2); Bioactivity(53),,984,,3,8,7,125.3,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antiproliferative agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,8664962,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8664962&database=RX&origin=ReaxysOutput&ln=,OC(=O)CCC(O)=O.ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=C2C=CC=C3)C=C1,,,,,,IC50,μM,>,10,,,,,,,1,,,,,,"Article; Bold, Guido; Schnell, Christian; Furet, Pascal; McSheehy, Paul; Brüggen, Josef; Mestan, Jürgen; Manley, Paul W.; Drückes, Peter; Burglin, Marion; Dürler, Ursula; Loretan, Jacqueline; Reuter, Robert; Wartmann, Markus; Theuer, Andreas; Bauer-Probst, Beatrice; Martiny-Baron, Georg; Allegrini, Peter; Goepfert, Arnaud; Wood, Jeanette; Littlewood-Evans, Amanda; Journal of Medicinal Chemistry; vol. 59; 1; (2016); p. 132 - 146;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68050086&database=RX&origin=ReaxysOutput&ln=
,CN1C(NC2=CC=C(C=C2)C(F)(F)F)=NC2=C1C=CC(OC1=CC=NC(=C1)C1=NC=C(N1)C(F)(F)F)=C2,11337399,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11337399&database=RX&origin=ReaxysOutput&ln=,(88 of 100),927880-90-8,Raf-265; CHIR-265; 1-methyl-5-((2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yl)oxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine,C24H16F6N6O,C24H16F6N6O,518.421,,,YABJJWZLRMPFSI-UHFFFAOYSA-N,,,,Identification(953); Physical Data(7); Spectra(12); Bioactivity(66),15,973,5.396,2,6,7,80.65,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,11337399,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11337399&database=RX&origin=ReaxysOutput&ln=,CN1C(NC2=CC=C(C=C2)C(F)(F)F)=NC2=C1C=CC(OC1=CC=NC(=C1)C1=NC=C(N1)C(F)(F)F)=C2,CHIR-265/RAF-265,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,C[C@@H]1CCN(C[C@@H]1N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N,11647225,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11647225&database=RX&origin=ReaxysOutput&ln=,(89 of 100),,"tasocitinib; Tofacitinib; (+/-)-CP 690550; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; xeljanz",C16H20N6O,C16H20N6O,312.374,,,UJLAWZDWDVHWOW-YPMHNXCESA-N,,,,Identification(694); Physical Data(29); Spectra(38); Bioactivity(390),269,956,1.341,1,7,4,88.91,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,11647225,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11647225&database=RX&origin=ReaxysOutput&ln=,C[C@@H]1CCN(C[C@@H]1N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N,Tofacitinib,0.500000 µM,,,,inhibition percentage,%,,-6.54,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,C[C@@H]1CCN(C[C@@H]1N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N,11647225,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11647225&database=RX&origin=ReaxysOutput&ln=,(89 of 100),,"tasocitinib; Tofacitinib; (+/-)-CP 690550; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; xeljanz",C16H20N6O,C16H20N6O,312.374,,,UJLAWZDWDVHWOW-YPMHNXCESA-N,,,,Identification(694); Physical Data(29); Spectra(38); Bioactivity(390),269,956,1.341,1,7,4,88.91,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,11647225,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11647225&database=RX&origin=ReaxysOutput&ln=,C[C@@H]1CCN(C[C@@H]1N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N,CP-690550,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,C[C@@H]1CCN(C[C@@H]1N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N,11647225,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11647225&database=RX&origin=ReaxysOutput&ln=,(89 of 100),,"tasocitinib; Tofacitinib; (+/-)-CP 690550; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; xeljanz",C16H20N6O,C16H20N6O,312.374,,,UJLAWZDWDVHWOW-YPMHNXCESA-N,,,,Identification(694); Physical Data(29); Spectra(38); Bioactivity(390),269,956,1.341,1,7,4,88.91,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,11647225,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11647225&database=RX&origin=ReaxysOutput&ln=,C[C@@H]1CCN(C[C@@H]1N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N,103905419,3 nM,,,,pKi,,<,5.2,,,,,,,5.2,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,C[C@@H]1CCN(C[C@@H]1N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N,11647225,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11647225&database=RX&origin=ReaxysOutput&ln=,(89 of 100),,"tasocitinib; Tofacitinib; (+/-)-CP 690550; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile; xeljanz",C16H20N6O,C16H20N6O,312.374,,,UJLAWZDWDVHWOW-YPMHNXCESA-N,,,,Identification(694); Physical Data(29); Spectra(38); Bioactivity(390),269,956,1.341,1,7,4,88.91,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,11647225,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11647225&database=RX&origin=ReaxysOutput&ln=,C[C@@H]1CCN(C[C@@H]1N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N,tofacitinib,0.0001 - 10 μM,,,,IC50,μM,>,10,,,,,,,1,,,,,,"Article; Goedken, Eric R.; Argiriadi, Maria A.; Banach, David L.; Fiamengo, Bryan A.; Foley, Sage E.; Frank, Kristine E.; George, Jonathan S.; Harris, Christopher M.; Hobson, Adrian D.; Ihle, David C.; Marcotte, Douglas; Merta, Philip J.; Michalak, Mark E.; Murdock, Sara E.; Tomlinson, Medha J.; Voss, Jeffrey W.; Journal of Biological Chemistry; vol. 290; 8; (2015); p. 4573 - 4589;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D66259160&database=RX&origin=ReaxysOutput&ln=
,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,23334373,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D23334373&database=RX&origin=ReaxysOutput&ln=,(90 of 100),1421373-65-0,osimertinib; azd9291; N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide; tagrisso; N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide; mereletinib,C28H33N7O2,C28H33N7O2,499.616,,,DUYJMQONPNNFPI-UHFFFAOYSA-N,,,,Identification(597); Physical Data(43); Spectra(58); Bioactivity(344),111,920,3.596,2,8,11,87.55,4,1,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK was determined,,,,,,,23334373,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D23334373&database=RX&origin=ReaxysOutput&ln=,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,,,,,,IC50,nM,=,231,,,,,,,6.64,,,,,,"Article; Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.; Journal of Medicinal Chemistry; vol. 57; 20; (2014); p. 8249 - 8267;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64263856&database=RX&origin=ReaxysOutput&ln=
,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,23334373,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D23334373&database=RX&origin=ReaxysOutput&ln=,(90 of 100),1421373-65-0,osimertinib; azd9291; N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide; tagrisso; N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide; mereletinib,C28H33N7O2,C28H33N7O2,499.616,,,DUYJMQONPNNFPI-UHFFFAOYSA-N,,,,Identification(597); Physical Data(43); Spectra(58); Bioactivity(344),111,920,3.596,2,8,11,87.55,4,1,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Percent inhibition of ALK kinase upon incubation with the compound at 1 uM concentration,,,,,,,23334373,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D23334373&database=RX&origin=ReaxysOutput&ln=,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,,,,,,inhibition percentage,%,=,66,,,,,,,,,,,,,"Article; Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.; Journal of Medicinal Chemistry; vol. 57; 20; (2014); p. 8249 - 8267;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64263856&database=RX&origin=ReaxysOutput&ln=
,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,23334373,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D23334373&database=RX&origin=ReaxysOutput&ln=,(90 of 100),1421373-65-0,osimertinib; azd9291; N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide; tagrisso; N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide; mereletinib,C28H33N7O2,C28H33N7O2,499.616,,,DUYJMQONPNNFPI-UHFFFAOYSA-N,,,,Identification(597); Physical Data(43); Spectra(58); Bioactivity(344),111,920,3.596,2,8,11,87.55,4,1,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,23334373,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D23334373&database=RX&origin=ReaxysOutput&ln=,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,osimertinib,,,,,IC50,nM,,177,,,,,,,6.75,,,,,,"Article; Jang, Jaebong; Son, Jung Beom; To, Ciric; Bahcall, Magda; Kim, So Young; Kang, Seock Yong; Mushajiang, Mierzhati; Lee, Younho; Jänne, Pasi A.; Choi, Hwan Geun; Gray, Nathanael S.; European Journal of Medicinal Chemistry; vol. 136; (2017); p. 497 - 510;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71227487&database=RX&origin=ReaxysOutput&ln=
,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,23334373,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D23334373&database=RX&origin=ReaxysOutput&ln=,(90 of 100),1421373-65-0,osimertinib; azd9291; N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide; tagrisso; N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide; mereletinib,C28H33N7O2,C28H33N7O2,499.616,,,DUYJMQONPNNFPI-UHFFFAOYSA-N,,,,Identification(597); Physical Data(43); Spectra(58); Bioactivity(344),111,920,3.596,2,8,11,87.55,4,1,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,HEK293 cell line,,23334373,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D23334373&database=RX&origin=ReaxysOutput&ln=,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,osimertinib,<= 10000 nM,,,,inhibition percentage,,Not active,,,,,,,,1,,,,,,Patent; UNIVERSITY OF TORONTO; US2019/91205; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76360573&database=RX&origin=ReaxysOutput&ln=
,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,23334373,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D23334373&database=RX&origin=ReaxysOutput&ln=,(90 of 100),1421373-65-0,osimertinib; azd9291; N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide; tagrisso; N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide; mereletinib,C28H33N7O2,C28H33N7O2,499.616,,,DUYJMQONPNNFPI-UHFFFAOYSA-N,,,,Identification(597); Physical Data(43); Spectra(58); Bioactivity(344),111,920,3.596,2,8,11,87.55,4,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,23334373,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D23334373&database=RX&origin=ReaxysOutput&ln=,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,osimertinib,,,,,IC50,μM,,0.1178,,,,,,,6.93,,,,,,"Article; Li, Wei;Yao, Han;Gu, Chenxi;Ren, Yuanyuan;Liu, Jiadai;An, Baijiao;Hu, Wenhao;Li, Xingshu;Chan, Albert S.C.; Bioorganic Chemistry; vol. 129; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120730616&database=RX&origin=ReaxysOutput&ln=
,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,23334373,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D23334373&database=RX&origin=ReaxysOutput&ln=,(90 of 100),1421373-65-0,osimertinib; azd9291; N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide; tagrisso; N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide; mereletinib,C28H33N7O2,C28H33N7O2,499.616,,,DUYJMQONPNNFPI-UHFFFAOYSA-N,,,,Identification(597); Physical Data(43); Spectra(58); Bioactivity(344),111,920,3.596,2,8,11,87.55,4,1,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,23334373,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D23334373&database=RX&origin=ReaxysOutput&ln=,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,osimertinib,,,,,IC50,μM,,2.016,,,,,,,5.69,,,,,,"Article; Li, Wei;Yao, Han;Gu, Chenxi;Ren, Yuanyuan;Liu, Jiadai;An, Baijiao;Hu, Wenhao;Li, Xingshu;Chan, Albert S.C.; Bioorganic Chemistry; vol. 129; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120730616&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,(91 of 100),,"4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline; WHI-P154",C16H14BrN3O3,C16H14BrN3O3,376.209,heterocyclic,,CBIAKDAYHRWZCU-UHFFFAOYSA-N,,,,Identification(825); Physical Data(2); Spectra(8); Bioactivity(70),5,869,2.978,2,3,4,76.5,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,,Toxicity/Safety Pharmacology,Cell/tumor cell: proliferation/viability/growth,,,,,,NCI-H1299 cell line,,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,WHI-P154,,,,,IC50,µM,,26.9375,,,,,,,4.57,,,,,,Patent; ACADEMIA SINICA; US2012/129869; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20130131&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,(91 of 100),,"4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline; WHI-P154",C16H14BrN3O3,C16H14BrN3O3,376.209,heterocyclic,,CBIAKDAYHRWZCU-UHFFFAOYSA-N,,,,Identification(825); Physical Data(2); Spectra(8); Bioactivity(70),5,869,2.978,2,3,4,76.5,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,Histidine,694,Arginine",,Transfected,Inhibitor,,Toxicity/Safety Pharmacology,Cell/tumor cell: proliferation/viability/growth,,,,,,NCI-H1299 cell line,,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,WHI-P154,,,,,IC50,µM,,11.7901,,,,,,,4.93,,,,,,Patent; ACADEMIA SINICA; US2012/129869; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20130131&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,(91 of 100),,"4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline; WHI-P154",C16H14BrN3O3,C16H14BrN3O3,376.209,heterocyclic,,CBIAKDAYHRWZCU-UHFFFAOYSA-N,,,,Identification(825); Physical Data(2); Spectra(8); Bioactivity(70),5,869,2.978,2,3,4,76.5,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,Glutamic acid,1384,Lysine",,Transfected,Inhibitor,,Toxicity/Safety Pharmacology,Cell/tumor cell: proliferation/viability/growth,,,,,,NCI-H1299 cell line,,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,WHI-P154,,,,,IC50,µM,,9.4238,,,,,,,5.03,,,,,,Patent; ACADEMIA SINICA; US2012/129869; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20130131&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,(91 of 100),,"4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline; WHI-P154",C16H14BrN3O3,C16H14BrN3O3,376.209,heterocyclic,,CBIAKDAYHRWZCU-UHFFFAOYSA-N,,,,Identification(825); Physical Data(2); Spectra(8); Bioactivity(70),5,869,2.978,2,3,4,76.5,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,JAK3 Inhibitor II,0.500000 µM,,,,inhibition percentage,%,,87.55,,,,,,,7.15,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,(91 of 100),,"4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline; WHI-P154",C16H14BrN3O3,C16H14BrN3O3,376.209,heterocyclic,,CBIAKDAYHRWZCU-UHFFFAOYSA-N,,,,Identification(825); Physical Data(2); Spectra(8); Bioactivity(70),5,869,2.978,2,3,4,76.5,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,,Toxicity/Safety Pharmacology,Cell/tumor cell: proliferation/viability/growth,,,,,,U-87MG cell line,,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,compound A,10 µM,,,,inhibition percentage,%,,15,,,,,,,1,,,506008,DMSO,Other compound,Patent; CUREGENE; ASTELLAS PHARMA INC.; US2008/90776; (2008); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D460936&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,(91 of 100),,"4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline; WHI-P154",C16H14BrN3O3,C16H14BrN3O3,376.209,heterocyclic,,CBIAKDAYHRWZCU-UHFFFAOYSA-N,,,,Identification(825); Physical Data(2); Spectra(8); Bioactivity(70),5,869,2.978,2,3,4,76.5,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against NPM-ALK kinase,,,,,,,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,,,,,,IC50,µM,=,10,,,,,,,5,,,,,,"Review; Gunby, Rosalind H.; Sala, Elisa; Tartari, Carmen J.; Puttini, Miriam; Gambacorti-Passerini, Carlo; Mologni, Luca; Anti-Cancer Agents in Medicinal Chemistry; vol. 7; 6; (2007); p. 594 - 611;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D24929181&database=RX&origin=ReaxysOutput&ln=
,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,(91 of 100),,"4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline; WHI-P154",C16H14BrN3O3,C16H14BrN3O3,376.209,heterocyclic,,CBIAKDAYHRWZCU-UHFFFAOYSA-N,,,,Identification(825); Physical Data(2); Spectra(8); Bioactivity(70),5,869,2.978,2,3,4,76.5,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vitro (Efficacy),,In vitro percent inhibition of human glioma U-87 MG cell growth expressing full length ALK polypeptide upon incubation for 3 days at 37 degree C at 10 uM compound concentration by Luminescent Cell Viability Assay,,,,,U-87MG cell line,,8787580,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8787580&database=RX&origin=ReaxysOutput&ln=,COC1=CC2=C(C=C1OC)C(NC1=CC=C(O)C(Br)=C1)=NC=N2,,,,,Cell growth,inhibition percentage,%,=,15,,,,,,,,,,,,,Patent; CUREGENE; ASTELLAS PHARMA INC.; EP1914240; (2009); B1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D62542324&database=RX&origin=ReaxysOutput&ln=
,CCNC(=O)C1=NOC(=C1C1=CC=C(CN2CCOCC2)C=C1)C1=CC(C(C)C)=C(O)C=C1O,12046798,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12046798&database=RX&origin=ReaxysOutput&ln=,(92 of 100),747412-49-3,"5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide; AUY922; NVP-AUY922; luminespib; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide",C26H31N3O5,C26H31N3O5,465.549,,,NDAZATDQFDPQBD-UHFFFAOYSA-N,,,,Identification(786); Physical Data(7); Spectra(7); Bioactivity(162),13,857,4.034,3,4,8,108.06,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,12046798,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12046798&database=RX&origin=ReaxysOutput&ln=,CCNC(=O)C1=NOC(=C1C1=CC=C(CN2CCOCC2)C=C1)C1=CC(C(C)C)=C(O)C=C1O,,,,,,IC50,nM,,12.4,,,,,,,7.91,,,,,,"Article; Geng, Kaijun; Liu, Hongchun; Song, Zilan; Zhang, Chi; Zhang, Minmin; Yang, Hong; Cao, Jingchen; Geng, Meiyu; Shen, Aijun; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 152; (2018); p. 76 - 86;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73691759&database=RX&origin=ReaxysOutput&ln=
,CN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1,19641026,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D19641026&database=RX&origin=ReaxysOutput&ln=,(93 of 100),1197160-78-3,"gedatolisib; PKI-587; PF-05212384; 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; 1-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]-urea; PF-'384",C32H41N9O4,C32H41N9O4,615.735,,,DWZAEMINVBZMHQ-UHFFFAOYSA-N,,,,Identification(834); Physical Data(6); Spectra(12); Bioactivity(123),12,848,2.645,2,13,10,128.29,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,19641026,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D19641026&database=RX&origin=ReaxysOutput&ln=,CN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1,PKI-587,1 µM,,,,inhibition percentage,%,,2,,,,,,,1,,,73010,ATP,CoEnzyme,"Article; Mallon, Robert; Feldberg, Larry R.; Lucas, Judy; Chaudhary, Inder; Dehnhardt, Christoph; Delos Santos, Efren; Chen, Zecheng; Dos Santos, Osvaldo; Ayral-Kaloustian, Semiramis; Venkatesan, Aranapakam; Hollander, Irwin; Clinical Cancer Research; vol. 17; 10; (2011); p. 3193 - 3203;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D32146499&database=RX&origin=ReaxysOutput&ln=
,CN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1,19641026,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D19641026&database=RX&origin=ReaxysOutput&ln=,(93 of 100),1197160-78-3,"gedatolisib; PKI-587; PF-05212384; 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; 1-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]-urea; PF-'384",C32H41N9O4,C32H41N9O4,615.735,,,DWZAEMINVBZMHQ-UHFFFAOYSA-N,,,,Identification(834); Physical Data(6); Spectra(12); Bioactivity(123),12,848,2.645,2,13,10,128.29,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,19641026,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D19641026&database=RX&origin=ReaxysOutput&ln=,CN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1,,10 μM,,,,residual binding percentage,%,,95,,,,,,,,,,,,,"Article; Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jürgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.; Journal of Medicinal Chemistry; vol. 60; 17; (2017); p. 7524 - 7538;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72081213&database=RX&origin=ReaxysOutput&ln=
,CN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1,19641026,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D19641026&database=RX&origin=ReaxysOutput&ln=,(93 of 100),1197160-78-3,"gedatolisib; PKI-587; PF-05212384; 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; 1-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]-urea; PF-'384",C32H41N9O4,C32H41N9O4,615.735,,,DWZAEMINVBZMHQ-UHFFFAOYSA-N,,,,Identification(834); Physical Data(6); Spectra(12); Bioactivity(123),12,848,2.645,2,13,10,128.29,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],"ALK tyrosine kinase receptor [human]:Mutated:Substitution,1,c,1156,y",human,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,19641026,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D19641026&database=RX&origin=ReaxysOutput&ln=,CN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1,,10 μM,,,,residual binding percentage,%,,95,,,,,,,,,,,,,"Article; Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jürgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.; Journal of Medicinal Chemistry; vol. 60; 17; (2017); p. 7524 - 7538;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72081213&database=RX&origin=ReaxysOutput&ln=
,CN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1,19641026,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D19641026&database=RX&origin=ReaxysOutput&ln=,(93 of 100),1197160-78-3,"gedatolisib; PKI-587; PF-05212384; 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; 1-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]-urea; PF-'384",C32H41N9O4,C32H41N9O4,615.735,,,DWZAEMINVBZMHQ-UHFFFAOYSA-N,,,,Identification(834); Physical Data(6); Spectra(12); Bioactivity(123),12,848,2.645,2,13,10,128.29,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],"ALK tyrosine kinase receptor [human]:Mutated:Substitution,1,l,1196,m",human,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,19641026,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D19641026&database=RX&origin=ReaxysOutput&ln=,CN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1,,10 μM,,,,residual binding percentage,%,,100,,,,,,,,,,,,,"Article; Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jürgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.; Journal of Medicinal Chemistry; vol. 60; 17; (2017); p. 7524 - 7538;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72081213&database=RX&origin=ReaxysOutput&ln=
,FC1=C(F)C(NC2=CC=C(I)C=C2Cl)=C(C=C1)C(=O)NOCC1CC1,10032343,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10032343&database=RX&origin=ReaxysOutput&ln=,(94 of 100),,"2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; PD 184352; CI-1040",C17H14ClF2IN2O2,C17H14ClF2IN2O2,478.665,isocyclic,,GFMMXOIFOQCCGU-UHFFFAOYSA-N,,,,Identification(648); Physical Data(2); Spectra(7); Bioactivity(181),5,789,5.975,2,2,7,50.36,3,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,10032343,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D10032343&database=RX&origin=ReaxysOutput&ln=,FC1=C(F)C(NC2=CC=C(I)C=C2Cl)=C(C=C1)C(=O)NOCC1CC1,CI-1040,,,,,Kd (dissociation constant),nM,>,10000,,,,,,,1,,,506008,DMSO,Other compound,"Article; Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 29; 11; (2011); p. 1046 - 1051;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009910&database=RX&origin=ReaxysOutput&ln=
,CC1=CC(NC(=O)NC2=CC=C(C=C2)C2=CC=CC3=C2C(N)=NN3)=C(F)C=C1,11008713,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11008713&database=RX&origin=ReaxysOutput&ln=,(95 of 100),796967-16-3,linifanib; ABT-869; 1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea; N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea,C21H18FN5O,C21H18FN5O,375.405,,,MPVGZUGXCQEXTM-UHFFFAOYSA-N,,,,Identification(709); Physical Data(5); Spectra(11); Bioactivity(189),40,788,4.654,4,6,5,95.83,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Binding,,Enterobacteria phage T7,,,,,,11008713,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11008713&database=RX&origin=ReaxysOutput&ln=,CC1=CC(NC(=O)NC2=CC=C(C=C2)C2=CC=CC3=C2C(N)=NN3)=C(F)C=C1,ABT-869,,,,,Kd (dissociation constant),nM,,1600,,,,,,,5.8,,,506008; 8187252; 1719757,DMSO; Tween 20; Dithiothreitol,Other compound; Other compound; Other compound,"Article; Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.; Nature Biotechnology; vol. 26; 1; (2008); p. 127 - 132;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D25316241&database=RX&origin=ReaxysOutput&ln=
,CC1=CC(NC(=O)NC2=CC=C(C=C2)C2=CC=CC3=C2C(N)=NN3)=C(F)C=C1,11008713,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11008713&database=RX&origin=ReaxysOutput&ln=,(95 of 100),796967-16-3,linifanib; ABT-869; 1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea; N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea,C21H18FN5O,C21H18FN5O,375.405,,,MPVGZUGXCQEXTM-UHFFFAOYSA-N,,,,Identification(709); Physical Data(5); Spectra(11); Bioactivity(189),40,788,4.654,4,6,5,95.83,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,11008713,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11008713&database=RX&origin=ReaxysOutput&ln=,CC1=CC(NC(=O)NC2=CC=C(C=C2)C2=CC=CC3=C2C(N)=NN3)=C(F)C=C1,103904340,3 nM,,,,pKi,,,5.4,,,,,,,5.4,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,CC1=CC(NC(=O)NC2=CC=C(C=C2)C2=CC=CC3=C2C(N)=NN3)=C(F)C=C1,11008713,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11008713&database=RX&origin=ReaxysOutput&ln=,(95 of 100),796967-16-3,linifanib; ABT-869; 1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea; N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea,C21H18FN5O,C21H18FN5O,375.405,,,MPVGZUGXCQEXTM-UHFFFAOYSA-N,,,,Identification(709); Physical Data(5); Spectra(11); Bioactivity(189),40,788,4.654,4,6,5,95.83,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,In vitro inhibitory activity of compound against ALK in presence of 82 uM ATP upon incubation for 1 h,,,,,,,11008713,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11008713&database=RX&origin=ReaxysOutput&ln=,CC1=CC(NC(=O)NC2=CC=C(C=C2)C2=CC=CC3=C2C(N)=NN3)=C(F)C=C1,,,,,,qualitative,,Not Published,,,,,,,,,,,,ATP,Other compound,Patent; CHINA NATIONAL PHARMACEUTICAL GROUP CORPORATION; WO2012/89137; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20156058&database=RX&origin=ReaxysOutput&ln=
,CC1=CC(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12,7995521,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7995521&database=RX&origin=ReaxysOutput&ln=,(96 of 100),194413-58-6,"semaxanib; SU5416; semaxinib; (Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one; (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-Indol-2-one",C15H14N2O,C15H14N2O,238.289,heterocyclic,,WUWDLXZGHZSWQZ-WQLSENKSSA-N,,,,Identification(580); Physical Data(7); Spectra(12); Bioactivity(195),44,778,2.328,2,3,1,44.89,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,7995521,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7995521&database=RX&origin=ReaxysOutput&ln=,CC1=CC(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12,VEGF Receptor 2 Kinase Inhibitor III,0.500000 µM,,,,inhibition percentage,%,,52.59,,,,,,,6.35,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,CC1=CC(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12,7995521,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7995521&database=RX&origin=ReaxysOutput&ln=,(96 of 100),194413-58-6,"semaxanib; SU5416; semaxinib; (Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one; (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-Indol-2-one",C15H14N2O,C15H14N2O,238.289,heterocyclic,,WUWDLXZGHZSWQZ-WQLSENKSSA-N,,,,Identification(580); Physical Data(7); Spectra(12); Bioactivity(195),44,778,2.328,2,3,1,44.89,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,7995521,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7995521&database=RX&origin=ReaxysOutput&ln=,CC1=CC(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12,SU5416,,,,,IC50,µM,,1.2,,,,,,,5.92,,,506008,DMSO,Solvent,"Article; Mologni, Luca; Rostagno, Roberta; Brussolo, Stefania; Knowles, Phillip P.; Kjaer, Svend; Murray-Rust, Judith; Rosso, Enrico; Zambon, Alfonso; Scapozza, Leonardo; McDonald, Neil Q.; Lucchini, Vittorio; Gambacorti-Passerini, Carlo; Bioorganic and Medicinal Chemistry; vol. 18; 4; (2010); p. 1482 - 1496;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D8856094&database=RX&origin=ReaxysOutput&ln=
,CC1=CC(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12,7995521,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7995521&database=RX&origin=ReaxysOutput&ln=,(96 of 100),194413-58-6,"semaxanib; SU5416; semaxinib; (Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one; (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-Indol-2-one",C15H14N2O,C15H14N2O,238.289,heterocyclic,,WUWDLXZGHZSWQZ-WQLSENKSSA-N,,,,Identification(580); Physical Data(7); Spectra(12); Bioactivity(195),44,778,2.328,2,3,1,44.89,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,7995521,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7995521&database=RX&origin=ReaxysOutput&ln=,CC1=CC(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12,103905112,3 nM,,,,pKi,,,6.7,,,,,,,6.7,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol,CoEnzyme; Solvent; Other compound,"Article; Metz, James T.; Johnson, Eric F.; Soni, Niru B.; Merta, Philip J.; Kifle, Lemma; Hajduk, Philip J.; Nature Chemical Biology; vol. 7; 4; (2011); p. 200 - 202;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D31919682&database=RX&origin=ReaxysOutput&ln=
,CC1=CC(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12,7995521,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7995521&database=RX&origin=ReaxysOutput&ln=,(96 of 100),194413-58-6,"semaxanib; SU5416; semaxinib; (Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one; (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-Indol-2-one",C15H14N2O,C15H14N2O,238.289,heterocyclic,,WUWDLXZGHZSWQZ-WQLSENKSSA-N,,,,Identification(580); Physical Data(7); Spectra(12); Bioactivity(195),44,778,2.328,2,3,1,44.89,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,7995521,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D7995521&database=RX&origin=ReaxysOutput&ln=,CC1=CC(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12,7,,,,,IC50,µM,,1.81,,,,,,,5.74,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol; Brij-35 detergent; Phosphatase inhibitor cocktail; Protease inhibitor cocktail,CoEnzyme; Solvent; Other compound; Other compound; Other compound; Other compound,"Article; Okamoto, Masako; Kojima, Hirotatsu; Saito, Nae; Okabe, Takayoshi; Masuda, Yoshiaki; Furuya, Toshio; Nagano, Tetsuo; Bioorganic and Medicinal Chemistry; vol. 19; 10; (2011); p. 3086 - 3095;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D9045720&database=RX&origin=ReaxysOutput&ln=
,OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1,12883594,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12883594&database=RX&origin=ReaxysOutput&ln=,(97 of 100),,"cobimetinib; GDC-0973; (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone; XL518; cotellic; [3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-((s)-3-hydroxy-3-piperidin-2-yl-azetidin-1-yl)-methanone; [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl]methanone; [3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(2S)-(piperidin-2-yl)azetidin-1-yl]methanone; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl} methanone; RG7420; [14C]-GDC-0973",C21H21F3IN3O2,C21H21F3IN3O2,531.316,,,BSMCAPRUBJMWDF-KRWDZBQOSA-N,,,,Identification(681); Physical Data(14); Spectra(22); Bioactivity(237),50,753,4.817,3,5,5,64.6,3,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,In vitro inhibitory concentration of compound against ALK was determined in presence of ATP,,,,,,,12883594,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D12883594&database=RX&origin=ReaxysOutput&ln=,OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1,,,,,,IC50,nM,>,10000,,,,,,,1,,,,ATP,Other compound,"Article; Rice, Kenneth D.; Aay, Naing; Anand, Neel K.; Blazey, Charles M.; Bowles, Owen J.; Bussenius, Joerg; Costanzo, Simona; Curtis, Jeffry K.; Defina, Steven C.; Dubenko, Larisa; Engst, Stefan; Joshi, Anagha A.; Kennedy, Abigail R.; Kim, Angie I.; Koltun, Elena S.; Lougheed, Julie C.; Manalo, Jean-Claire L.; Martini, Jean-Francois; Nuss, John M.; Peto, Csaba J.; Tsang, Tsze H.; Yu, Peiwen; Johnston, Stuart; ACS Medicinal Chemistry Letters; vol. 3; 5; (2012); p. 416 - 421;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20145682&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,Inhibitory activity of compound against ALK was determined,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,qualitative,,Not Published,,,,,,,,,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2012/106540; (2012); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D20172668&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,Inhibitory concentration of the compound against non-Hodgkin’s Ki-positive large cell lymphoma Karpas-299 cells transfected with NPM-ANAPLASTIC LYMPHOMA KINASE by measuring cell proliferation,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,IC50,nM,=,22.8,,,,,,,7.64,,,,,,"Note; Chen, Jianyong; Jiang, Cheng; Wang, Shaomeng; Journal of Medicinal Chemistry; vol. 56; 14; (2013); p. 5673 - 5674;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D38327361&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,Inhibitory concentration of the compound against Ba/F3 cells transfected with NPM-ANAPLASTIC LYMPHOMA KINASE by measuring cell proliferation,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,IC50,nM,=,26,,,,,,,7.59,,,,,,"Note; Chen, Jianyong; Jiang, Cheng; Wang, Shaomeng; Journal of Medicinal Chemistry; vol. 56; 14; (2013); p. 5673 - 5674;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D38327361&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,Inhibitory concentration of the compound against Anaplastic lymphoma kinase,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,pM,=,200,,,,,,,9.7,,,,,,"Note; Chen, Jianyong; Jiang, Cheng; Wang, Shaomeng; Journal of Medicinal Chemistry; vol. 56; 14; (2013); p. 5673 - 5674;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D38327361&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,Inhibitory concentration of the compound against Anaplastic lymphoma kinase,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,=,40.7,,,,,,,7.39,,,,,,"Note; Chen, Jianyong; Jiang, Cheng; Wang, Shaomeng; Journal of Medicinal Chemistry; vol. 56; 14; (2013); p. 5673 - 5674;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D38327361&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,Inhibitory concentration of the compound against proliferation of Ba/F3-TEL cells expressing ALK kinase,,,,,BA/F3-TEL cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,= 6.25 mg/kg,oral administration,,cell proliferation,IC50,nM,=,40.7,,,,,,,7.39,,,,,,"Article; Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, Annemarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves; Journal of Medicinal Chemistry; vol. 56; 14; (2013); p. 5675 - 5690;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D38327339&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,Inhibitory concentration of the compound (dissolved in DMSO) against proliferation of Ba/F3 cells expressing NPM-ALK using Bright-Glo luciferase assay,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,= 6.25 mg/kg,oral administration,,cell proliferation,IC50,nM,=,26,,,,,,,7.59,,,,,,"Article; Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, Annemarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves; Journal of Medicinal Chemistry; vol. 56; 14; (2013); p. 5675 - 5690;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D38327339&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK kinase upon incubation for 60 minutes at 30 degree C using mobility shift assay,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,= 6.25 mg/kg,oral administration,,,IC50,µM,=,0.0002,,,,,,,9.7,,,,,,"Article; Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, Annemarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves; Journal of Medicinal Chemistry; vol. 56; 14; (2013); p. 5675 - 5690;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D38327339&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,"Inhibitory concentration of compound (Dissolved in DMSO) against ALK using 20 ug/ml POLY (GLU,TYR)4:1(SIGMA) as substrate in presence of 10 uM of ATP with 50 mM HEPES buffer, pH 7.4 upon incubation for 60 mins at 37 degree C by ELISA",,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,=,3.4,,,,,,,8.47,,,,,,"Article; Song, Zilan; Yang, Yanhong; Liu, Zhiqing; Peng, Xia; Guo, Junfeng; Yang, Xinying; Wu, Kui; Ai, Jing; Ding, Jian; Geng, Meiyu; Zhang, Ao; Journal of Medicinal Chemistry; vol. 58; 1; (2015); p. 197 - 211;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D64671986&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro median-effective dose of the compound against proliferation of neuroblastoma NB-1691 cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,NB-1691 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,ED50,nM,=,761.6,,,,,,,6.12,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma NB-1691 cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,NB-1691 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,IC50,nM,=,1933,,,,,,,5.71,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma SK-N-F1 cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,SK-N-FI cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,IC50,nM,=,3475,,,,,,,5.46,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma NB-1643 het cell line expressing mutant R1275Q ALK upon incubation for 72 hrs,,,,,NB-1643 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,IC50,nM,=,222,,,,,,,6.65,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma SK-N-AS cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,SK-N-AS cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,IC50,nM,=,2153,,,,,,,5.67,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro median-effective dose of the compound against proliferation of neuroblastoma SK-N-BE(2)-C cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,SK-N-BE(2)-C cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,ED50,nM,=,349.5,,,,,,,6.46,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma SK-N-BE(2)-C cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,SK-N-BE(2)-C cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,IC50,nM,=,602.7,,,,,,,6.22,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro median-effective dose of the compound against against proliferation of neuroblastoma SH-SY5Y cell line expressing mutant F1174L ALK upon incubation for 72 hrs,,,,,SH-SY5Y cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,ED50,nM,=,1500,,,,,,,5.82,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma SH-SY5Y cell line expressing mutant F1174L ALK upon incubation for 72 hrs,,,,,SH-SY5Y cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,IC50,nM,=,963.15,,,,,,,6.02,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro median-effective dose of the compound against proliferation of neuroblastoma NB-1643 het cell line expressing mutant R1275Q ALK upon incubation for 72 hrs,,,,,NB-1643 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,ED50,nM,=,172.7,,,,,,,6.76,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro median-effective dose of the compound against proliferation of neuroblastoma NBEBC1 cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,NB-EbC1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,ED50,nM,=,1662,,,,,,,5.78,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against proliferation of neuroblastoma NBEBC1 cell line expressing wild-type ALK upon incubation for 72 hrs,,,,,NB-EbC1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,IC50,nM,=,1924.7,,,,,,,5.72,,,,,,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2015/31666; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D65595037&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against ALK kinase,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,=,0.2,,,,,,,9.7,,,,,,Patent; ROCHE HOLDING AG; WO2015/66452; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D66155960&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of compound against wild type ALK using HOMOGENEOUS TIME RESOLVED FLUORESCENCE (HTRF) ASSAY,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,=,14,,,,,,,7.85,,,,,,"Article; Kang, Ga Ae; Lee, Minji; Song, Dawn; Lee, Heung Kyoung; Ahn, Sunjoo; Park, Chi Hoon; Lee, Chong Ock; Yun, Chang Soo; Jung, Heejung; Kim, Pilho; Ha, Jae Du; Cho, Sung Yun; Kim, Hyoung Rae; Hwang, Jong Yeon; Bioorganic and Medicinal Chemistry Letters; vol. 25; 18; (2015); p. 3992 - 3998;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D66875192&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of compound against ALK L1196M mutant using HOMOGENEOUS TIME RESOLVED FLUORESCENCE (HTRF) ASSAY,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,=,29,,,,,,,7.54,,,,,,"Article; Kang, Ga Ae; Lee, Minji; Song, Dawn; Lee, Heung Kyoung; Ahn, Sunjoo; Park, Chi Hoon; Lee, Chong Ock; Yun, Chang Soo; Jung, Heejung; Kim, Pilho; Ha, Jae Du; Cho, Sung Yun; Kim, Hyoung Rae; Hwang, Jong Yeon; Bioorganic and Medicinal Chemistry Letters; vol. 25; 18; (2015); p. 3992 - 3998;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D66875192&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of compound against wild type ALK using 5 ul ADENOSINE TRIPHOSPHATE (ATP) as substrate upon incubation at RT for 30 mins,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,µM,=,0.001,,,,,,,9,,,,,,Patent; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY; BAYER AG; WO2015/130014; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67118864&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of compound against L1196M mutant ALK using 5 ul ADENOSINE TRIPHOSPHATE (ATP) as substrate upon incubation at RT for 30 mins,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,µM,=,0.009,,,,,,,8.05,,,,,,Patent; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY; BAYER AG; WO2015/130014; (2015); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67118864&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against mutant ANAPLASTIC LYMPHOMA KINASE L1196M upon incubation for 30 mins at RT in presence of 5 ul ATP using Biotinylated peptide as susbstrate by HOMOGENEOUS TIME RESOLVED FLUORESCENCE (HTRF) ASSAY,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,µM,=,0.005,,,,,,,8.3,,,,,,Patent; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY; WO2015/194764; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68727379&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against wild type ANAPLASTIC LYMPHOMA KINASE upon incubation for 30 mins at RT in presence of 5 ul ATP using Biotinylated peptide as substrate by HOMOGENEOUS TIME RESOLVED FLUORESCENCE (HTRF) ASSAY,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,µM,=,0.001,,,,,,,9,,,,,,Patent; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY; WO2015/194764; (2015); A2;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D68727379&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against mutant ANAPLASTIC LYMPHOMA KINASE L1196M using HTRF KINEASE TK ASSAY,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,qualitative,nM,=,29,,,,,,,,,,,,,Article; Chang Soo Yun; Chi Hoon Park; Chong Ock Lee; Dawn Song; Hyoung Rae Kim; Jong Yeon Hwang; Minji Lee; Sunjoo Ahn; Bioorganic and medicinal chemistry letters; vol. 26; (2016); p. 1720 - 1725;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69040353&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Mutated:Substitution,,,,cytotoxic agent,In Vitro (Efficacy),,Cytotoxic concentration of the compound against proliferation of BA/F3 cells expressing mutant ANAPLASTIC LYMPHOMA KINASE L1196M upon incubation for 72 hrs using WST-8 CELL PROLIFERATION ASSAY,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,cell proliferation,CC50 (cytotoxic concentration),nM,=,75,,,,,,,7.12,,,,,,Article; Chang Soo Yun; Chi Hoon Park; Chong Ock Lee; Dawn Song; Hyoung Rae Kim; Jong Yeon Hwang; Minji Lee; Sunjoo Ahn; Bioorganic and medicinal chemistry letters; vol. 26; (2016); p. 1720 - 1725;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69040353&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,inhibitory activity,In Vitro (Efficacy),,Inhibitory concentration of the compound against wild type ANAPLASTIC LYMPHOMA KINASE using HTRF KINEASE TK ASSAY,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,=,14,,,,,,,7.85,,,,,,Article; Chang Soo Yun; Chi Hoon Park; Chong Ock Lee; Dawn Song; Hyoung Rae Kim; Jong Yeon Hwang; Minji Lee; Sunjoo Ahn; Bioorganic and medicinal chemistry letters; vol. 26; (2016); p. 1720 - 1725;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69040353&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nmol/l,,2.3,,,,,,,8.64,,,73010,ATP,Other compound,"Article; Wang, Yu; Zhang, Guogang; Hu, Gang; Bu, Yanxin; Lei, Hongrui; Zuo, Daiying; Han, Mengting; Zhai, Xin; Gong, Ping; European Journal of Medicinal Chemistry; vol. 123; (2016); p. 80 - 89;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69330748&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,Leucine,1196,Methionine",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nmol/l,,64,,,,,,,7.19,,,73010,ATP,Other compound,"Article; Wang, Yu; Zhang, Guogang; Hu, Gang; Bu, Yanxin; Lei, Hongrui; Zuo, Daiying; Han, Mengting; Zhai, Xin; Gong, Ping; European Journal of Medicinal Chemistry; vol. 123; (2016); p. 80 - 89;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69330748&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,Leucine,1196,Methionine",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,,29,,,,,,,7.54,,,,,,"Article; Song, Dawn; Lee, Minji; Park, Chi Hoon; Ahn, Sunjoo; Yun, Chang Soo; Lee, Chong Ock; Kim, Hyoung Rae; Hwang, Jong Yeon; Bioorganic and Medicinal Chemistry Letters; vol. 26; 7; (2016); p. 1720 - 1725;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69310511&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,,14,,,,,,,7.85,,,,,,"Article; Song, Dawn; Lee, Minji; Park, Chi Hoon; Ahn, Sunjoo; Yun, Chang Soo; Lee, Chong Ock; Kim, Hyoung Rae; Hwang, Jong Yeon; Bioorganic and Medicinal Chemistry Letters; vol. 26; 7; (2016); p. 1720 - 1725;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69310511&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,Leucine,1196,Methionine",,,Inhibitor,cytotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,CC50 (cytotoxic concentration),nM,,75,,,,,,,7.12,,,,,,"Article; Song, Dawn; Lee, Minji; Park, Chi Hoon; Ahn, Sunjoo; Yun, Chang Soo; Lee, Chong Ock; Kim, Hyoung Rae; Hwang, Jong Yeon; Bioorganic and Medicinal Chemistry Letters; vol. 26; 7; (2016); p. 1720 - 1725;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69310511&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,CC50 (cytotoxic concentration),nM,,38,,,,,,,7.42,,,,,,"Article; Song, Dawn; Lee, Minji; Park, Chi Hoon; Ahn, Sunjoo; Yun, Chang Soo; Lee, Chong Ock; Kim, Hyoung Rae; Hwang, Jong Yeon; Bioorganic and Medicinal Chemistry Letters; vol. 26; 7; (2016); p. 1720 - 1725;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D69310511&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,,inhibition percentage,%,,97,,,,,,,7.28,,,,,,"Article; Achary, Raghavendra; Yun, Jeong In; Park, Chi Min; Mathi, Gangadhar Rao; Lee, Joo Yun; Ha, Jae Du; Chae, Chong Hak; Ahn, Sunjoo; Park, Chi Hoon; Lee, Chong Ock; Hwang, Jong Yeon; Yun, Chang-Soo; Jung, Hee Jung; Cho, Sung Yun; Kim, Hyoung Rae; Kim, Pilho; Bioorganic and Medicinal Chemistry; vol. 24; 2; (2016); p. 207 - 219;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67810807&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,0.014,,,,,,,7.85,,,,,,"Article; Achary, Raghavendra; Yun, Jeong In; Park, Chi Min; Mathi, Gangadhar Rao; Lee, Joo Yun; Ha, Jae Du; Chae, Chong Hak; Ahn, Sunjoo; Park, Chi Hoon; Lee, Chong Ock; Hwang, Jong Yeon; Yun, Chang-Soo; Jung, Hee Jung; Cho, Sung Yun; Kim, Hyoung Rae; Kim, Pilho; Bioorganic and Medicinal Chemistry; vol. 24; 2; (2016); p. 207 - 219;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67810807&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,Leucine,1196,Methionine",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,0.029,,,,,,,7.54,,,,,,"Article; Achary, Raghavendra; Yun, Jeong In; Park, Chi Min; Mathi, Gangadhar Rao; Lee, Joo Yun; Ha, Jae Du; Chae, Chong Hak; Ahn, Sunjoo; Park, Chi Hoon; Lee, Chong Ock; Hwang, Jong Yeon; Yun, Chang-Soo; Jung, Hee Jung; Cho, Sung Yun; Kim, Hyoung Rae; Kim, Pilho; Bioorganic and Medicinal Chemistry; vol. 24; 2; (2016); p. 207 - 219;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67810807&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,Glycine,1202,Arginine",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,0.02,,,,,,,7.7,,,,,,"Article; Achary, Raghavendra; Yun, Jeong In; Park, Chi Min; Mathi, Gangadhar Rao; Lee, Joo Yun; Ha, Jae Du; Chae, Chong Hak; Ahn, Sunjoo; Park, Chi Hoon; Lee, Chong Ock; Hwang, Jong Yeon; Yun, Chang-Soo; Jung, Hee Jung; Cho, Sung Yun; Kim, Hyoung Rae; Kim, Pilho; Bioorganic and Medicinal Chemistry; vol. 24; 2; (2016); p. 207 - 219;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67810807&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,Glycine,1269,Alanine",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,0.0021,,,,,,,8.68,,,,,,"Article; Achary, Raghavendra; Yun, Jeong In; Park, Chi Min; Mathi, Gangadhar Rao; Lee, Joo Yun; Ha, Jae Du; Chae, Chong Hak; Ahn, Sunjoo; Park, Chi Hoon; Lee, Chong Ock; Hwang, Jong Yeon; Yun, Chang-Soo; Jung, Hee Jung; Cho, Sung Yun; Kim, Hyoung Rae; Kim, Pilho; Bioorganic and Medicinal Chemistry; vol. 24; 2; (2016); p. 207 - 219;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67810807&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Insertion,1,Threonine,1151,Threonine,Insertion,2,Leucine,1152,Threonine",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,0.0017,,,,,,,8.77,,,,,,"Article; Achary, Raghavendra; Yun, Jeong In; Park, Chi Min; Mathi, Gangadhar Rao; Lee, Joo Yun; Ha, Jae Du; Chae, Chong Hak; Ahn, Sunjoo; Park, Chi Hoon; Lee, Chong Ock; Hwang, Jong Yeon; Yun, Chang-Soo; Jung, Hee Jung; Cho, Sung Yun; Kim, Hyoung Rae; Kim, Pilho; Bioorganic and Medicinal Chemistry; vol. 24; 2; (2016); p. 207 - 219;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67810807&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,Phenylalanine,1174,Leucine",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,0.0024,,,,,,,8.62,,,,,,"Article; Achary, Raghavendra; Yun, Jeong In; Park, Chi Min; Mathi, Gangadhar Rao; Lee, Joo Yun; Ha, Jae Du; Chae, Chong Hak; Ahn, Sunjoo; Park, Chi Hoon; Lee, Chong Ock; Hwang, Jong Yeon; Yun, Chang-Soo; Jung, Hee Jung; Cho, Sung Yun; Kim, Hyoung Rae; Kim, Pilho; Bioorganic and Medicinal Chemistry; vol. 24; 2; (2016); p. 207 - 219;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67810807&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,Cysteine,1156,Tyrosine",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,0.0042,,,,,,,8.38,,,,,,"Article; Achary, Raghavendra; Yun, Jeong In; Park, Chi Min; Mathi, Gangadhar Rao; Lee, Joo Yun; Ha, Jae Du; Chae, Chong Hak; Ahn, Sunjoo; Park, Chi Hoon; Lee, Chong Ock; Hwang, Jong Yeon; Yun, Chang-Soo; Jung, Hee Jung; Cho, Sung Yun; Kim, Hyoung Rae; Kim, Pilho; Bioorganic and Medicinal Chemistry; vol. 24; 2; (2016); p. 207 - 219;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D67810807&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,r",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.048,,,,,,,7.32,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1152,r; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,DFCI076 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,1 nM - 10 μM,,,,IC50,μM,,0.092,,,,,,,7.04,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1269,a; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,DFCI114 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,1 nM - 10 μM,,,,IC50,μM,,0.041,,,,,,,7.39,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Wild,,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,41,,,,,,,7.39,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Wild,,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.026,,,,,,,7.59,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.624,,,,,,,6.2,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,c,1156,y",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.153,,,,,,,6.82,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1152,r; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,2.364,,,,,,,5.63,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1269,a; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.035,,,,,,,7.46,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,s,1206,y",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.029,,,,,,,7.54,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,c,1156,y",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,164,,,,,,,6.79,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,r",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,64,,,,,,,7.19,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1152,r; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2747,,,,,,,5.56,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,444,,,,,,,6.35,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1269,a; Echinoderm microtubule-associated protein-like 4:Wild",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,57,,,,,,,7.24,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,"Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Mutated:Substitution,1,s,1206,y",,Transfected; Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,33,,,,,,,7.48,,,,,,Patent; DANA-FARBER CANCER INSTITUTE; WO2017/53657; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D70975709&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,14,,,,,,,7.85,,,73010,ATP,Substrate,"Article; Achary, Raghavendra; Mathi, Gangadhar Rao; Lee, Dong Ho; Yun, Chang Soo; Lee, Chong Ock; Kim, Hyoung Rae; Park, Chi Hoon; Kim, Pilho; Hwang, Jong Yeon; Bioorganic and Medicinal Chemistry Letters; vol. 27; 10; (2017); p. 2185 - 2191;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71078018&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,CC50 (cytotoxic concentration),nM,,38,,,,,,,7.42,,,,,,"Article; Achary, Raghavendra; Mathi, Gangadhar Rao; Lee, Dong Ho; Yun, Chang Soo; Lee, Chong Ock; Kim, Hyoung Rae; Park, Chi Hoon; Kim, Pilho; Hwang, Jong Yeon; Bioorganic and Medicinal Chemistry Letters; vol. 27; 10; (2017); p. 2185 - 2191;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71078018&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,20,,,,,,,7.7,,,,,,"Article; Jang, Jaebong; Son, Jung Beom; To, Ciric; Bahcall, Magda; Kim, So Young; Kang, Seock Yong; Mushajiang, Mierzhati; Lee, Younho; Jänne, Pasi A.; Choi, Hwan Geun; Gray, Nathanael S.; European Journal of Medicinal Chemistry; vol. 136; (2017); p. 497 - 510;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71227487&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,35,,,,,,,7.46,,,,,,"Article; Wang, Yu; Chen, Shaowei; Hu, Gang; Wang, Jiao; Gou, Wenfeng; Zuo, Daiying; Gu, Yucheng; Gong, Ping; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 143; (2018); p. 123 - 136;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72656773&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1269,a",,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,3.9,,,,,,,8.41,,,,,,"Article; Wang, Yu; Chen, Shaowei; Hu, Gang; Wang, Jiao; Gou, Wenfeng; Zuo, Daiying; Gu, Yucheng; Gong, Ping; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 143; (2018); p. 123 - 136;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72656773&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,c,1156,y",,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2.9,,,,,,,8.54,,,,,,"Article; Wang, Yu; Chen, Shaowei; Hu, Gang; Wang, Jiao; Gou, Wenfeng; Zuo, Daiying; Gu, Yucheng; Gong, Ping; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 143; (2018); p. 123 - 136;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72656773&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,91,,,,,,,7.04,,,,,,"Article; Wang, Yu; Chen, Shaowei; Hu, Gang; Wang, Jiao; Gou, Wenfeng; Zuo, Daiying; Gu, Yucheng; Gong, Ping; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 143; (2018); p. 123 - 136;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72656773&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,s,1206,y",,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,4.6,,,,,,,8.34,,,,,,"Article; Wang, Yu; Chen, Shaowei; Hu, Gang; Wang, Jiao; Gou, Wenfeng; Zuo, Daiying; Gu, Yucheng; Gong, Ping; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 143; (2018); p. 123 - 136;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72656773&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2.9,,,,,,,8.54,,,,,,"Article; Wang, Yu; Chen, Shaowei; Hu, Gang; Wang, Jiao; Gou, Wenfeng; Zuo, Daiying; Gu, Yucheng; Gong, Ping; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 143; (2018); p. 123 - 136;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72656773&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,RMS cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,<,1,,,,,,,6,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,alveolar rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,cleaved,amount increase,,Active,,,,Poly [ADP-ribose] polymerase (gene PARP),,,,,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,embryonal rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,cleaved,amount increase,,Not active,,,,Poly [ADP-ribose] polymerase (gene PARP),,,,1,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,embryonal rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,cleaved,amount increase,,Not active,,,,Poly [ADP-ribose] polymerase (gene PARP),,,,1,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,alveolar rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,G0/G1 cell cycle arrest,percentage increase,,Active,,,,,,,,,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,embryonal rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,cells in S phase,percentage decrease,,Active,,,,,,,,,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,alveolar rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,cleaved,amount increase,,Active,,,,Poly [ADP-ribose] polymerase (gene PARP),,,,,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,25 mg/kg,oral administration,Repeated,,amount increase,,High,,,,Caspase-3,,,,,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,50 mg/kg,oral administration,Repeated,,amount increase,,High,,,,Caspase-3,,,,,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,25 mg/kg,oral administration,Repeated,Vascularization,percentage increase,,Active,,,,,,,,,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,50 mg/kg,oral administration,Repeated,Vascularization,percentage increase,,Active,,,,,,,,,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,25 - 50 mg/kg,oral administration,Repeated,phosphorylation,percentage change,,Not active,,,,Ephrin type-B receptor 2,,,,1,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,25 - 50 mg/kg,oral administration,Repeated,phosphorylation,percentage change,,Not active,,,,RAC family serine/threonine-protein kinase homolog,,,,1,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,human,,,,synovial sarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,<= 5 μM,,,,inhibition percentage,,High,,,,,,,,,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,alveolar rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,inhibition percentage,,Not active,,,,,,,,1,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,alveolar rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,inhibition percentage,,Not active,,,,,,,,1,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,embryonal rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,inhibition percentage,,Not active,,,,,,,,1,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,embryonal rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,inhibition percentage,,Not active,,,,,,,,1,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,human,,,,synovial sarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,inhibition percentage,,Not active,,,,,,,,1,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,alveolar rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,<= 5 μM,,,,IC50,μM,,0.5,,,,,,,6.3,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,embryonal rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,<= 5 μM,,,,IC50,μM,,0.87,,,,,,,6.06,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,alveolar rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,<= 5 μM,,,,IC50,μM,,0.3,,,,,,,6.52,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,embryonal rhabdomyosarcoma cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,<= 5 μM,,,,IC50,μM,,1,,,,,,,6,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,50 mg/kg,oral administration,Repeated,Tumor growth,percentage,%,,21.3,,S,,,,,,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,25 mg/kg,oral administration,Repeated,Tumor growth,percentage,%,,21.2,,S,,,,,,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,50 mg/kg,oral administration,Repeated,Ki67 positive cells,percentage,%,,16.6,,S,,,,,,,,,,,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72426874&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,0.001,,,,,,,9,,,,,,Patent; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY; US2017/145007; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72668320&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,L1196M cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,0.005,,,,,,,8.3,,,,,,Patent; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY; US2017/145007; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72668320&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,0.041,,,,,,,7.39,,,,,,Patent; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY; US2017/145007; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72668320&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,0.019,,,,,,,7.72,,,,,,Patent; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY; US2017/145007; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72668320&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,3.4,,,,,,,8.47,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SU-DHL-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,122,,,,,,,6.91,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,84,,,,,,,7.08,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3-EML4-ALK cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,10.7,,,,,,,7.97,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3-EML4-ALK cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,54.9,,,,,,,7.26,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3-EML4-ALK cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,726,,,,,,,6.14,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC78 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,>,1000,,,,,,,6,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,>,1000,,,,,,,6,,,,,,"Article; Geng, Kaijun; Xia, Zongjun; Ji, Yinchun; Zhang, Ruisi (Ruthy); Sun, Deqiao; Ai, Jing; Song, Zilan; Geng, Meiyu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 144; (2018); p. 386 - 397;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D72881632&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.04 - 2500 nM,,,Kinase activity,IC50,nM,,2.7,,,,,,,8.57,,,,,,Patent; SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.; EP3202765; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73059743&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.004 - 1000 nM,,,,IC50,nM,,3.9,,,,,,,8.41,,,,,,Patent; SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.; EP3202765; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73059743&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,2.5 nM - 10 μM,,,,IC50,nM,,138.1,,,,,,,6.86,,,,,,Patent; SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.; EP3202765; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73059743&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.61 - 10000 nM,,,,IC50,nM,,48.06,,,,,,,7.32,,,,,,Patent; SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.; EP3202765; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73059743&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,2.5 nM - 10 μM,,,,IC50,nM,,29.98,,,,,,,7.52,,,,,,Patent; SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.; EP3202765; (2017); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73059743&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Echinoderm microtubule-associated protein-like 4 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,818511893 + 818533525,,,,,ALK tyrosine kinase receptor [human]; Echinoderm microtubule-associated protein-like 4 [human],ALK tyrosine kinase receptor [human]:Chimera + Echinoderm microtubule-associated protein-like 4 [human]:Chimera,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,100 nM,,,Degradation,amount decrease,,Not active,,,,ALK tyrosine kinase receptor,,,,1,,,,,,"Article; Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian; European Journal of Medicinal Chemistry; vol. 151; (2018); p. 304 - 314;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73546418&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Radioligand (/ligand),,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,<= 3000 nM,,,,Kd (dissociation constant),nM,,1.3,,,,,,,8.89,,,,,,"Article; Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian; European Journal of Medicinal Chemistry; vol. 151; (2018); p. 304 - 314;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73546418&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Echinoderm microtubule-associated protein-like 4 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,818511893 + 818533525,,,,,ALK tyrosine kinase receptor [human]; Echinoderm microtubule-associated protein-like 4 [human],ALK tyrosine kinase receptor [human]:Chimera + Echinoderm microtubule-associated protein-like 4 [human]:Chimera,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,100 nM,,,tyrosine 1507 phosphorylation,inhibition percentage,,Not active,,,,ALK tyrosine kinase receptor,,,,1,,,,,,"Article; Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian; European Journal of Medicinal Chemistry; vol. 151; (2018); p. 304 - 314;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73546418&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Nucleophosmin [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + npm; npm1; nucleolar phosphoprotein b23; nucleolar protein no38; nucleophosmin; numatrin,818511893 + 818246336,,,,,ALK tyrosine kinase receptor [human]; Nucleophosmin [human],ALK tyrosine kinase receptor [human]:Chimera + Nucleophosmin [human]:Chimera,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,SU-DHL-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,30 nM,,,Degradation,amount decrease,,Not active,,,,ALK tyrosine kinase receptor,,,,1,,,,,,"Article; Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian; European Journal of Medicinal Chemistry; vol. 151; (2018); p. 304 - 314;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73546418&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Nucleophosmin [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + npm; npm1; nucleolar phosphoprotein b23; nucleolar protein no38; nucleophosmin; numatrin,818511893 + 818246336,,,,,ALK tyrosine kinase receptor [human]; Nucleophosmin [human],ALK tyrosine kinase receptor [human]:Chimera + Nucleophosmin [human]:Chimera,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,SU-DHL-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,30 nM,,,,inhibition percentage,,Active,,,,,,,,7.52,,,,,,"Article; Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian; European Journal of Medicinal Chemistry; vol. 151; (2018); p. 304 - 314;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73546418&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Nucleophosmin [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + npm; npm1; nucleolar phosphoprotein b23; nucleolar protein no38; nucleophosmin; numatrin,818511893 + 818246336,,,,,ALK tyrosine kinase receptor [human]; Nucleophosmin [human],ALK tyrosine kinase receptor [human]:Chimera + Nucleophosmin [human]:Chimera,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,SU-DHL-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,100 nM,,,,protein expression level increase,,Low,,,,ALK tyrosine kinase receptor,,,,,,,32522362,"2-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-N-(17-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)acetamide",Inhibitor,"Article; Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian; European Journal of Medicinal Chemistry; vol. 151; (2018); p. 304 - 314;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73546418&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Nucleophosmin [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + npm; npm1; nucleolar phosphoprotein b23; nucleolar protein no38; nucleophosmin; numatrin,818511893 + 818246336,,,,,ALK tyrosine kinase receptor [human]; Nucleophosmin [human],ALK tyrosine kinase receptor [human]:Chimera + Nucleophosmin [human]:Chimera,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,SU-DHL-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,100 nM,,,,protein expression level increase,,Low,,,,ALK tyrosine kinase receptor,,,,,,,32522357,"2-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)acetamide",Inhibitor,"Article; Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian; European Journal of Medicinal Chemistry; vol. 151; (2018); p. 304 - 314;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73546418&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.041 μM,,,,inhibition percentage,%,,-5,,,,,,,1,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.0046 μM,,,,inhibition percentage,%,,-7,,,,,,,1,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.37 μM,,,,inhibition percentage,%,,20,,,,,,,1,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,3.3 μM,,,,inhibition percentage,%,,71,,,,,,,5.87,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.0045 μM,,,,inhibition percentage,%,,-15,,,,,,,1,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.041 μM,,,,inhibition percentage,%,,-6,,,,,,,1,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.37 μM,,,,inhibition percentage,%,,5,,,,,,,1,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,3.3 μM,,,,inhibition percentage,%,,99,,,,,,,6.76,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,KP-N-RT-BM-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.0046 μM,,,,inhibition percentage,%,,-16,,,,,,,1,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,KP-N-RT-BM-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.041 μM,,,,inhibition percentage,%,,3,,,,,,,1,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,KP-N-RT-BM-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.37 μM,,,,inhibition percentage,%,,43,,,,,,,6.31,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,KP-N-RT-BM-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,3.3 μM,,,,inhibition percentage,%,,91,,,,,,,6.49,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.0015 μM,,,,inhibition percentage,%,,-11,,,,,,,1,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.014 μM,,,,inhibition percentage,%,,45,,,,,,,7.77,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.12 μM,,,,inhibition percentage,%,,86,,,,,,,7.71,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1.1 μM,,,,inhibition percentage,%,,97,,,,,,,7.24,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,cleaved PARP,cleaved PARP level increase,,Active,,,,,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,cleaved PARP,cleaved PARP level increase,,Active,,,,,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,,percentage increase,,Active,,,,Bcl-2-like protein 11,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,,percentage increase,,Active,,,,IAP-like protein p27,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,cleaved PARP,cleaved PARP level increase,,Active,,,,,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,,percentage increase,,Active,,,,Bcl-2-binding component 3,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,,percentage increase,,Active,,,,Bcl-2-binding component 3,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,KP-N-RT-BM-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,,percentage increase,,Active,,,,Bcl-2-binding component 3,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,,percentage increase,,Active,,,,Bcl-2-like protein 11,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,,percentage increase,,Active,,,,Bcl-2-like protein 11,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,KP-N-RT-BM-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,,percentage increase,,Active,,,,Bcl-2-like protein 11,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,SH-SY5Y cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,,percentage increase,,Active,,,,IAP-like protein p27,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Kelly cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,,percentage increase,,Active,,,,IAP-like protein p27,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,KP-N-RT-BM-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,,percentage increase,,Active,,,,IAP-like protein p27,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,1 μM,,,,percentage increase,,Active,,,,Bcl-2-binding component 3,,,,6,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,50 mg/kg,oral administration,Repeated,cleaved PARP,cleaved PARP level increase,,Active,,,,,,,,,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,50 mg/kg,oral administration,Repeated,cleaved PARP,cleaved PARP level increase,,Active,,,,,,,,,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,50 mg/kg,oral administration,Repeated,cleaved PARP,cleaved PARP level increase,,Active,,,,,,,,,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.001 - 1 μM,,,,inhibition percentage,,Active,,,,,,,,9,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.2 μM,,,,inhibition percentage,,Active,,,,,,,,6.7,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,E3 ubiquitin-protein ligase Mdm2; ALK tyrosine kinase receptor,cdm2; double minute 2 protein; e3 ubiquitin-protein ligase mdm2; edm2; hdm2; mdm2; oncoprotein mdm2; p53-binding protein mdm2; ring-type e3 ubiquitin transferase mdm2; xdm2 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,817003158 + 820152764,,,,ipr:ipr028340 + ipr:ipr026830,E3 ubiquitin-protein ligase Mdm2; ALK tyrosine kinase receptor,E3 ubiquitin-protein ligase Mdm2:Wild; ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NB1 cell line (neuroblastoma),,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,0.001 - 1 μM,,,,inhibition percentage,,Active,,,,,,,,9,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,50 mg/kg,oral administration,Repeated,,inhibition percentage,,Active,,,,,,,,,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,50 mg/kg,oral administration,Repeated,,inhibition percentage,,Active,,,,,,,,,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,50 mg/kg,oral administration,Repeated,,inhibition percentage,,Active,,,,,,,,,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,E3 ubiquitin-protein ligase Mdm2; ALK tyrosine kinase receptor,cdm2; double minute 2 protein; e3 ubiquitin-protein ligase mdm2; edm2; hdm2; mdm2; oncoprotein mdm2; p53-binding protein mdm2; ring-type e3 ubiquitin transferase mdm2; xdm2 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,817003158 + 820152764,,,,ipr:ipr028340 + ipr:ipr026830,E3 ubiquitin-protein ligase Mdm2; ALK tyrosine kinase receptor,E3 ubiquitin-protein ligase Mdm2:Wild; ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,oral administration,Repeated,,inhibition percentage,,Active,,,,,,,,,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,E3 ubiquitin-protein ligase Mdm2; ALK tyrosine kinase receptor,cdm2; double minute 2 protein; e3 ubiquitin-protein ligase mdm2; edm2; hdm2; mdm2; oncoprotein mdm2; p53-binding protein mdm2; ring-type e3 ubiquitin transferase mdm2; xdm2 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,817003158 + 820152764,,,,ipr:ipr028340 + ipr:ipr026830,E3 ubiquitin-protein ligase Mdm2; ALK tyrosine kinase receptor,E3 ubiquitin-protein ligase Mdm2:Wild; ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,oral administration,Repeated,,inhibition percentage,,Active,,,,,,,,,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,E3 ubiquitin-protein ligase Mdm2; ALK tyrosine kinase receptor,cdm2; double minute 2 protein; e3 ubiquitin-protein ligase mdm2; edm2; hdm2; mdm2; oncoprotein mdm2; p53-binding protein mdm2; ring-type e3 ubiquitin transferase mdm2; xdm2 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,817003158 + 820152764,,,,ipr:ipr028340 + ipr:ipr026830,E3 ubiquitin-protein ligase Mdm2; ALK tyrosine kinase receptor,E3 ubiquitin-protein ligase Mdm2:Wild; ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,oral administration,Repeated,,inhibition percentage,,Active,,,,,,,,,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,E3 ubiquitin-protein ligase Mdm2; ALK tyrosine kinase receptor,cdm2; double minute 2 protein; e3 ubiquitin-protein ligase mdm2; edm2; hdm2; mdm2; oncoprotein mdm2; p53-binding protein mdm2; ring-type e3 ubiquitin transferase mdm2; xdm2 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,817003158 + 820152764,,,,ipr:ipr028340 + ipr:ipr026830,E3 ubiquitin-protein ligase Mdm2; ALK tyrosine kinase receptor,E3 ubiquitin-protein ligase Mdm2:Wild; ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,oral administration,Repeated,,inhibition percentage,,Active,,,,,,,,,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,50 mg/kg,oral administration,Repeated,,inhibition percentage,,Active,,,,,,,,,,,,,,"Article; Wang, Hui Qin; Halilovic, Ensar; Li, Xiaoyan; Liang, Jinsheng; Cao, Yichen; Rakiec, Daniel P.; Ruddy, David A.; Jeay, Sebastien; Wuerthner, Jens U.; Timple, Noelito; Kasibhatla, Shailaja; Li, Nanxin; Williams, Juliet A.; Sellers, William R.; Huang, Alan; Li, Fang; eLife; vol. 6; (2017);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D71243484&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,<= 10000 nM,,,,IC50,nM,,0.14,,,,,,,9.85,,,73010,ATP,Other compound,"Article; Powell, Chelsea E.; Gao, Yang; Tan, Li; Donovan, Katherine A.; Nowak, Radoslaw P.; Loehr, Amanda; Bahcall, Magda; Fischer, Eric S.; Jänne, Pasi A.; George, Rani E.; Gray, Nathanael S.; Journal of Medicinal Chemistry; vol. 61; 9; (2018); p. 4249 - 4255;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73713964&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Hep-G2 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,2 nmol/l,,,,percentage of late apoptotic cells increase,,Active,,,S,,,,,8.7,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,HCCLM3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,2 nmol/l,,,,percentage of late apoptotic cells increase,,Active,,,S,,,,,8.7,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,MHCC97-H cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.01 - 10000 nM,,,,IC50,nM,,5.56,,,,,,,8.25,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Huh-7 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.01 - 10000 nM,,,,IC50,nM,,7.19,,,,,,,8.14,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Hep 3B2.1-7 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.01 - 10000 nM,,,,IC50,nM,,2.36,,,,,,,8.63,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.01 - 10000 nM,,,,IC50,nM,,1.79,,,,,,,8.75,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,2 nmol/l,,,Number of cells,inhibition percentage,%,,23,,S,,,,,1,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCCLM3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.01 - 10000 nM,,,,IC50,nM,,0.83,,,,,,,9.08,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCCLM3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,2 nmol/l,,,Number of cells,inhibition percentage,%,,17,,S,,,,,1,,,,,,"Article; Yu, Zhen; Zhao, Ronglei; Anti-Cancer Drugs; vol. 29; 6; (2018); p. 513 - 519;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73916667&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,activity percentage,nM,,0.61,,,,,,,,,,,,,Patent; UNIVERSITY OF MICHIGAN; WO2018/94134; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73945653&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,s,1206,y",,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,,1.6,,,,,,,8.8,,,,,,Patent; UNIVERSITY OF MICHIGAN; WO2018/94134; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73945653&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,,13.8,,,,,,,7.86,,,,,,Patent; UNIVERSITY OF MICHIGAN; WO2018/94134; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73945653&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,f,1197,m",,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,,3.5,,,,,,,8.46,,,,,,Patent; UNIVERSITY OF MICHIGAN; WO2018/94134; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73945653&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1269,a",,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,,1.9,,,,,,,8.72,,,,,,Patent; UNIVERSITY OF MICHIGAN; WO2018/94134; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73945653&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,,1.1,,,,,,,8.96,,,,,,Patent; UNIVERSITY OF MICHIGAN; WO2018/94134; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D73945653&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,0.007,,,,,,,8.15,,,,,,"Article; Kang, Chung Hyo; Lee, Dong Ho; Lee, Chong Ock; Du Ha, Jae; Park, Chi Hoon; Hwang, Jong Yeon; Biochemical and Biophysical Research Communications; vol. 505; 2; (2018); p. 542 - 547;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75037896&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Echinoderm microtubule-associated protein-like 4 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,818511893 + 818533525,q9um73 + q9hc35,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 4cgc,,,ALK tyrosine kinase receptor [human]; Echinoderm microtubule-associated protein-like 4 [human],ALK tyrosine kinase receptor [human]:Wild + Echinoderm microtubule-associated protein-like 4 [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.026,,,,,,,7.59,,,,,,"Article; Guo, Ming; Zuo, Daiying; Zhang, Junlong; Xing, Lingyun; Gou, Wenfeng; Jiang, Feng; Jiang, Nan; Zhang, Dajun; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 158; (2018); p. 322 - 333;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74852954&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Nucleophosmin [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + npm; npm1; nucleolar phosphoprotein b23; nucleolar protein no38; nucleophosmin; numatrin,818511893 + 818246336,q9um73 + p06748,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 2llh; 2p1b; 2vxd; 5ehd,,,ALK tyrosine kinase receptor [human]; Nucleophosmin [human],ALK tyrosine kinase receptor [human]:Wild + Nucleophosmin [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.041,,,,,,,7.39,,,,,,"Article; Guo, Ming; Zuo, Daiying; Zhang, Junlong; Xing, Lingyun; Gou, Wenfeng; Jiang, Feng; Jiang, Nan; Zhang, Dajun; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 158; (2018); p. 322 - 333;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74852954&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,2.9,,,,,,,5.54,,,,,,"Article; Guo, Ming; Zuo, Daiying; Zhang, Junlong; Xing, Lingyun; Gou, Wenfeng; Jiang, Feng; Jiang, Nan; Zhang, Dajun; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 158; (2018); p. 322 - 333;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74852954&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,BEAS-2B cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,1 μmol/l,,,,cell growth inhibition (%),,Active,,,S,,,,,6,,,8464529,cilengitide,Other compound,"Article; Noh, Ka-Won; Sohn, Insuk; Song, Ji-Young; Shin, Hyun-Tae; Kim, Yu-Jin; Jung, Kyungsoo; Sung, Minjung; Kim, Mingi; An, Sungbin; Han, Joungho; Lee, Se-Hoon; Lee, Mi-Sook; Choi, Yoon-La; Clinical Cancer Research; vol. 24; 17; (2018); p. 4162 - 4174;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74782871&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,50 mg/kg,oral administration,Repeated,,TGI (tumor growth inhibition rate),,Active,,,,,,,,,,,8464529,cilengitide,Other compound,"Article; Noh, Ka-Won; Sohn, Insuk; Song, Ji-Young; Shin, Hyun-Tae; Kim, Yu-Jin; Jung, Kyungsoo; Sung, Minjung; Kim, Mingi; An, Sungbin; Han, Joungho; Lee, Se-Hoon; Lee, Mi-Sook; Choi, Yoon-La; Clinical Cancer Research; vol. 24; 17; (2018); p. 4162 - 4174;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74782871&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2.3,,,,,,,8.64,,,,,,"Article; Xing, Lingyun; Jing, Tongfei; Zhang, Junlong; Guo, Ming; Miao, Xiuqi; Jiang, Feng; Zhai, Xin; Bioorganic Chemistry; vol. 81; (2018); p. 689 - 699;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D75002233&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-[2-isopropoxy-5-methyl-4-(4-piperidinyl)phenyl]-N4-[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine",25 mg/kg,oral administration,Repeated,,TGI (tumor growth inhibition rate),,Low,,,,,,,,,,,,,,Patent; MASS GENERAL BRIGHAM INC; NOVARTIS AG; Novartis (w/o Sandoz); WO2018/130928; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74535356&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-[2-isopropoxy-5-methyl-4-(4-piperidinyl)phenyl]-N4-[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine",25 mg/kg,oral administration,Repeated,,TGI (tumor growth inhibition rate),,Low,,,,,,,,,,,,,,Patent; MASS GENERAL BRIGHAM INC; NOVARTIS AG; Novartis (w/o Sandoz); WO2018/130928; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74535356&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,MGH049-1A cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-[2-isopropoxy-5-methyl-4-(4-piperidinyl)phenyl]-N4-[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine",0.5 μM,,,Crystal violet absorbance,percentage,%,,35,,,,,,,,,,,,,Patent; MASS GENERAL BRIGHAM INC; NOVARTIS AG; Novartis (w/o Sandoz); WO2018/130928; (2018); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D74535356&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],"ALK tyrosine kinase receptor [human]:Mutated:Substitution,1,f,1174,l",human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,Kelly cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,1E-07 - 0.0001 M,,,phosphorylation,IC50,nM,,79,,,,,,,7.1,,,,,,"Article; Watts, Ellen; Heidenreich, David; Tucker, Elizabeth; Raab, Monika; Strebhardt, Klaus; Chesler, Louis; Knapp, Stefan; Bellenie, Benjamin; Hoelder, Swen; Journal of Medicinal Chemistry; vol. 62; 5; (2019); p. 2618 - 2637;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76114337&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,97,,,,,,,4.01,,,,,,"Article; Das, Debasis; Wang, Jingbing; Li, Yong; Shi, Jingli; Hong, Jian; Bioorganic and Medicinal Chemistry Letters; vol. 29; 12; (2019); p. 1514 - 1517;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76431687&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,27.2,,,,,,,4.57,,,,,,"Article; Das, Debasis; Wang, Jingbing; Li, Yong; Shi, Jingli; Hong, Jian; Bioorganic and Medicinal Chemistry Letters; vol. 29; 12; (2019); p. 1514 - 1517;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76431687&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,198,,,,,,,3.7,,,,,,"Article; Das, Debasis; Wang, Jingbing; Li, Yong; Shi, Jingli; Hong, Jian; Bioorganic and Medicinal Chemistry Letters; vol. 29; 12; (2019); p. 1514 - 1517;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76431687&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,47.65,,,,,,,4.32,,,,,,"Article; Das, Debasis; Wang, Jingbing; Li, Yong; Shi, Jingli; Hong, Jian; Bioorganic and Medicinal Chemistry Letters; vol. 29; 12; (2019); p. 1514 - 1517;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76431687&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,f,1174,l",,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,114.3,,,,,,,3.94,,,,,,"Article; Das, Debasis; Wang, Jingbing; Li, Yong; Shi, Jingli; Hong, Jian; Bioorganic and Medicinal Chemistry Letters; vol. 29; 12; (2019); p. 1514 - 1517;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76431687&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,10 mg/kg,oral administration,Repeated,,TGI (tumor growth inhibition rate),%,,26,,,,,,,,,,,,,"Article; Das, Debasis; Wang, Jingbing; Li, Yong; Shi, Jingli; Hong, Jian; Bioorganic and Medicinal Chemistry Letters; vol. 29; 12; (2019); p. 1514 - 1517;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76431687&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,epidermal growth factor-activated receptor [human]; ALK tyrosine kinase receptor [human],epidermal growth factor-activated receptor + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,epidermal growth factor-activated receptor [human]; ALK tyrosine kinase receptor [human],epidermal growth factor-activated receptor [human]:Wild; ALK tyrosine kinase receptor [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,survival rate decrease,,Not active,,,,,,,,1,,,,,,Patent; JEUK CO LTD; YONSEI UNIVERSITY; US2019/46514; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76026543&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.15,,,,,,,6.82,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3-EML4-ALK (G1202R) cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,1.01,,,,,,,6,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,>,5,,,,,,,5.3,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HCC78 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.067,,,,,,,7.17,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,A549 (G1202R) cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.081,,,,,,,7.09,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,A-549 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,1.61,,,,,,,5.79,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.02,,,,,,,7.7,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2.3,,,,,,,8.64,,,,,,"Article; Lei, Hongrui; Jiang, Nan; Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Liu, Yang; Xu, Haowen; Gong, Ping; Zuo, Daiying; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 171; (2019); p. 297 - 309;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76267875&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2387,,,,,,,5.62,,,,,,Patent; ARROMAX PHARMATECH SUZHOU CO LTD; EP3466943; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76435749&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,35.57,,,,,,,7.45,,,,,,Patent; ARROMAX PHARMATECH SUZHOU CO LTD; EP3466943; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76435749&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,35.57,,,,,,,7.45,,,,,,Patent; ARROMAX PHARMATECH SUZHOU CO LTD; EP3466943; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76435749&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,27.2,,,,,,,7.57,,,,,,Patent; ARROMAX PHARMATECH SUZHOU CO LTD; EP3466943; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76435749&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,30 mg/kg,oral administration,Repeated,,TGI (tumor growth inhibition rate),%,,94.7,,,,,,,,,,,,,Patent; HANGZHOU REX PHARMACEUTICAL; EP3476848; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76548012&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,30 mg/kg,oral administration,Repeated,,TGI (tumor growth inhibition rate),%,,95.3,,,,,,,,,,,,,Patent; HANGZHOU REX PHARMACEUTICAL; EP3476848; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76548012&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,40.7,,,,,,,7.39,,,,,,Patent; HANGZHOU REX PHARMACEUTICAL; EP3476848; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76548012&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,40 - 85,,,,,,,7.4,,,,,,Patent; HANGZHOU REX PHARMACEUTICAL; EP3476848; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76548012&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor (F1174L) [human],alk tyrosine kinase receptor (f1174l),819146149,q9um73,,,,ALK tyrosine kinase receptor (F1174L) [human],ALK tyrosine kinase receptor (F1174L) [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3-TEL-ALK cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,36.1,,,,,,,7.44,,,,,,Patent; HANGZHOU REX PHARMACEUTICAL; EP3476848; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76548012&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [zebra fish],alk tyrosine kinase receptor,824647732,,,,,ALK tyrosine kinase receptor [zebra fish],ALK tyrosine kinase receptor [zebra fish]:Wild,zebra fish,Non Transfected,,,In Vitro (Efficacy),,,zebra fish,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,15 μM,,,of the formation of iridophore pigment cells,inhibition percentage,%,,95,,,,,,,6.1,,,,,,Patent; HANGZHOU REX PHARMACEUTICAL; EP3476848; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76548012&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,30 mg/kg,oral administration,Repeated,,tumor volume,mm3,,17,,,,,,,,,,,,,Patent; HANGZHOU REX PHARMACEUTICAL; EP3476848; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76548012&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Echinoderm microtubule-associated protein-like 4 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,818511893 + 818533525,q9um73 + q9hc35,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 4cgc,,,ALK tyrosine kinase receptor [human]; Echinoderm microtubule-associated protein-like 4 [human],ALK tyrosine kinase receptor [human]:Wild + Echinoderm microtubule-associated protein-like 4 [human]:Wild,human,Non Transfected,Inhibitor,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,15 - 30 nM,,,,enzyme activity rate increase,,Not active,,,,Caspase-3; Caspase-7,,,,1,,,,,,Patent; UNIVERSITY OF ILLINOIS (SYSTEM); WO2019/99873; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76818618&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Echinoderm microtubule-associated protein-like 4 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,818511893 + 818533525,q9um73 + q9hc35,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 4cgc,,,ALK tyrosine kinase receptor [human]; Echinoderm microtubule-associated protein-like 4 [human],ALK tyrosine kinase receptor [human]:Wild + Echinoderm microtubule-associated protein-like 4 [human]:Wild,human,Non Transfected,Inhibitor,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,15 - 30 nM,,,,cleaved PARP level increase,,Low,,,,,,,,,,,,,,Patent; UNIVERSITY OF ILLINOIS (SYSTEM); WO2019/99873; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76818618&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Echinoderm microtubule-associated protein-like 4 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,818511893 + 818533525,q9um73 + q9hc35,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 4cgc,,,ALK tyrosine kinase receptor [human]; Echinoderm microtubule-associated protein-like 4 [human],ALK tyrosine kinase receptor [human]:Wild + Echinoderm microtubule-associated protein-like 4 [human]:Wild,human,Non Transfected,Inhibitor,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,15 - 30 nM,,,Procaspase-3,enzyme activity rate increase,,Not active,,,,,,,,1,,,,,,Patent; UNIVERSITY OF ILLINOIS (SYSTEM); WO2019/99873; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76818618&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Echinoderm microtubule-associated protein-like 4 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,818511893 + 818533525,q9um73 + q9hc35,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 4cgc,,,ALK tyrosine kinase receptor [human]; Echinoderm microtubule-associated protein-like 4 [human],ALK tyrosine kinase receptor [human]:Wild + Echinoderm microtubule-associated protein-like 4 [human]:Wild,human,Non Transfected,Inhibitor,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,15 - 30 nM,,,,protein expression level decrease,,Not active,,,,Dual specificity mitogen-activated protein kinase kinase 1,,,,1,,,,,,Patent; UNIVERSITY OF ILLINOIS (SYSTEM); WO2019/99873; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76818618&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Echinoderm microtubule-associated protein-like 4 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,818511893 + 818533525,q9um73 + q9hc35,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 4cgc,,,ALK tyrosine kinase receptor [human]; Echinoderm microtubule-associated protein-like 4 [human],ALK tyrosine kinase receptor [human]:Wild + Echinoderm microtubule-associated protein-like 4 [human]:Wild,human,Non Transfected,Inhibitor,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,15 - 30 nM,,,,protein expression level decrease,,Not active,,,,Dual specificity mitogen-activated protein kinase kinase 2,,,,1,,,,,,Patent; UNIVERSITY OF ILLINOIS (SYSTEM); WO2019/99873; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76818618&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human];+Echinoderm microtubule-associated protein-like 4 [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,818511893 + 818533525,q9um73 + q9hc35,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 4cgc,,,ALK tyrosine kinase receptor [human]; Echinoderm microtubule-associated protein-like 4 [human],ALK tyrosine kinase receptor [human]:Wild + Echinoderm microtubule-associated protein-like 4 [human]:Wild,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,15 - 30 nM,,,,protein phosphorylation level decrease,,Not active,,,,"Mitogen-activated protein (MAP) kinase, ERK1/2",,,,1,,,,,,Patent; UNIVERSITY OF ILLINOIS (SYSTEM); WO2019/99873; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76818618&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antiinflammatory agent,In Vitro (Efficacy),,,C57BL 6 mouse,,,,bone marrow derived macrophage,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine",10 μM,,,,fold change,no unit,,0.08,,,Interferon beta,,,,,,,27584913,,Inductive agent,Patent; COMMONWEALTH SYSTEM OF HIGHER EDUCATION; US2019/167710; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76998845&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antiinflammatory agent,In Vitro (Efficacy),,,C57BL 6 mouse,,,,peritoneum macrophage,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine",10 μM,,,,change rate,,Active,,,,Interferon beta,,,,5,,,27584913,,Inductive agent,Patent; COMMONWEALTH SYSTEM OF HIGHER EDUCATION; US2019/167710; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76998845&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antiinflammatory agent,In Vitro (Efficacy),,,human,,,,peripheral blood mononuclear cell,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine",10 μM,,,,change rate,,Active,,,,Interferon beta,,,,5,,,27584913,,Inductive agent,Patent; COMMONWEALTH SYSTEM OF HIGHER EDUCATION; US2019/167710; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76998845&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antiinflammatory agent,In Vitro (Efficacy),,,,,,,RAW 264.7 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine",10 μM,,,,decrease rate,,Active,,,,Interferon beta,,,,5,,,27584913,,Inductive agent,Patent; COMMONWEALTH SYSTEM OF HIGHER EDUCATION; US2019/167710; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76998845&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antiinflammatory agent,In Vitro (Efficacy),,,,,,,THP-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine",10 μM,,,,decrease rate,,Active,,,,Interferon beta,,,,5,,,27584913,,Inductive agent,Patent; COMMONWEALTH SYSTEM OF HIGHER EDUCATION; US2019/167710; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76998845&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antiinflammatory agent,In Vitro (Efficacy),,,,,,,J774A1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine",10 μM,,,,decrease rate,,Active,,,,Interferon beta,,,,5,,,27584913,,Inductive agent,Patent; COMMONWEALTH SYSTEM OF HIGHER EDUCATION; US2019/167710; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76998845&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,cytotoxic agent,Toxicity/Safety Pharmacology,,,C57BL 6 mouse,,,,peritoneum macrophage,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine",10 μM,,,,percentage of viable cells decrease,,Not active,,,,,,,,1,,,27584913,,Inductive agent,Patent; COMMONWEALTH SYSTEM OF HIGHER EDUCATION; US2019/167710; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76998845&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,cytotoxic agent,Toxicity/Safety Pharmacology,,,,,,,RAW 264.7 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine",10 μM,,,,percentage of viable cells decrease,,Not active,,,,,,,,1,,,27584913,,Inductive agent,Patent; COMMONWEALTH SYSTEM OF HIGHER EDUCATION; US2019/167710; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76998845&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,cytotoxic agent,Toxicity/Safety Pharmacology,,,,,,,THP-1 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine",10 μM,,,,percentage of viable cells decrease,,Not active,,,,,,,,1,,,27584913,,Inductive agent,Patent; COMMONWEALTH SYSTEM OF HIGHER EDUCATION; US2019/167710; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76998845&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,cytotoxic agent,Toxicity/Safety Pharmacology,,,C57BL 6 mouse,,,,bone marrow derived macrophage,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine",10 μM,,,,percentage of viable cells decrease,,Not active,,,,,,,,1,,,27584913,,Inductive agent,Patent; COMMONWEALTH SYSTEM OF HIGHER EDUCATION; US2019/167710; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76998845&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,,antiendotoxic agent,In Vivo (Animal models),,,C57BL 6 mouse,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine",20 mg/kg,oral administration,Single,,survival rate,%,,77.77,,,,,,,,,,8187061,lipopolysaccharide,Inductive agent,Patent; COMMONWEALTH SYSTEM OF HIGHER EDUCATION; US2019/167710; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76998845&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,,protective agent,In Vivo (Animal models),,,C57BL 6 mouse,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine",20 mg/kg,intraperitoneal administration,Repeated,,survival rate,%,,88.23,,,,,,,,,,,,,Patent; COMMONWEALTH SYSTEM OF HIGHER EDUCATION; US2019/167710; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D76998845&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,2.9,,,,,,,5.54,,,,,,"Article; Radaram, Bhasker; Pisaneschi, Federica; Rao, Yi; Yang, Ping; Piwnica-Worms, David; Alauddin, Mian M.; European Journal of Medicinal Chemistry; vol. 182; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77505619&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,3.1,,,,,,,8.51,,,73010,ATP,Substrate,"Article; Lei, Hongrui; Jia, Fang; Cao, Meng; Wang, Jie; Guo, Ming; Zhu, Minglin; Zuo, Daiying; Zhai, Xin; Bioorganic and Medicinal Chemistry; vol. 27; 20; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77636227&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,197,,,,,,,6.71,,,73010,ATP,Substrate,"Article; Lei, Hongrui; Jia, Fang; Cao, Meng; Wang, Jie; Guo, Ming; Zhu, Minglin; Zuo, Daiying; Zhai, Xin; Bioorganic and Medicinal Chemistry; vol. 27; 20; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77636227&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2.7,,,,,,,8.57,,,73010,ATP,Substrate,"Article; Lei, Hongrui; Jia, Fang; Cao, Meng; Wang, Jie; Guo, Ming; Zhu, Minglin; Zuo, Daiying; Zhai, Xin; Bioorganic and Medicinal Chemistry; vol. 27; 20; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77636227&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,50.3,,,,,,,7.3,,,,,,"Article; Shen, Jiwei; Wang, Junfang; Du, Jianan; Wang, Lijing; Zhou, Xuejiao; Chang, Xing; Li, Zengqiang; Zhai, Xin; Zuo, Daiying; Wu, Yingliang; Toxicology and Applied Pharmacology; vol. 383; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D77978849&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor (F1245C) [human],alk tyrosine kinase receptor (f1245c),819146153,q9um73,,,,ALK tyrosine kinase receptor (F1245C) [human],ALK tyrosine kinase receptor (F1245C) [human]:Wild,human,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,30 mg/kg,oral administration,Repeated,,T-C (tumor growth delay time),,Active,,,,,,,,,,,,,,"Article; Amos Burke, G. A.; Blanco-Aparicio, Carmen; Högler, Sandra; Han, Miaojun; Jahangiri, Leila; Kai Lim, Hong; Kenner, Lukas; Kodajova, Petra; Lee, Liam C.; Luo, Ji; Manners, Eleanor; Martinez, Sonia; Matthews, Jamie D.; Merkel, Olaf; Pastor, Joaquin; Probst, Nicola A.; Prokoph, Nina; Reynolds, C. Patrick; Tangermann, Simone; Trigg, Ricky M.; Turner, Suzanne D.; de los Fayos Alonso, Ines Garces; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D78470657&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor (F1245C) [human],alk tyrosine kinase receptor (f1245c),819146153,q9um73,,,,ALK tyrosine kinase receptor (F1245C) [human],ALK tyrosine kinase receptor (F1245C) [human]:Wild,human,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,30 mg/kg,oral administration,Repeated,where an event was defined as a tumor reaching 15 mm in any direction,event-free survival time,d,,19,,,,,,,,,,,,,"Article; Amos Burke, G. A.; Blanco-Aparicio, Carmen; Högler, Sandra; Han, Miaojun; Jahangiri, Leila; Kai Lim, Hong; Kenner, Lukas; Kodajova, Petra; Lee, Liam C.; Luo, Ji; Manners, Eleanor; Martinez, Sonia; Matthews, Jamie D.; Merkel, Olaf; Pastor, Joaquin; Probst, Nicola A.; Prokoph, Nina; Reynolds, C. Patrick; Tangermann, Simone; Trigg, Ricky M.; Turner, Suzanne D.; de los Fayos Alonso, Ines Garces; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D78470657&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor (F1174L) [human],alk tyrosine kinase receptor (f1174l),819146149,q9um73,,,,ALK tyrosine kinase receptor (F1174L) [human],ALK tyrosine kinase receptor (F1174L) [human]:Wild,human,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,30 mg/kg,oral administration,Repeated,where an event was defined as a tumor reaching 15 mm in any direction,event-free survival time,d,,9,,,,,,,,,,,,,"Article; Amos Burke, G. A.; Blanco-Aparicio, Carmen; Högler, Sandra; Han, Miaojun; Jahangiri, Leila; Kai Lim, Hong; Kenner, Lukas; Kodajova, Petra; Lee, Liam C.; Luo, Ji; Manners, Eleanor; Martinez, Sonia; Matthews, Jamie D.; Merkel, Olaf; Pastor, Joaquin; Probst, Nicola A.; Prokoph, Nina; Reynolds, C. Patrick; Tangermann, Simone; Trigg, Ricky M.; Turner, Suzanne D.; de los Fayos Alonso, Ines Garces; Nature Communications; vol. 10; 1; (2019);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D78470657&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor;+Nucleophosmin,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + npm; npm1; nucleolar phosphoprotein b23; nucleolar protein no38; nucleophosmin; numatrin,820152764 + 820016608,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Nucleophosmin,ALK tyrosine kinase receptor:Chimera + Nucleophosmin:Chimera,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.02,,,,,,,7.7,,,,,,"Article; Gong, Ping; Guo, Ming; Liu, Sicong; Miao, Xiuqi; Xing, Lingyun; Yin, Shiliang; Zhai, Xin; Zhang, Dajun; Zhang, Hong; Bioorganic Chemistry; vol. 94; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D78644700&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor;+Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,ALK tyrosine kinase receptor:Chimera + Echinoderm microtubule-associated protein-like 4:Chimera,,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.165,,,,,,,6.78,,,,,,"Article; Gong, Ping; Guo, Ming; Liu, Sicong; Miao, Xiuqi; Xing, Lingyun; Yin, Shiliang; Zhai, Xin; Zhang, Dajun; Zhang, Hong; Bioorganic Chemistry; vol. 94; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D78644700&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2.3,,,,,,,8.64,,,,,,"Article; Gong, Ping; Guo, Ming; Liu, Sicong; Miao, Xiuqi; Xing, Lingyun; Yin, Shiliang; Zhai, Xin; Zhang, Dajun; Zhang, Hong; Bioorganic Chemistry; vol. 94; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D78644700&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor;+Echinoderm microtubule-associated protein-like 4,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120,820152764 + 820068176,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Echinoderm microtubule-associated protein-like 4,ALK tyrosine kinase receptor:Wild + Echinoderm microtubule-associated protein-like 4:Wild,,Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,A-549 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.1 - 1 μM,,,,IC50,nM,,425.8,,,,,,,6.37,,,,,,"Article; Gou, Wenfeng; Guo, Ming; Li, Zengqiang; Shen, Jiwei; Wu, Yingliang; Xu, Xiaobo; Zhai, Xin; Zhang, Xiaoning; Zhou, Xuejiao; Zuo, Daiying; Biochimica et Biophysica Acta - Molecular Cell Research; vol. 1867; 7; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79457678&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2.9,,,,,,,8.54,,,,,,"Article; Gou, Wenfeng; Guo, Ming; Li, Zengqiang; Shen, Jiwei; Wu, Yingliang; Xu, Xiaobo; Zhai, Xin; Zhang, Xiaoning; Zhou, Xuejiao; Zuo, Daiying; Biochimica et Biophysica Acta - Molecular Cell Research; vol. 1867; 7; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79457678&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,apoptosis rate,%,,26.07,,,,,,,,,,,,,"Article; Gou, Wenfeng; Guo, Ming; Li, Zengqiang; Shen, Jiwei; Wu, Yingliang; Xu, Xiaobo; Zhai, Xin; Zhang, Xiaoning; Zhou, Xuejiao; Zuo, Daiying; Biochimica et Biophysica Acta - Molecular Cell Research; vol. 1867; 7; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79457678&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,cytotoxic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,25 nM,,,nuclear shrinkage and fragmentation,observed parameter,,Active,,,,,,,,7.6,,,,,,"Article; Cao, Meng; Guo, Ming; Jiang, Nan; Li, Tong; Wang, Jie; Wei, Shangfei; Xing, Lingyun; Zhai, Xin; Zuo, Daiying; New Journal of Chemistry; vol. 44; 15; (2020); p. 5850 - 5861;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79606854&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,cytotoxic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,25 nM,,,,percentage of apoptotic cells increase,,Active,,,,,,,,7.6,,,,,,"Article; Cao, Meng; Guo, Ming; Jiang, Nan; Li, Tong; Wang, Jie; Wei, Shangfei; Xing, Lingyun; Zhai, Xin; Zuo, Daiying; New Journal of Chemistry; vol. 44; 15; (2020); p. 5850 - 5861;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79606854&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,cytotoxic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,25 nM,,,,percentage of early apoptotic cells increase,,Active,,,,,,,,7.6,,,,,,"Article; Cao, Meng; Guo, Ming; Jiang, Nan; Li, Tong; Wang, Jie; Wei, Shangfei; Xing, Lingyun; Zhai, Xin; Zuo, Daiying; New Journal of Chemistry; vol. 44; 15; (2020); p. 5850 - 5861;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79606854&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,cytotoxic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,25 nM,,,,percentage of late apoptotic cells increase,,Active,,,,,,,,7.6,,,,,,"Article; Cao, Meng; Guo, Ming; Jiang, Nan; Li, Tong; Wang, Jie; Wei, Shangfei; Xing, Lingyun; Zhai, Xin; Zuo, Daiying; New Journal of Chemistry; vol. 44; 15; (2020); p. 5850 - 5861;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79606854&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,cytotoxic agent,In Vitro (Efficacy),,,,,,,NCI-H460 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.2,,,,,,,6.7,,,,,,"Article; Cao, Meng; Guo, Ming; Jiang, Nan; Li, Tong; Wang, Jie; Wei, Shangfei; Xing, Lingyun; Zhai, Xin; Zuo, Daiying; New Journal of Chemistry; vol. 44; 15; (2020); p. 5850 - 5861;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79606854&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,cytotoxic agent,In Vitro (Efficacy),,,,,,,A-549 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.79,,,,,,,6.1,,,,,,"Article; Cao, Meng; Guo, Ming; Jiang, Nan; Li, Tong; Wang, Jie; Wei, Shangfei; Xing, Lingyun; Zhai, Xin; Zuo, Daiying; New Journal of Chemistry; vol. 44; 15; (2020); p. 5850 - 5861;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79606854&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,cytotoxic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.027,,,,,,,7.57,,,,,,"Article; Cao, Meng; Guo, Ming; Jiang, Nan; Li, Tong; Wang, Jie; Wei, Shangfei; Xing, Lingyun; Zhai, Xin; Zuo, Daiying; New Journal of Chemistry; vol. 44; 15; (2020); p. 5850 - 5861;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79606854&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,cytotoxic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.099,,,,,,,7,,,,,,"Article; Cao, Meng; Guo, Ming; Jiang, Nan; Li, Tong; Wang, Jie; Wei, Shangfei; Xing, Lingyun; Zhai, Xin; Zuo, Daiying; New Journal of Chemistry; vol. 44; 15; (2020); p. 5850 - 5861;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79606854&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Proto-oncogene tyrosine-protein kinase ROS [human];+ALK tyrosine kinase receptor [human],c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818268477 + 818511893,p08922 + q9um73,3zbf; 4uxl + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],Proto-oncogene tyrosine-protein kinase ROS [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,cytotoxic agent,In Vitro (Efficacy),,,,,,,HCC78 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.074,,,,,,,7.13,,,,,,"Article; Cao, Meng; Guo, Ming; Jiang, Nan; Li, Tong; Wang, Jie; Wei, Shangfei; Xing, Lingyun; Zhai, Xin; Zuo, Daiying; New Journal of Chemistry; vol. 44; 15; (2020); p. 5850 - 5861;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79606854&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,8.9,,,,,,,8.05,,,73010,ATP,Substrate,"Article; Cao, Meng; Guo, Ming; Jiang, Nan; Li, Tong; Wang, Jie; Wei, Shangfei; Xing, Lingyun; Zhai, Xin; Zuo, Daiying; New Journal of Chemistry; vol. 44; 15; (2020); p. 5850 - 5861;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79606854&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2.3,,,,,,,8.64,,,73010,ATP,Substrate,"Article; Cao, Meng; Guo, Ming; Jiang, Nan; Li, Tong; Wang, Jie; Wei, Shangfei; Xing, Lingyun; Zhai, Xin; Zuo, Daiying; New Journal of Chemistry; vol. 44; 15; (2020); p. 5850 - 5861;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D79606854&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,189 nM,,,G1 arrest,increase rate,,Active,,,S,,,,,6.72,,,,,,"Article; Wang, Lijing; Xu, Xiaobo; Liu, Tong; Wang, Junfang; Shen, Jiwei; Guo, Ming; Wu, Yingliang; Zhai, Xin; Zuo, Daiying; Journal of Pharmacy and Pharmacology; vol. 72; 10; (2020); p. 1370 - 1382;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80165401&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,100 nM,,,,apoptosis rate increase,,Active,,,S,,,,,7,,,,,,"Article; Wang, Lijing; Xu, Xiaobo; Liu, Tong; Wang, Junfang; Shen, Jiwei; Guo, Ming; Wu, Yingliang; Zhai, Xin; Zuo, Daiying; Journal of Pharmacy and Pharmacology; vol. 72; 10; (2020); p. 1370 - 1382;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80165401&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,41,,,,,,,7.39,,,,,,"Article; Wang, Lijing; Xu, Xiaobo; Liu, Tong; Wang, Junfang; Shen, Jiwei; Guo, Ming; Wu, Yingliang; Zhai, Xin; Zuo, Daiying; Journal of Pharmacy and Pharmacology; vol. 72; 10; (2020); p. 1370 - 1382;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80165401&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,A-549 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,1025,,,,,,,5.99,,,,,,"Article; Wang, Lijing; Xu, Xiaobo; Liu, Tong; Wang, Junfang; Shen, Jiwei; Guo, Ming; Wu, Yingliang; Zhai, Xin; Zuo, Daiying; Journal of Pharmacy and Pharmacology; vol. 72; 10; (2020); p. 1370 - 1382;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80165401&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HEK293T cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,725,,,,,,,6.14,,,,,,"Article; Wang, Lijing; Xu, Xiaobo; Liu, Tong; Wang, Junfang; Shen, Jiwei; Guo, Ming; Wu, Yingliang; Zhai, Xin; Zuo, Daiying; Journal of Pharmacy and Pharmacology; vol. 72; 10; (2020); p. 1370 - 1382;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80165401&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,L-02 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2165,,,,,,,5.66,,,,,,"Article; Wang, Lijing; Xu, Xiaobo; Liu, Tong; Wang, Junfang; Shen, Jiwei; Guo, Ming; Wu, Yingliang; Zhai, Xin; Zuo, Daiying; Journal of Pharmacy and Pharmacology; vol. 72; 10; (2020); p. 1370 - 1382;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80165401&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antiproliferative agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.039,,,,,,,7.41,,,,,,"Article; Cao, Meng; Chen, Yuxiang; Guo, Ming; Wei, Shangfei; Zhai, Xin; Zhao, Tianming; Bioorganic and Medicinal Chemistry; vol. 28; 20; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80617899&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antiproliferative agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.041,,,,,,,7.39,,,,,,"Article; Cao, Meng; Chen, Yuxiang; Guo, Ming; Wei, Shangfei; Zhai, Xin; Zhao, Tianming; Bioorganic and Medicinal Chemistry; vol. 28; 20; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80617899&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antiproliferative agent,In Vitro (Efficacy),,,,,,,A-549 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,>,10,,,,,,,1,,,,,,"Article; Cao, Meng; Chen, Yuxiang; Guo, Ming; Wei, Shangfei; Zhai, Xin; Zhao, Tianming; Bioorganic and Medicinal Chemistry; vol. 28; 20; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80617899&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2.4,,,,,,,8.62,,,73010,ATP,Substrate,"Article; Cao, Meng; Chen, Yuxiang; Guo, Ming; Wei, Shangfei; Zhai, Xin; Zhao, Tianming; Bioorganic and Medicinal Chemistry; vol. 28; 20; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80617899&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],"ALK tyrosine kinase receptor [human]:Mutated:Substitution,1,l,1196,m",human,Non Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,7.6,,,,,,,8.12,,,73010,ATP,Substrate,"Article; Cao, Meng; Chen, Yuxiang; Guo, Ming; Wei, Shangfei; Zhai, Xin; Zhao, Tianming; Bioorganic and Medicinal Chemistry; vol. 28; 20; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80617899&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,Non Transfected,Inhibitor,antiproliferative agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.026,,,,,,,7.59,,,,,,"Article; Chen, Yuxiang; Guo, Ming; Li, Tong; Li, Wei; Wei, Shangfei; Zhai, Xin; Zhao, Tianming; Zhu, Minglin; Bioorganic and Medicinal Chemistry; vol. 28; 20; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80618080&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2.9,,,,,,,8.54,,,,,,"Article; Chen, Yuxiang; Guo, Ming; Li, Tong; Li, Wei; Wei, Shangfei; Zhai, Xin; Zhao, Tianming; Zhu, Minglin; Bioorganic and Medicinal Chemistry; vol. 28; 20; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80618080&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,35,,,,,,,7.46,,,,,,"Article; Chen, Yuxiang; Guo, Ming; Li, Tong; Li, Wei; Wei, Shangfei; Zhai, Xin; Zhao, Tianming; Zhu, Minglin; Bioorganic and Medicinal Chemistry; vol. 28; 20; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80618080&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,80,,,,,,,7.1,,,,,,"Article; Chen, Yuxiang; Guo, Ming; Li, Tong; Li, Wei; Wei, Shangfei; Zhai, Xin; Zhao, Tianming; Zhu, Minglin; Bioorganic and Medicinal Chemistry; vol. 28; 20; (2020);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D80618080&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.3 - 10000 nM,,,,IC50,nM,,1164,,,,,,,5.94,,,,,,Patent; JAPANESE FOUNDATION FOR CANCER RESEARCH; US2020/397786; (2020); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82226992&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.3 - 10000 nM,,,,IC50,nM,,685.2,,,,,,,6.16,,,,,,Patent; JAPANESE FOUNDATION FOR CANCER RESEARCH; US2020/397786; (2020); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82226992&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.3 - 10000 nM,,,,IC50,nM,,1043,,,,,,,5.98,,,,,,Patent; JAPANESE FOUNDATION FOR CANCER RESEARCH; US2020/397786; (2020); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82226992&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.3 - 10000 nM,,,,IC50,nM,,1020,,,,,,,5.99,,,,,,Patent; JAPANESE FOUNDATION FOR CANCER RESEARCH; US2020/397786; (2020); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82226992&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.3 - 10000 nM,,,,IC50,nM,,576.6,,,,,,,6.24,,,,,,Patent; JAPANESE FOUNDATION FOR CANCER RESEARCH; US2020/397786; (2020); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82226992&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.3 - 10000 nM,,,,IC50,nM,,1007,,,,,,,6,,,,,,Patent; JAPANESE FOUNDATION FOR CANCER RESEARCH; US2020/397786; (2020); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82226992&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.3 - 10000 nM,,,,IC50,nM,,524.3,,,,,,,6.28,,,,,,Patent; JAPANESE FOUNDATION FOR CANCER RESEARCH; US2020/397786; (2020); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82226992&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.3 - 10000 nM,,,,IC50,nM,,780.5,,,,,,,6.11,,,,,,Patent; JAPANESE FOUNDATION FOR CANCER RESEARCH; US2020/397786; (2020); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82226992&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,25 mg/kg,intragastric administration,Repeated,,TGI (tumor growth inhibition rate),%,,49,,,,,,,,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Yue, Lin; Pu, Chunlan; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Rui; European Journal of Medicinal Chemistry; vol. 212; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82186885&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,nM,,0.81,,,,,,,9.09,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Yue, Lin; Pu, Chunlan; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Rui; European Journal of Medicinal Chemistry; vol. 212; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82186885&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,1.3,,,,,,,5.89,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Yue, Lin; Pu, Chunlan; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Rui; European Journal of Medicinal Chemistry; vol. 212; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82186885&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H1299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,2.92,,,,,,,5.53,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Yue, Lin; Pu, Chunlan; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Rui; European Journal of Medicinal Chemistry; vol. 212; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82186885&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,A-549 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,1.32,,,,,,,5.88,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Yue, Lin; Pu, Chunlan; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Rui; European Journal of Medicinal Chemistry; vol. 212; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82186885&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,HeLa cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,0.94,,,,,,,6.03,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Yue, Lin; Pu, Chunlan; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Rui; European Journal of Medicinal Chemistry; vol. 212; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82186885&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,,,,,,IC50,μM,,1.1,,,,,,,5.96,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Yue, Lin; Pu, Chunlan; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Rui; European Journal of Medicinal Chemistry; vol. 212; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82186885&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,0.61,,,,,,,9.21,,,73010,ATP,Substrate,"Article; Chen, Jianyong; Zhou, Yunlong; Dong, Xuyuan; Liu, Liu; Bai, Longchuan; McEachern, Donna; Przybranowski, Sally; Yang, Chao-Yie; Stuckey, Jeanne; Li, Xiaoqin; Wen, Bo; Zhao, Ting; Sun, Siwei; Sun, Duxin; Jiao, Lingling; Jing, Yu; Guo, Ming; Yang, Dajun; Wang, Shaomeng; Journal of Medicinal Chemistry; vol. 63; 22; (2020); p. 13994 - 14016;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81671443&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antineoplastic agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,50 mg/kg,oral administration,Repeated,,TGI (tumor growth inhibition rate),%,,57,,,,,,,,,,,,,"Article; Chen, Jianyong; Zhou, Yunlong; Dong, Xuyuan; Liu, Liu; Bai, Longchuan; McEachern, Donna; Przybranowski, Sally; Yang, Chao-Yie; Stuckey, Jeanne; Li, Xiaoqin; Wen, Bo; Zhao, Ting; Sun, Siwei; Sun, Duxin; Jiao, Lingling; Jing, Yu; Guo, Ming; Yang, Dajun; Wang, Shaomeng; Journal of Medicinal Chemistry; vol. 63; 22; (2020); p. 13994 - 14016;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81671443&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],"ALK tyrosine kinase receptor [human]:Mutated:Substitution,1,f,1197,m",human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,3.5,,,,,,,8.46,,,73010,ATP,Substrate,"Article; Chen, Jianyong; Zhou, Yunlong; Dong, Xuyuan; Liu, Liu; Bai, Longchuan; McEachern, Donna; Przybranowski, Sally; Yang, Chao-Yie; Stuckey, Jeanne; Li, Xiaoqin; Wen, Bo; Zhao, Ting; Sun, Siwei; Sun, Duxin; Jiao, Lingling; Jing, Yu; Guo, Ming; Yang, Dajun; Wang, Shaomeng; Journal of Medicinal Chemistry; vol. 63; 22; (2020); p. 13994 - 14016;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81671443&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],"ALK tyrosine kinase receptor [human]:Mutated:Substitution,1,g,1269,a",human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,1.9,,,,,,,8.72,,,73010,ATP,Substrate,"Article; Chen, Jianyong; Zhou, Yunlong; Dong, Xuyuan; Liu, Liu; Bai, Longchuan; McEachern, Donna; Przybranowski, Sally; Yang, Chao-Yie; Stuckey, Jeanne; Li, Xiaoqin; Wen, Bo; Zhao, Ting; Sun, Siwei; Sun, Duxin; Jiao, Lingling; Jing, Yu; Guo, Ming; Yang, Dajun; Wang, Shaomeng; Journal of Medicinal Chemistry; vol. 63; 22; (2020); p. 13994 - 14016;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81671443&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,1.1,,,,,,,8.96,,,73010,ATP,Substrate,"Article; Chen, Jianyong; Zhou, Yunlong; Dong, Xuyuan; Liu, Liu; Bai, Longchuan; McEachern, Donna; Przybranowski, Sally; Yang, Chao-Yie; Stuckey, Jeanne; Li, Xiaoqin; Wen, Bo; Zhao, Ting; Sun, Siwei; Sun, Duxin; Jiao, Lingling; Jing, Yu; Guo, Ming; Yang, Dajun; Wang, Shaomeng; Journal of Medicinal Chemistry; vol. 63; 22; (2020); p. 13994 - 14016;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81671443&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,,,,,ALK tyrosine kinase receptor [human],"ALK tyrosine kinase receptor [human]:Mutated:Substitution,1,s,1206,y",human,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,1.6,,,,,,,8.8,,,73010,ATP,Substrate,"Article; Chen, Jianyong; Zhou, Yunlong; Dong, Xuyuan; Liu, Liu; Bai, Longchuan; McEachern, Donna; Przybranowski, Sally; Yang, Chao-Yie; Stuckey, Jeanne; Li, Xiaoqin; Wen, Bo; Zhao, Ting; Sun, Siwei; Sun, Duxin; Jiao, Lingling; Jing, Yu; Guo, Ming; Yang, Dajun; Wang, Shaomeng; Journal of Medicinal Chemistry; vol. 63; 22; (2020); p. 13994 - 14016;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D81671443&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1,818511893 + 818268477,q9um73 + p08922,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 3zbf; 4uxl,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],ALK tyrosine kinase receptor [human]:Wild; Proto-oncogene tyrosine-protein kinase ROS [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.08,,,,,,,7.1,,,,,,"Article; Guo, Ming; Zuo, Daiying; Zhao, Tianming; Li, Xiangyu; Cao, Jianshuang; Qiu, Yuxuan; Wei, Shangfei; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 214; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82739191&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + c-ros receptor tyrosine kinase; mcf3; proto-oncogene c-ros; proto-oncogene c-ros-1; proto-oncogene tyrosine-protein kinase ros; receptor tyrosine kinase c-ros oncogene 1; ros; ros1,818511893 + 818268477,q9um73 + p08922,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4 + 3zbf; 4uxl,,,ALK tyrosine kinase receptor [human]; Proto-oncogene tyrosine-protein kinase ROS [human],ALK tyrosine kinase receptor [human]:Wild; Proto-oncogene tyrosine-protein kinase ROS [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.15,,,,,,,6.82,,,,,,"Article; Guo, Ming; Zuo, Daiying; Zhao, Tianming; Li, Xiangyu; Cao, Jianshuang; Qiu, Yuxuan; Wei, Shangfei; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 214; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82739191&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,3.5,,,,,,,8.46,,,,,,"Article; Guo, Ming; Zuo, Daiying; Zhao, Tianming; Li, Xiangyu; Cao, Jianshuang; Qiu, Yuxuan; Wei, Shangfei; Zhai, Xin; European Journal of Medicinal Chemistry; vol. 214; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82739191&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,protein tyrosine kinase inhibitor,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,,Not determined/not detected,,,,,,,,,,,,,,Patent; PRIMEGENE BEIJING; EP3786167; (2021); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D83057361&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.031,,,,,,,7.51,,,,,,"Article; Li, Zheng; Guo, Ming; Cao, Meng; Zhao, Tianming; Li, Mingzhu; Zhai, Xin; Bioorganic and Medicinal Chemistry; vol. 37; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D83412367&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228-Luc cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.107,,,,,,,6.97,,,,,,"Article; Li, Zheng; Guo, Ming; Cao, Meng; Zhao, Tianming; Li, Mingzhu; Zhai, Xin; Bioorganic and Medicinal Chemistry; vol. 37; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D83412367&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,A549 (G1202R) cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,>,10,,,,,,,1,,,,,,"Article; Li, Zheng; Guo, Ming; Cao, Meng; Zhao, Tianming; Li, Mingzhu; Zhai, Xin; Bioorganic and Medicinal Chemistry; vol. 37; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D83412367&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,3.2,,,,,,,8.49,,,,,,"Article; Li, Zheng; Guo, Ming; Cao, Meng; Zhao, Tianming; Li, Mingzhu; Zhai, Xin; Bioorganic and Medicinal Chemistry; vol. 37; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D83412367&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,7.6,,,,,,,8.12,,,,,,"Article; Li, Zheng; Guo, Ming; Cao, Meng; Zhao, Tianming; Li, Mingzhu; Zhai, Xin; Bioorganic and Medicinal Chemistry; vol. 37; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D83412367&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,172,,,,,,,6.76,,,,,,"Article; Li, Zheng; Guo, Ming; Cao, Meng; Zhao, Tianming; Li, Mingzhu; Zhai, Xin; Bioorganic and Medicinal Chemistry; vol. 37; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D83412367&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,antiproliferative agent,In Vivo (Animal models),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,20 mg/day/kg,oral administration,,,TGI (tumor growth inhibition rate),%,,34,,,,,,,,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Pu, Chunlan; Yue, Lin; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Deyu; Fan, Shilong; Li, Rui; Journal of Medicinal Chemistry; vol. 64; 3; (2021); p. 1558 - 1569;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82569084&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,200 nM,,,,inhibition percentage,%,,100.1,,,,,,,,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Pu, Chunlan; Yue, Lin; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Deyu; Fan, Shilong; Li, Rui; Journal of Medicinal Chemistry; vol. 64; 3; (2021); p. 1558 - 1569;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82569084&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,20 nM,,,,inhibition percentage,%,,100.52,,,,,,,,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Pu, Chunlan; Yue, Lin; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Deyu; Fan, Shilong; Li, Rui; Journal of Medicinal Chemistry; vol. 64; 3; (2021); p. 1558 - 1569;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82569084&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,1.3,,,,,,,5.89,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Pu, Chunlan; Yue, Lin; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Deyu; Fan, Shilong; Li, Rui; Journal of Medicinal Chemistry; vol. 64; 3; (2021); p. 1558 - 1569;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82569084&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antiproliferative agent,In Vitro (Efficacy),,,,,,,NCI-H1299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,2.92,,,,,,,5.53,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Pu, Chunlan; Yue, Lin; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Deyu; Fan, Shilong; Li, Rui; Journal of Medicinal Chemistry; vol. 64; 3; (2021); p. 1558 - 1569;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82569084&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antiproliferative agent,In Vitro (Efficacy),,,,,,,A-549 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,1.32,,,,,,,5.88,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Pu, Chunlan; Yue, Lin; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Deyu; Fan, Shilong; Li, Rui; Journal of Medicinal Chemistry; vol. 64; 3; (2021); p. 1558 - 1569;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82569084&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antiproliferative agent,In Vitro (Efficacy),,,,,,,HeLa cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.94,,,,,,,6.03,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Pu, Chunlan; Yue, Lin; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Deyu; Fan, Shilong; Li, Rui; Journal of Medicinal Chemistry; vol. 64; 3; (2021); p. 1558 - 1569;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82569084&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antiproliferative agent,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,1.1,,,,,,,5.96,,,,,,"Article; Yan, Guoyi; Zhong, Xinxin; Pu, Chunlan; Yue, Lin; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Deyu; Fan, Shilong; Li, Rui; Journal of Medicinal Chemistry; vol. 64; 3; (2021); p. 1558 - 1569;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D82569084&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HeLa cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,1 μM,,,,decrease rate,,Active,,,,Leukocyte tyrosine kinase receptor,,,,6,,,,,,Patent; UNIVERSITY OF OSLO; WO2021/83555; (2021); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D84115616&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HeLa cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,1 μM,,,of endoplasmic reticulum to golgi apparatus trafficking of endoplasmic reticlum exit sites(ERES),inhibition rate,,Active,,,,,,,,6,,,,,,Patent; UNIVERSITY OF OSLO; WO2021/83555; (2021); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D84115616&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HeLa cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,1 μM,,,of immunoglobulin release,inhibition rate,,Active,,,,,,,,6,,,,,,Patent; UNIVERSITY OF OSLO; WO2021/83555; (2021); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D84115616&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,toxic substance,Toxicity/Safety Pharmacology,,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,50 mg/kg,oral administration,Repeated,,plasma cell density decrease,,Active,,,,,,,,,,,,,,Patent; UNIVERSITY OF OSLO; WO2021/83555; (2021); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D84115616&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,phosphotransferase inhibitor,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,<,1,,,,,,,9,,,,,,"Article; Pan, Tao; Dan, Yanrong; Guo, Dafeng; Jiang, Junhao; Ran, Dongzhi; Zhang, Lin; Tian, Binghua; Yuan, Jianyong; Yu, Yu; Gan, Zongjie; European Journal of Medicinal Chemistry; vol. 224; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D93835987&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [mouse],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,821117021,p97793,,,,ALK tyrosine kinase receptor [mouse],ALK tyrosine kinase receptor [mouse]:Wild,mouse,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3-ALK cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,7.11,,,,,,,8.15,,,,,,"Article; Wu, Feng; Yao, Han; Li, Wei; Zhang, Niuniu; Fan, Yangyang; Chan, Albert S.C.; Li, Xingshu; An, Baijiao; Bioorganic and Medicinal Chemistry Letters; vol. 48; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D95001495&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,22.1,,,,,,,7.66,,,,,,"Article; Wu, Feng; Yao, Han; Li, Wei; Zhang, Niuniu; Fan, Yangyang; Chan, Albert S.C.; Li, Xingshu; An, Baijiao; Bioorganic and Medicinal Chemistry Letters; vol. 48; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D95001495&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor;+Tropomyosin alpha-3 chain,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + gamma-tropomyosin; htm5; tpm-5; tpm3; tpm5; tropomyosin alpha-3 chain; tropomyosin-3; tropomyosin-5,820152764 + 820064627,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Tropomyosin alpha-3 chain,ALK tyrosine kinase receptor:Wild + Tropomyosin alpha-3 chain:Wild,,Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.104,,,,,,,6.98,,,,,,"Article; Li, Tong; Li, Changtao; Yang, Jing; Guo, Ming; Cao, Zhi; Wang, Xinyu; Jiang, Nan; Zhai, Xin; Bioorganic and Medicinal Chemistry; vol. 47; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D101720703&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor;+Nucleophosmin,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246 + npm; npm1; nucleolar phosphoprotein b23; nucleolar protein no38; nucleophosmin; numatrin,820152764 + 820016608,,,,ipr:ipr026830,ALK tyrosine kinase receptor; Nucleophosmin,ALK tyrosine kinase receptor:Wild + Nucleophosmin:Wild,,Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.042,,,,,,,7.38,,,,,,"Article; Li, Tong; Li, Changtao; Yang, Jing; Guo, Ming; Cao, Zhi; Wang, Xinyu; Jiang, Nan; Zhai, Xin; Bioorganic and Medicinal Chemistry; vol. 47; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D101720703&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,3.1,,,,,,,5.51,,,,,,"Article; Li, Tong; Li, Changtao; Yang, Jing; Guo, Ming; Cao, Zhi; Wang, Xinyu; Jiang, Nan; Zhai, Xin; Bioorganic and Medicinal Chemistry; vol. 47; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D101720703&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,11,m,96",,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,27,,,,,,,4.57,,,,,,"Article; Li, Tong; Li, Changtao; Yang, Jing; Guo, Ming; Cao, Zhi; Wang, Xinyu; Jiang, Nan; Zhai, Xin; Bioorganic and Medicinal Chemistry; vol. 47; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D101720703&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,54,,,,,,,7.27,,,8469413,vincristine,Other compound,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,>,200,,,,,,,6.7,,,8469413,vincristine,Other compound,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,21,,,,,,,7.68,,,8469413,vincristine,Other compound,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,198,,,,,,,6.7,,,8469413,vincristine,Other compound,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,percentage of apoptotic cells increase,,Low,,,,,,,,,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,fold increase apoptotic cell,no unit,~,2,,,,,,,,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H1975 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,>,200,,,,,,,6.7,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H596 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,>,200,,,,,,,6.7,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Calu-6 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,>,200,,,,,,,6.7,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,HCC78 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,>,200,,,,,,,6.7,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,apoptosis inducing factor,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,500 nM,,,Microtubule Nucleation,decrease rate,,Not active,,,,,,,,1,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,500 nM,,,Microtubule Nucleation,decrease rate,,Active,,,,,,,,6.3,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H3122 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,23 - 48,,,,,,,7.64,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,>,200,,,,,,,6.7,,,,,,"Article; Sampson, Josephina;Ju, Hyun-Min;Song, Ji-Young;Fry, Andrew M.;Bayliss, Richard;Choi, Jene; Cancers; vol. 14; 3; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D115510150&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,c2orf2; echinoderm microtubule-associated protein-like 4; emap-4; emapl4; eml4; restrictedly overexpressed proliferation-associated protein; ropp 120 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820068176 + 820152764,,,,ipr:ipr026830,Echinoderm microtubule-associated protein-like 4; ALK tyrosine kinase receptor,Echinoderm microtubule-associated protein-like 4:Wild; ALK tyrosine kinase receptor:Wild,,Transfected; Transfected,Inhibitor,cytotoxic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,>,10 - 100,,,,,,,8,,,,,,Patent; NUVALENT; PHARMA RESOURCES GMBH; WO2021/226269; (2021); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D105723270&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,SH-SY5Y cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,63 nM,,,,percentage of cellular fraction affected,%,,31,,,,,,,,,,,,,"Letter; Boloix, Ariadna; Burgos-Panadero, Rebeca; Devis-Jauregui, Laura; Gallego, Soledad; Guillén, Gabriela; Jiménez, Carlos; Krauss, Rolf; Llobet-Navas, David; Majem, Blanca; Masanas, Marc; Masiá, Nuria; Moreno, Lucas; Navarro, Alexandra; Noguera, Rosa; Olivan, Mireia; Rodriguez-Sodupe, Pau; Roma, Josep; Sánchez de Toledo, Josep; Santamaria, Anna; Segura, Miguel F.; Soriano, Aroa; Suárez-Cabrera, Leticia; Toledano, Ignasi; Villanueva, Alberto; Clinical and Translational Medicine; vol. 11; 10; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D104859995&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,SH-SY5Y cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,94 nM,,,,percentage of cellular fraction affected,%,,41,,,,,,,,,,,,,"Letter; Boloix, Ariadna; Burgos-Panadero, Rebeca; Devis-Jauregui, Laura; Gallego, Soledad; Guillén, Gabriela; Jiménez, Carlos; Krauss, Rolf; Llobet-Navas, David; Majem, Blanca; Masanas, Marc; Masiá, Nuria; Moreno, Lucas; Navarro, Alexandra; Noguera, Rosa; Olivan, Mireia; Rodriguez-Sodupe, Pau; Roma, Josep; Sánchez de Toledo, Josep; Santamaria, Anna; Segura, Miguel F.; Soriano, Aroa; Suárez-Cabrera, Leticia; Toledano, Ignasi; Villanueva, Alberto; Clinical and Translational Medicine; vol. 11; 10; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D104859995&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,SH-SY5Y cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,125 nM,,,,percentage of cellular fraction affected,%,,50,,,,,,,,,,,,,"Letter; Boloix, Ariadna; Burgos-Panadero, Rebeca; Devis-Jauregui, Laura; Gallego, Soledad; Guillén, Gabriela; Jiménez, Carlos; Krauss, Rolf; Llobet-Navas, David; Majem, Blanca; Masanas, Marc; Masiá, Nuria; Moreno, Lucas; Navarro, Alexandra; Noguera, Rosa; Olivan, Mireia; Rodriguez-Sodupe, Pau; Roma, Josep; Sánchez de Toledo, Josep; Santamaria, Anna; Segura, Miguel F.; Soriano, Aroa; Suárez-Cabrera, Leticia; Toledano, Ignasi; Villanueva, Alberto; Clinical and Translational Medicine; vol. 11; 10; (2021);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D104859995&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.02,,,,,,,7.7,,,,,,"Article; Wang, Xinyue; Hu, Yiran; Zou, Xinyu; Wang, Pengfei; Yue, Hao; Guo, Mingzhang; Li, Zefei; Gong, Ping; Bioorganic and Medicinal Chemistry; vol. 66; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D117408443&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.03,,,,,,,7.52,,,,,,"Article; Wang, Xinyue; Hu, Yiran; Zou, Xinyu; Wang, Pengfei; Yue, Hao; Guo, Mingzhang; Li, Zefei; Gong, Ping; Bioorganic and Medicinal Chemistry; vol. 66; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D117408443&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,l,1196,m",,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,0.83,,,,,,,9.08,,,73010,ATP,Other compound,"Article; Wang, Xinyue; Hu, Yiran; Zou, Xinyu; Wang, Pengfei; Yue, Hao; Guo, Mingzhang; Li, Zefei; Gong, Ping; Bioorganic and Medicinal Chemistry; vol. 66; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D117408443&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,"ALK tyrosine kinase receptor:Mutated:Substitution,1,g,1202,r",,Transfected,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,17.23,,,,,,,7.76,,,73010,ATP,Other compound,"Article; Wang, Xinyue; Hu, Yiran; Zou, Xinyu; Wang, Pengfei; Yue, Hao; Guo, Mingzhang; Li, Zefei; Gong, Ping; Bioorganic and Medicinal Chemistry; vol. 66; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D117408443&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,1.2,,,,,,,8.92,,,73010,ATP,Other compound,"Article; Wang, Xinyue; Hu, Yiran; Zou, Xinyu; Wang, Pengfei; Yue, Hao; Guo, Mingzhang; Li, Zefei; Gong, Ping; Bioorganic and Medicinal Chemistry; vol. 66; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D117408443&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,protein tyrosine kinase inhibitor,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,3.2,,,,,,,8.49,,,,,,"Article; Guo, Ming; Jiang, Nan; Liu, Shuyu; Wang, Hao; Wang, Xinyu; Wei, Shangfei; Yang, Jing; Zhai, Xin; Zhang, Jiahao; European Journal of Medicinal Chemistry; vol. 238; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D117856776&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.001 - 10 μM,,,,IC50,μM,,99.7,,,,,,,4,,,,,,"Article; Chang, Xing;Wang, Junfang;Bian, Jiang;Liu, Zi;Guo, Ming;Li, Zengqiang;Wu, Yingliang;Zhai, Xin;Zuo, Daiying; Toxicology and Applied Pharmacology; vol. 450; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D118364301&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Jurkat cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,0.001 - 10 μM,,,,IC50,μM,,2296.3,,,,,,,2.64,,,,,,"Article; Chang, Xing;Wang, Junfang;Bian, Jiang;Liu, Zi;Guo, Ming;Li, Zengqiang;Wu, Yingliang;Zhai, Xin;Zuo, Daiying; Toxicology and Applied Pharmacology; vol. 450; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D118364301&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor (F1174L) [human]; ALK tyrosine kinase receptor (R1275Q) [human],alk tyrosine kinase receptor (f1174l) + alk tyrosine kinase receptor (r1275q),819146149 + 819146158,q9um73 + q9um73,,,,ALK tyrosine kinase receptor (F1174L) [human]; ALK tyrosine kinase receptor (R1275Q) [human],ALK tyrosine kinase receptor (F1174L) [human]:Wild; ALK tyrosine kinase receptor (R1275Q) [human]:Wild,human; human,Non Transfected; Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,CLB-Ga cell line; SH-SY5Y cell line; Kelly cell line; TR14 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,GI50,μM,,0.19,,,,,,,6.72,,,,,,"Article; Fischer-Mertens, Janina;Otte, Felix;Roderwieser, Andrea;Rosswog, Carolina;Kahlert, Yvonne;Werr, Lisa;Hellmann, Anna-Maria;Berding, Maya;Chiu, Bill;Bartenhagen, Christoph;Fischer, Matthias; Cellular Oncology; vol. 45; 5; (2022); p. 991 - 1003;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D119220460&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,SK-N-BE(2)-C cell line; IMR-32 cell line; LS cell line (neuroblastoma); GI-ME-N cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,GI50,μM,,0.61,,,,,,,6.21,,,,,,"Article; Fischer-Mertens, Janina;Otte, Felix;Roderwieser, Andrea;Rosswog, Carolina;Kahlert, Yvonne;Werr, Lisa;Hellmann, Anna-Maria;Berding, Maya;Chiu, Bill;Bartenhagen, Christoph;Fischer, Matthias; Cellular Oncology; vol. 45; 5; (2022); p. 991 - 1003;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D119220460&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,Karpas-299 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.047,,,,,,,7.33,,,,,,"Article; Cui, Youbao;Tan, Zehui;Liu, Shuyu;Cao, Zhi;Shao, Bin;Guo, Mengrao;Jiang, Nan;Zhai, Xin; Bioorganic and Medicinal Chemistry Letters; vol. 75; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120331487&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.162,,,,,,,6.79,,,,,,"Article; Cui, Youbao;Tan, Zehui;Liu, Shuyu;Cao, Zhi;Shao, Bin;Guo, Mengrao;Jiang, Nan;Zhai, Xin; Bioorganic and Medicinal Chemistry Letters; vol. 75; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120331487&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,protein kinase inhibitor,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,3.5,,,,,,,8.46,,,,,,"Article; Cui, Youbao;Tan, Zehui;Liu, Shuyu;Cao, Zhi;Shao, Bin;Guo, Mengrao;Jiang, Nan;Zhai, Xin; Bioorganic and Medicinal Chemistry Letters; vol. 75; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120331487&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,antineoplastic agent,In Vitro (Efficacy),,,,,,,,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,nM,,2.6,,,,,,,8.59,,,,,,"Article; Yang, Jing;Ma, Deyi;Liu, Shuyu;Tan, Zehui;Guo, Ming;Cao, Zhi;Zhang, Jiahao;Zhai, Xin; European Journal of Medicinal Chemistry; vol. 241; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D119264256&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,Hep-G2 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.94,,,,,,,6.03,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,SK-N-BE(2) cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.04,,,,,,,7.4,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,A-549 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,2.36,,,,,,,5.63,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,MDA-MB-231 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,1.09,,,,,,,5.96,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,4.32,,,,,,,5.36,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,A-549 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,1 μM,,,,percentage of cells in G1 phase,%,,68.17,,,,,,,,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,A-549 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,1 μM,,,,percentage of cells in G2 phase,%,,25.37,,,,,,,,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,A-549 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,1 μM,,,,percentage of cells in S phase,%,,6.46,,,,,,,1,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,1 μM,,,,percentage of cells in G1 phase,%,,79.06,,,,,,,,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,1 μM,,,,percentage of cells in G2 phase,%,,7.15,,,,,,,,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,Histone deacetylase 1 [human];+ALK tyrosine kinase receptor [human],hd1; hdac1; histone deacetylase 1; protein deacetylase hdac1; protein decrotonylase hdac1; rpd3l1 + alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818480413 + 818511893,q13547 + q9um73,4bkx; 5icn; 6z2j; 6z2k; 7ao8; 7ao9; 7aoa + 2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human]; Histone deacetylase 1 [human],Histone deacetylase 1 [human]:Wild + ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic cytotoxic,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,1 μM,,,,percentage of cells in S phase,%,,13.79,,,,,,,1,,,,,,"Article; Guo, Dafeng;Yu, Yu;Long, Binyu;Deng, Ping;Ran, Dongzhi;Han, Lei;Zheng, Jiecheng;Gan, Zongjie; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 37; 1; (2022); p. 2512 - 2529;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120329250&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,Ba/F3 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.007,,,,,,,8.15,,,,,,"Article; Li, Wei;Yao, Han;Gu, Chenxi;Ren, Yuanyuan;Liu, Jiadai;An, Baijiao;Hu, Wenhao;Li, Xingshu;Chan, Albert S.C.; Bioorganic Chemistry; vol. 129; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120730616&database=RX&origin=ReaxysOutput&ln=
,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,(98 of 100),1032900-25-6,"ceritinib; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine; zykadia",C28H36ClN5O3S,C28H36ClN5O3S,558.145,,,VERWOWGGCGHDQE-UHFFFAOYSA-N,,,,Identification(589); Physical Data(72); Spectra(35); Bioactivity(167),238,739,6.546,3,7,9,113.62,2,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,antineoplastic agent,Toxicity/Safety Pharmacology,,,,,,,NCI-H2228 cell line,,18383989,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D18383989&database=RX&origin=ReaxysOutput&ln=,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2S(=O)(=O)C(C)C)=N1,ceritinib,,,,,IC50,μM,,0.0221,,,,,,,7.66,,,,,,"Article; Li, Wei;Yao, Han;Gu, Chenxi;Ren, Yuanyuan;Liu, Jiadai;An, Baijiao;Hu, Wenhao;Li, Xingshu;Chan, Albert S.C.; Bioorganic Chemistry; vol. 129; (2022);",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D120730616&database=RX&origin=ReaxysOutput&ln=
,C(CN1CCCCC1)OC1=CC=C(C=C1)C1=CN2N=CC(=C2N=C1)C1=CC=NC=C1,11725482,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11725482&database=RX&origin=ReaxysOutput&ln=,(99 of 100),,"dorsomorphin; compound C; 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine; AMPK inhibitor; AMPK inhibitor compound C; BML-275; HY-13418A; P5499",C24H25N5O,C24H25N5O,399.495,,,XHBVYDAKJHETMP-UHFFFAOYSA-N,,,,Identification(415); Physical Data(1); Spectra(1); Bioactivity(394),9,739,3.717,0,5,6,55.55,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,Baculovirus-infected insect cell,,11725482,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11725482&database=RX&origin=ReaxysOutput&ln=,C(CN1CCCCC1)OC1=CC=C(C=C1)C1=CN2N=CC(=C2N=C1)C1=CC=NC=C1,"AMPK Inhibitor, Compound C",0.500000 µM,,,,inhibition percentage,%,,15.52,,,,,,,1,,,73010; 73010; 506008; 1719757,ATP; [33P]-ATP; DMSO; Dithiothreitol; Brij-35 detergent,CoEnzyme; Marker; Solvent; Other compound; Other compound,"Article; Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.; Nature Biotechnology; vol. 29; 11; (2011); p. 1039 - 1045;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D33009915&database=RX&origin=ReaxysOutput&ln=
,C(CN1CCCCC1)OC1=CC=C(C=C1)C1=CN2N=CC(=C2N=C1)C1=CC=NC=C1,11725482,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11725482&database=RX&origin=ReaxysOutput&ln=,(99 of 100),,"dorsomorphin; compound C; 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine; AMPK inhibitor; AMPK inhibitor compound C; BML-275; HY-13418A; P5499",C24H25N5O,C24H25N5O,399.495,,,XHBVYDAKJHETMP-UHFFFAOYSA-N,,,,Identification(415); Physical Data(1); Spectra(1); Bioactivity(394),9,739,3.717,0,5,6,55.55,4,2,ALK tyrosine kinase receptor [human],alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,818511893,q9um73,2kup; 2kuq; 2xb7; 2xba; 2xp2; 2yfx; 2yhv; 2yjr; 2yjs; 2ys5; 2yt2; 3aox; 3l9p; 3lcs; 3lct; 4anl; 4anq; 4ans; 4ccb; 4ccu; 4cd0; 4cli; 4clj; 4cmo; 4cmt; 4cmu; 4cnh; 4ctb; 4ctc; 4dce; 4fnw; 4fnx; 4fny; 4fnz; 4fob; 4foc; 4fod; 4joa; 4mkc; 4tt7; 4z55; 5a9u; 5aa8; 5aa9; 5aaa; 5aab; 5aac; 5fto; 5ftq; 5imx; 5iug; 5iuh; 5iui; 5kz0; 5vz5; 6at9; 6cdt; 6e0r; 6ebw; 6edl; 6mx8; 7btt; 7jy4; 7jyr; 7jys; 7jyt; 7nwz; 7nx3; 7nx4,,,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Non Transfected,Inhibitor,liver protective agent,In Vitro (Efficacy),,,human,,,,liver cell,,11725482,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D11725482&database=RX&origin=ReaxysOutput&ln=,C(CN1CCCCC1)OC1=CC=C(C=C1)C1=CN2N=CC(=C2N=C1)C1=CC=NC=C1,dorsomorphin,,,,Log2 fold-increase,fold increase,no unit,,0.57,,,UDP-glucuronosyltransferase 1-1,,,,,,,,,,Patent; CAMP4 THERAPEUTICS CORPORATION INC; WO2019/195855; (2019); A1;,https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D78032343&database=RX&origin=ReaxysOutput&ln=
,COC1=C(OC)C=C2C(NC3=CC=C(O)C=C3)=NC=NC2=C1,8154591,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8154591&database=RX&origin=ReaxysOutput&ln=,(100 of 100),202475-60-3,"WHI-P131; janex 1; 4-((6,7-dimethoxyquinazolin-4-yl)amino)phenol; 6,7-dimethoxy-N-(4-hydroxyphenyl)-4-quinazolinamine",C16H15N3O3,C16H15N3O3,297.313,heterocyclic,,HOZUXBLMYUPGPZ-UHFFFAOYSA-N,,,,Identification(748); Physical Data(4); Spectra(9); Bioactivity(102),28,733,2.18,2,3,4,76.5,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),Enzymology inhibition,,,,,,,,8154591,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8154591&database=RX&origin=ReaxysOutput&ln=,COC1=C(OC)C=C2C(NC3=CC=C(O)C=C3)=NC=NC2=C1,8,,,,,IC50,µM,,2.4,,,,,,,5.62,,,73010; 506008; 1719757,ATP; DMSO; Dithiothreitol; Brij-35 detergent; Phosphatase inhibitor cocktail; Protease inhibitor cocktail,CoEnzyme; Solvent; Other compound; Other compound; Other compound; Other compound,"Article; Okamoto, Masako; Kojima, Hirotatsu; Saito, Nae; Okabe, Takayoshi; Masuda, Yoshiaki; Furuya, Toshio; Nagano, Tetsuo; Bioorganic and Medicinal Chemistry; vol. 19; 10; (2011); p. 3086 - 3095;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D9045720&database=RX&origin=ReaxysOutput&ln=
,COC1=C(OC)C=C2C(NC3=CC=C(O)C=C3)=NC=NC2=C1,8154591,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8154591&database=RX&origin=ReaxysOutput&ln=,(100 of 100),202475-60-3,"WHI-P131; janex 1; 4-((6,7-dimethoxyquinazolin-4-yl)amino)phenol; 6,7-dimethoxy-N-(4-hydroxyphenyl)-4-quinazolinamine",C16H15N3O3,C16H15N3O3,297.313,heterocyclic,,HOZUXBLMYUPGPZ-UHFFFAOYSA-N,,,,Identification(748); Physical Data(4); Spectra(9); Bioactivity(102),28,733,2.18,2,3,4,76.5,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,,,In Vitro (Efficacy),,"In vitro inhibitory concentration of compound against ALK in presence of 1 uM [GAMMA-32P]ATP upon incubation in 25 mM HEPES, pH 7.1 at 20 degree C for 2-10 min",,,,,,,8154591,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8154591&database=RX&origin=ReaxysOutput&ln=,COC1=C(OC)C=C2C(NC3=CC=C(O)C=C3)=NC=NC2=C1,,,,,,IC50,µM,=,10,,,,,,,5,,,,[GAMMA-32P]ATP,Other compound,"Article; Tartari, Carmen J.; Scapozza, Leonardo; Gambacorti-Passerini, Carlo; Current Topics in Medicinal Chemistry; vol. 11; 11; (2011); p. 1406 - 1419;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D32250622&database=RX&origin=ReaxysOutput&ln=
,COC1=C(OC)C=C2C(NC3=CC=C(O)C=C3)=NC=NC2=C1,8154591,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8154591&database=RX&origin=ReaxysOutput&ln=,(100 of 100),202475-60-3,"WHI-P131; janex 1; 4-((6,7-dimethoxyquinazolin-4-yl)amino)phenol; 6,7-dimethoxy-N-(4-hydroxyphenyl)-4-quinazolinamine",C16H15N3O3,C16H15N3O3,297.313,heterocyclic,,HOZUXBLMYUPGPZ-UHFFFAOYSA-N,,,,Identification(748); Physical Data(4); Spectra(9); Bioactivity(102),28,733,2.18,2,3,4,76.5,4,2,ALK tyrosine kinase receptor,alk; alk tyrosine kinase receptor; anaplastic lymphoma kinase; cd246,820152764,,,,ipr:ipr026830,ALK tyrosine kinase receptor,ALK tyrosine kinase receptor:Wild,,,Inhibitor,,In Vitro (Efficacy),,In vitro inhibitory concentration of the compound against NPM-ALK kinase,,,,,,,8154591,https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN%3D8154591&database=RX&origin=ReaxysOutput&ln=,COC1=C(OC)C=C2C(NC3=CC=C(O)C=C3)=NC=NC2=C1,,,,,,IC50,µM,=,10,,,,,,,5,,,,,,"Review; Gunby, Rosalind H.; Sala, Elisa; Tartari, Carmen J.; Puttini, Miriam; Gambacorti-Passerini, Carlo; Mologni, Luca; Anti-Cancer Agents in Medicinal Chemistry; vol. 7; 6; (2007); p. 594 - 611;",https://www.reaxys.com/reaxys/secured/hopinto.do?context=C&query=CNR.CNR%3D24929181&database=RX&origin=ReaxysOutput&ln=
Disclaimer: please refer to our Terms and Conditions on authorized use of Reaxys data.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Copyright © 2023 Elsevier Life Sciences IP Limited except certain content provided by third parties. Reaxys is a trademark of Elsevier Life Sciences IP Limited.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
